AIDS	other-disease
fears	O
and	O
homophobia	O
among	O
volunteers	O
in	O
an	O
AIDS	other-disease
prevention	O
program	O
.	O

performed	O
2016	O
a	O
meta-analysis	O
with	O
the	O
largest	O
dataset	O
available	O
on	O
genotype-phenotype	O
associations	O
in	O
DCM	other-disease
and	O
mutations	O
in	O
lamin	O
(	O
LMNA	other-disease
)	O
,	O
phospholamban	O
(	O
PLN	other-disease
)	O
,	O
RNA	O
Binding	O
Motif	O
Protein	O
20	O
(	O
RBM20	O
)	O
,	O
Cardiac	O
Myosin	O
Binding	O
Protein	O
C	O
(	O
MYBPC3	O
)	O
,	O
Myosin	O
Heavy	O
Chain	O
7	O
(	O
MYH7	O
)	O
,	O
Cardiac	O
Troponin	O
T	O
2	O
(	O
TNNT2	O
)	O
,	O
and	O
Cardiac	O
Troponin	O
I	O
(	O
TNNI3	O
)	O
.	O

For	O
example	O
,	O
some	O
diseases	O
like	O
Autoimmune	other-disease
GFAP	other-disease
Astrocytopathy	other-disease
or	O
variants	other-disease
of	other-disease
CIDP	other-disease
that	O
affects	O
the	O
CNS	other-disease
(	O
CIDP	O
is	O
the	O
chronic	O
counterpart	O
of	O
Guillain–Barré	other-disease
syndrome	other-disease
)	O
could	O
be	O
included	O
.	O

Some	O
studies	O
have	O
shown	O
that	O
1	O
in	O
every	O
7	O
couples	O
will	O
fail	O
to	O
conceive	O
due	O
to	O
infertility	other-disease
problems	O
.	O

Albinism	other-disease
is	O
a	O
genetic	O
abnormality	O
in	O
which	O
little	O
or	O
no	O
pigment	O
is	O
found	O
in	O
human	O
hair	O
,	O
eyes	O
,	O
and	O
skin	O
.	O

Post-traumatic	other-disease
stress	other-disease
disorder	other-disease
is	O
a	O
disabling	O
condition	O
that	O
can	O
be	O
caused	O
by	O
after	O
some	O
kind	O
of	O
life-threatening	O
trauma	O
.	O

Thus	O
,	O
for	O
a	O
brief	O
time	O
malaria	other-disease
was	O
used	O
as	O
treatment	O
for	O
tertiary	other-disease
syphilis	other-disease
because	O
it	O
produced	O
prolonged	O
and	O
high	other-disease
fevers	other-disease
(	O
a	O
form	O
of	O
pyrotherapy	O
)	O
.	O

``	O
Diseases	O
of	O
Canaries	O
``	O
is	O
a	O
comprehensive	O
work	O
which	O
contains	O
much	O
information	O
on	O
:	O
Anatomy	O
–	O
Feeding	O
–	O
Feeding	O
Experiments	O
–	O
Insects	O
and	O
Parasites	O
–	O
The	O
Moult	O
–	O
Injuries	O
–	O
Septic	other-disease
Fever	other-disease
–	O
Sepsis	other-disease
–	O
Necrosis	other-disease
–	O
Diarrhea	other-disease
–	O
Aspergillosis	other-disease
–	O
Bacteriology	O
–	O
Pathogenic	O
Organisms	O
–	O
Drugs	O
.	O

People	O
with	O
this	O
form	O
of	O
agnosia	other-disease
have	O
difficulty	O
in	O
determining	O
and	O
identifying	O
the	O
motivational	O
and	O
emotional	O
significance	O
of	O
external	O
social	O
events	O
,	O
and	O
may	O
appear	O
emotionless	O
or	O
agnostic	O
(	O
uncertainty	O
or	O
general	O
indecisiveness	O
about	O
a	O
particular	O
thing	O
)	O
.	O

In	O
essence	O
,	O
atrophic	other-disease
candidiasis	other-disease
appears	O
like	O
pseudomembranous	other-disease
candidiasis	other-disease
without	O
the	O
superficial	O
desquamating	O
layer	O
.	O

Activation	other-disease
syndrome	other-disease
is	O
a	O
form	O
of	O
stimulation	O
(	O
sometimes	O
suicidal	O
)	O
or	O
agitation	O
that	O
has	O
been	O
observed	O
in	O
association	O
with	O
some	O
psychoactive	O
drugs	O
.	O

Nocturnal	other-disease
enuresis	other-disease
,	O
also	O
called	O
bedwetting	other-disease
,	O
is	O
involuntary	O
urination	O
while	O
asleep	O
after	O
the	O
age	O
at	O
which	O
bladder	O
control	O
usually	O
begins	O
.	O

People	O
suffering	O
from	O
Bothnia	other-disease
dystrophy	other-disease
have	O
a	O
homozygous	O
C	O
to	O
T	O
base	O
pair	O
substitution	O
in	O
exon	O
7	O
of	O
the	O
RLBP1	O
gene	O
.	O

NEPs	O
successfully	O
serve	O
as	O
one	O
component	O
of	O
HIV	other-disease
prevention	O
strategies	O
.	O

High	O
amounts	O
of	O
GM3	O
also	O
displayed	O
a	O
high	O
amount	O
of	O
caveolin-1	O
,	O
a	O
molecule	O
which	O
has	O
been	O
shown	O
to	O
inhibit	O
ovarian	other-disease
cancer	other-disease
growth	O
.	O

The	O
device	O
treats	O
a	O
congenital	other-disease
disorder	other-disease
in	O
the	O
heart	O
known	O
as	O
a	O
patent	other-disease
ductus	other-disease
arteriosus	other-disease
(	O
PDA	other-disease
)	O
.	O

LQT1	O
is	O
the	O
most	O
common	O
subtype	O
of	O
Romano–Ward	other-disease
syndrome	O
,	O
responsible	O
for	O
30	O
to	O
35	O
%	O
of	O
all	O
cases	O
.	O

The	O
United	O
States	O
Preventive	O
Services	O
Task	O
Force	O
(	O
USPSTF	O
)	O
recommends	O
screening	O
for	O
gonorrhea	other-disease
in	O
women	O
at	O
increased	O
risk	O
of	O
infection	O
,	O
which	O
includes	O
all	O
sexually	O
active	O
women	O
younger	O
than	O
25	O
years	O
.	O

Hyperchloremia	other-disease
can	O
affect	O
oxygen	O
transport	O
.	O

Initial	O
orthostatic	other-disease
hypotension	other-disease
is	O
frequently	O
characterized	O
by	O
a	O
systolic	O
blood	O
pressure	O
decrease	O
of	O
≥40	O
mmHg	O
or	O
diastolic	O
blood	O
pressure	O
decrease	O
of	O
≥20	O
mmHg	O
within	O
15	O
seconds	O
of	O
standing	O
.	O

Tuberculin	O
reaction	O
or	O
Type	other-disease
1	other-disease
diabetes	other-disease
belong	O
to	O
this	O
category	O
of	O
autoimmunity	O
.	O

Symptoms	O
generally	O
occur	O
at	O
the	O
age	O
of	O
40	O
,	O
and	O
are	O
often	O
accompanied	O
by	O
depression	other-disease
and	O
psychosis	other-disease
.	O

In	O
meningoencephalitis	other-disease
cases	O
,	O
higher	O
protein	O
levels	O
in	O
CSF	O
and	O
a	O
lower	O
CSF	O
glucose	O
to	O
blood	O
glucose	O
ratio	O
are	O
associated	O
with	O
longer	O
periods	O
of	O
hospitalization	O
.	O

The	O
interest	O
created	O
by	O
the	O
documentary	O
highlighted	O
a	O
need	O
for	O
increased	O
scientific	O
research	O
,	O
as	O
well	O
as	O
caution	O
against	O
``	O
bad	O
medicine	O
''	O
and	O
raising	O
false	O
hopes	O
:	O
Ed	O
Maa	O
,	O
a	O
specialist	O
in	O
epilepsy	other-disease
,	O
stated	O
:	O
``	O
This	O
is	O
not	O
going	O
away	O
.	O

Infertility	O
associated	O
with	O
viable	O
,	O
but	O
immotile	O
sperm	O
may	O
be	O
caused	O
by	O
primary	other-disease
ciliary	other-disease
dyskinesia	other-disease
.	O

Disruptions	O
in	O
the	O
plantar	O
fascia	O
's	O
normal	O
mechanical	O
movement	O
during	O
standing	O
and	O
walking	O
(	O
known	O
as	O
the	O
Windlass	O
mechanism	O
)	O
place	O
excess	O
strain	O
on	O
the	O
calcaneal	O
tuberosity	O
and	O
seem	O
to	O
contribute	O
to	O
the	O
development	O
of	O
plantar	other-disease
fasciitis	other-disease
.	O

Charcot-Marie-Tooth	other-disease
neuropathy	O
,	O
X-linked	O
3	O
(	O
dominant	O
)	O
is	O
a	O
protein	O
that	O
in	O
humans	O
is	O
encoded	O
by	O
the	O
CMTX3	O
gene	O
.	O

Other	O
names	O
for	O
dry	O
eye	O
include	O
dry	O
eye	O
syndrome	O
,	O
keratoconjunctivitis	other-disease
sicca	other-disease
(	O
KCS	other-disease
)	O
,	O
dysfunctional	other-disease
tear	other-disease
syndrome	other-disease
,	O
lacrimal	other-disease
keratoconjunctivitis	other-disease
,	O
evaporative	other-disease
tear	other-disease
deficiency	other-disease
,	O
aqueous	other-disease
tear	other-disease
deficiency	other-disease
,	O
and	O
LASIK-induced	other-disease
neurotrophic	other-disease
epitheliopathy	other-disease
(	O
LNE	other-disease
)	O
.	O

Eosinophilic	other-disease
granuloma	other-disease
is	O
a	O
form	O
of	O
Langerhans	other-disease
cell	other-disease
histiocytosis	other-disease
.	O

TBS	other-disease
is	O
an	O
autosomal	O
dominant	O
involving	O
the	O
a	O
mutation	O
of	O
the	O
gene	O
SALL1	O
,	O
which	O
encodes	O
a	O
transcriptional	O
repressor	O
which	O
interacts	O
with	O
TRF1	O
/	O
PIN2	O
and	O
localizes	O
to	O
pericentromeric	O
heterochromatin	O
.	O

In	O
2007	O
,	O
the	O
UAE	O
government	O
attempted	O
to	O
cover	O
up	O
information	O
on	O
the	O
rape	O
of	O
a	O
French	O
teenage	O
boy	O
by	O
three	O
Emirati	O
locals	O
,	O
one	O
of	O
whose	O
HIV	other-disease
-positive	O
status	O
was	O
hidden	O
by	O
Emirati	O
authorities	O
.	O

If	O
a	O
patient	O
does	O
not	O
exhibit	O
mitochondrial	O
DNA	O
mutations	O
,	O
there	O
are	O
other	O
ways	O
that	O
they	O
can	O
be	O
diagnosed	O
with	O
MERRF	other-disease
.	O

Much	O
of	O
the	O
success	O
of	O
the	O
Global	O
Programme	O
on	O
AIDS	O
was	O
attributed	O
to	O
Mann	O
,	O
who	O
also	O
had	O
autonomy	O
over	O
the	O
Global	O
Programme	O
on	O
AIDS	other-disease
,	O
which	O
Nakajima	O
wanted	O
to	O
take	O
away	O
.	O

Along	O
with	O
Stunt	O
,	O
Pancreatic	O
Cancer	O
Action	O
has	O
the	O
support	O
of	O
many	O
leading	O
clinicians	O
and	O
researchers	O
in	O
the	O
pancreatic	other-disease
cancer	other-disease
field	O
,	O
along	O
with	O
others	O
whose	O
lives	O
have	O
been	O
touched	O
by	O
pancreatic	other-disease
cancer	other-disease
in	O
some	O
way	O
.	O

He	O
continued	O
to	O
conduct	O
research	O
and	O
publish	O
books	O
in	O
his	O
later	O
years	O
,	O
focusing	O
in	O
his	O
last	O
years	O
on	O
the	O
search	O
for	O
a	O
vaccine	O
against	O
HIV	other-disease
.	O

Hypertension	other-disease
may	O
be	O
asymptomatic	O
or	O
may	O
lead	O
to	O
symptoms	O
such	O
as	O
headache	O
,	O
dizziness	O
,	O
vision	O
changes	O
,	O
or	O
kidney	O
disease	O
.	O

Thrombocytopenic	other-disease
purpura	other-disease
are	O
purpura	other-disease
associated	O
with	O
a	O
reduction	O
in	O
circulating	O
blood	O
platelets	O
which	O
can	O
result	O
from	O
a	O
variety	O
of	O
causes	O
,	O
such	O
as	O
kaposi	other-disease
sarcoma	other-disease
.	O

On	O
October	O
23	O
,	O
2020	O
,	O
an	O
article	O
from	O
The	O
Denver	O
Post	O
revealed	O
that	O
in	O
late	O
September	O
2020	O
,	O
Moor	O
had	O
taken	O
up	O
a	O
temporary	O
roll	O
as	O
a	O
player-coach	O
with	O
Colorado	O
amid	O
a	O
COVID-19	other-disease
outbreak	O
that	O
left	O
the	O
entire	O
coaching	O
staff	O
unavailable	O
.	O

It	O
was	O
notable	O
for	O
featuring	O
the	O
first	O
use	O
of	O
fireworks	O
at	O
the	O
site	O
since	O
2008	O
and	O
for	O
being	O
held	O
amid	O
the	O
ongoing	O
COVID-19	other-disease
pandemic	O
.	O

Beyond	O
that	O
,	O
however	O
,	O
clinicians	O
generally	O
treat	O
to	O
avoid	O
thrombosis	other-disease
.	O

Oncogenic	O
PKC-iota	O
can	O
promote	O
melanoma	other-disease
cell	O
invasion	O
by	O
up-regulating	O
PKC-ι	O
/	O
Par6	O
pathway	O
during	O
EMT	O
.	O

Adrenocortical	other-disease
carcinoma	other-disease
is	O
remarkable	O
for	O
the	O
many	O
hormonal	O
syndromes	O
that	O
can	O
occur	O
in	O
patients	O
with	O
steroid	O
hormone	O
-producing	O
(	O
``	O
functional	O
''	O
)	O
tumors	O
,	O
including	O
Cushing	other-disease
's	other-disease
syndrome	other-disease
,	O
Conn	other-disease
syndrome	other-disease
,	O
virilization	O
,	O
and	O
feminization	O
.	O

Septic	other-disease
shock	other-disease
is	O
a	O
result	O
of	O
a	O
systemic	O
response	O
to	O
infection	O
or	O
multiple	O
infectious	O
causes	O
.	O

Decreases	O
in	O
GFAP	O
expression	O
have	O
been	O
reported	O
in	O
Down	other-disease
's	other-disease
syndrome	other-disease
,	O
schizophrenia	other-disease
,	O
bipolar	other-disease
disorder	other-disease
and	O
depression	other-disease
.	O

On	O
April	O
2	O
,	O
Ayaka	O
's	O
diagnosis	O
of	O
Graves	other-disease
'	other-disease
disease	other-disease
was	O
made	O
public	O
.	O

New	O
evidence	O
is	O
showing	O
an	O
increased	O
risk	O
for	O
late	O
onset	O
Type	other-disease
1	other-disease
diabetes	other-disease
in	O
Heterozygotes	O
(	O
which	O
includes	O
ambiguous	O
Type	other-disease
I/Type	other-disease
II	other-disease
diabetes	other-disease
)	O
.	O

Ernst	O
caught	O
diphtheria	other-disease
as	O
a	O
child	O
of	O
seven	O
,	O
and	O
drew	O
and	O
painted	O
during	O
his	O
long	O
convalescence	O
.	O

Implicit	O
cognition	O
plays	O
a	O
strong	O
role	O
for	O
patients	O
with	O
both	O
bipolar	other-disease
and	other-disease
unipolar	other-disease
disorder	other-disease
.	O

The	O
condition	O
causes	O
a	O
functional	other-disease
blindness	other-disease
to	O
subtle	O
non-verbal	O
social-emotional	O
cues	O
in	O
voice	O
,	O
gesture	O
,	O
and	O
facial	O
expression	O
.	O

The	O
song	O
was	O
recorded	O
to	O
bring	O
hope	O
to	O
Isla	O
and	O
Jude	O
;	O
two	O
young	O
Australian	O
siblings	O
suffering	O
from	O
the	O
rare	O
and	O
fatal	O
disease	O
Sanfilippo	other-disease
Syndrome	other-disease
.	O

documented	O
the	O
cumulative	O
risk	O
for	O
bulimia	other-disease
nervosa	other-disease
for	O
those	O
born	O
before	O
1950	O
,	O
from	O
1950	O
to	O
1959	O
,	O
and	O
after	O
1959	O
.	O

The	O
alpha-1	O
fraction	O
does	O
not	O
disappear	O
in	O
alpha	other-disease
1-antitrypsin	other-disease
deficiency	other-disease
,	O
however	O
,	O
because	O
other	O
proteins	O
,	O
including	O
alpha-lipoprotein	O
and	O
orosomucoid	O
,	O
also	O
migrate	O
there	O
.	O

In	O
2000	O
,	O
a	O
70-year-old	O
man	O
presented	O
with	O
akinetopsia	other-disease
.	O

At	O
that	O
time	O
,	O
there	O
was	O
a	O
large	O
epidemic	other-disease
of	other-disease
Typhoid	other-disease
fever	other-disease
in	O
Serbia	O
caused	O
by	O
interaction	O
with	O
the	O
Austro-Hungarian	O
soldiers	O
.	O

The	O
short-term	O
effects	O
are	O
explained	O
by	O
a	O
hypothesis	O
that	O
states	O
that	O
depression	other-disease
is	O
acutely	O
brought	O
on	O
by	O
an	O
immediate	O
decrease	O
in	O
catecholamines	O
in	O
the	O
brain	O
.	O

Arthur	O
J.	O
Ammann	O
(	O
born	O
August	O
12	O
,	O
1936	O
)	O
is	O
a	O
pediatric	O
immunologist	O
and	O
advocate	O
known	O
for	O
his	O
research	O
on	O
HIV	other-disease
transmission	O
and	O
his	O
role	O
in	O
the	O
development	O
of	O
the	O
first	O
successful	O
vaccine	O
to	O
prevent	O
pneumococcal	O
infection	O
in	O
1977	O
.	O

Proteinuria	O
is	O
usually	O
the	O
first	O
sign	O
of	O
kidney	O
involvement	O
and	O
either	O
rapidly	O
or	O
years	O
after	O
suffering	O
from	O
asymptomatic	O
deposition	O
of	O
protein	O
in	O
the	O
urine	O
,	O
kidney	O
failure	O
occurs	O
in	O
around	O
5	O
%	O
of	O
NPS	other-disease
patients	O
.	O

In	O
breast	other-disease
cancer	other-disease
brachyury	O
expression	O
is	O
associated	O
with	O
recurrence	O
,	O
metastasis	O
and	O
reduced	O
survival	O
.	O

Obstructive	O
(	O
OSA	other-disease
)	O
is	O
the	O
most	O
common	O
form	O
.	O

Initially	O
there	O
is	O
a	O
precursor	O
lesion	O
called	O
serous	other-disease
endometrial	other-disease
intraepithelial	other-disease
carcinoma	other-disease
.Mutation	O
is	O
found	O
in	O
TP53	O
gene	O
which	O
is	O
a	O
tumor	O
suppressor	O
gene	O
even	O
in	O
precursor	O
lesion	O
suggesting	O
early	O
involvement	O
of	O
this	O
gene	O
.	O

In	O
February	O
1700	O
,	O
Havers	O
reported	O
to	O
the	O
Royal	O
Society	O
on	O
a	O
Chinese	O
practice	O
of	O
smallpox	other-disease
inoculation	O
,	O
which	O
involved	O
inhaling	O
dried	O
matter	O
from	O
a	O
smallpox	other-disease
pustule	O
.	O

Seven	O
cholera	other-disease
pandemics	other-disease
have	O
occurred	O
in	O
the	O
past	O
200	O
years	O
,	O
with	O
the	O
first	O
pandemic	other-disease
originating	other-disease
in	O
India	O
in	O
1817	O
.	O

Individuals	O
with	O
Pitt–Hopkins	other-disease
syndrome	other-disease
typically	O
have	O
a	O
happy	O
,	O
excitable	O
demeanor	O
with	O
frequent	O
smiling	O
and	O
laughter	O
.	O

A	O
few	O
individuals	O
carry	O
a	O
mutation	O
known	O
as	O
CCR5-Δ32	O
in	O
the	O
CCR5	O
gene	O
,	O
protecting	O
them	O
against	O
these	O
strains	O
of	O
HIV	other-disease
.	O

In	O
2005	O
,	O
a	O
field	O
evaluation	O
of	O
a	O
novel	O
handheld	O
microscope	O
was	O
undertaken	O
in	O
Uganda	O
for	O
the	O
diagnosis	O
of	O
intestinal	other-disease
schistosomiasis	other-disease
by	O
a	O
team	O
led	O
by	O
Russell	O
Stothard	O
from	O
the	O
Natural	O
History	O
Museum	O
of	O
London	O
,	O
working	O
with	O
the	O
Schistosomiasis	O
Control	O
Initiative	O
,	O
London	O
.	O

Beginning	O
in	O
Colombia	O
,	O
smallpox	other-disease
spread	O
rapidly	O
before	O
the	O
Spanish	O
invaders	O
first	O
arrived	O
in	O
the	O
empire	O
.	O

Large	O
,	O
swollen	O
conchae	O
,	O
often	O
referred	O
to	O
clinically	O
as	O
turbinates	O
,	O
may	O
lead	O
to	O
blockage	O
of	O
nasal	other-disease
breathing	other-disease
.	O

The	O
Organization	O
(	O
2016	O
)	O
also	O
termed	O
a	O
third	O
type	O
of	O
intestinal	other-disease
T	other-disease
cell	other-disease
lymphoma	other-disease
that	O
could	O
not	O
be	O
classified	O
as	O
ATL	other-disease
or	O
MEITL	other-disease
as	O
intestinal	other-disease
T	other-disease
cell	other-disease
lymphoma	other-disease
,	O
not	O
otherwise	O
specified	O
.	O

Trinucleotide	other-disease
repeat	other-disease
disorders	other-disease
also	O
follow	O
a	O
non-Mendelian	O
pattern	O
of	O
inheritance	O
.	O

There	O
is	O
research	O
showing	O
that	O
in	O
people	O
with	O
gluten	other-disease
ataxia	other-disease
early	O
diagnosis	O
and	O
treatment	O
with	O
a	O
gluten	other-disease
-free	O
diet	O
can	O
improve	O
ataxia	O
and	O
prevent	O
its	O
progression	O
.	O

Plaque-induced	other-disease
gingivitis	other-disease
and	O
the	O
more	O
severe	O
stage	O
plaque	O
induced	O
periodontitis	other-disease
are	O
the	O
most	O
common	O
of	O
the	O
periodontal	O
diseases	O
.	O

Patients	O
can	O
relapse	O
even	O
after	O
a	O
TCD	O
allogeneic	O
bone	O
marrow	O
transplant	O
,	O
though	O
patients	O
with	O
chronic	other-disease
myelogenous	other-disease
leukemia	other-disease
(	O
CML	other-disease
)	O
who	O
receive	O
a	O
donor	O
lymphocyte	O
infusion	O
(	O
DLI	O
)	O
can	O
restore	O
complete	O
remission	O
.	O

Herpes	other-disease
simplex	O
is	O
a	O
double-stranded	O
DNA	O
virus	O
.	O

A	O
meta-analysis	O
of	O
the	O
psychological	O
treatment	O
of	O
obesity	other-disease
in	O
children	O
and	O
adolescents	O
found	O
family-based	O
behavioral	O
treatment	O
(	O
FBT	O
)	O
and	O
Parent-Only	O
Behavior	O
treatment	O
to	O
be	O
the	O
most	O
effective	O
practices	O
in	O
treating	O
obesity	O
in	O
children	O
within	O
a	O
psychological	O
framework	O
.	O

Some	O
symptoms	O
of	O
BFLS	other-disease
are	O
discernible	O
at	O
birth	O
,	O
but	O
they	O
develop	O
over	O
time	O
.	O

Copps	O
continued	O
as	O
mayor	O
until	O
1976	O
when	O
he	O
was	O
forced	O
to	O
retire	O
following	O
a	O
heart	other-disease
attack	other-disease
while	O
running	O
in	O
the	O
Around	O
the	O
Bay	O
Road	O
Race	O
.	O

About	O
6	O
%	O
of	O
people	O
have	O
insomnia	other-disease
that	O
is	O
not	O
due	O
to	O
another	O
problem	O
and	O
lasts	O
for	O
more	O
than	O
a	O
month	O
.	O

They	O
may	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
diplopia	other-disease
(	O
double	other-disease
vision	other-disease
)	O
,	O
asthenopia	other-disease
(	O
eye	O
strain	O
)	O
,	O
transient	other-disease
blurred	other-disease
vision	other-disease
,	O
difficulty	other-disease
sustaining	other-disease
near-visual	other-disease
function	other-disease
,	O
abnormal	other-disease
fatigue	other-disease
,	O

HCM	other-disease
is	O
most	O
commonly	O
inherited	O
from	O
a	O
person	O
's	O
parents	O
in	O
an	O
autosomal	O
dominant	O
pattern	O
.	O

Nodular	other-disease
vasculitis	other-disease
is	O
a	O
skin	O
condition	O
characterized	O
by	O
small	O
,	O
tender	O
,	O
reddened	O
nodules	O
on	O
the	O
legs	O
,	O
mostly	O
on	O
the	O
calves	O
and	O
shins	O
.	O

Plasma	O
fibronectin	O
levels	O
are	O
decreased	O
in	O
acute	O
inflammation	O
or	O
following	O
surgical	O
trauma	O
and	O
in	O
patients	O
with	O
disseminated	other-disease
intravascular	other-disease
coagulation	other-disease
.	O

The	O
vine	O
ripens	O
late	O
and	O
is	O
susceptible	O
to	O
many	O
grape	O
diseases	O
including	O
oidium	other-disease
.	O

Biotron	O
develops	O
novel	O
small	O
molecule	O
antiviral	O
therapeutics	O
targeting	O
Hepatitis	other-disease
C	other-disease
and	O
HIV	O
.	O

Barotrauma	other-disease
generally	O
manifests	O
as	O
sinus	other-disease
or	O
middle	other-disease
ear	other-disease
effects	other-disease
,	O
decompression	other-disease
sickness	other-disease
(	O
DCS	other-disease
)	O
,	O
lung	other-disease
overpressure	other-disease
injuries	other-disease
and	O
injuries	O
resulting	O
from	O
external	O
squeezes	O
.	O

Signs	O
and	O
symptoms	O
of	O
hemolytic	other-disease
anemia	other-disease
may	O
include	O
:	O

However	O
,	O
due	O
to	O
2019-20	O
pandemic	O
of	O
Coronavirus	other-disease
,	O
the	O
contest	O
was	O
cancelled	O
.	O

``	O
Up	O
to	O
70	O
percent	O
of	O
men	O
with	O
prostate	other-disease
cancer	other-disease
have	O
lost	O
one	O
copy	O
of	O
the	O
``	O
PTEN	O
``	O
gene	O
at	O
the	O
time	O
of	O
diagnosis	O
''	O
.	O

The	O
Flight	O
112	O
incident	O
was	O
one	O
of	O
the	O
several	O
superspreading	O
events	O
that	O
contributed	O
to	O
the	O
dissemination	O
of	O
the	other-disease
SARS	other-disease
virus	other-disease
in	O
2003	O
.	O

The	O
endoscopic	O
appearance	O
of	O
GAVE	other-disease
is	O
similar	O
to	O
portal	other-disease
hypertensive	other-disease
gastropathy	other-disease
,	O
but	O
is	O
not	O
the	O
same	O
condition	O
,	O
and	O
may	O
be	O
concurrent	O
with	O
cirrhosis	O
of	O
the	O
liver	O
.	O

The	O
exophoria	other-disease
at	O
near	O
often	O
recurs	O
after	O
several	O
years	O
,	O
although	O
most	O
patients	O
remain	O
asymptomatic	O
.	O

Mutational	O
defects	O
in	O
the	O
``	O
Ercc5	O
``	O
(	O
``	O
Xpg	O
``	O
)	O
gene	O
can	O
cause	O
either	O
the	O
cancer-prone	other-disease
condition	other-disease
xeroderma	other-disease
pigmentosum	other-disease
(	other-disease
XP	other-disease
)	other-disease
alone	other-disease
,	O
or	O
in	O
combination	O
with	O
the	O
severe	other-disease
neurodevelopmental	other-disease
disorder	other-disease
Cockayne	other-disease
syndrome	other-disease
(	O
CS	other-disease
)	O
or	O
the	O
infantile	other-disease
lethal	other-disease
cerebro-oculo-facio-skeletal	other-disease
syndrome	other-disease
.	O

The	O
observation	O
that	O
DFNA5	O
is	O
epigenetically	O
inactivated	O
in	O
a	O
large	O
number	O
of	O
cancers	O
of	O
frequent	O
types	O
(	O
gastric	other-disease
,	O
colorectal	other-disease
,	O
and	O
breast	other-disease
)	O
is	O
another	O
important	O
finding	O
and	O
is	O
in	O
line	O
with	O
its	O
apoptosis-inducing	O
properties	O
.	O

The	O
term	O
``	O
fibromyalgia	other-disease
``	O
is	O
from	O
New	O
Latin	O
``	O
fibro-	O
''	O
,	O
meaning	O
``	O
fibrous	O
tissues	O
''	O
,	O
Greek	O
μυώ	O
``	O
myo-	O
''	O
,	O
``	O
muscle	O
''	O
,	O
and	O
Greek	O
άλγος	O
``	O
algos	O
''	O
,	O
``	O
pain	O
''	O
;	O
thus	O
,	O
the	O
term	O
literally	O
means	O
``	O
muscle	O
and	O
fibrous	O
connective	O
tissue	O
pain	O
''	O
.	O

Ten	O
years	O
later	O
that	O
number	O
increased	O
to	O
more	O
than	O
430,000	O
as	O
a	O
result	O
of	O
chronic	O
conditions	O
developing	O
such	O
as	O
diabetes	other-disease
and	O
hypertension	other-disease
.	O

The	O
exact	O
cause	O
of	O
desquamative	other-disease
gingivitis	other-disease
can	O
not	O
be	O
determined	O
about	O
a	O
third	O
of	O
cases	O
.	O

It	O
is	O
used	O
as	O
a	O
topical	O
cream	O
against	O
fungal	O
skin	O
infections	O
,	O
including	O
``	O
Trichophyton	other-disease
mentagrophytes	other-disease
``	O
,	O
``	O
T.	other-disease
rubrum	other-disease
``	O
,	O
``	O
Epidermophyton	other-disease
floccosum	other-disease
``	O
and	O
``	O
Candida	other-disease
albicans	other-disease
``	O
.	O

The	O
new	O
corporate	O
entity	O
was	O
scheduled	O
to	O
launch	O
on	O
1	O
June	O
2020	O
but	O
due	O
to	O
the	O
COVID-19	other-disease
pandemic	O
it	O
was	O
postponed	O
and	O
did	O
n't	O
officially	O
came	O
into	O
existence	O
until	O
10	O
July	O
2020	O
.	O

Kenneth	O
Levin	O
,	O
a	O
Harvard	O
psychiatrist	O
,	O
says	O
that	O
Jewish	O
self-hatred	O
has	O
two	O
causes	O
:	O
Stockholm	other-disease
syndrome	other-disease
,	O
where	O
``	O
population	O
segments	O
under	O
chronic	O
siege	O
commonly	O
embrace	O
the	O
indictments	O
of	O
their	O
besiegers	O
however	O
bigoted	O
and	O
outrageous	O
''	O
,	O
as	O
well	O
as	O
``	O
the	O
psychodynamics	O
of	O
abused	O
children	O
,	O
who	O
almost	O
invariably	O
blame	O
themselves	O
for	O
their	O
predicament	O
,	O
ascribe	O
it	O
to	O
their	O
being	O
``	O
bad	O
,	O
''	O
and	O
nurture	O
fantasies	O
that	O
by	O
becoming	O
``	O
good	O
''	O
they	O
can	O
mollify	O
their	O
abusers	O
and	O
end	O
their	O
torment	O
.	O
''	O

Based	O
on	O
this	O
research	O
,	O
Merck	O
developed	O
an	O
important	O
antiprotease	O
drug	O
for	O
the	O
treatment	O
of	O
AIDS	other-disease
.	O

In	O
Morquio	other-disease
syndrome	other-disease
,	O
the	O
specific	O
GAG	O
which	O
builds	O
up	O
in	O
the	O
body	O
is	O
called	O
keratan	O
sulfate	O
.	O

He	O
documented	O
the	O
importance	O
of	O
theta-to-beta	O
ratios	O
in	O
ADHD	other-disease
and	O
developed	O
theta	O
suppression-beta	O
enhancement	O
protocols	O
to	O
decrease	O
these	O
ratios	O
and	O
improve	O
student	O
performance	O
.	O

Amantadine	O
was	O
first	O
used	O
for	O
the	O
treatment	O
of	O
influenza	other-disease
A	other-disease
.	O

Hypertrophic	other-disease
cardiomyopathy	other-disease
involves	O
enlargement	O
and	O
``	O
thickening	O
''	O
of	O
the	O
heart	O
muscle	O
.	O

In	O
the	O
United	O
States	O
,	O
chlorination	O
of	O
the	O
water	O
kills	O
Hepatitis	other-disease
A	other-disease
virus	O
that	O
enters	O
the	O
water	O
supply	O
.	O

Hemoglobin	O
analysis	O
is	O
important	O
for	O
the	O
diagnosis	O
of	O
alpha-thalassemia	other-disease
as	O
it	O
determines	O
the	O
types	O
and	O
percentages	O
of	O
types	O
of	O
hemoglobin	O
present	O
.	O

Njølstad	other-disease
syndrom	other-disease
e	O
is	O
a	O
syndrome	O
characterized	O
by	O
non-immune	other-disease
hydrops	other-disease
fetalis	other-disease
(	O
NIHF	other-disease
)	O
,	O
congenital	other-disease
pulmonary	other-disease
lymphangiectasia	other-disease
(	O
CPL	other-disease
)	O
.	O

Genetic	O
disorder	O
of	O
the	O
ATP7B	O
gene	O
may	O
cause	O
Wilson	other-disease
's	other-disease
disease	other-disease
,	O
a	O
disease	O
in	O
which	O
copper	O
accumulates	O
in	O
tissues	O
,	O
leading	O
to	O
neurological	O
or	O
psychiatric	O
issues	O
and	O
liver	O
diseases	O
.	O

In	O
the	O
older	O
girl	O
the	O
genitalia	O
were	O
large	O
enough	O
at	O
the	O
age	O
of	O
6	O
months	O
to	O
permit	O
vaginal	O
examination	O
for	O
diagnosis	O
of	O
a	O
left	other-disease
ovarian	other-disease
tumor	other-disease
which	O
was	O
removed	O
soon	O
afterward	O
.	O

Alpha-fetoprotein	O
,	O
human	O
chorionic	O
gonadotropin	O
(	O
the	O
``	O
pregnancy	O
hormone	O
``	O
)	O
,	O
and	O
LDH-1	O
are	O
the	O
typical	O
tumor	O
markers	O
used	O
to	O
spot	O
testicular	O
germ	O
cell	O
tumors	other-disease
.	O

Thus	O
,	O
diarrhea	other-disease
can	O
be	O
categorized	O
into	O
secretory	other-disease
diarrhea	other-disease
,	O
an	O
excess	other-disease
of	other-disease
secretion	other-disease
,	O
or	O
osmotic	other-disease
diarrhea	other-disease
which	O
is	O
a	O
lack	O
of	O
absorption	O
.	O

QT	other-disease
prolongation	other-disease
is	O
detectable	O
but	O
was	O
considered	O
to	O
be	O
too	O
low	O
to	O
be	O
of	O
clinical	O
importance	O
in	O
a	O
study	O
.	O

In	O
2012	O
,	O
she	O
announced	O
that	O
she	O
is	O
suffering	O
from	O
idiopathic	other-disease
thrombocytopenic	other-disease
purpura	other-disease
and	O
systemic	other-disease
lupus	other-disease
erythematosus	other-disease
.	O

The	O
formation	O
of	O
coronary	other-disease
thrombosis	other-disease
generally	O
follows	O
the	O
same	O
mechanism	O
as	O
other	O
blood	O
clots	O
in	O
the	O
body	O
,	O
the	O
coagulation	O
cascade	O
.	O

Paraplegia	other-disease
is	O
an	O
impairment	O
in	O
motor	O
or	O
sensory	O
function	O
of	O
the	O
lower	O
extremities	O
.	O

Distal	other-disease
intestinal	other-disease
obstruction	other-disease
syndrome	other-disease
(	O
DIOS	other-disease
)	O
involves	O
obstruction	O
of	O
the	O
distal	O
part	O
of	O
the	O
small	O
intestines	O
by	O
thickened	O
intestinal	O
content	O
and	O
occurs	O
in	O
about	O
20	O
%	O
of	O
mainly	O
adult	O
individuals	O
with	O
cystic	other-disease
fibrosis	other-disease
.	O

World	O
War	O
I	O
's	O
impact	O
on	O
colleges	O
in	O
the	O
country	O
,	O
and	O
the	O
Spanish	other-disease
flu	other-disease
pandemic	other-disease
of	O
1918	O
eliminated	O
most	O
of	O
that	O
year	O
's	O
scheduled	O
college	O
football	O
games	O
.	O

``	O
He	O
first	O
advanced	O
the	O
term	O
schizophrenia	other-disease
in	O
1908	O
in	O
a	O
paper	O
based	O
on	O
a	O
study	O
of	O
647	O
Burghölzli	O
patients	O
.	O

The	O
term	O
blepharospasm	other-disease
[	O
'blef-a-ro-spaz-m	O
]	O
can	O
be	O
applied	O
to	O
any	O
abnormal	O
blinking	O
or	O
eyelid	O
tic	O
or	O
twitch	O
resulting	O
from	O
any	O
cause	O
,	O
ranging	O
from	O
dry	other-disease
eyes	other-disease
to	O
Tourette	other-disease
's	other-disease
syndrome	other-disease
to	O
tardive	other-disease
dyskinesia	other-disease
.	O

Ovarian	other-disease
cancer	other-disease
is	O
a	O
cancer	O
that	O
forms	O
in	O
or	O
on	O
an	O
ovary	O
.	O

Vaccinations	O
were	O
required	O
for	O
“	O
nine	O
‘	O
vaccine-preventable	O
diseases	O
’	O
”	O
including	O
:	O
“	O
mumps	other-disease
,	O
measles	other-disease
,	O
rubella	other-disease
,	O
polio	other-disease
,	O
tetanus	other-disease
and	O
diphtheria	other-disease
toxoids	other-disease
,	O
pertussis	other-disease
,	O
influenza	other-disease
type	other-disease
B	other-disease
and	O
hepatitis	other-disease
B	other-disease
”	O
.	O

The	O
risk	O
,	O
however	O
,	O
varies	O
depending	O
on	O
the	O
degree	O
of	O
hyperuricemia	other-disease
.	O

The	O
Panic	O
and	O
Agoraphobia	O
Scale	O
(	O
PAS	O
)	O
is	O
a	O
rating	O
scale	O
developed	O
for	O
measuring	O
severity	O
of	O
agoraphobia	other-disease
with	O
or	O
without	O
panic	O
attacks	O
.	O

Transient	other-disease
myeloproliferative	other-disease
disease	O
is	O
the	O
abnormal	O
proliferation	O
of	O
a	O
clone	O
of	O
noncancerous	O
megakaryoblasts	O
in	O
the	O
liver	O
and	O
bone	O
marrow	O
.	O

The	O
Cavaliers	O
struggled	O
in	O
their	O
next	O
two	O
seasons	O
,	O
finishing	O
19–63	O
in	O
2018–19	O
and	O
19–46	O
in	O
the	O
2019–20	O
season	O
prior	O
to	O
its	O
suspension	O
due	O
to	O
the	O
COVID-19	other-disease
pandemic	O
.	O

A	O
third	O
type	O
of	O
pituitary	other-disease
adenoma	other-disease
secretes	O
excess	O
ACTH	O
,	O
which	O
in	O
turn	O
,	O
causes	O
an	O
excess	O
of	O
cortisol	O
to	O
be	O
secreted	O
and	O
is	O
the	O
cause	O
of	O
Cushing	other-disease
's	O
disease	O
.	O

Cattle	other-disease
Tick	other-disease
is	O
the	O
largest	O
costing	O
disease	O
in	O
the	O
beef	O
industry	O
with	O
an	O
estimated	O
economical	O
impact	O
of	O
an	O
estimated	O
$	O
161	O
million	O
AUD	O
annually	O
.	O

Her	O
early	O
work	O
characterizing	O
the	O
role	O
of	O
the	O
histamine	O
receptor	O
on	O
mast	O
cells	O
has	O
now	O
become	O
relevant	O
to	O
the	O
context	O
of	O
cancer	other-disease
.	O

In	O
2020	O
,	O
the	O
bucket	O
was	O
widely	O
used	O
in	O
the	O
African	O
continent	O
and	O
the	O
global	O
community	O
to	O
fight	O
the	O
novel	O
pandemic	O
Coronavirus	other-disease
(	O
COVID-19	other-disease
)	O
or	O
SARS-COV-2	other-disease
.	O

Separation	other-disease
anxiety	other-disease
disorder	other-disease
(	O
SAD	other-disease
)	O
is	O
the	O
most	O
common	O
anxiety	O
disorder	O
in	O
children	O
which	O
is	O
characterized	O
by	O
an	O
“	O
excessive	O
fear	O
response	O
to	O
real	O
or	O
imagined	O
separation	O
from	O
a	O
caregiver	O
”	O
.	O

There	O
are	O
many	O
purported	O
remedies	O
for	O
shin-bang	other-disease
.	O

Atrophic	other-disease
candidiasis	other-disease
appears	O
as	O
thin	O
,	O
atrophic	O
epithelium	O
,	O
which	O
is	O
non-keratinized	O
.	O

In	O
light	O
of	O
this	O
life-threatening	O
complication	O
,	O
all	O
suspected	O
cases	O
of	O
botulism	other-disease
are	O
treated	O
as	O
medical	O
emergencies	O
,	O
and	O
public	O
health	O
officials	O
are	O
usually	O
involved	O
to	O
identify	O
the	O
source	O
and	O
take	O
steps	O
to	O
prevent	O
further	O
cases	O
from	O
occurring	O
.	O

In	O
addition	O
to	O
the	O
genetic	O
associations	O
,	O
the	O
HLA	O
haplotype	O
A2B40	O
is	O
also	O
a	O
genetic	O
predisposition	O
to	O
PSP	other-disease
.	O

Survivors	O
with	O
global	other-disease
aphasia	other-disease
may	O
have	O
great	O
difficulty	O
understanding	O
and	O
forming	O
words	O
and	O
sentences	O
,	O
and	O
generally	O
experience	O
a	O
great	O
deal	O
of	O
difficulty	O
when	O
trying	O
to	O
communicate	O
.	O

In	O
2002	O
,	O
763,917	O
new	O
cases	O
were	O
detected	O
worldwide	O
,	O
and	O
in	O
that	O
year	O
the	O
WHO	O
listed	O
India	O
,	O
Brazil	O
,	O
Madagascar	O
,	O
Mozambique	O
,	O
Tanzania	O
and	O
Nepal	O
as	O
having	O
90	O
%	O
of	O
Hansen	other-disease
's	other-disease
disease	other-disease
cases	O
.	O

Production	O
loss	O
and	O
prevention	O
efforts	O
are	O
the	O
largest	O
costs	O
associated	O
with	O
Pestivirus	other-disease
(	O
BVDV	other-disease
)	O
.	O

From	O
1958–1983	O
there	O
were	O
986	O
outbreaks	O
of	O
botulism	other-disease
in	O
China	O
involving	O
4,377	O
people	O
with	O
548	O
deaths	O
.	O

Swine	other-disease
flu	other-disease
is	O
one	O
of	O
many	O
diseases	O
that	O
are	O
contracted	O
by	O
person	O
to	O
person	O
contact	O
.	O

Estimates	O
for	O
the	O
incidence	O
of	O
androgen	other-disease
insensitivity	other-disease
syndrome	other-disease
are	O
based	O
on	O
a	O
relatively	O
small	O
population	O
size	O
,	O
thus	O
are	O
known	O
to	O
be	O
imprecise	O
.	O

The	O
Japanese	O
Imperial	O
Army	O
's	O
Noborito	O
Institute	O
cultivated	O
anthrax	other-disease
and	O
``	other-disease
Yersinia	other-disease
pestis	other-disease
''	other-disease
;	O
furthermore	O
,	O
it	O
produced	O
enough	O
cowpox	other-disease
viruses	other-disease
to	O
infect	O
the	O
entire	O
United	O
States	O
.	O

PKHD1	other-disease
is	O
involved	O
.	O

Most	O
cases	O
of	O
plantar	other-disease
fasciitis	other-disease
resolve	O
with	O
time	O
and	O
conservative	O
methods	O
of	O
treatment	O
.	O

Second	O
,	O
partial	O
STAT1	O
deficiency	O
can	O
also	O
be	O
an	O
autosomal	O
dominant	O
mutation	O
;	O
phenotypically	O
causing	O
impaired	O
IFNg	O
responses	O
and	O
causing	O
patients	O
to	O
suffer	O
with	O
selective	other-disease
intracellular	other-disease
bacterial	other-disease
diseases	other-disease
(	O
MSMD	other-disease
)	O

By	O
contrast	O
,	O
in	O
colon	other-disease
cancer	other-disease
hedgehog	O
signalling	O
appears	O
to	O
antagonise	O
Wnt	O
.	O

People	O
with	O
Geschwind	other-disease
syndrome	other-disease
reported	O
higher	O
rates	O
of	O
atypical	O
or	O
altered	O
sexuality	O
.	O

This	O
GTPase	O
protein	O
domain	O
is	O
found	O
in	O
all	O
eukaryotic	O
tubulin	O
chains	O
,	O
as	O
well	O
as	O
the	O
bacterial	O
protein	O
TubZ	O
,	O
the	O
archaeal	O
protein	O
CetZ	O
,	O
and	O
the	O
FtsZ	O
protein	O
family	O
widespread	O
in	O
Bacteria	other-disease
and	O
Archaea	other-disease
.	O

Severe	O
bite	O
from	O
larger	O
species	O
may	O
cause	O
a	O
dangerous	O
and	O
life-threatening	O
anaphylaxis	other-disease
if	O
not	O
treated	O
.	O

For	O
women	O
with	O
PKU	other-disease
,	O
it	O
is	O
important	O
for	O
the	O
health	O
of	O
their	O
children	O
to	O
maintain	O
low	O
Phe	O
levels	O
before	O
and	O
during	O
pregnancy	O
.	O

Mann	O
died	O
in	O
the	O
crash	O
of	O
Swissair	O
Flight	O
111	O
in	O
1998	O
along	O
with	O
his	O
second	O
wife	O
,	O
AIDS	other-disease
researcher	O
Mary	O
Lou	O
Clements-Mann	O
.	O

Compartment	other-disease
syndrome	other-disease
is	O
a	O
condition	O
in	O
which	O
increased	O
pressure	O
within	O
one	O
of	O
the	O
body	O
's	O
anatomical	O
compartments	O
results	O
in	O
insufficient	O
blood	O
supply	O
to	O
tissue	O
within	O
that	O
space	O
.	O

It	O
is	O
used	O
for	O
treatment	O
of	O
acute	other-disease
lymphoblastic	other-disease
leukemia	other-disease
and	O
Chronic	other-disease
myelogenous	other-disease
leukemia	other-disease
in	O
blast	other-disease
crisis	other-disease
.	O

This	O
virulence	O
factor	O
induces	O
vomiting	O
and	O
has	O
been	O
associated	O
with	O
food	other-disease
posioning	other-disease
in	O
humans	O
.	O

In	O
contrast	O
with	O
hyp	other-disease
''	other-disease
er	other-disease
''	other-disease
hidrosis	other-disease
,	O
which	O
is	O
a	O
socially	O
troubling	O
yet	O
often	O
benign	O
condition	O
,	O
the	O
consequences	O
of	O
untreated	O
hypohidrosis	other-disease
include	O
hyperthermia	O
,	O
heat	O
stroke	O
and	O
death	O
.	O

In	O
February	O
2008	O
,	O
Erie	O
County	O
experienced	O
a	O
potential	O
Hepatitis	other-disease
A	other-disease
emergency	O
when	O
an	O
infected	O
employee	O
handled	O
produce	O
at	O
a	O
popular	O
supermarket	O
.	O

Watsu	O
has	O
been	O
proposed	O
as	O
a	O
therapy	O
for	O
fibromyalgia	other-disease
syndrome	other-disease
,	O
and	O
for	O
rehabilitating	O
patients	O
after	O
a	O
stroke	other-disease
.	O

While	O
viruses	O
are	O
associated	O
with	O
less	O
than	O
20	O
%	O
of	O
adult	O
cases	O
of	O
travelers	O
'	O
diarrhea	other-disease
,	O
they	O
may	O
be	O
responsible	O
for	O
nearly	O
70	O
%	O
of	O
cases	O
in	O
infants	O
and	O
children	O
.	O

The	O
symptoms	O
of	O
a	O
Staph	O
Infection	O
include	O
a	O
collection	other-disease
of	other-disease
pus	other-disease
,	O
such	O
as	O
a	O
boil	other-disease
or	O
furuncle	other-disease
,	O
or	O
a	O
bscess	other-disease
.	O

Babies	O
with	O
BFLS	other-disease
are	O
born	O
at	O
normal	O
weight	O
but	O
have	O
muscle	O
hypotonia	O
and	O
difficulty	O
feeding	O
.	O

The	O
symptoms	O
to	O
dysgraphia	other-disease
are	O
often	O
overlooked	O
or	O
attributed	O
to	O
the	O
student	O
being	O
lazy	O
,	O
unmotivated	O
,	O
not	O
caring	O
,	O
or	O
having	O
delayed	O
visual-motor	O
processing	O
.	O

OCD	other-disease
is	O
sometimes	O
considered	O
an	O
anxiety	O
disorder	O
.	O

Diarrhea	other-disease
due	O
to	O
viral	O
agents	O
is	O
unaffected	O
by	O
antibiotic	O
therapy	O
,	O
but	O
is	O
usually	O
self-limited	O
.	O

Suffering	O
from	O
plantar	other-disease
fasciitis	other-disease
and	O
a	O
stress	other-disease
fracture	other-disease
,	O
Jennings	O
finished	O
last	O
in	O
the	O
marathon	O
at	O
the	O
2012	O
Olympics	O
in	O
a	O
time	O
of	O
3:22:11	O
,	O
an	O
hour	O
behind	O
winner	O
Tiki	O
Gelana	O
.	O

A	O
Dry	other-disease
cough	other-disease
is	O
a	O
persistent	O
cough	O
where	O
no	O
mucus	O
is	O
present	O
,	O
this	O
can	O
be	O
a	O
sign	O
of	O
an	O
infection	O
.	O

Cerebral	other-disease
palsy	other-disease
is	O
due	O
to	O
abnormal	O
development	O
or	O
damage	O
occurring	O
to	O
the	O
developing	O
brain	O
.	O

He	O
started	O
``	O
The	O
Wedge	O
``	O
,	O
a	O
``	O
safe	O
sex	O
''	O
AIDS	other-disease
prevention	O
organization	O
for	O
teens	O
in	O
San	O
Francisco	O
.	O

It	O
has	O
been	O
reported	O
that	O
diflunisal	other-disease
has	O
some	O
antibacterial	O
activity	O
``	O
in	O
vitro	O
``	O
against	O
``	O
Francisella	O
tularensis	O
``	O
live	O
vaccine	O
strain	O
(	O
LVS	O
)	O
.	O

Uterine	other-disease
fibroids	other-disease
are	O
benign	O
tumors	O
made	O
of	O
muscle	O
cells	O
and	O
other	O
tissues	O
located	O
in	O
and	O
around	O
the	O
wall	O
of	O
the	O
uterus	O
.	O

Healthy	O
eating	O
is	O
a	O
key	O
factor	O
in	O
wellness	O
,	O
and	O
prevention	O
of	O
chronic	O
diseases	O
,	O
such	O
as	O
diabetes	other-disease
,	O
obesity	other-disease
,	O
heart	other-disease
disease	other-disease
and	O
cancer	O
.	O

Andrea	O
died	O
in	O
Florence	O
at	O
age	O
44	O
during	O
an	O
outbreak	O
of	O
Bubonic	other-disease
Plague	other-disease
at	O
the	O
end	O
of	O
September	O
1530	O
.	O

In	O
Egypt	O
,	O
the	O
number	O
of	O
cases	O
of	O
neonatal	other-disease
tetanus	other-disease
dropped	O
from	O
4,000	O
to	O
fewer	O
than	O
500	O
annually	O
as	O
the	O
result	O
of	O
an	O
immunisation	O
campaign	O
.	O

The	O
types	O
of	O
Emery–Dreifuss	other-disease
muscular	other-disease
dystrophy	other-disease
are	O
distinguished	O
by	O
their	O
pattern	O
of	O
inheritance	O
:	O
X-linked	O
,	O
autosomal	O
dominant	O
,	O
and	O
autosomal	O
recessive	O
.	O

This	O
effectively	O
divides	O
the	O
cataract	other-disease
into	O
four	O
quadrants	O
that	O
are	O
more	O
easily	O
removed	O
by	O
phacoemulsification	O
.	O

However	O
,	O
prolonged	O
or	O
repeated	O
skin	O
contact	O
may	O
cause	O
dermatitis	other-disease
.	O

However	O
,	O
PCOS	other-disease
and	O
idiopathic	other-disease
hirsutism	other-disease
make	O
up	O
90	O
%	O
of	O
cases	O
.	O

This	O
episode	O
is	O
considered	O
one	O
of	O
the	O
later	O
outbreaks	O
of	O
the	O
centuries-long	O
pandemic	O
of	O
bubonic	O
plague	O
that	O
began	O
with	O
the	O
Black	other-disease
Death	other-disease
.	O

Amyloid	O
beta	O
may	O
be	O
primarily	O
vascular	O
,	O
as	O
in	O
cerebral	other-disease
amyloid	other-disease
angiopathy	other-disease
,	O
or	O
in	O
senile	O
plaques	O
in	O
white	O
matter	O
.	O

Risk	O
factors	O
for	O
cardiomegaly	O
include	O
a	O
family	O
history	O
of	O
heart	other-disease
disease	other-disease
,	O
diabetes	other-disease
,	O
obesity	other-disease
,	O
hypertension	other-disease
,	O
history	O
of	O
alcohol	O
or	O
drug	O
abuse	O
,	O
the	O
lifestyle	O
that	O
consists	O
of	O
little	O
or	O
no	O
exercise	O
.	O

Unfortunately	O
,	O
the	O
kidneys	O
are	O
often	O
underdeveloped	O
resulting	O
in	O
a	O
30	O
%	O
death	O
rate	O
in	O
newborns	O
with	O
ARPKD	other-disease
.	O

PKC-ι	O
inhibition	O
or	O
knockdown	O
resulted	O
an	O
increase	O
E-cadherin	O
and	O
RhoA	O
levels	O
while	O
decreasing	O
total	O
Vimentin	O
,	O
phophorylated	O
Vimentin	O
(	O
S39	O
)	O
and	O
Par6	O
in	O
metastatic	O
melanoma	other-disease
cells	O
.	O

The	O
most	O
common	O
cause	O
of	O
expressive	other-disease
aphasia	other-disease
is	O
stroke	other-disease
.	O

Additionally	O
,	O
they	O
may	O
be	O
suffering	O
from	O
penile	other-disease
dysmorphophobia	other-disease
.	O

If	O
a	O
hemoglobin	O
tests	O
shows	O
that	O
a	O
person	O
's	O
levels	O
are	O
below	O
normal	O
,	O
it	O
means	O
they	O
have	O
a	O
low	O
red	O
blood	O
cell	O
count	O
,	O
which	O
is	O
known	O
as	O
anemia	other-disease
.	O

Bell	other-disease
's	other-disease
palsy	other-disease
is	O
characterized	O
by	O
a	O
one-sided	O
facial	O
droop	O
that	O
comes	O
on	O
within	O
72	O
hours	O
.	O

HLA-B15	other-disease
allele	other-disease
*	other-disease
1502	other-disease
is	O
associated	O
with	O
the	O
severe	O
skin	O
conditions	O
Stevens–Johnson	other-disease
syndrome	other-disease
(	O
SJS	other-disease
)	O
and	O
toxic	other-disease
epidermal	other-disease
necrolysis	other-disease
(	O
TEN	other-disease
)	O
caused	O
by	O
carbamazepine	O
drug	O
sensitivity	O
in	O
East	O
Asians	O
.	O

An	O
association	O
between	O
thyroid	other-disease
disease	other-disease
and	O
myasthenia	other-disease
gravis	other-disease
has	O
been	O
recognized	O
.	O

Graphic	O
designer	O
Baxter	O
Orr	O
did	O
his	O
own	O
take	O
on	O
Fairey	O
's	O
work	O
:	O
a	O
piece	O
called	O
Protect	O
,	O
with	O
the	O
iconic	O
Obey	O
Giant	O
face	O
covered	O
by	O
a	O
SARS	other-disease
(	O
respiratory	O
)	O
mask	O
.	O

Elephantiasis	other-disease
(	O
medically	O
known	O
as	O
Lymphatic	other-disease
filariasis	other-disease
)	O
is	O
a	O
disease	O
that	O
causes	O
extreme	O
swelling	O
of	O
limbs	O
often	O
in	O
the	O
legs	O
and	O
feet	O
.	O

Excited	O
catatonia	other-disease
is	O
characterized	O
by	O
bizarre	O
,	O
non–goal-directed	O
hyperactivity	O
and	O
impulsiveness	O
.	O

Gastroesophageal	other-disease
reflux	other-disease
disease	O
is	O
the	O
most	O
common	O
cause	O
of	O
heartburn	O
.	O

Between	O
10	O
%	O
to	O
20	O
%	O
of	O
heavy	O
drinkers	O
will	O
develop	O
cirrhosis	other-disease
of	O
the	O
liver	O
(	O
NIAAA	O
,	O
1993	O
)	O
.	O

There	O
is	O
controversy	O
about	O
the	O
classification	O
,	O
diagnosis	O
,	O
and	O
treatment	O
of	O
fibromyalgia	other-disease
.	O

Former	O
What	O
Now	O
host	O
,	O
Virginie	O
Le	O
Brun	O
was	O
announced	O
to	O
have	O
been	O
cast	O
as	O
the	O
over	O
achieving	O
doctor	O
with	O
Aspergers	other-disease
.	O

When	O
Mary	O
Vierra	O
contracted	O
tuberculosis	other-disease
in	O
her	O
youth	O
,	O
she	O
was	O
forced	O
to	O
convalesce	O
at	O
a	O
nearby	O
hospital	O
,	O
often	O
for	O
months	O
at	O
a	O
time	O
during	O
treatment	O
.	O

However	O
,	O
the	O
Pac-12	O
Tournament	O
,	O
along	O
with	O
all	O
postseason	O
tournaments	O
,	O
was	O
cancelled	O
amid	O
the	O
COVID-19	other-disease
pandemic	O
.	O

A	O
patient	O
with	O
GSD	other-disease
,	O
type	O
1b	O
was	O
treated	O
with	O
a	O
liver	O
transplant	O
at	O
UCSF	O
Medical	O
Center	O
in	O
1993	O
that	O
resulted	O
in	O
the	O
resolution	O
of	O
hypoglycemic	O
episodes	O
and	O
the	O
need	O
for	O
the	O
patient	O
to	O
stay	O
away	O
from	O
natural	O
sources	O
of	O
sugar	O
.	O

The	O
overall	O
5-year	O
survival	O
rate	O
for	O
follicular	other-disease
thyroid	other-disease
cancer	other-disease
is	O
91	O
%	O
,	O
and	O
the	O
10-year	O
survival	O
rate	O
is	O
85	O
%	O
.	O

The	O
BBC	O
later	O
reversed	O
the	O
decision	O
,	O
claiming	O
the	O
original	O
move	O
was	O
due	O
to	O
the	O
Coronavirus	other-disease
social-distancing	O
measures	O
,	O
and	O
that	O
they	O
would	O
now	O
be	O
sung	O
.	O

It	O
is	O
also	O
being	O
studied	O
in	O
the	O
treatment	O
of	O
other	O
types	O
of	O
cancer	O
,	O
such	O
as	O
lung	other-disease
cancer	other-disease
.	O

The	O
town	O
was	O
hit	O
by	O
the	O
Black	other-disease
Plague	other-disease
during	O
the	O
16th	O
and	O
17th	O
centuries	O
,	O
and	O
experienced	O
fires	O
in	O
1590	O
and	O
1610	O
.	O

These	O
features	O
likely	O
contribute	O
to	O
the	O
mild	O
immunodeficiency	O
seen	O
with	O
BENTA	other-disease
disease	O
.	O

Attention	other-disease
deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
(	O
ADHD	other-disease
)	O
is	O
common	O
in	O
this	O
population	O
,	O
and	O
children	O
with	O
the	O
disorder	O
may	O
also	O
engage	O
in	O
substance	O
abuse	O
.	O

It	O
contains	O
inactivated	O
purified	O
surface	O
fragments	O
(	O
subunits	O
)	O
from	O
the	O
three	O
different	O
strains	O
of	O
the	O
influenza	O
virus	O
(	O
A/H1N1	other-disease
,	O
A/H3N2	other-disease
,	O
and	O
Influenza	other-disease
B	other-disease
virus	other-disease
)	O
that	O
are	O
selected	O
and	O
distributed	O
by	O
the	O
World	O
Health	O
Organization	O
,	O
on	O
the	O
basis	O
of	O
their	O
latest	O
recommendations	O
.	O

The	O
organization	O
has	O
a	O
commitment	O
in	O
the	O
mentoring	O
of	O
young	O
researchers	O
,	O
and	O
is	O
dedicated	O
to	O
finding	O
cures	O
for	O
cancer	other-disease
and	O
cardiovascular	other-disease
diseases	other-disease
by	O
identifying	O
their	O
underlying	O
molecular	O
mechanisms	O
.	O

Yellow	other-disease
Fever	other-disease
was	O
a	O
disease	O
that	O
caused	O
thousands	O
of	O
deaths	O
,	O
and	O
many	O
people	O
to	O
flee	O
the	O
afflicted	O
areas	O
.	O

While	O
there	O
are	O
no	O
diseases	O
directly	O
attributed	O
to	O
TERRA	other-disease
dysfunction	other-disease
,	O
a	O
number	O
of	O
diseases	O
related	O
to	O
inappropriate	other-disease
telomere	other-disease
shortening	other-disease
and	O
cellular	other-disease
aging	other-disease
may	O
have	O
dysfunctional	other-disease
TERRA	other-disease
expression	O
as	O
one	O
of	O
their	O
causative	O
factors	O
.	O

The	other-disease
LQT3	other-disease
subtype	other-disease
of	other-disease
Romano–Ward	other-disease
syndrome	other-disease
i	other-disease
s	O
caused	O
by	O
variants	O
in	O
the	O
``	O
SCN5A	O
``	O
gene	O
located	O
on	O
chromosome	O
3p21–24	O
.	O

NOD	other-disease
mice	O
have	O
polymorphisms	O
in	O
the	O
Idd3	O
locus	O
which	O
are	O
linked	O
to	O
IL-2	O
production	O
.	O

People	O
with	O
this	O
disorder	O
have	O
inadequate	O
levels	O
of	O
an	O
enzyme	O
that	O
helps	O
break	O
down	O
the	O
amino	O
acid	O
valine	O
,	O
resulting	O
in	O
a	O
buildup	O
of	O
valine	O
in	O
the	O
urine	O
,	O
a	O
symptom	O
called	O
valinuria	other-disease
.	O

Most	O
people	O
with	O
CAD	other-disease
have	O
symptoms	O
of	O
hemolytic	other-disease
anemia	other-disease
(	O
destruction	O
of	O
red	O
blood	O
cells	O
,	O
causing	O
low	O
levels	O
of	O
red	O
blood	O
cells	O
)	O
.	O

Bipolar	other-disease
disorder	other-disease
patients	O
with	O
low	O
implicit	O
self-esteem	O
are	O
more	O
defensive	O
.	O

Tolomeo	O
suffered	O
a	O
pulmonary	other-disease
edema	other-disease
and	O
was	O
admitted	O
to	O
hospital	O
where	O
she	O
received	O
a	O
blood	O
transfusion	O
.	O

Also	O
,	O
STAT4	O
mutations	O
have	O
been	O
associated	O
with	O
rheumatoid	other-disease
arthritis	other-disease
,	O
and	O
STAT6	O
mutations	O
are	O
linked	O
to	O
asthma	other-disease
.	O

Aortic	O
valve	O
replacement	O
using	O
conventional	O
cryopreserved	O
homografts	O
is	O
currently	O
performed	O
only	O
in	O
about	O
3	O
%	O
of	O
all	O
patients	O
,	O
mostly	O
to	O
treat	O
acute	other-disease
aortic	other-disease
valve	other-disease
endocarditis.1	other-disease
Severe	O
calcification	O
of	O
conventional	O
homografts	O
frequently	O
occurs	O
and	O
is	O
the	O
main	O
reason	O
for	O
its	O
restrictive	O
use	O
,	O
however	O
,	O
current	O
guidelines	O
confirm	O
homografts	O
as	O
a	O
valid	O
alternative	O
for	O
young	O
patients	O
requiring	O
anatomical	O
reconstruction	O
of	O
the	O
outflow	O
tract	O
.	O

During	O
the	O
COVID-19	other-disease
pandemic	O
in	O
2020	O
,	O
the	O
neighborhood	O
businesses	O
suffered	O
from	O
little	O
revenue	O
,	O
as	O
the	O
event	O
centers	O
had	O
canceled	O
all	O
events	O
.	O

One	O
week	O
later	O
,	O
4,500	O
Philadelphians	O
were	O
declared	O
dead	O
of	O
the	O
Spanish	other-disease
flu	other-disease
and	O
47,000	O
people	O
were	O
infected	O
.	O

Cardiac	other-disease
sarcoidosis	other-disease
can	O
cause	O
fibrosis	O
,	O
granuloma	O
formation	O
,	O
or	O
the	O
accumulation	O
of	O
fluid	O
in	O
the	O
interstitium	O
of	O
the	O
heart	O
,	O
or	O
a	O
combination	O
of	O
the	O
former	O
two	O
.	O

This	O
is	O
a	O
sign	O
an	O
individual	O
has	O
prediabetes	other-disease
or	O
has	O
progressed	O
to	O
develop	O
type	other-disease
2	other-disease
diabetes	other-disease
.	O

The	O
1897	O
Gallaudet	O
Bison	O
football	O
team	O
represented	O
the	O
Gallaudet	O
Bison	O
of	O
Gallaudet	O
University	O
,	O
a	O
college	O
for	O
deaf-mutes	other-disease
,	O
in	O
the	O
1897	O
college	O
football	O
season	O
.	O

Use	O
of	O
the	O
term	O
``	O
Da	other-disease
Costa	other-disease
's	other-disease
syndrome	other-disease
``	O
peaked	O
in	O
the	O
early	O
20th	O
century	O
.	O

If	O
the	O
vaccine	O
is	O
combined	O
hepatitis	other-disease
A	other-disease
and	O
hepatitis	other-disease
B	other-disease
,	O
up	O
to	O
4	O
doses	O
may	O
be	O
required	O
.	O

This	O
assay	O
is	O
recognized	O
by	O
the	O
Center	O
for	O
Disease	O
Control	O
and	O
Prevention	O
as	O
a	O
special	O
TB	other-disease
blood	O
test	O
with	O
an	O
accuracy	O
of	O
diagnosing	O
active	O
TB	other-disease
&	O
gt	O
;	O
80	O
%	O
.	O

type	other-disease
3	other-disease
diabetes	other-disease
is	O
a	O
condition	O
which	O
can	O
follow	O
after	O
initially	O
being	O
diagnosed	O
with	O
type	other-disease
2	other-disease
diabetes	other-disease
.	O

When	O
controlling	O
for	O
PTSD	other-disease
symptoms	O
and	O
demographic	O
factors	O
,	O
regular	O
cannabis	O
use	O
was	O
still	O
significantly	O
related	O
to	O
sexual	O
trauma	O
.	O

In	O
2010	O
,	O
Kiwanis	O
International	O
pledged	O
to	O
raise	O
$	O
110	O
million	O
to	O
eliminate	O
maternal	O
and	O
neonatal	other-disease
tetanus	other-disease
throughout	O
the	O
world	O
in	O
partnership	O
with	O
UNICEF	O
.	O

Around	O
5	O
to	O
10	O
%	O
of	O
all	O
patients	O
with	O
cystic	other-disease
fibrosis	other-disease
develop	O
bronchiectasis	other-disease
.	O

Delayed	O
bleeding	O
may	O
also	O
occur	O
at	O
the	O
site	O
of	O
polyp	other-disease
removal	other-disease
up	O
to	O
a	O
week	O
after	O
the	O
procedure	O
,	O
and	O
a	O
repeat	O
procedure	O
can	O
then	O
be	O
performed	O
to	O
treat	O
the	O
bleeding	O
site	O
.	O

Other	O
important	O
considerations	O
before	O
a	O
PVE	O
include	O
co-morbidities	O
such	O
as	O
diabetes	other-disease
,	O
procedure	O
type	O
and	O
the	O
extent	O
of	O
planned	O
resection	O
.	O

This	O
is	O
associated	O
with	O
poorer	O
asthma	other-disease
control	O
.	O

Urinary	other-disease
tract	other-disease
infection	other-disease
is	O
the	O
most	O
common	O
complication	O
of	O
intermittent	other-disease
catheterization	other-disease
.	O

Health	O
issues	O
with	O
purebred	O
dogs	O
and	O
objections	O
to	O
dog	O
sports	O
and	O
dog	O
showing	O
have	O
been	O
extensively	O
covered	O
in	O
these	O
articles	O
-	O
Criticism	O
of	O
dog	O
showing	O
|	O
Genetic	other-disease
disease	other-disease
|	O
List	O
of	O
dog	O
diseases	O
|	O
Canine	O
reproduction	O
|	O
Inbreeding	O
and	O
others	O
.	O

Cyclopamine	O
is	O
under	O
investigation	O
as	O
a	O
possible	O
treatment	O
for	O
several	O
cancers	O
(	O
such	O
as	O
basal	other-disease
cell	other-disease
carcinoma	other-disease
and	O
medulloblastoma	other-disease
)	O
and	O
skin	other-disease
disorders	other-disease
(	O
such	O
as	O
psoriasis	other-disease
)	O
,	O
which	O
result	O
from	O
excessive	O
Hh	O
activity	O
.	O

Beta	other-disease
thalassemia	other-disease
is	O
caused	O
by	O
mutations	O
to	O
or	O
deletions	O
of	O
the	O
HBB	O
gene	O
leading	O
to	O
reduced	O
or	O
absent	O
synthesis	O
of	O
the	O
beta	O
chains	O
of	O
hemoglobin	O
that	O
result	O
in	O
variable	O
outcomes	O
ranging	O
from	O
severe	O
anemia	O
to	O
clinically	O
asymptomatic	O
individuals	O
.	O

The	O
Swine	other-disease
Flu	other-disease
(	O
also	O
known	O
as	O
H1N1	other-disease
)	O
epidemic	O
is	O
a	O
recent	O
disease	O
emerging	O
in	O
the	O
early	O
21st	O
century	O
.	O

In	O
2016	O
,	O
Edvardson	O
et	O
al.	O
,	O
identified	O
homozygosity	O
for	O
Arg204Trp	O
mutation	O
in	O
the	O
PLEKHG2	O
gene	O
in	O
the	O
patients	O
with	O
dystonia	other-disease
or	O
postnatal	other-disease
microcephaly	other-disease
.	O

CD36	O
recognises	O
oxidized	O
low	O
density	O
lipoprotein	O
,	O
long	O
chain	O
fatty	O
acids	O
,	O
anionic	O
phospholipids	O
,	O
collagen	O
types	O
I	O
,	O
IV	O
and	O
V	O
,	O
thrombospondin	O
and	O
``	O
Plasmodium	other-disease
falciparum	other-disease
``	O
infected	O
erythrocytes	O
.	O

Olfactory	O
dysfunction	O
(	O
loss	O
of	O
sense	O
of	O
smell	O
)	O
is	O
common	O
in	O
Parkinson	other-disease
’	O
s	O
disease	O
,	O
and	O
has	O
also	O
been	O
reported	O
to	O
occur	O
in	O
patients	O
with	O
essential	O
tremor	O
.	O

A	O
speech	other-disease
disorder	other-disease
known	O
as	O
stuttering	O
is	O
seen	O
to	O
be	O
associated	O
with	O
underactivity	O
in	O
Broca	O
's	O
area	O
.	O

P53	O
mutations	O
in	O
the	O
primary	O
prostate	other-disease
cancer	other-disease
are	O
relatively	O
low	O
and	O
are	O
more	O
frequently	O
seen	O
in	O
metastatic	O
settings	O
,	O
hence	O
,	O
p53	O
mutations	O
are	O
a	O
late	O
event	O
in	O
the	O
pathology	O
.	O

Traditionally	O
,	O
gonorrhea	other-disease
was	O
diagnosed	O
with	O
Gram	O
stain	O
and	O
culture	O
;	O
however	O
,	O
newer	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-based	O
testing	O
methods	O
are	O
becoming	O
more	O
common	O
.	O

Da	other-disease
Costa	other-disease
's	other-disease
syndrome	other-disease
is	O
named	O
for	O
the	O
surgeon	O
Jacob	O
Mendes	O
Da	O
Costa	O
,	O
who	O
first	O
observed	O
it	O
in	O
soldiers	O
during	O
the	O
American	O
Civil	O
War	O
.	O

Inhibiting	O
the	O
interaction	O
between	O
mdm2	O
and	O
p53	O
stabilizes	O
p53	O
,	O
and	O
is	O
thought	O
to	O
selectively	O
induce	O
a	O
growth-inhibiting	O
state	O
called	O
senescence	other-disease
in	other-disease
cancer	other-disease
cells	other-disease
.	O

Additionally	O
,	O
the	O
USPSTF	O
also	O
recommends	O
routine	O
screening	O
in	O
people	O
who	O
have	O
previously	O
tested	O
positive	O
for	O
gonorrhea	other-disease
or	O
have	O
multiple	O
sexual	O
partners	O
and	O
individuals	O
who	O
use	O
condoms	O
inconsistently	O
,	O
provide	O
sexual	O
favors	O
for	O
money	O
,	O
or	O
have	O
sex	O
while	O
under	O
the	O
influence	O
of	O
alcohol	O
or	O
drugs	O
.	O

Patients	O
with	O
concern	O
for	O
cardiac	O
tamponade	O
may	O
present	O
with	O
abnormal	O
vitals	O
and	O
what	O
's	O
classically	O
known	O
as	O
the	O
Beck	other-disease
's	other-disease
triad	other-disease
,	O
which	O
consists	O
of	O
hypotension	O
(	O
low	O
blood	O
pressure	O
)	O
,	O
jugular	O
venous	O
distension	O
and	O
distant	O
heart	O
sounds	O
.	O

In	O
this	O
case	O
,	O
the	O
delusion	other-disease
does	O
not	O
cease	O
to	O
be	O
a	O
delusion	other-disease
because	O
the	O
content	O
later	O
turns	O
out	O
to	O
be	O
verified	O
as	O
true	O
or	O
the	O
partner	O
actually	O
chose	O
to	O
engage	O
in	O
the	O
behavior	O
of	O
which	O
they	O
were	O
being	O
accused	O
.	O

Most	O
cases	O
of	O
mumps	other-disease
deafness	O
affect	O
just	O
one	O
ear	O
and	O
are	O
temporary	O
,	O
but	O
permanent	O
hearing	O
loss	O
occurs	O
in	O
0.005	O
%	O
of	O
infections	O
.	O

It	O
has	O
been	O
used	O
to	O
treat	O
hypertension	other-disease
and	O
cardiac	other-disease
failure	other-disease
,	other-disease
and	O
to	O
treat	O
pre-eclampsia	other-disease
during	O
pregnancy	O
.	O

Jeffrey	O
Weit	O
z	O
is	O
a	O
Canadian	O
bioscientist	O
,	O
currently	O
the	O
Canada	O
Research	O
Chair	O
in	O
Thrombosis	other-disease
and	O
Endowed	O
Chair	O
in	O
Cardiovascular	O
Medicine	O
at	O
McMaster	O
University	O
.	O

In	O
later	O
stages	O
,	O
changes	O
to	O
the	O
structure	O
of	O
the	O
lung	O
,	O
such	O
as	O
bronchiectasis	other-disease
,	O
occur	O
.	O

HMGB1	O
has	O
been	O
proposed	O
as	O
a	O
target	O
for	O
cancer	O
therapy	O
,	O
and	O
as	O
a	O
vector	O
for	O
reducing	O
inflammation	O
from	O
SARS-CoV-2	other-disease
infection	O
.	O

Research	O
has	O
identified	O
over	O
2,000	O
cystic	other-disease
fibrosis	other-disease
associated	O
mutations	O
in	O
the	O
gene	O
encoding	O
for	O
the	O
cystic	other-disease
fibrosis	other-disease
transmembrane	O
conductance	O
regulator	O
at	O
varying	O
degrees	O
of	O
frequency	O
within	O
the	O
disease	O
carrying	O
population	O
.	O

Researchers	O
have	O
identified	O
an	O
increase	O
of	O
suppressor	O
of	O
cytokine	O
signaling	O
3	O
(	O
SOCS3	O
)	O
in	O
a	O
large	O
number	O
of	O
STAT	other-disease
GOF	other-disease
patients	O
.	O

The	O
development	O
of	O
any	O
of	O
the	O
cancers	O
associated	O
with	O
PSC	other-disease
predicts	O
a	O
poor	O
prognosis	O
.	O

(	O
``	O
Jackie	O
’	O
s	O
tale	O
sets	O
alarm	O
bells	O
ringing	O
:	O
how	O
Woman	O
’	O
s	O
Own	O
sexed	O
up	O
Addison	other-disease
’	other-disease
s	other-disease
disease	other-disease
for	O
its	O
own	O
ends	O
.	O

By	O
1958	O
it	O
was	O
accepted	O
that	O
Hansen	other-disease
's	O
disease	O
patients	O
could	O
be	O
released	O
from	O
isolation	O
without	O
risk	O
to	O
the	O
community	O
after	O
three	O
consecutive	O
negative	O
monthly	O
smears	O
.	O

Vaccinating	O
girls	O
with	O
HPV	O
vaccine	O
before	O
their	O
initial	O
sexual	O
contact	O
has	O
been	O
claimed	O
to	O
reduce	O
incidence	O
of	O
VIN	other-disease
.	O

Vazif	O
Meylanov	O
died	O
on	O
January	O
11	O
,	O
2015	O
,	O
in	O
Makhachkala	O
after	O
suffering	O
from	O
Alzheimer	other-disease
disease	O
for	O
years	O
.	O

He	O
died	O
after	O
suffering	O
from	O
a	O
Pneumonia	other-disease
in	O
Apan	O
,	O
Hidalgo	O
.	O

giardiasis	other-disease
,	O
toxoplasmosis	other-disease
,	O
cryptosporidiosis	other-disease
,	O
trichomoniasis	other-disease
,	O
Chagas	other-disease
disease	other-disease
,	O
leishmaniasis	other-disease
,	O
African	other-disease
trypanosomiasis	other-disease
(	O
sleeping	other-disease
sickness	other-disease
)	O
,	O
``	other-disease
Acanthamoeba	other-disease
''	other-disease
keratitis	other-disease
,	O
and	O
primary	other-disease
amoebic	other-disease
meningoencephalitis	other-disease
(	O
naegleriasis	other-disease
)	O
.	O

It	O
was	O
1938	O
,	O
the	O
following	O
year	O
after	O
the	O
incident	O
,	O
when	O
he	O
was	O
finally	O
diagnosed	O
with	O
Myositis	other-disease
ossificans	other-disease
progressiva	other-disease
,	O
which	O
is	O
now	O
known	O
as	O
Fibrodysplasia	other-disease
Ossificans	other-disease
Progressiva	other-disease
(	O
FOP	other-disease
)	O
.	O

Other	O
possibilities	O
that	O
have	O
been	O
advanced	O
have	O
included	O
cystic	other-disease
fibrosis	other-disease
,	O
cirrhosis	other-disease
,	O
and	O
alpha	other-disease
1-antitrypsin	other-disease
deficiency	other-disease
.	O

Rasmussen	other-disease
's	other-disease
aneurysm	other-disease
is	O
a	O
pulmonary	O
artery	O
aneurysm	O
associated	O
with	O
a	O
cavitary	O
lung	O
lesion	O
.	O

Boris	O
'	O
later	O
childhood	O
was	O
also	O
marked	O
with	O
sickness	O
as	O
he	O
suffered	O
from	O
Rheumatic	other-disease
fever	other-disease
when	O
he	O
was	O
12	O
.	O

Studies	O
suggest	O
that	O
the	O
defective	O
enzyme	O
could	O
allow	O
cells	O
to	O
grow	O
and	O
divide	O
unchecked	O
,	O
leading	O
to	O
the	O
formation	O
of	O
hamartomas	other-disease
and	O
cancerous	other-disease
tumors	other-disease
.	O

About	O
half	O
of	O
patients	O
have	O
associated	O
dystonia	other-disease
,	O
including	O
cervical	other-disease
dystonia	other-disease
,	O
writer	other-disease
's	other-disease
cramp	other-disease
,	O
spasmodic	other-disease
dysphonia	other-disease
,	O
and	O
cranial	other-disease
dystonia	other-disease
,	O
and	O
20	O
%	O
of	O
the	O
patients	O
had	O
associated	O
parkinsonism	other-disease
.	O

Albinism	other-disease
is	O
only	O
seen	O
in	O
about	O
1	O
of	O
every	O
1,800	O
birds	O
.	O

Use	O
of	O
these	O
drugs	O
has	O
been	O
associated	O
with	O
a	O
decrease	O
in	O
depression	other-disease
and	O
increased	O
functioning	O
in	O
social	O
and	O
work	O
environments	O
.	O

Wicksteed	other-disease
Park	other-disease
was	O
awarded	O
a	O
further	O
£	O
1.78	O
million	O
by	O
the	O
National	O
Lottery	O
Heritage	O
Fund	O
in	O
2018	O
for	O
a	O
project	O
to	O
preserve	O
the	O
park	O
's	O
history	O
.	O

A	O
child	O
between	O
12-14	O
is	O
considered	O
to	O
have	O
Anemia	other-disease
if	O
they	O
have	O
less	O
than	O
120g/L	O
of	O
hemoglobin	O
in	O
their	O
blood	O
.	O

Between	O
2000	O
and	O
2006	O
,	O
several	O
hundred	O
children	O
in	O
Finland	O
had	O
serious	O
adverse	O
events	O
from	O
the	O
vaccine	O
,	O
including	O
osteitis	other-disease
and	O
osteomyelitis	other-disease
,	O
disseminated	O
(	O
usually	O
fatal	O
)	O
BCG	other-disease
infection	other-disease
,	O
arthritis	other-disease
,	O
and	O
lymph	other-disease
node	other-disease
abscesses	other-disease
.	O

A	O
fibrin	other-disease
ring	other-disease
granuloma	other-disease
,	O
also	O
known	O
as	O
doughnut	other-disease
granuloma	other-disease
,	O
is	O
a	O
histopathological	O
finding	O
that	O
is	O
characteristic	O
of	O
Q	other-disease
fever	other-disease
.	O

In	O
some	O
situations	O
,	O
however	O
,	O
AMS	other-disease
progresses	O
to	O
HACE	other-disease
without	O
these	O
symptoms	O
.	O

Although	O
what	O
causes	O
pedophilia	other-disease
is	O
not	O
yet	O
known	O
,	O
researchers	O
began	O
reporting	O
a	O
series	O
of	O
findings	O
linking	O
pedophilia	other-disease
with	O
brain	O
structure	O
and	O
function	O
,	O
beginning	O
in	O
2002	O
.	O

Studies	O
have	O
found	O
that	O
patients	O
with	O
schizophrenia	other-disease
fail	O
to	O
show	O
a	O
reduced	O
response	O
to	O
the	O
second	O
click	O
.	O

It	O
was	O
originally	O
described	O
by	O
Fritz	O
Valdemar	O
Rasmussen	O
in	O
association	O
with	O
cavitary	O
lung	O
lesions	O
of	O
tuberculosis	other-disease
,	O
and	O
was	O
described	O
in	O
up	O
to	O
5	O
%	O
of	O
autopsies	O
of	O
those	O
with	O
chronic	other-disease
tuberculosis	other-disease
.	O

MIA	O
PaCa-2	O
is	O
a	O
human	O
pancreatic	O
cancer	O
cell	O
line	O
used	O
extensively	O
in	O
pancreatic	other-disease
cancer	other-disease
research	O
and	O
therapy	O
development	O
.	O

However	O
,	O
investors	O
were	O
reluctant	O
to	O
provide	O
funding	O
due	O
to	O
concerns	O
over	O
the	O
impact	O
on	O
the	O
aviation	O
industry	O
of	O
the	O
Iraq	O
War	O
and	O
Severe	other-disease
acute	other-disease
respiratory	other-disease
syndrome	other-disease
epidemic	O
.	O

Migraine	other-disease
surgery	O
is	O
usually	O
reserved	O
for	O
migraine	other-disease
patients	O
who	O
fail	O
more	O
conservative	O
therapy	O
or	O
who	O
can	O
not	O
tolerate	O
the	O
side	O
effects	O
of	O
drugs	O
used	O
to	O
treat	O
their	O
migraines	other-disease
.	O

In	O
2000	O
,	O
NAMRU-3	O
successfully	O
investigated	O
the	O
first	O
outbreak	O
of	O
Rift	other-disease
Valley	other-disease
fever	other-disease
outside	O
Africa	O
in	O
Yemen	O
.	O

The	O
normal	O
human	O
spleen	O
measures	O
about	O
125	O
millimeters	O
in	O
length	O
,	O
and	O
splenomegaly	other-disease
is	O
an	O
important	O
clinical	O
sign	O
.	O

A	O
amoebic	O
liver	O
abscess	O
is	O
a	O
type	O
of	O
liver	O
abscess	O
caused	O
by	O
amebiasis	other-disease
.	O

Approximately	O
six	O
weeks	O
later	O
,	O
Jenner	O
then	O
introduced	O
an	O
active	O
sample	O
of	O
the	O
smallpox	other-disease
virus	O
into	O
Phipps	O
to	O
test	O
the	O
theory	O
.	O

This	O
hypersecretion	O
often	O
results	O
in	O
the	O
formation	O
of	O
a	O
pituitary	other-disease
adenoma	other-disease
(	O
tumour	O
)	O
,	O
which	O
are	O
benign	O
apart	O
from	O
a	O
tiny	O
fraction	O
.	O

Takotsubo	other-disease
cardiomyopathy	other-disease
or	O
``	O
Broken	other-disease
heart	other-disease
syndrome	other-disease
``	O
is	O
commonly	O
described	O
as	O
a	O
physical	O
pain	O
in	O
the	O
chest	O
or	O
heart	O
or	O
stomach	O
area	O
,	O
which	O
is	O
due	O
to	O
the	O
emotional	O
stress	O
caused	O
by	O
a	O
traumatic	O
breakup	O
or	O
the	O
death	O
of	O
a	O
loved	O
one	O
.	O

He	O
was	O
diagnosed	O
with	O
septic	other-disease
arthritis	other-disease
caused	O
by	O
an	O
infection	O
which	O
nearly	O
killed	O
him	O
.	O

He	O
demonstrated	O
that	O
SMR	other-disease
training	O
can	O
improve	O
attention	O
and	O
academic	O
performance	O
in	O
children	O
diagnosed	O
with	O
Attention	other-disease
Deficit	other-disease
Disorder	other-disease
with	other-disease
Hyperactivity	other-disease
(	O
ADHD	other-disease
)	O
.	O

Rabies	other-disease
takes	O
an	O
economic	O
toll	O
on	O
Tanzania	O
;	O
costs	O
due	O
to	O
rabies	O
include	O
medical	O
expenses	O
,	O
control	O
of	O
infected	O
dogs	O
,	O
and	O
safety	O
inspections	O
in	O
local	O
communities	O
.	O

Jarvis	O
promoted	O
the	O
idea	O
that	O
apple	O
cider	O
vinegar	O
and	O
honey	O
could	O
be	O
used	O
to	O
cure	O
arthritis	other-disease
,	O
diabetes	other-disease
,	O
high	other-disease
blood	other-disease
pressure	other-disease
,	O
heart	other-disease
disease	other-disease
and	O
many	O
others	O
.	O

For	O
example	O
,	O
decreased	O
synchrony	O
of	O
gamma	O
oscillations	O
has	O
been	O
observed	O
in	O
auditory	O
cortex	O
of	O
FXS	other-disease
patients	O
.	O

William	O
Adams	O
described	O
the	O
Forward	O
Bending	O
Test	O
for	O
scoliosis	other-disease
in	O
1865	O
.	O

Among	O
the	O
possibilities	O
for	O
differential	O
diagnosis	O
of	O
protein	other-disease
S	other-disease
deficiency	other-disease
are-	O
Antiphospholipid	other-disease
syndrome	other-disease
,	O
disseminated	other-disease
intravascular	other-disease
coagulation	other-disease
and	O
antithrombin	other-disease
deficiency	other-disease
(	O
though	O
this	O
list	O
is	O
not	O
exhaustive	O
)	O

Anaphylactic	other-disease
shock	other-disease
can	O
be	O
provoked	O
in	O
allergic	O
persons	O
by	O
the	O
``	O
previous	O
''	O
use	O
of	O
latex	O
in	O
an	O
area	O
:	O
latex	O
is	O
typically	O
powdered	O
to	O
prevent	O
sticking	O
,	O
latex	O
proteins	O
become	O
attached	O
to	O
the	O
particles	O
of	O
powder	O
,	O
and	O
the	O
powder	O
becomes	O
airborne	O
when	O
the	O
latex	O
item	O
is	O
used	O
,	O
triggering	O
potentially	O
life-threatening	O
Type	O
I	O
reactions	O
when	O
the	O
latex-contaminated	O
powder	O
is	O
inhaled	O
by	O
susceptible	O
persons	O
.	O

She	O
later	O
won	O
damages	O
from	O
University	O
Hospital	O
Coventry	O
in	O
relation	O
to	O
alleged	O
shortcomings	O
with	O
her	O
care	O
and	O
treatment	O
for	O
cervical	other-disease
cancer	other-disease
.	O

Simian	other-disease
virus	other-disease
5	other-disease
and	O
type	other-disease
II	other-disease
human	other-disease
parainfluenza	other-disease
virus	other-disease
express	O
a	O
protein	O
,	O
named	O
``	O
V	O
''	O
,	O
which	O
acts	O
as	O
a	O
substrate	O
receptor	O
and	O
bridges	O
an	O
interaction	O
between	O
DDB1	O
and	O
STAT	O
proteins	O
(	O
the	O
structure	O
of	O
the	O
CRL4ASV5V	O
complex	O
is	O
pictured	O
in	O
the	O
inset	O
)	O
-	O
thus	O
inducing	O
STAT1	O
ubiquitination	O
and	O
degradation	O

In	O
1999	O
,	O
the	O
world	O
incidence	O
of	O
Hansen	other-disease
's	other-disease
disease	other-disease
was	O
estimated	O
to	O
be	O
640,000	O
.	O

One	O
must	O
also	O
differentiate	O
ischemic	other-disease
colitis	other-disease
,	O
which	O
often	O
resolves	O
on	O
its	O
own	O
,	O
from	O
the	O
more	O
immediately	O
life-threatening	O
condition	O
of	O
acute	other-disease
mesenteric	other-disease
ischemia	other-disease
of	O
the	O
small	O
bowel	O
.	O

NIHL	other-disease
can	O
affect	O
either	O
one	O
or	O
both	O
ears	O
.	O

He	O
engaged	O
in	O
research	O
on	O
tuberculosis	O
,	O
became	O
president	O
of	O
``	O
Nasjonalforeningen	O
mot	O
tuberkulosen	O
``	O
(	O
the	O
National	O
Society	O
Against	O
Tuberculosis	O
)	O
,	O
and	O
initiated	O
the	O
preventive	O
Tuberculin	other-disease
skin	O
test	O
for	O
school	O
children	O
.	O

These	O
conditions	O
are	O
characterized	O
by	O
multiple	O
tumor-like	O
growths	O
called	O
hamartomas	other-disease
and	O
an	O
increased	O
risk	O
of	O
developing	O
certain	O
cancers	O
.	O

Loss	O
of	O
LKB1	O
activity	O
is	O
associated	O
with	O
highly	O
aggressive	O
HER2	O
HER2+	other-disease
breast	other-disease
cancer	other-disease
.	O

``	O
14th	O
century	O
''	O
:	O
after	O
the	O
Black	other-disease
Death	other-disease
(	O
1348–1350	O
)	O
Niall	O
O	O
’	O
Neill	O
refurbished	O
the	O
church	O
for	O
the	O
Franciscan	O
Order	O

Of	O
interest	O
,	O
there	O
is	O
an	O
association	O
of	O
primary	O
ciliary	O
dyskinesia	O
with	O
left-right	O
anatomic	O
abnormalities	O
such	O
as	O
situs	O
inversus	O
(	O
a	O
combination	O
of	O
findings	O
known	O
as	O
Kartagener	other-disease
's	O
syndrome	O
)	O
and	O
other	O
heterotaxic	O
defects	O
.	O

Ian	O
Frazer	O
,	O
one	O
of	O
the	O
developers	O
of	O
the	O
Gardasil	other-disease
cervical	other-disease
cancer	other-disease
vaccine	O
,	O
is	O
the	O
scientific	O
advisor	O
to	O
ACCF	O
.	O

He	O
made	O
several	O
attempts	O
to	O
escape	O
and	O
his	O
health	O
had	O
deteriorated	O
to	O
such	O
an	O
extent	O
that	O
shortly	O
after	O
his	O
repatriation	O
to	O
Britain	O
he	O
succumbed	O
to	O
Spanish	other-disease
Influenza	other-disease
on	O
31	O
December	O
1918	O
.	O

However	O
,	O
these	O
physical	O
examination	O
findings	O
are	O
also	O
present	O
in	O
Valentino	other-disease
’	other-disease
s	other-disease
Syndrome	other-disease
.	O

The	O
first	O
symptom	O
of	O
NIHL	other-disease
may	O
be	O
difficulty	O
hearing	O
a	O
conversation	O
against	O
a	O
noisy	O
background	O
.	O

She	O
had	O
lived	O
with	O
Multiple	other-disease
sclerosis	other-disease
for	O
15	O
years	O
.	O

It	O
is	O
also	O
being	O
trialed	O
in	O
humans	O
to	O
study	O
its	O
efficacy	O
in	O
treatment	O
of	O
breast	other-disease
cancer	other-disease
in	O
women	O
,	O
and	O
in	O
treating	O
precocious	other-disease
puberty	other-disease
and	O
congenital	other-disease
adrenal	other-disease
hyperplasia	other-disease
in	O
male	O
and	O
female	O
children	O
.	O

In	O
a	O
person	O
who	O
is	O
compensated	O
,	O
this	O
may	O
show	O
cardiomegaly	other-disease
(	O
visible	O
enlargement	O
of	O
the	O
heart	O
)	O
,	O
quantified	O
as	O
the	O
cardiothoracic	O
ratio	O
(	O
proportion	O
of	O
the	O
heart	O
size	O
to	O
the	O
chest	O
)	O
.	O

It	O
follows	O
then	O
that	O
,	O
on	O
the	O
basis	O
of	O
the	O
fact	O
that	O
ventricular	other-disease
fibrillation	other-disease
itself	O
is	O
common	O
,	O
idiopathic	other-disease
ventricular	other-disease
fibrillation	other-disease
accounts	O
for	O
an	O
appreciable	O
mortality	O
.	O

Apart	O
from	O
colony	other-disease
collapse	other-disease
disorder	other-disease
,	O
losses	O
outside	O
the	O
US	O
have	O
been	O
attributed	O
to	O
causes	O
including	O
pesticide	O
seed	O
dressings	O
,	O
using	O
neonicotinoids	O
such	O
as	O
Clothianidin	O
,	O
Imidacloprid	O
and	O
Thiamethoxam	O
.	O

In	O
women	O
military	O
veterans	O
,	O
a	O
higher	O
proportion	O
of	O
cannabis	O
users	O
who	O
had	O
experienced	O
childhood	O
and	O
adult	O
sexual	O
trauma	O
,	O
had	O
higher	O
levels	O
Post-Traumatic	other-disease
Stress	other-disease
Disorder	other-disease
(	O
PTSD	other-disease
)	O
diagnosis	O
when	O
compared	O
to	O
those	O
with	O
no	O
drug	O
use	O
.	O

Oliguria	other-disease
when	O
&	O
lt	O
;	O
400	O
mL	O
(	O
millilitres	O
)	O
are	O
produced	O
,	O
and	O
anuria	O
one	O
of	O
&	O
lt	O
;	O
100	O
mL	O
per	O
day	O
.	O

Pemphigus	other-disease
foliaceus	other-disease
has	O
been	O
recognized	O
in	O
pet	O
dogs	O
,	O
cats	O
,	O
and	O
horses	O
and	O
is	O
the	O
most	O
common	O
autoimmune	O
skin	O
disease	O
diagnosed	O
in	O
veterinary	O
medicine	O
.	O

Eosinophilic	other-disease
cellulitis	other-disease
is	O
of	O
unknown	O
cause	O
.	O

Chronic	O
ischemia	O
of	O
the	O
brain	O
may	O
result	O
in	O
a	O
form	O
of	O
dementia	O
called	O
vascular	other-disease
dementia	other-disease
.	O

BPH	other-disease
is	O
a	O
result	O
of	O
the	O
ongoing	O
process	O
of	O
testosterone	O
being	O
converted	O
to	O
dihydrotestosterone	O
which	O
stimulates	O
prostate	O
growth	O
.	O

The	O
FMR1	O
knockout	O
rat	O
model	O
of	O
FXS	other-disease
exhibits	O
an	O
increased	O
ratio	O
of	O
slow	O
(	O
~25-50	O
Hz	O
)	O
to	O
fast	O
(	O
~55-100	O
Hz	O
)	O
gamma	O
waves	O
.	O

Keogh	O
contracted	O
the	O
Spanish	other-disease
Flu	other-disease
towards	O
the	O
end	O
of	O
the	O
war	O
,	O
but	O
recovered	O
in	O
time	O
to	O
join	O
the	O
right-wing	O
militia	O
group	O
Freikorps	O
which	O
operated	O
out	O
of	O
Munich	O
.	O

This	O
may	O
become	O
useful	O
in	O
therapies	O
against	O
malignancies	other-disease
like	O
multiple	other-disease
myeloma	other-disease
.	O

``	O
T.	O
whipplei	O
``	O
is	O
one	O
of	O
the	O
Actinomycetes	O
,	O
and	O
is	O
a	O
distant	O
relative	O
of	O
``	O
Mycobacterium	O
avium-intracellulare	O
``	O
and	O
``	O
Mycobacterium	O
paratuberculosis	O
``	O
,	O
explaining	O
in	O
part	O
why	O
Whipple	other-disease
's	other-disease
disease	other-disease
is	O
similar	O
to	O
the	O
diseases	O
caused	O
by	O
these	O
bacteria	O
.	O

Mitochondria	O
function	O
In	O
control	O
mice	O
that	O
did	O
not	O
have	O
mammary	other-disease
tumors	other-disease
were	O
not	O
affected	O
by	O
AZD8055	O
/	O
2-DG	O
treatments	O
.	O

Multifocal	other-disease
motor	other-disease
neuropathy	other-disease
(	O
MMN	other-disease
)	O
with	O
conduction	O
block	O
is	O
closely	O
related	O
to	O
CIDP	other-disease
(	O
chronic	other-disease
inflammatory	other-disease
demyelinating	other-disease
polyneuropathy	other-disease
)	O
.	O

About	O
10	O
%	O
of	O
cases	O
are	O
due	O
to	O
endometrial	other-disease
cancer	other-disease
.	O

The	O
tumor	other-disease
often	O
has	O
a	O
cauliflower-like	O
appearance	O
.	O

Additionally	O
,	O
research	O
suggests	O
that	O
confabulation	O
can	O
be	O
seen	O
in	O
patients	O
with	O
frontal	other-disease
lobe	other-disease
syndrome	other-disease
,	O
which	O
involves	O
an	O
insult	O
to	O
the	O
frontal	O
lobe	O
as	O
a	O
result	O
of	O
disease	O
or	O
traumatic	other-disease
brain	other-disease
injury	other-disease
(	O
TBI	other-disease
)	O
.	O

Overdose	O
may	O
result	O
in	O
central	O
nervous	O
system	O
toxicity	O
,	O
cardiovascular	other-disease
toxicity	other-disease
,	O
tendon/articular	other-disease
toxicity	other-disease
,	O
and	O
hepatic	other-disease
toxicity	other-disease
as	O
well	O
as	O
kidney	other-disease
failure	other-disease
and	O
seizure	other-disease
.	O

If	O
a	O
person	O
becomes	O
sick	O
with	O
swine	other-disease
flu	other-disease
,	O
antiviral	O
drugs	O
can	O
make	O
the	O
illness	O
milder	O
and	O
make	O
the	O
patient	O
feel	O
better	O
faster	O
.	O

However	O
,	O
amantadine	O
-resistant	O
influenza	O
viruses	O
were	O
first	O
reported	O
during	O
the	O
1980	O
influenza	other-disease
A	other-disease
epidemic	O
and	O
resistance	O
frequency	O
continued	O
to	O
rise	O
into	O
the	O
early	O
2000s	O
.	O

This	O
discovery	O
was	O
championed	O
by	O
Julius	O
Wagner-Jauregg	O
,	O
who	O
won	O
the	O
1927	O
Nobel	O
Prize	O
for	O
Medicine	O
for	O
his	O
discovery	O
of	O
the	O
therapeutic	O
value	O
of	O
malaria	other-disease
inoculation	O
in	O
the	O
treatment	O
of	O
neurosyphilis	other-disease
.	O

The	O
village	O
was	O
badly	O
affected	O
by	O
the	O
French	other-disease
Dysentery	other-disease
Epidemic	other-disease
of	other-disease
1779	other-disease
such	O
that	O
250	O
died	O
and	O
the	O
graveyard	O
had	O
to	O
be	O
extended	O
this	O
may	O
be	O
the	O
origin	O
of	O
the	O
five	O
crosses	O
(	O
Les	O
Cinq	O
Croix	O
)	O

Affected	O
species	O
include	O
other	O
mammals	O
and	O
birds	O
,	O
giving	O
influenza	other-disease
A	other-disease
the	O
opportunity	O
for	O
a	O
major	O
reorganization	O
of	O
surface	O
antigens	O
.	O

Individuals	O
with	O
BENTA	other-disease
disease	O
have	O
polyclonal	O
B	O
cell	O
lymphocytosis	O
(	O
i.e	O
.	O

Edema	other-disease
and	O
its	O
complication	O
Papillamitosis	other-disease
are	O
only	O
partially	O
reversible	O
and	O
soon	O
becomes	O
hard	O
,	O
which	O
is	O
mainly	O
confirmed	O
on	O
palpation	O
.	O

In	O
very	O
low	O
birth	O
weight	O
infants	O
(	O
VLBWI	other-disease
)	O
,	O
systemic	other-disease
fungus	other-disease
infection	other-disease
is	O
a	O
hospital-acquired	O
infection	O
with	O
serious	O
consequences	O
.	O

mTOR	O
inhibitors	O
are	O
effective	O
at	O
shrinking	O
the	O
size	O
of	O
lymphangioleiomyomatosis	other-disease
,	O
and	O
can	O
lead	O
to	O
total	O
resolution	O
.	O

Risk	O
factors	O
for	O
acute	O
cases	O
include	O
swimming	O
,	O
minor	O
trauma	O
from	O
cleaning	O
,	O
using	O
hearing	O
aids	O
and	O
ear	O
plugs	O
,	O
and	O
other	O
skin	O
problems	O
,	O
such	O
as	O
psoriasis	other-disease
and	O
dermatitis	other-disease
.	O

This	O
provides	O
support	O
for	O
the	O
idea	O
that	O
dysthymia	other-disease
is	O
caused	O
in	O
part	O
by	O
heredity	O
.	O

Within	O
the	O
ICD-10	O
category	O
scheme	O
,	O
disinhibited	other-disease
attachment	other-disease
disorder	other-disease
specifically	O
excludes	O
Asperger	other-disease
syndrome	other-disease
(	O
F84.5	O
)	O
,	O
hospitalism	other-disease
in	other-disease
children	other-disease
(	O
F43.2	O
)	O
,	O
and	O
hyperkinetic	other-disease
disorders	other-disease
(	O
F90.-	O
)	O
.	O

However	O
Shen	O
Qi	O
,	O
who	O
has	O
a	O
brain	other-disease
tumor	other-disease
,	O
can	O
see	O
Du	O
even	O
without	O
desiring	O
death	O
nor	O
possessing	O
a	O
rock	O
.	O

Folic	other-disease
acid	other-disease
deficiency	other-disease
is	O
a	O
common	O
association	O
of	O
nutritional	other-disease
anemia	other-disease
and	O
iron	other-disease
deficiency	other-disease
anemia	other-disease
is	O
the	O
most	O
common	O
nutritional	O
disorder	O
.	O

He	O
is	O
board	O
certified	O
in	O
internal	O
medicine	O
;	O
allergy	other-disease
,	O
asthma	other-disease
and	O
immunology	other-disease
;	O
and	O
diagnostic	O
laboratory	O
immunology	O
.	O

Later	O
,	O
the	O
throat	O
problem	O
of	O
Prince	O
Frederick	O
was	O
proved	O
to	O
be	O
a	O
rare	O
case	O
of	O
Laryngeal	other-disease
Cancer	other-disease
and	O
he	O
succumbed	O
to	O
his	O
illness	O
on	O
15	O
June	O
1888	O
,	O
just	O
after	O
99	O
days	O
of	O
ruling	O
as	O
the	O
German	O
Emperor	O
Kaiser	O
Frederick	O
III	O

Many	O
neurodegenerative	other-disease
diseases	other-disease
–	O
including	O
amyotrophic	other-disease
lateral	other-disease
sclerosis	other-disease
,	O
multiple	other-disease
sclerosis	other-disease
,	O
Parkinson	other-disease
's	other-disease
disease	other-disease
,	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
,	O
Huntington	other-disease
's	other-disease
disease	other-disease
,	O
and	O
prion	other-disease
diseases	other-disease
–	O
occur	O
as	O
a	O
result	O
of	O
neurodegenerative	O
processes	O
.	O

Spinal	other-disease
stenosis	other-disease
is	O
a	O
narrowing	O
of	O
the	O
canal	O
which	O
can	O
occur	O
in	O
any	O
region	O
of	O
the	O
spine	O
and	O
can	O
be	O
caused	O
by	O
a	O
number	O
of	O
factors	O
.	O

Laboratory	O
rats	O
infected	O
with	O
Borna	other-disease
disease	other-disease
virus	O
show	O
some	O
symptoms	O
similar	O
to	O
those	O
of	O
autism	O
but	O
blood	O
studies	O
of	O
autistic	O
children	O
show	O
no	O
evidence	O
of	O
infection	O
by	O
this	O
virus	O
.	O

Aseptic	other-disease
meningitis	other-disease
is	O
the	O
inflammation	O
of	O
the	O
meninges	O
,	O
a	O
membrane	O
covering	O
the	O
brain	O
and	O
spinal	O
cord	O
,	O
in	O
patients	O
whose	O
cerebral	O
spinal	O
fluid	O
test	O
result	O
is	O
negative	O
with	O
routine	O
bacterial	O
cultures	O
.	O

Holmes	O
is	O
part	O
of	O
a	O
research	O
team	O
aimed	O
at	O
developing	O
inexpensive	O
yet	O
effective	O
therapies	O
to	O
help	O
refugees	O
recover	O
from	O
PTSD	other-disease
and	O
other	O
trauma-related	O
psychological	O
disorders	O
.	O

Between	O
10	O
%	O
and	O
30	O
%	O
of	O
adults	O
have	O
insomnia	other-disease
at	O
any	O
given	O
point	O
in	O
time	O
and	O
up	O
to	O
half	O
of	O
people	O
have	O
insomnia	other-disease
in	O
a	O
given	O
year	O
.	O

Other	O
winners	O
devoted	O
their	O
work	O
to	O
aiding	O
individuals	O
who	O
had	O
a	O
specific	O
illness	O
,	O
such	O
as	O
Albert	O
Pujols	O
,	O
whose	O
daughter	O
suffers	O
from	O
Down	other-disease
syndrome	other-disease
,	O
and	O
who	O
devoted	O
the	O
Pujols	O
Family	O
Foundation	O
to	O
helping	O
those	O
with	O
the	O
disorder	O
,	O
and	O
Ryan	O
Zimmerman	O
,	O
who	O
established	O
the	O
ziMS	O
Foundation	O
to	O
raise	O
money	O
for	O
multiple	O
sclerosis	O
,	O
the	O
disease	O
which	O
afflicts	O
his	O
mother	O
.	O

The	O
attack	O
rate	O
for	O
mumps	other-disease
in	O
students	O
who	O
received	O
three	O
doses	O
of	O
the	O
vaccine	O
was	O
lower	O
than	O
those	O
who	O
had	O
two	O
.	O

Meyer-Bahlburg	O
also	O
discussed	O
sexual	O
attraction	O
by	O
individuals	O
with	O
partial	O
androgen	O
insensitivity	O
syndrome	O
,	O
5α-Reductase	other-disease
deficiency	other-disease
and	O
17β-Hydroxysteroid	other-disease
dehydrogenase	other-disease
III	other-disease
deficiency	other-disease
,	O
stating	O
that	O
sexual	O
attraction	O
towards	O
females	O
in	O
individuals	O
with	O
these	O
conditions	O
was	O
facilitated	O
by	O
``	O
prenatal	O
exposure	O
to	O
and	O
utilization	O
of	O
androgens	O
.	O
''	O

The	O
amount	O
of	O
fresh	O
frozen	O
plasma	O
required	O
to	O
reverse	O
disseminated	O
intravascular	O
coagulation	O
associated	O
with	O
purpura	other-disease
fulminans	other-disease
may	O
lead	O
to	O
complications	O
of	O
fluid	O
overload	O
and	O
death	O
,	O
especially	O
in	O
neonates	O
,	O
such	O
as	O
transfusion-related	O
acute	O
lung	O
injury	O
.	O

As	O
a	O
survivor	O
of	O
viral	other-disease
meningitis	other-disease
,	O
she	O
felt	O
a	O
need	O
to	O
spread	O
awareness	O
of	O
the	O
disease	O
.	O

Huntington	other-disease
's	other-disease
disease	other-disease
is	O
a	O
neurodegenerative	O
disease	O
and	O
most	O
common	O
inherited	O
cause	O
of	O
chorea	other-disease
.	O

Mesulam	O
's	O
original	O
description	O
in	O
1982	O
of	O
progressive	O
language	O
problems	O
caused	O
by	O
neurodegenerative	other-disease
disease	other-disease
(	O
which	O
he	O
called	O
primary	other-disease
progressive	other-disease
aphasia	other-disease
(	O
PPA	other-disease
)	O
included	O
patients	O
with	O
progressive	O
nonfluent	O
(	O
aphasia	other-disease
,	O
semantic	other-disease
dementia	other-disease
,	O
and	O
logopenic	other-disease
progressive	other-disease
aphasia	other-disease
.	O

Kempf	O
coined	O
the	O
term	O
``	O
homosexual	other-disease
panic	other-disease
``	O
for	O
the	O
condition	O
,	O
and	O
classified	O
it	O
as	O
an	O
acute	O
pernicious	O
dissociative	O
disorder	O
,	O
meaning	O
that	O
it	O
involved	O
a	O
disruption	O
in	O
typical	O
perception	O
and	O
memory	O
functions	O
.	O

Peripheral	other-disease
neuropathy	other-disease
and	O
mononeuropathy	other-disease
can	O
be	O
a	O
result	O
of	O
a	O
variety	O
of	O
factors	O
,	O
but	O
are	O
a	O
result	O
of	O
one	O
of	O
three	O
methods	O
:	O

Ulcerative	other-disease
colitis	other-disease
(	O
UC	other-disease
)	O
is	O
a	O
long-term	O
condition	O
that	O
results	O
in	O
inflammation	O
and	O
ulcers	O
of	O
the	O
colon	O
and	O
rectum	O
.	O

Birt–Hogg–Dubé	other-disease
syndrome	other-disease
is	O
caused	O
by	O
mutations	O
in	O
the	O
``	O
FLCN	O
''	O
gene	O
(	O
located	O
at	O
chromosome	O
17p11.2	O
)	O
,	O
which	O
encodes	O
a	O
protein	O
named	O
folliculin	O
.	O

A	O
2001	O
report	O
from	O
the	O
United	O
Nations	O
Office	O
for	O
the	O
Coordination	O
of	O
Humanitarian	O
Affairs	O
(	O
OCHA	O
)	O
noted	O
that	O
the	O
villagers	O
were	O
suffering	O
from	O
waterborne	O
diseases	O
such	O
as	O
Guinea	other-disease
worm	other-disease
,	O
river	other-disease
blindness	other-disease
and	O
cholera	other-disease
,	O
which	O
could	O
be	O
reduced	O
if	O
the	O
people	O
were	O
given	O
the	O
infrastructure	O
and	O
taught	O
how	O
to	O
build	O
good	O
riverbed	O
wells	O
,	O
and	O
were	O
given	O
water	O
and	O
sanitation	O
education	O
.	O

He	O
next	O
encountered	O
cholera	other-disease
while	O
working	O
with	O
MDM	O
in	O
Grand	O
Comorro	O
in	O
1998	O
.	O

Ciprofloxacin	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
gonorrhea	other-disease
in	O
many	O
countries	O
,	O
but	O
this	O
recommendation	O
is	O
widely	O
regarded	O
as	O
obsolete	O
due	O
to	O
resistance	O
development	O
.	O

WSMV	other-disease
is	O
semi-persistently	O
transmitted	O
by	O
the	O
wheat	O
curl	O
mite	O
(	O
``	O
Aceria	O
tosichella	O
``	O
)	O
,	O
a	O
small	O
,	O
cigar-shaped	O
insect	O
that	O
can	O
produce	O
a	O
single	O
generation	O
within	O
10	O
days	O
under	O
optimum	O
temperature-	O
approximately	O
27	O
°C	O
.	O

The	O
population	O
of	O
people	O
with	O
gluten	other-disease
ataxia	other-disease
and	O
other	O
neurological	O
conditions	O
appears	O
to	O
have	O
a	O
different	O
HLA	O
distribution	O
,	O
in	O
particular	O
more	O
HLA-DQ1	O
,	O
compared	O
to	O
most	O
persons	O
with	O
celiac	O
disease	O
,	O
who	O
have	O
HLA-DQ2	O
and	O
HLA-DQ8	O
.	O

Crohn	other-disease
's	other-disease
disease	other-disease
cytokines	O
are	O
of	O
the	O
type	O
1	O
(	O
``	O
Th1	O
''	O
)	O
cytokines	O
,	O
which	O
include	O
TNF-α	O
,	O
interleukin-2	O
,	O
and	O
interferon	O
γ	O
.	O
Ulcerative	other-disease
colitis	other-disease
was	O
less	O
conclusively	O
linked	O
to	O
the	O
production	O
of	O
``	O
Th2	O
''	O
cytokines	O
.	O

Atherosclerosis	other-disease
contributes	O
to	O
coronary	other-disease
thrombos	other-disease
is	O
formation	O
by	O
facilitating	O
blood	O
stasis	O
as	O
well	O
as	O
causing	O
local	O
endothelial	O
injury	O
.	O

The	O
most	O
common	O
causes	O
of	O
splenomegaly	other-disease
in	O
developed	O
countries	O
are	O
infectious	other-disease
mononucleosis	other-disease
,	O
splenic	O
infiltration	O
with	O
cancer	O
cells	O
from	O
a	O
hematological	O
malignancy	O
and	O
portal	other-disease
hypertension	other-disease
(	O
most	O
commonly	O
secondary	O
to	O
liver	O
disease	O
,	O
and	O
sarcoidosis	O
)	O
.	O

Spasm	other-disease
means	O
``	O
uncontrolled	O
muscle	O
contraction	O
''	O
.	O

Children	O
living	O
near	O
the	O
Chernobyl	O
nuclear	O
power	O
plant	O
during	O
the	O
catastrophe	O
of	O
1986	O
have	O
experienced	O
a	O
60-fold	O
increase	O
in	O
the	O
incidence	O
of	O
thyroid	other-disease
cancer	other-disease
.	O

This	O
is	O
not	O
the	O
same	O
as	O
the	O
Pratt	O
Test	O
,	O
which	O
checks	O
for	O
a	O
DVT	other-disease
by	O
compressing	O
a	O
vein	O
with	O
the	O
hands	O
.	O

Neonatal	other-disease
bowel	other-disease
obstruction	other-disease
(	O
NBO	other-disease
)	O
or	O
neonatal	other-disease
intestinal	other-disease
obstruction	other-disease
is	O
the	O
most	O
common	O
surgical	O
emergency	O
in	O
the	O
neonatal	O
period	O
.	O

Typhoid	other-disease
fever	other-disease
is	O
one	O
of	O
Afghanistan	O
's	O
major	O
infectious	O
diseases	O
in	O
terms	O
of	O
food/waterborne	O
diseases	O
.	O

However	O
,	O
its	O
use	O
as	O
a	O
cancer	O
treatment	O
is	O
restricted	O
due	O
to	O
serious	O
side	O
effects	O
such	O
as	O
pulmonary	other-disease
edema	other-disease
.	O

Michael	O
Houghton	O
's	O
laboratory	O
at	O
Chiron	O
Corporation	O
ultimately	O
identified	O
the	O
agent	O
associated	O
with	O
NANBH	other-disease
,	O
now	O
known	O
as	O
Hepatitis	other-disease
C	other-disease
,	O
in	O
1989	O
.	O

She	O
served	O
on	O
the	O
American	O
Psychiatric	O
Association	O
DSM-IV	O
Subcommittee	O
on	O
Gender	other-disease
Identity	other-disease
Disorders	other-disease
.	O

In	O
1918	O
,	O
the	O
Spanish	other-disease
influenza	other-disease
epidemic	other-disease
took	O
1,500	O
victims	O
in	O
a	O
month	O
.	O

Huntington	other-disease
's	O
disease	O
is	O
a	O
disease	O
characterized	O
by	O
minor	O
coordination	O
problems	O
,	O
jerking	O
eye	O
movements	O
,	O
and	O
uncontrollable	O
movement	O
of	O
peripheral	O
limbs	O
.	O

Porphyria	other-disease
cutanea	other-disease
tarda	other-disease
is	O
implicated	O
in	O
the	O
origin	O
of	O
vampire	O
myths	O
.	O

In	O
the	O
airways	O
of	O
patients	O
with	O
asthma	other-disease
,	O
the	O
expression	O
of	O
adenosine	O
receptors	O
is	O
upregulated	O
.	O

In	O
his	O
prize-winning	O
book	O
,	O
``	O
De	O
Iritide	O
``	O
(	O
1835	O
)	O
,	O
he	O
made	O
contributions	O
involving	O
investigations	O
of	O
iritis	other-disease
and	O
sympathetic	other-disease
ophthalmia	other-disease
.	O

Blood	O
flukes	O
can	O
cause	O
the	O
trematodiases	other-disease
Schistosomiasis	other-disease
which	O
can	O
cause	O
reactions	O
on	O
skin	O
.	O

It	O
is	O
classified	O
as	O
type	other-disease
II	other-disease
lupus	other-disease
nephritis	other-disease
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
.	O

Currently	O
,	O
amantadine	O
is	O
no	O
longer	O
recommended	O
for	O
the	O
treatment	O
of	O
influenza	other-disease
A	other-disease
due	O
to	O
a	O
high	O
level	O
of	O
amantadine	O
resistance	O
among	O
circulating	O
influenza	other-disease
A	other-disease
viruses	O
.	O

In	O
small	O
dosages	O
,	O
it	O
is	O
very	O
efficient	O
in	O
the	O
therapy	O
of	O
systemic	other-disease
lupus	other-disease
erythematosus	other-disease
,	O
autoimmune	other-disease
hemolytic	other-disease
anemia	other-disease
,	O
granulomatosis	other-disease
with	other-disease
polyangiitis	other-disease
,	O
and	O
other	O
autoimmune	O
diseases	O
.	O

Before	O
2013	O
,	O
the	O
subtypes	O
of	O
schizophrenia	other-disease
were	O
classified	O
as	O
paranoid	O
,	O
disorganized	O
,	O
catatonic	O
,	O
undifferentiated	O
,	O
and	O
residual	O
type	O
.	O

Coccidiosis	other-disease
typically	O
results	O
in	O
diarrhoea	other-disease
,	O
weight	O
loss	O
and	O
dehydration	O
.	O

Sexual	other-disease
dysfunction	other-disease
often	O
accompanies	O
anxiety	other-disease
disorders	other-disease
,	O
although	O
it	O
is	O
difficult	O
to	O
determine	O
whether	O
anxiety	O
causes	O
the	O
sexual	other-disease
dysfunction	other-disease
or	O
whether	O
they	O
arise	O
from	O
a	O
common	O
cause	O
.	O

In	O
cases	O
of	O
homozygous	O
protein	O
C	O
deficiency	O
,	O
episodes	O
of	O
purpura	other-disease
fulminans	other-disease
and	O
other	O
thrombotic	O
events	O
are	O
recurrent	O
.	O

CEC	O
Entertainment	O
,	O
Inc	O
.	O
,	O
Peter	O
Piper	O
Pizza	O
's	O
parent	O
company	O
,	O
filed	O
for	O
bankruptcy	O
in	O
2020	O
due	O
to	O
the	O
significant	O
financial	O
strain	O
brought	O
on	O
by	O
the	O
COVID-19	other-disease
pandemic	O
.	O

In	O
1962	O
NAMRU-3	O
investigators	O
described	O
the	O
natural	O
infection	O
cycle	O
of	O
West	other-disease
Nile	other-disease
fever	other-disease
,	O
which	O
involves	O
mosquitoes	O
and	O
birds	O
as	O
primary	O
vectors	O
and	O
hosts	O
.	O

They	O
discussed	O
organizing	O
a	O
new	O
campaign	O
to	O
retake	O
Missouri	O
,	O
but	O
Jackson	O
died	O
of	O
pneumonia	other-disease
and	O
stomach	other-disease
cancer	other-disease
before	O
such	O
actions	O
took	O
place	O
.	O

There	O
is	O
an	O
association	O
with	O
Pendred	other-disease
syndrome	other-disease
and	O
incomplete	O
cochlear	O
partition	O
(	O
so	O
called	O
``	O
Mondini	O
dysplasia	O
''	O
)	O
.	O

Desquamative	other-disease
gingivitis	other-disease
is	O
a	O
descriptive	O
clinical	O
term	O
,	O
not	O
a	O
diagnosis	O
.	O

Said	O
organization	O
stated	O
that	O
excluding	O
marginalised	O
groups	O
would	O
compromise	O
efforts	O
to	O
stop	O
the	O
spread	O
of	O
AIDS	other-disease
in	O
Uganda	O
,	O
a	O
social	O
problem	O
to	O
the	O
point	O
that	O
a	O
full	O
5.4	O
%	O
of	O
the	O
adult	O
population	O
had	O
been	O
infected	O
with	O
HIV	other-disease
by	O
the	O
year	O
2007	O
.	O

Research	O
proposes	O
patients	O
with	O
bipolar	other-disease
disorder	other-disease
show	O
more	O
common	O
implicit	O
and	O
depressive	O
self-referencing	O
than	O
unipolar	O
patients	O
.	O

This	O
deficiency	O
can	O
lead	O
to	O
a	O
decrease	O
in	O
memory	O
,	O
judgement	O
and	O
the	O
ability	O
to	O
reason	O
,	O
of	O
which	O
are	O
key	O
symptoms	O
of	O
Alzheimer	other-disease
's	O
disease	O
.	O

Polyuria	other-disease
is	O
a	O
condition	O
of	O
excessive	O
urine	O
production	O
(	O
&	O
gt	O
;	O
2.5	O
L/day	O
)	O
.	O

Korsakoff	other-disease
's	other-disease
syndrome	other-disease
is	O
also	O
characterized	O
by	O
profound	O
amnesia	O
,	O
disorientation	O
and	O
frequent	O
confabulation	O
(	O
making	O
up	O
or	O
inventing	O
information	O
to	O
compensate	O
for	O
poor	O
memory	O
)	O
.	O

Usually	O
this	O
hypoglycemia	other-disease
can	O
easily	O
be	O
treated	O
with	O
more	O
frequent	O
feedings	O
or	O
medical	O
doses	O
of	O
glucose	O
.	O

He	O
died	O
after	O
a	O
long	O
battle	O
with	O
Alzheimers	other-disease
in	O
2000	O
,	O
aged	O
68	O
.	O

Aphasia	other-disease
is	O
the	O
inability	O
to	O
speak	O
,	O
read	O
,	O
write	O
or	O
understand	O
speech	O
.	O

It	O
is	O
associated	O
with	O
diabetes	other-disease
and	O
long-term	O
tobacco	O
smoking	O
.	O

This	O
is	O
opposite	O
to	O
the	O
upregulated	O
expression	O
seen	O
in	O
SZ	other-disease
patient	O
brains	O
.	O

Janette	O
Howard	O
,	O
the	O
wife	O
of	O
the	O
then-Prime	O
Minister	O
of	O
Australia	O
,	O
John	O
Howard	O
,	O
was	O
diagnosed	O
with	O
cervical	other-disease
cancer	other-disease
in	O
1996	O
,	O
and	O
first	O
spoke	O
publicly	O
about	O
the	O
disease	O
in	O
2006	O
.	O

CA1	other-disease
also	O
mediates	O
hemorrhagic	O
retinal	O
and	O
cerebral	O
vascular	O
permeability	O
through	O
prekallikrein	O
activation	O
and	O
serine	O
protease	O
factor	O
XIIa	O
generation	O
.	O

From	O
1902	O
to	O
1905	O
it	O
treated	O
tuberculosis	O
sufferers	O
from	O
Eastern	O
sweatshops	O
,	O
until	O
rich	O
neighbors	O
forced	O
them	O
to	O
stop	O
treating	O
TB	other-disease
patients	O
.	O

Some	O
data	O
does	O
suggest	O
that	O
even	O
after	O
that	O
age	O
,	O
symptoms	O
can	O
be	O
alleviated	O
via	O
surgical	O
intervention	O
,	O
including	O
prevention	O
of	O
Arrhythmogenic	other-disease
right	other-disease
ventricular	other-disease
dysplasia	other-disease
and	O
other	O
associated	O
cardiac	O
abnormalities	O
.	O

Two	O
disorders	O
,	O
achondroplasia	other-disease
and	O
growth	O
hormone	O
deficiency	O
,	O
are	O
responsible	O
for	O
the	O
majority	O
of	O
human	O
dwarfism	other-disease
cases	O
.	O

Schwartz	O
is	O
credited	O
with	O
the	O
clinical	O
description	O
of	O
new	O
subtypes	O
of	O
Kaposi	other-disease
's	other-disease
sarcoma	other-disease
:	O
telangiectatic	other-disease
Kaposi	other-disease
's	other-disease
sarcoma	other-disease
,	O
keloidal	other-disease
Kaposi	other-disease
's	other-disease
sarcoma	other-disease
and	O
ecchymotic	other-disease
Kaposi	other-disease
’	other-disease
s	other-disease
sarcoma	other-disease
.	O

The	O
condition	O
was	O
formerly	O
called	O
Huntington	other-disease
's	other-disease
chorea	other-disease
but	O
was	O
renamed	O
because	O
of	O
the	O
important	O
non-choreic	O
features	O
including	O
cognitive	O
decline	O
and	O
behavioural	O
change	O
.	O

Without	O
dietary	O
intervention	O
,	O
mild	other-disease
HPA	other-disease
patients	O
have	O
blood	O
Phe	O
levels	O
higher	O
than	O
those	O
with	O
normal	O
PAH	O
activity	O
.	O

Their	O
training	O
was	O
disrupted	O
by	O
Chitwood	O
's	O
contraction	O
of	O
mononucleosis	other-disease
(	O
glandular	other-disease
fever	other-disease
)	O
.	O

Exhaustion	O
can	O
develop	O
during	O
chronic	O
infections	O
,	O
sepsis	other-disease
and	O
cancer	other-disease
.	O

Recently	O
described	O
syndromes	O
such	O
as	O
the	O
Brugada	other-disease
Syndrome	other-disease
may	O
give	O
clues	O
to	O
the	O
underlying	O
mechanism	O
of	O
ventricular	other-disease
arrhythmias	other-disease
.	O

Microcephaly	other-disease
and	O
seizures	other-disease
may	O
occur	O
.	O

Persons	O
receiving	O
excessive	O
Botox	O
treatments	O
and	O
thus	O
losing	O
disproportionate	O
facial	O
expression	O
features	O
may	O
be	O
incorrectly	O
identified	O
as	O
suffering	O
from	O
hypomimia	other-disease
.	O

LMNA	other-disease
and	O
PLN	other-disease
mutation	O
carriers	O
showed	O
a	O
high	O
prevalence	O
of	O
cardiac	O
transplantation	O
and	O
ventricular	O
arrhythmia	O
.	O

These	O
neurodegenerative	O
diseases	O
are	O
commonly	O
called	O
``	O
prion	other-disease
diseases	other-disease
``	O
.	O

AIDS	other-disease
is	O
defined	O
as	O
the	O
clinical	O
stage	O
IV	O
of	O
the	O
HIV	O
infection	O
.	O

Thalassemia	other-disease
prevalence	O
in	O
India	O
is	O
3-4	O
%	O
,	O
with	O
10,000	O
to	O
12,000	O
reported	O
thalassemia	other-disease
births	O
taking	O
place	O
every	O
year	O
.	O

Stuporous	O
catatonia	other-disease
is	O
characterized	O
by	O
immobility	O
during	O
which	O
patients	O
may	O
show	O
reduced	O
responsiveness	O
to	O
the	O
environment	O
(	O
stupor	O
)	O
,	O
rigid	O
poses	O
(	O
posturing	O
)	O
,	O
an	O
inability	O
to	O
speak	O
(	O
mutism	other-disease
)	O
,	O
and	O
waxy	O
flexibility	O
(	O
in	O
which	O
they	O
maintain	O
positions	O
after	O
being	O
placed	O
in	O
them	O
by	O
someone	O
else	O
)	O
.	O

Some	O
people	O
with	O
sleep	other-disease
apnea	other-disease
are	O
unaware	O
they	O
have	O
the	O
condition	O
.	O

Hugh	O
Antoine	O
d'Arcy	O
died	O
of	O
bronchitis	other-disease
and	O
chronic	other-disease
heart	other-disease
problems	other-disease
in	O
1925	O
in	O
New	O
York	O
City	O
.	O

Duchenne	other-disease
muscular	other-disease
dystrophy	other-disease
(	O
DMD	other-disease
)	O
is	O
a	O
severe	O
type	O
of	O
muscular	O
dystrophy	O
that	O
primarily	O
affects	O
boys	O
.	O

On	O
13	O
March	O
,	O
Formula	O
E	O
and	O
the	O
FIA	O
announced	O
a	O
temporary	O
suspension	O
of	O
the	O
season	O
in	O
response	O
to	O
the	O
COVID-19	other-disease
pandemic	O
.	O

Permanent	other-disease
junctional	other-disease
reciprocating	other-disease
tachycardia	other-disease
(	O
PJRT	other-disease
)	O
is	O
a	O
rare	O
cardiac	O
arrhythmia	O
.	O

Baltimore	O
also	O
faced	O
numerous	O
outbreaks	O
of	O
smallpox	other-disease
in	O
the	O
18th	O
and	O
19th	O
centuries	O
.	O

Gigantism	other-disease
and	O
flightlessness	O
are	O
almost	O
exclusively	O
correlated	O
.	O

Matteo	O
was	O
diagnosed	O
with	O
leukodystrophy	other-disease
(	O
specifically	O
an	O
AGS	other-disease
)	O
shortly	O
after	O
his	O
birth	O
.	O

The	O
joints	O
in	O
gout	other-disease
can	O
often	O
become	O
swollen	O
and	O
lose	O
function	O
.	O

Claustrophobia	other-disease
also	O
plays	O
a	O
great	O
part	O
in	O
special	O
effects	O
.	O

Monkeypox	other-disease
occurs	O
naturally	O
only	O
in	O
Africa	O
,	O
particularly	O
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
.	O

Weems	O
died	O
in	O
prison	O
of	O
an	O
AIDS	other-disease
-related	O
disease	O
in	O
1986	O
.	O

Eyelid	other-disease
dermatitis	other-disease
is	O
commonly	O
related	O
to	O
atopic	other-disease
dermatitis	other-disease
or	O
allergic	other-disease
contact	other-disease
dermatitis	other-disease
.	O

CD36	O
interacts	O
with	O
a	O
number	O
of	O
ligands	O
,	O
including	O
collagen	O
types	O
I	O
and	O
IV	O
,	O
thrombospondin	O
,	O
erythrocytes	O
parasitized	O
with	O
``	O
Plasmodium	other-disease
falciparum	other-disease
``	O
,	O
platelet-agglutinating	O
protein	O
p37	O
,	O
oxidized	O
low	O
density	O
lipoprotein	O
and	O
long-chain	O
fatty	O
acids	O
.	O

Unlike	O
the	O
accessory	O
pathway	O
in	O
a	O
more	O
common	O
cause	O
of	O
AVRT	other-disease
,	O
Wolff-Parkinson-White	other-disease
syndrome	O
,	O
the	O
accessory	O
pathway	O
in	O
PJRT	other-disease
conducts	O
slowly	O
.	O

Several	O
causes	O
have	O
been	O
speculated	O
,	O
including	O
a	O
capillary	other-disease
leak	other-disease
syndrome	other-disease
from	O
cytokine	O
release	O
from	O
the	O
differentiating	O
myeloid	O
cells	O
.	O

She	O
has	O
studied	O
the	O
impact	O
of	O
diagnosing	O
chronic	other-disease
obstructive	other-disease
pulmonary	other-disease
disease	other-disease
(	O
COPD	other-disease
)	O
in	O
primary	O
care	O
.	O

This	O
change	O
causes	O
UWA-101	O
to	O
lack	O
cytotoxicity	O
and	O
MDMA	O
-like	O
behavioral	O
effects	O
in	O
animals	O
,	O
but	O
while	O
retaining	O
similar	O
or	O
slightly	O
improved	O
anti-	O
Parkinsonian	other-disease
effectiveness	O
when	O
compared	O
to	O
MDMA	O
.	O

Brucellosis	other-disease
first	O
came	O
to	O
the	O
attention	O
of	O
British	O
medical	O
officers	O
in	O
the	O
1850s	O
in	O
Malta	O
during	O
the	O
Crimean	O
War	O
,	O
and	O
was	O
referred	O
to	O
as	O
Malta	other-disease
Fever	other-disease
.	O

The	O
zonules	O
of	O
Zinn	O
are	O
difficult	O
to	O
visualize	O
using	O
a	O
slit	O
lamp	O
,	O
but	O
may	O
be	O
seen	O
with	O
exceptional	O
dilation	O
of	O
the	O
pupil	O
,	O
or	O
if	O
a	O
coloboma	other-disease
of	other-disease
the	other-disease
iris	other-disease
or	O
a	O
subluxation	other-disease
of	other-disease
the	other-disease
lens	other-disease
is	O
present	O
.	O

Agents	O
with	O
an	O
effect	O
on	O
hepatic	O
cytochrome	O
P450	O
pathways	O
or	O
conjugation	O
can	O
alter	O
the	O
rate	O
of	O
diazepam	other-disease
metabolism	O
.	O

There	O
is	O
evidence	O
to	O
indicate	O
that	O
Wernicke	other-disease
encephalopathy	other-disease
is	O
underdiagnosed	O
.	O

Herpes	other-disease
simplex	other-disease
virus	other-disease
is	O
commonly	O
found	O
in	O
humans	O
,	O
yet	O
uncommonly	O
results	O
in	O
systemic	O
manifestations	O
.	O

The	O
Genetic	O
and	O
Rare	O
Diseases	O
Information	O
Center	O
(	O
GARD	O
)	O
states	O
that	O
pernicious	other-disease
anemia	other-disease
is	O
one	O
of	O
the	O
conditions	O
associated	O
with	O
GAVE	other-disease
's	O
,	O
and	O
one	O
separate	O
study	O
showed	O
that	O
over	O
three-fourths	O
of	O
the	O
patients	O
in	O
the	O
study	O
with	O
GAVE	other-disease
's	O
had	O
some	O
kind	O
of	O
Vitamin	O
B12	O
deficiency	O
including	O
the	O
associated	O
condition	O
pernicious	other-disease
anemia	other-disease
.	O

In	O
2005	O
,	O
a	O
research	O
study	O
at	O
Malmö	O
University	O
's	O
Faculty	O
of	O
Odontology	O
suggested	O
that	O
performing	O
unprotected	O
oral	O
sex	O
on	O
a	O
person	O
infected	O
with	O
HPV	other-disease
might	O
increase	O
the	O
risk	O
of	O
oral	other-disease
cancer	other-disease
.	O

QKI	O
gene	O
expression	O
is	O
decreased	O
in	O
specific	O
brain	O
regions	O
in	O
SZ	other-disease
and	O
it	O
has	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
SZ	other-disease
SZ	other-disease
.	O

In	O
the	O
most	O
recent	O
session	O
Rep	O
.	O
Primavera	O
sponsored	O
legislation	O
extending	O
the	O
Breast	O
and	O
Cervical	O
Cancer	other-disease
Treatment	O
and	O
Prevention	O
program	O
through	O
2019	O
.	O

Acquired	O
haemophilia	other-disease
A	other-disease
(	O
AHA	other-disease
)	O
is	O
a	O
rare	O
but	O
potentially	O
life-threatening	O
bleeding	O
disorder	O
characterized	O
by	O
autoantibodies	O
directed	O
against	O
coagulation	O
factor	O
VIII	O
.	O

Decompression	other-disease
sickness	other-disease
requires	O
supersaturation	O
of	O
tissues	O
during	O
the	O
decompression	O
of	O
ascent	O
,	O
and	O
is	O
bubble	O
formation	O
is	O
affected	O
by	O
ascent	O
rate	O
and	O
the	O
amount	O
of	O
gas	O
dissolved	O
in	O
the	O
tissues	O
during	O
exposure	O
to	O
pressure	O
while	O
breathing	O
.	O

CD	other-disease
is	O
differentiated	O
from	O
oppositional	other-disease
defiant	other-disease
disorder	other-disease
(	O
ODD	other-disease
)	O
in	O
that	O
children	O
with	O
ODD	other-disease
do	O
not	O
commit	O
aggressive	O
or	O
antisocial	O
acts	O
against	O
other	O
people	O
,	O
animals	O
,	O
and	O
property	O
,	O
though	O
many	O
children	O
diagnosed	O
with	O
ODD	other-disease
are	O
subsequently	O
rediagnosed	O
with	O
CD	other-disease
.	O

In	O
1985	O
,	O
he	O
was	O
diagnosed	O
with	O
AIDS	other-disease
and	O
became	O
active	O
in	O
AIDS	other-disease
prevention	O
education	O
.	O

It	O
is	O
used	O
to	O
prevent	O
and	O
treat	O
scurvy	other-disease
.	O

On	O
18	O
March	O
2020	O
,	O
Virgin	O
Australia	O
CEO	O
Paul	O
Scurrah	O
announced	O
the	O
grounding	O
of	O
the	O
equivalent	O
of	O
53	O
planes	O
due	O
to	O
the	O
ongoing	O
COVID-19	other-disease
pandemic	O
,	O
effective	O
30	O
March	O
.	O

Symptoms	O
of	O
floppy	other-disease
infant	other-disease
syndrome	other-disease
and	O
the	O
neonatal	other-disease
benzodiazepine	other-disease
withdrawal	other-disease
syndrome	other-disease
have	O
been	O
reported	O
to	O
persist	O
from	O
hours	O
to	O
months	O
after	O
birth	O
.	O

Fibrin	O
ring	O
granulomas	O
may	O
also	O
be	O
seen	O
in	O
Hodgkin	other-disease
's	other-disease
disease	other-disease
and	O
infectious	other-disease
mononucleosis	other-disease
.	O

Neonatal	other-disease
hypoglycemia	other-disease
,	O
low	O
blood	O
glucose	O
in	O
the	O
first	O
month	O
of	O
life	O
,	O
occurs	O
in	O
about	O
half	O
of	O
children	O
with	O
BWS	other-disease
.	O

Candidiasis	O
is	O
associated	O
with	O
retinopathy	other-disease
,	O
prematurity	other-disease
and	O
negative	O
neurodevelopmental	O
consequences	O
.	O

The	O
direct	O
cause	O
of	O
feline	other-disease
idiopathic	other-disease
cystitis	other-disease
is	O
unknown	O
.	O

There	O
is	O
some	O
evidence	O
of	O
a	O
genetic	O
basis	O
for	O
all	O
types	O
of	O
depression	other-disease
,	other-disease
including	O
dysthymia	other-disease
.	O

On	O
the	O
one	O
hand	O
,	O
lipodystrophy	other-disease
seems	O
to	O
be	O
mainly	O
due	O
to	O
HIV-1	O
protease	O
inhibitors	O
.	O

His	O
name	O
entered	O
into	O
the	O
history	O
of	O
medicine	O
in	O
1872	O
,	O
when	O
he	O
described	O
for	O
the	O
first	O
time	O
Kaposi	other-disease
's	other-disease
sarcoma	other-disease
,	O
a	O
cancer	O
of	O
the	O
skin	O
,	O
which	O
he	O
had	O
discovered	O
in	O
five	O
elderly	O
male	O
patients	O
and	O
which	O
he	O
initially	O
named	O
``	O
idiopathic	other-disease
multiple	other-disease
pigmented	other-disease
sarcoma	other-disease
``	O
.	O

People	O
with	O
diabetes	other-disease
are	O
at	O
risk	O
of	O
a	O
severe	O
form	O
of	O
``	O
malignant	O
otitis	other-disease
externa	other-disease
``	O
.	O

The	O
management	O
of	O
low	other-disease
back	other-disease
pain	other-disease
often	O
includes	O
medications	O
for	O
the	O
duration	O
that	O
they	O
are	O
beneficial	O
.	O

Licking	O
of	O
open	O
wounds	O
by	O
dogs	O
could	O
transmit	O
rabies	other-disease
if	O
the	O
dog	O
is	O
infected	O
with	O
rabies	other-disease
,	O
although	O
this	O
is	O
said	O
by	O
the	O
CDC	O
to	O
be	O
rare	O
.	O

Those	O
with	O
Werner	other-disease
's	other-disease
syndrome	other-disease
suffer	O
from	O
osteoporosis	other-disease
,	O
cataracts	other-disease
,	O
and	O
cardiovascular	other-disease
disease	other-disease
,	O
but	O
not	O
neurodegeneration	other-disease
or	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
;	O
those	O
with	O
Down	other-disease
syndrome	other-disease
suffer	O
type	other-disease
2	other-disease
diabetes	other-disease
and	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
,	O
but	O
not	O
high	O
blood	other-disease
pressure	other-disease
,	O
osteoporosis	other-disease
or	O
cataracts	other-disease
.	O

The	O
first	O
appearance	O
of	O
mono-ADP-ribosylation	O
occurred	O
a	O
year	O
later	O
during	O
a	O
study	O
of	O
toxins	O
:	O
corynebacterium	other-disease
diphtheria	other-disease
diphtheria	other-disease
toxin	other-disease
was	O
shown	O
to	O
be	O
dependent	O
on	O
NAD+	O
in	O
order	O
for	O
it	O
to	O
be	O
completely	O
effective	O
,	O
leading	O
to	O
the	O
discovery	O
of	O
enzymatic	O
conjugation	O
of	O
a	O
single	O
ADP-ribose	O
group	O
by	O
mono-ADP-ribosyl	O
transferase	O
.	O

WEA	other-disease
is	O
present	O
in	O
about	O
a	O
fifth	O
of	O
patients	O
with	O
asthma	other-disease
and	O
a	O
wide	O
variety	O
of	O
conditions	O
at	O
work	O
,	O
including	O
irritant	O
chemicals	O
,	O
dusts	O
,	O
second-hand	O
smoke	O
,	O
common	O
allergens	O
that	O
may	O
be	O
present	O
at	O
work	O
,	O
as	O
well	O
as	O
other	O
“	O
exposures	O
”	O
such	O
as	O
emotional	O
stress	O
,	O
worksite	O
temperature	O
,	O
and	O
physical	O
exertion	O
can	O
exacerbate	O
asthma	other-disease
symptoms	O
in	O
these	O
patients	O
.	O

Penile	other-disease
dysmorphophobi	other-disease
a	O
is	O
related	O
to	O
body	other-disease
dysmorphic	other-disease
disorder	other-disease
(	O
BDD	other-disease
)	O
,	O
defined	O
by	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders-Fourth	O
Edition	O
(	O
Text	O
Revision	O
)	O
(	O
DSM-IV-TR	O
)	O
as	O
a	O
condition	O
marked	O
by	O
excessive	O
preoccupation	O
with	O
an	O
imaginary	O
or	O
minor	O
defect	O
in	O
a	O
facial	O
feature	O
or	O
localized	O
part	O
of	O
the	O
body	O
.	O

Bullous	other-disease
keratopathy	other-disease
that	O
is	O
characterized	O
by	O
corneal	other-disease
stromal	other-disease
edema	other-disease
related	O
to	O
cell	O
loss	O
and	O
endothelial	O
decompensation	O
as	O
well	O
as	O
subepithelial	O
fibrosis	O
and	O
corneal	O
vascularization	O
in	O
further	O
cases	O
,	O
results	O
vision	O
problems	O
due	O
to	O
loss	O
of	O
corneal	O
transparency	O
.	O

...	O
A	O
non-pejorative	O
and	O
,	O
hopefully	O
,	O
reasonable	O
term	O
for	O
the	O
ever-narrowing	O
group	O
of	O
undiagnosed	O
face	O
pain	O
problems	O
:	O
Facepain	other-disease
of	other-disease
Obscure	other-disease
Etiology	other-disease
(	other-disease
FOE	other-disease
or	O
POE	other-disease
)	O
to	O
replace	O
atypical	O
facial	O
pain	O
in	O
the	O
Burchiel	O
classification	O
.	O
''	O

It	O
is	O
used	O
to	O
treat	O
asthma	O
,	O
including	O
asthma	O
attacks	O
,	O
exercise-induced	O
bronchoconstriction	O
,	O
and	O
chronic	other-disease
obstructive	other-disease
pulmonary	other-disease
disease	other-disease
(	O
COPD	other-disease
)	O
.	O

infantile	other-disease
esotropia	other-disease
)	O
receive	O
strabismus	O
surgery	O
within	O
the	O
first	O
few	O
years	O
or	O
two	O
of	O
their	O
life	O
,	O
this	O
goes	O
along	O
with	O
the	O
hope	O
that	O
they	O
may	O
yet	O
develop	O
their	O
full	O
potential	O
for	O
binocular	O
vision	O
including	O
stereopsis	O
.	O

Additionally	O
,	O
many	O
people	O
who	O
have	O
autism	other-disease
have	O
issues	O
with	O
communication	O
and	O
some	O
have	O
limited	O
or	O
no	O
speech	O
.	O

They	O
termed	O
it	O
``	O
mycotic	other-disease
pseudotuberculosis	other-disease
``	O
,	O
now	O
known	O
as	O
allergic	O
bronchopulmonary	other-disease
aspergillosis	other-disease
.	O

It	O
is	O
difficult	O
to	O
distinguish	O
from	O
,	O
and	O
has	O
been	O
found	O
to	O
co-occur	O
with	O
,	O
alexithymia	other-disease
.	O

MMN	other-disease
is	O
potentially	O
treatable	O
with	O
immunomodulation	O
.	O

Hypersensitivity	O
and	O
memory	O
deficits	O
in	O
Fragile	other-disease
X	other-disease
syndrome	O
may	O
be	O
linked	O
to	O
gamma	O
rhythm	O
abnormalities	O
in	O
sensory	O
cortex	O
and	O
hippocampus	O
.	O

Due	O
to	O
different	O
susceptibility	O
to	O
ischemia	other-disease
of	O
various	O
brain	O
regions	O
,	O
a	O
global	O
brain	other-disease
ischemia	other-disease
may	O
cause	O
focal	other-disease
brain	other-disease
infarction	other-disease
.	O

Pulmonary	O
arterial	O
hypertension	O
occurs	O
by	O
two	O
mechanisms	O
in	O
cardiac	other-disease
sarcoidosis	other-disease
:	O
reduced	O
left	O
heart	O
function	O
due	O
to	O
granulomas	O
weakening	O
the	O
heart	O
muscle	O
or	O
from	O
impaired	O
blood	O
flow	O
.	O

It	O
is	O
also	O
used	O
in	O
Pulmonary	other-disease
Aspergillosis	other-disease
in	O
a	O
dry	O
powder	O
inhalation	O
system	O
.	O

The	O
presence	O
of	O
the	O
blind	other-disease
spot	other-disease
scotoma	other-disease
can	O
be	O
demonstrated	O
subjectively	O
by	O
covering	O
one	O
eye	O
,	O
carefully	O
holding	O
fixation	O
with	O
the	O
open	O
eye	O
,	O
and	O
placing	O
an	O
object	O
(	O
such	O
as	O
one	O
's	O
thumb	O
)	O
in	O
the	O
lateral	O
and	O
horizontal	O
visual	O
field	O
,	O
about	O
15	O
degrees	O
from	O
fixation	O
(	O
see	O
the	O
blind	O
spot	O
article	O
)	O
.	O

There	O
is	O
no	O
clinical	O
disease	O
detected	O
,	O
however	O
children	O
of	O
affected	O
individuals	O
have	O
increased	O
risk	O
of	O
having	O
Hemoglobin	other-disease
D	other-disease
Disease	other-disease
,	O
Hemoglobin	other-disease
SD	other-disease
disease	other-disease
or	O
Beta-thalassemia	other-disease
Disease	other-disease
.	O

A	O
growing	O
hematoma	other-disease
causes	O
pressure	O
necrosis	O
of	O
the	O
bone	O
surrounding	O
the	O
hematoma	other-disease
,	O
but	O
only	O
on	O
rare	O
occasions	O
does	O
it	O
cause	O
facial	O
distortion	O
.	O

Isolated	other-disease
sleep	other-disease
paralysis	other-disease
is	O
commonly	O
seen	O
in	O
patients	O
that	O
have	O
been	O
diagnosed	O
with	O
narcolepsy	O
.	O

He	O
was	O
elected	O
a	O
Fellow	O
of	O
the	O
Royal	O
College	O
of	O
Physicians	O
in	O
1929	O
,	O
delivering	O
the	O
Croonian	O
Lecture	O
on	O
The	O
Natural	O
History	O
of	O
Bright	other-disease
's	other-disease
Disease	other-disease
in	O
1941	O
.	O

Pre-clinical	O
studies	O
that	O
simultaneously	O
targeted	O
mTOR	O
and	O
metabolism	O
with	O
AZD8055	O
(	O
inhibitor	O
of	O
mTORC1	O
and	O
mTORC2	O
)	O
and	O
2-DG	O
,	O
respectively	O
inhibited	O
mammary	other-disease
tumors	other-disease
from	O
forming	O
.	O

PIP	O
expression	O
is	O
necessary	O
for	O
viability	O
and	O
invasiveness	O
of	O
this	O
subtype	O
of	O
breast	other-disease
cancer	other-disease
.	O

The	O
most	O
consistent	O
aspect	O
of	O
therapy	O
in	O
CF	other-disease
is	O
limiting	O
and	O
treating	O
the	O
lung	O
damage	O
caused	O
by	O
thick	O
mucus	O
and	O
infection	O
,	O
with	O
the	O
goal	O
of	O
maintaining	O
quality	O
of	O
life	O
.	O

People	O
suffering	O
from	O
6PGD	O
or	O
G6PD	O
deficiency	O
(	O
or	O
both	O
)	O
are	O
at	O
risk	O
of	O
hemolytic	other-disease
anemia	other-disease
in	O
states	O
of	O
oxidative	O
stress	O
.	O

Insomnia	other-disease
is	O
40	O
%	O
more	O
common	O
in	O
women	O
than	O
in	O
men	O
.	O

The	O
most	O
common	O
metastasis	O
sites	O
for	O
colorectal	other-disease
cancer	other-disease
are	O
the	O
liver	O
,	O
the	O
lung	O
and	O
the	O
peritoneum	O
.	O

A	O
unilateral	O
single	O
palmar	O
crease	O
was	O
also	O
reported	O
in	O
a	O
case	O
of	O
chromosome	O
9	O
mutation	O
causing	O
Nevoid	other-disease
basal	other-disease
cell	other-disease
carcinoma	other-disease
syndrome	other-disease
and	O
Robinow	other-disease
syndrome	other-disease
.	O

That	O
incident	O
,	O
combined	O
with	O
years	O
of	O
chronic	other-disease
arthritis	other-disease
,	O
forced	O
him	O
to	O
cut	O
back	O
drastically	O
on	O
performances	O
.	O

In	O
a	O
monogamous	O
couple	O
,	O
a	O
seronegative	O
female	O
runs	O
a	O
greater	O
than	O
30	O
%	O
per	O
year	O
risk	O
of	O
contracting	O
an	O
HSV	other-disease
infection	O
from	O
a	O
seropositive	O
male	O
partner	O
.	O

Risk	O
factors	O
for	O
suicide	O
attempts	O
and	O
death	O
from	O
suicide	O
in	O
people	O
with	O
bipolar	other-disease
disorder	other-disease
include	O
older	O
age	O
,	O
prior	O
suicide	O
attempts	O
,	O
a	O
depressive	O
or	O
mixed	O
index	O
episode	O
(	O
first	O
episode	O
)	O
,	O
a	O
manic	O
index	O
episode	O
with	O
psychotic	O
symptoms	O
,	O
hopelessness	O
or	O
psychomotor	O
agitation	O
present	O
during	O
the	O
episodes	O
,	O
co-existing	O
anxiety	other-disease
disorder	other-disease
,	O
a	O
first	O
degree	O
relative	O
with	O
a	O
mood	other-disease
disorder	other-disease
or	O
suicide	O
,	O
interpersonal	O
conflicts	O
,	O
occupational	O
problems	O
,	O
bereavement	O
or	O
social	O
isolation	O
.	O

He	O
died	O
on	O
March	O
17	O
,	O
2020	O
at	O
his	O
home	O
in	O
Winston-Salem	O
,	O
North	O
Carolina	O
of	O
kidney	other-disease
failure	other-disease
.	O

Mirus	O
relates	O
the	O
history	O
of	O
the	O
area	O
,	O
where	O
victims	O
of	O
the	O
Black	other-disease
Plague	other-disease
were	O
massacred	O
on	O
the	O
orders	O
of	O
a	O
stranger	O
who	O
influenced	O
the	O
townspeople	O
to	O
turn	O
against	O
one	O
another	O
.	O

More	O
proximal	O
portions	O
of	O
the	O
artery	O
may	O
cause	O
spastic	other-disease
paraparesis	other-disease
and	O
sensory	other-disease
loss	other-disease
contralateral	other-disease
to	O
the	O
lesioned	O
side	O
.	O

This	O
disorder	O
should	O
not	O
be	O
confused	O
with	O
de	O
Quervain	other-disease
's	other-disease
thyroiditis	other-disease
which	O
is	O
another	O
form	O
of	O
subacute	O
thyroiditis	O
.	O

Candidiasis	other-disease
is	O
one	O
of	O
the	O
three	O
most	O
common	O
vaginal	O
infections	O
along	O
with	O
bacterial	other-disease
vaginosis	other-disease
and	O
trichomonas	other-disease
.	O

Thrombocytopenia	other-disease
is	O
defined	O
as	O
the	O
drop	O
in	O
platelet	O
count	O
from	O
the	O
normal	O
range	O
of	O
150,000	O
–400,000	O
/	O
μL	O
to	O
a	O
count	O
lower	O
than	O
150,000	O
/	O
μL	O
.	O

She	O
is	O
a	O
former	O
Chief	O
Scientific	O
Adviser	O
to	O
the	O
Alzheimer	O
's	O
Research	O
Trust	O
,	O
and	O
in	O
2012	O
was	O
appointed	O
a	O
CBE	O
for	O
her	O
contribution	O
to	O
Alzheimer	other-disease
's	O
research	O
.	O

Vitamin	other-disease
C	other-disease
deficiency	other-disease
also	O
has	O
detrimental	O
effects	O
on	O
the	O
South	O
African	O
population	O
.	O

For	O
example	O
,	O
in	O
cases	O
of	O
hypoalbuminemia	other-disease
the	O
calculated	O
value	O
of	O
the	O
anion	O
gap	O
should	O
be	O
increased	O
by	O
2.3	O
to	O
2.5	O
mEq/L	O
per	O
each	O
1	O
g/dL	O
decrease	O
in	O
serum	O
albumin	O
concentration	O
(	O
refer	O
to	O
Sample	O
calculations	O
,	O
below	O
)	O
.	O

Sometimes	O
a	O
CSF	other-disease
leak	other-disease
will	O
heal	O
on	O
its	O
own	O
.	O

Links	O
have	O
been	O
reported	O
between	O
oral	O
sex	O
and	O
oral	other-disease
cancer	other-disease
with	O
human	other-disease
papillomavirus	other-disease
(	O
HPV	other-disease
)	O
-infected	O
people	O
.	O

Extreme	O
shortness	O
in	O
humans	O
with	O
proportional	O
body	O
parts	O
usually	O
has	O
a	O
hormonal	O
cause	O
,	O
such	O
as	O
growth-hormone	O
deficiency	O
,	O
once	O
called	O
``	O
pituitary	other-disease
dwarfism	other-disease
``	O
.	O

Autism	O
spectrum	O
disorder	O
(	O
ASD	other-disease
)	O
is	O
a	O
range	O
of	O
complex	O
neurodevelopmental	O
disorders	O
,	O
characterized	O
by	O
social	O
impairments	O
,	O
communication	O
difficulties	O
,	O
and	O
restricted	O
,	O
repetitive	O
,	O
and	O
stereotyped	O
patterns	O
of	O
behavior	O
(	O
NINDS	O
,	O
2014	O
)	O
.	O

SSRIs	O
,	O
topical	O
anesthetics	O
,	O
and	O
psychotherapy	O
are	O
commonly	O
used	O
to	O
treat	O
premature	other-disease
ejaculation	other-disease
.	O

The	O
expression	O
of	O
miR-181c	O
is	O
relevant	O
to	O
characterize	O
a	O
Breast	other-disease
cancer	other-disease
form	O
,	O
the	O
HER2/neu	O
.	O

As	O
a	O
result	O
,	O
the	O
cells	O
are	O
inflexible	O
and	O
can	O
not	O
easily	O
flow	O
through	O
blood	O
vessels	O
,	O
increasing	O
the	O
risk	O
of	O
blood	other-disease
clots	other-disease
and	O
possibly	O
depriving	O
vital	O
organs	O
of	O
oxygen	O
.	O

When	O
the	O
depression	other-disease
is	O
caused	O
by	O
a	O
medication	O
,	O
drug	O
of	O
abuse	O
,	O
or	O
exposure	O
to	O
a	O
toxin	O
,	O
it	O
is	O
then	O
diagnosed	O
as	O
a	O
specific	other-disease
mood	other-disease
disorder	other-disease
(	O
previously	O
called	O
``	O
substance-induced	other-disease
mood	other-disease
disorder	other-disease
``	O
in	O
the	O
DSM-IV-TR	O
)	O
.	O

O	O
’	O
Laughlin	O
was	O
an	O
early	O
opponent	O
of	O
state	O
and	O
national	O
lockdowns	O
as	O
it	O
related	O
to	O
the	O
COVID-19	other-disease
pandemic	O
and	O
advocated	O
for	O
the	O
state	O
to	O
allow	O
visitors	O
to	O
return	O
to	O
nursing	O
homes	O
.	O

Atrophia	other-disease
Maculosa	other-disease
Varioliformis	other-disease
Cutis	other-disease
(	O
AMVC	other-disease
)	O
is	O
a	O
condition	O
involving	O
spontaneous	O
scarring	O
,	O
specifically	O
depressed	O
scars	O
on	O
the	O
face	O
which	O
occurs	O
over	O
a	O
period	O
of	O
months	O
to	O
years	O
.	O

Kristin	O
suffered	O
severe	O
postpartum	other-disease
psychosis	other-disease
(	O
PPP	other-disease
)	O
after	O
losing	O
her	O
unborn	O
child	O
on	O
December	O
5	O
,	O
1997	O
.	O

Epileptic	other-disease
and	O
migraine	other-disease
auras	O
are	O
due	O
to	O
the	O
involvement	O
of	O
specific	O
areas	O
of	O
the	O
brain	O
,	O
which	O
are	O
those	O
that	O
determine	O
the	O
symptoms	O
of	O
the	O
aura	O
.	O

One	O
early	O
description	O
of	O
HACE	other-disease
may	O
have	O
been	O
published	O
in	O
1969	O
after	O
a	O
group	O
of	O
Indian	O
soldiers	O
made	O
a	O
rapid	O
ascent	O
to	O
almost	O
.	O

Because	O
,	O
at	O
least	O
in	O
cases	O
of	O
genetically	O
recessive	other-disease
deafness	other-disease
,	O
village	O
sign	O
languages	O
are	O
used	O
by	O
large	O
numbers	O
of	O
hearing	O
people	O
who	O
also	O
use	O
spoken	O
languages	O
,	O
the	O
structures	O
of	O
village	O
sign	O
may	O
be	O
strongly	O
influenced	O
by	O
the	O
structure	O
of	O
the	O
spoken	O
languages	O
.	O

Many	O
people	O
with	O
personality	O
disorders	O
,	O
potentially	O
caused	O
or	O
made	O
worse	O
by	O
dysfunctional	O
upbringing	O
,	O
especially	O
Borderline	other-disease
Personality	other-disease
Disorder	other-disease
(	O
BPD	other-disease
)	O
and	O
some	O
others	O
,	O
perpetually	O
vascilate	O
between	O
the	O
poles	O
of	O
the	O
dialectic	O
conflict	O
,	O
with	O
resulting	O
instability	O
causing	O
problems	O
in	O
living	O
that	O
are	O
not	O
mediated	O
by	O
other	O
therapy	O
modalities	O
.	O

``	O
Brucella	O
ceti	O
''	O
,	O
most	O
prevalent	O
in	O
dolphins	O
,	O
has	O
been	O
shown	O
to	O
cause	O
chronic	O
disease	O
,	O
increasing	O
the	O
chance	O
of	O
failed	O
birth	O
and	O
miscarriages	O
,	O
male	other-disease
infertility	other-disease
,	O
neurobrucellosis	other-disease
,	O
cardiopathies	other-disease
,	O
bone	O
and	O
skin	O
lesions	O
,	O
strandings	O
and	O
death	O
.	O

He	O
was	O
a	O
member	O
of	O
the	O
Association	O
of	O
American	O
Physicians	O
and	O
Surgeons	O
and	O
served	O
as	O
Committee	O
chairman	O
with	O
the	O
American	O
Gastroenterological	O
Association	O
and	O
on	O
the	O
National	O
Scientific	O
Advisory	O
Board	O
of	O
the	O
National	O
Foundation	O
for	O
Ileitis	other-disease
and	O
Colitis	other-disease
.	O

This	O
defective	O
clearance	O
may	O
contribute	O
to	O
the	O
buildup	O
of	O
neurotoxic	O
amyloid-beta	O
that	O
is	O
thought	O
to	O
contribute	O
to	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
.	O

APP	O
is	O
best	O
known	O
as	O
the	O
precursor	O
molecule	O
whose	O
proteolysis	O
generates	O
amyloid	O
beta	O
(	O
Aβ	O
)	O
,	O
a	O
polypeptide	O
containing	O
37	O
to	O
49	O
amino	O
acid	O
residues	O
,	O
whose	O
amyloid	O
fibrillar	O
form	O
is	O
the	O
primary	O
component	O
of	O
amyloid	O
plaques	O
found	O
in	O
the	O
brains	O
of	O
Alzheimer	other-disease
's	O
disease	O
patients	O
.	O

The	O
duration	O
of	O
kidney	other-disease
ischemia	other-disease
does	O
not	O
affect	O
kidney	O
function	O
either	O
in	O
the	O
short	O
term	O
or	O
long	O
term	O
.	O

Oral	other-disease
submucous	other-disease
fibrosis	other-disease
,	O
one	O
such	O
disorder	O
,	O
is	O
a	O
malignant	O
condition	O
that	O
is	O
severely	O
debilitating	O
and	O
has	O
no	O
cure	O
.	O

Examples	O
of	O
neuropathic	other-disease
itch	other-disease
in	O
origin	O
are	O
notalgia	other-disease
paresthetica	other-disease
,	O
brachioradial	other-disease
pruritus	other-disease
,	O
brain	other-disease
tumors	other-disease
,	O
multiple	other-disease
sclerosis	other-disease
,	O
peripheral	other-disease
neuropathy	other-disease
,	O
and	O
nerve	other-disease
irritation	other-disease
.	O

On	O
March	O
6	O
,	O
a	O
woman	O
from	O
Pinal	O
County	O
was	O
diagnosed	O
with	O
COVID-19	other-disease
.	O

People	O
with	O
ASD	other-disease
who	O
experience	O
hyperacusis	other-disease
may	O
have	O
unpleasant	O
emotions	O
,	O
such	O
as	O
fear	O
and	O
anxiety	O
,	O
and	O
uncomfortable	O
physical	O
sensations	O
in	O
noisy	O
environments	O
with	O
loud	O
sounds	O
.	O

Acephalgic	other-disease
migraine	other-disease
is	O
a	O
neurological	O
syndrome	O
.	O

Some	O
argue	O
that	O
if	O
the	O
operation	O
is	O
performed	O
before	O
eight	O
years	O
of	O
age	O
,	O
few	O
cardiac	O
abnormalities	O
such	O
as	O
cardiac	other-disease
dysrhythmia	other-disease
are	O
expected	O
later	O
in	O
life	O
.	O

BFRBs	other-disease
are	O
among	O
the	O
most	O
poorly	O
understood	O
,	O
misdiagnosed	O
,	O
and	O
undertreated	O
groups	O
of	O
disorders	O
.	O

Chaudhuri	O
is	O
known	O
to	O
have	O
done	O
extensive	O
research	O
on	O
diseases	O
such	O
as	O
Cholera	other-disease
,	O
Malaria	other-disease
,	O
Amoebiasis	other-disease
and	O
Hypoproteinemia	other-disease
and	O
was	O
credited	O
with	O
contributions	O
to	O
chemotherapy	O
and	O
chemoprophylaxis	O
of	O
malaria	other-disease
.	O

Behnke	O
separated	O
the	O
symptoms	O
of	O
Arterial	other-disease
Gas	other-disease
Embolism	other-disease
(	O
AGE	other-disease
)	O
from	O
those	O
of	O
decompression	O
sickness	O
and	O
suggested	O
the	O
use	O
of	O
oxygen	O
in	O
recompression	O
therapy	O
.	O

Sickle-cell	other-disease
anemia	other-disease
is	O
associated	O
with	O
altered	O
average	O
vessel	O
diameter	O
.	O

Fearing	O
worse	O
,	O
Martin	O
's	O
testing	O
efforts	O
ruled	O
out	O
contagious	O
diseases	O
,	O
like	O
Lassa	other-disease
fever	other-disease
or	O
ebola	other-disease
which	O
have	O
much-higher	O
mortality	O
rates	O
.	O

With	O
extreme	O
rarity	O
,	O
infertility	O
and	O
premature	other-disease
menopause	other-disease
have	O
occurred	O
as	O
a	O
result	O
of	O
mumps	other-disease
oophoritis	other-disease
.	O

The	O
prison	O
has	O
a	O
Dangerous	other-disease
Severe	other-disease
Personality	other-disease
Disorder	other-disease
(	O
DSPD	other-disease
)	O
unit	O
and	O
a	O
Close	O
Supervision	O
Centre	O
(	O
CSC	O
)	O
.	O

It	O
was	O
approved	O
by	O
the	O
U.S.	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
for	O
the	O
treatment	O
of	O
mCRPC	other-disease
in	O
the	O
United	O
States	O
in	O
August	O
2012	O
,	O
and	O
for	O
the	O
treatment	O
of	O
nonmetastatic	other-disease
castration-resistant	other-disease
prostate	other-disease
cancer	other-disease
in	O
July	O
2018	O
.	O

Folic	O
acid	O
deficiency	O
is	O
a	O
common	O
association	O
of	O
nutritional	other-disease
anemia	other-disease
and	O
iron	other-disease
deficiency	other-disease
anemia	other-disease
is	O
the	O
most	O
common	O
nutritional	O
disorder	O
.	O

Specific	other-disease
language	other-disease
impairment	other-disease
is	O
a	O
disorder	O
that	O
prevents	O
children	O
from	O
developing	O
language	O
normally	O
.	O

In	O
2017	O
,	O
a	O
44-year-old	O
patient	O
with	O
MPS	other-disease
II	other-disease
was	O
treated	O
with	O
gene	O
therapy	O
in	O
an	O
attempt	O
to	O
prevent	O
further	O
damage	O
by	O
the	O
disease	O
.	O

The	O
availability	O
of	O
asparagine	O
is	O
also	O
important	O
for	O
protein	O
synthesis	O
during	O
replication	O
of	O
poxviruses	other-disease
.	O

In	O
1991	O
,	O
student	O
Jill	O
Stewart	O
started	O
IU	O
Dance	O
Marathon	O
in	O
honor	O
of	O
her	O
friend	O
,	O
Ryan	O
White	O
,	O
who	O
died	O
from	O
AIDS	other-disease
the	O
year	O
before	O
.	O

In	O
May	O
of	O
2020	O
,	O
Sandringham	O
Primary	O
banned	O
dairy	O
products	O
from	O
school	O
grounds	O
,	O
due	O
to	O
a	O
student	O
with	O
a	O
severe	O
allergy	other-disease
to	other-disease
dairy	other-disease
.	O

The	O
growth	O
of	O
dialysis	O
facilities	O
in	O
the	O
United	O
States	O
is	O
the	O
result	O
of	O
more	O
Americans	O
developing	O
end-stage	other-disease
renal	other-disease
disease	other-disease
.	O

Diseases	O
that	O
appear	O
to	O
be	O
increased	O
in	O
Heterozygotes	O
are	O
Celiac	other-disease
Disease	other-disease
and	O
Type	other-disease
1	other-disease
Diabetes	other-disease
.	O

Signs	O
of	O
a	O
nasal	O
TVT	other-disease
include	O
nasal	O
fistulae	O
,	O
nosebleeds	O
and	O
other	O
nasal	O
discharge	O
,	O
facial	O
swelling	O
,	O
and	O
enlargement	O
of	O
the	O
submandibular	O
lymph	O
nodes	O
.	O

However	O
,	O
monitoring	O
is	O
required	O
for	O
metabolic	O
side	O
effects	O
including	O
weight	O
gain	O
and	O
diabetes	other-disease
,	O
as	O
well	O
as	O
movement	O
disorders	O
related	O
to	O
extrapyramidal	O
side	O
effects	O
such	O
as	O
tardive	other-disease
dyskinesia	other-disease
.	O

Combining	O
a	O
psychological	O
evaluation	O
with	O
data	O
from	O
magnetic	O
resonance	O
imaging	O
,	O
Kaien	O
’	O
s	O
work	O
found	O
a	O
link	O
between	O
Major	other-disease
Depressive	other-disease
Disorder	other-disease
(	O
MDD	other-disease
)	O
and	O
shrinkage	O
of	O
an	O
area	O
called	O
the	O
limbic	O
system	O
.	O
''	O

Holtzman	O
's	O
lab	O
is	O
known	O
for	O
uncovering	O
how	O
apoE4	O
contributes	O
to	O
Alzheimer	other-disease
's	O
disease	O
as	O
well	O
as	O
how	O
synaptic	O
activity	O
and	O
sleep	O
modulate	O
amyloid	O
beta	O
and	O
tau	O
levels	O
in	O
the	O
brain	O
.	O

Its	O
Jenner	O
Building	O
,	O
a	O
former	O
smallpox	other-disease
hospital	O
,	O
is	O
a	O
Grade	O
II	O
listed	O
building	O
.	O

A	O
recombinant	O
,	O
slightly	O
modified	O
version	O
of	O
interleukin	O
1	O
receptor	O
antagonist	O
called	O
anakinra	O
is	O
used	O
in	O
the	O
treatment	O
of	O
rheumatoid	other-disease
arthritis	other-disease
,	O
an	O
autoimmune	O
disease	O
in	O
which	O
IL-1	O
plays	O
a	O
key	O
role	O
.	O

As	O
with	O
any	O
aneurysm	O
,	O
a	O
Rasmussen	other-disease
's	other-disease
aneurysm	other-disease
is	O
at	O
increased	O
risk	O
of	O
rupture	O
and	O
bleeding	O
into	O
the	O
lungs	O
.	O

DIOS	other-disease
was	O
previously	O
known	O
as	O
meconium	other-disease
ileus	other-disease
equivalent	O
,	O
a	O
name	O
which	O
highlights	O
its	O
similarity	O
to	O
the	O
intestinal	other-disease
obstruction	other-disease
seen	O
in	O
newborn	O
infants	O
with	O
cystic	other-disease
fibrosis	other-disease
.	O

Hypercoagulable	O
states	O
due	O
to	O
genetic	O
conditions	O
that	O
increase	O
the	O
risk	O
of	O
clotting	O
may	O
contribute	O
to	O
the	O
development	O
of	O
SVT	other-disease
,	O
such	O
as	O
factor	O
V	O
Leiden	O
,	O
prothrombin	O
20210A	O
mutation	O
,	O
and	O
protein	O
C	O
,	O
S	O
,	O
and	O
antithrombin	O
III	O
and	O
factor	O
XII	O
deficiency	O
.	O

SMYD3	O
trimethylates	O
a	O
lysine	O
residue	O
on	O
MAP3K2	O
,	O
which	O
causes	O
crosstalk	O
into	O
the	O
MAP	O
kinase	O
signaling	O
pathway	O
in	O
Ras-driven	other-disease
cancers	other-disease
.	O

Skin	O
lesions	O
are	O
edematous	other-disease
,	O
urticarialike	other-disease
annular	other-disease
papules	other-disease
and	O
plaques	other-disease
.	O

There	O
are	O
several	O
preventive	O
foot	O
hygiene	O
measures	O
that	O
can	O
prevent	O
athlete	other-disease
's	other-disease
foot	other-disease
and	O
reduce	O
recurrence	O
.	O

Some	O
of	O
these	O
mutations	O
are	O
not	O
directly	O
lethal	O
and	O
instead	O
confer	O
resistance	O
to	O
malaria	other-disease
,	O
particularly	O
in	O
Africa	O
where	O
malaria	other-disease
is	O
epidemic	O
.	O

Blood	O
tests	O
are	O
also	O
used	O
to	O
identify	O
and	O
measure	O
tumor	other-disease
markers	O
(	O
usually	O
proteins	O
present	O
in	O
the	O
bloodstream	O
)	O
that	O
are	O
specific	O
to	O
testicular	O
cancer	other-disease
.	O

Glial	other-disease
scarring	other-disease
is	O
a	O
consequence	O
of	O
several	O
neurodegenerative	O
conditions	O
,	O
as	O
well	O
as	O
injury	O
that	O
severs	O
neural	O
material	O
.	O

Talley	O
also	O
has	O
a	O
strong	O
interest	O
in	O
gastrointestinal	other-disease
complications	other-disease
in	O
diabetes	other-disease
.	O

Miroscopically	O
there	O
are	O
epithelioid	other-disease
granulomas	other-disease
and	O
vasculitis	other-disease
in	O
the	O
subcutaneous	O
tissue	O
,	O
making	O
it	O
a	O
form	O
of	O
panicullitis	other-disease
.	O

The	O
gait	O
of	O
PVL	other-disease
patients	O
with	O
spastic	other-disease
diplegia	other-disease
exhibits	O
an	O
unusual	O
pattern	O
of	O
flexing	O
during	O
walking	O
.	O

Generally	O
,	O
these	O
conditions	O
cause	O
other	O
signs	O
and	O
symptoms	O
as	O
well	O
,	O
and	O
pneumothorax	other-disease
is	O
not	O
usually	O
the	O
primary	O
finding	O
.	O

Café	other-disease
au	other-disease
lait	other-disease
spots	other-disease
are	O
often	O
harmless	O
but	O
may	O
be	O
associated	O
with	O
syndromes	O
such	O
as	O
neurofibromatosis	other-disease
type	other-disease
1	other-disease
and	O
McCune–Albright	other-disease
syndrome	O
.	O

Neuromuscular	O
disease	O
can	O
be	O
caused	O
by	O
autoimmune	O
disorders	O
,	O
genetic	O
or	O
hereditary	O
disorders	O
such	O
as	O
channelopathies	other-disease
,	O
or	O
neurodegenerative	other-disease
diseases	other-disease
.	O

Canine	O
chromosome	O
7	O
is	O
expressed	O
in	O
the	O
hippocampus	O
of	O
the	O
brain	O
,	O
the	O
same	O
area	O
that	O
Obsessive	other-disease
Compulsive	other-disease
Disorder	other-disease
is	O
expressed	O
in	O
human	O
patients	O
.	O

Marinacci	O
(	O
1960	O
)	O
applied	O
EMG	O
biofeedback	O
to	O
neuromuscular	O
disorders	O
(	O
where	O
proprioception	O
is	O
disrupted	O
)	O
including	O
Bell	other-disease
Palsy	other-disease
(	O
one-sided	O
facial	O
paralysis	O
)	O
,	O
polio	other-disease
,	O
and	O
stroke	O
.	O

This	O
disorder	O
can	O
cause	O
disfigurement	O
and	O
possibly	O
death	O
and	O
can	O
lead	O
to	O
gigantism	O
,	O
a	O
hormone	O
disorder	O
shown	O
in	O
“	O
giants	other-disease
”	O
such	O
as	O
André	O
the	O
Giant	O
,	O
where	O
it	O
occurs	O
before	O
the	O
epiphyseal	O
plates	O
in	O
bones	O
close	O
in	O
puberty	O
.	O

It	O
has	O
been	O
shown	O
to	O
be	O
a	O
target	O
of	O
autoantibodies	O
in	O
the	O
human	O
autoimmune	O
diseases	O
,	O
polymyositis	other-disease
or	O
dermatomyositis	O

Brain	other-disease
damage	other-disease
of	O
various	O
types	O
ranging	O
from	O
stroke-like	O
focal	O
effects	O
to	O
impaired	O
memory	O
and	O
thinking	O
can	O
occur	O
.	O

The	O
progressive	O
degeneration	O
of	O
the	O
motor	O
neurons	O
in	O
ALS	other-disease
eventually	O
leads	O
to	O
their	O
death	O
.	O

While	O
the	O
exact	O
cause	O
of	O
pre-eclampsia	other-disease
remains	O
unclear	O
,	O
there	O
is	O
strong	O
evidence	O
that	O
a	O
major	O
cause	O
predisposing	O
a	O
susceptible	O
woman	O
to	O
pre-eclampsia	other-disease
is	O
an	O
abnormally	O
implanted	O
placenta	O
.	O

Jankowski	O
is	O
an	O
expert	O
in	O
reflux	other-disease
esophagitis	other-disease
,	O
Barrett	other-disease
's	other-disease
esophagus	other-disease
,	O
acute	O
medicine	O
and	O
clinical	O
trials	O
as	O
well	O
as	O
in	O
cancer	O
prevention	O
and	O
health	O
promotion	O
.	O

Corticosteroid	O
nasal	O
sprays	O
can	O
be	O
used	O
to	O
relieve	O
the	O
symptoms	O
of	O
sinusitis	other-disease
,	O
hay	other-disease
fever	other-disease
,	O
allergic	other-disease
rhinitis	other-disease
and	O
non-allergic	other-disease
(	other-disease
perennial	other-disease
)	other-disease
rhinitis	other-disease
.	O

Mitochondrial	O
disorders	O
,	O
including	O
MERRF	other-disease
,	O
may	O
present	O
at	O
any	O
age	O
.	O

Our	O
knowledge	O
of	O
renal	other-disease
ischemia	other-disease
comes	O
from	O
animal	O
studies	O
.	O

Borna	other-disease
disease	O
viruses	other-disease
1	other-disease
and	other-disease
2	other-disease
are	O
neurotropic	O
viruses	O
and	O
members	O
of	O
the	O
``	O
Bornaviridae	other-disease
``	O
family	O
within	O
the	O
``	O
Mononegavirales	other-disease
``	O
order	O
.	O

Implicit	O
cognition	O
is	O
another	O
influential	O
predictor	O
for	O
bipolar	other-disease
disorder	other-disease
and	O
unipolar	other-disease
disorder	other-disease
.	O

The	O
Ames	O
strain	O
came	O
to	O
wide	O
public	O
attention	O
during	O
the	O
2001	O
anthrax	other-disease
attacks	O
when	O
seven	O
letters	O
containing	O
it	O
were	O
mailed	O
to	O
media	O
outlets	O
and	O
US	O
Senators	O
on	O
September	O
18	O
,	O
2001	O
and	O
October	O
9	O
,	O
2001	O
.	O

Brucellosis	other-disease
affects	O
almost	O
all	O
mammals	O
.	O

Cardiac	other-disease
sarcoidosis	other-disease
may	O
also	O
cause	O
congestive	O
heart	O
failure	O
when	O
granulomas	O
cause	O
myocardial	O
fibrosis	O
and	O
scarring	O
.	O

Teva	O
and	O
Technion	O
filed	O
patent	O
applications	O
for	O
this	O
racemically	O
pure	O
compound	O
,	O
methods	O
to	O
make	O
it	O
,	O
and	O
methods	O
to	O
use	O
it	O
to	O
treat	O
Parkinsons	other-disease
and	O
other	O
disorders	O
,	O
and	O
Technion	O
eventually	O
assigned	O
its	O
rights	O
to	O
Teva	O
.	O

The	O
three	O
diseases	O
are	O
classified	O
together	O
as	O
the	O
GM2	other-disease
gangliosidoses	O
,	O
because	O
each	O
disease	O
represents	O
a	O
distinct	O
molecular	O
point	O
of	O
failure	O
in	O
the	O
activation	O
of	O
the	O
same	O
enzyme	O
,	O
beta-hexosaminidase	O
.	O

Expansions	O
of	O
the	O
triplet	O
repeat	O
in	O
the	O
huntington	O
's	O
gene	O
leads	O
to	O
loss	O
of	O
interaction	O
with	O
HIP14	O
which	O
Yanai	O
and	O
colleagues	O
speculate	O
is	O
involved	O
in	O
the	O
pathology	O
of	O
Huntington	other-disease
's	other-disease
disease	other-disease
.	O

Alexander	O
(	O
Sandor	O
)	O
Stephen	O
Gallus	O
(	O
born	O
5	O
June	O
1940	O
in	O
Sopron	O
,	O
Hungary	O
)	O
is	O
a	O
medical	O
researcher	O
in	O
haemostasis	other-disease
and	O
thrombosis	other-disease
,	O
the	O
son	O
of	O
archaeologist	O
Sandor	O
Gallus	O
,	O
and	O
the	O
husband	O
of	O
former	O
Australian	O
politician	O
Chris	O
Gallus	O
.	O

Wasting	other-disease
-	O
Wasting	other-disease
is	O
when	O
a	O
child	O
's	O
weight	O
is	O
too	O
low	O
for	O
their	O
height	O
.	O

For	O
example	O
,	O
Japan	O
has	O
no	O
mandatory	O
mumps	other-disease
vaccination	O
and	O
is	O
fourth	O
in	O
the	O
world	O
in	O
mumps	other-disease
cases	O
,	O
after	O
China	O
,	O
Nepal	O
and	O
Burkina	O
Faso	O
,	O
according	O
to	O
data	O
from	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
.	O

Beers	O
was	O
diagnosed	O
with	O
Osteochondritis	other-disease
dissecans	other-disease
in	O
2006	O
,	O
at	O
the	O
age	O
of	O
12	O
.	O

Shurugwi	O
has	O
not	O
escaped	O
the	O
scourge	O
of	O
the	O
AIDS	other-disease
pandemic	O
with	O
many	O
of	O
its	O
youthful	O
people	O
succumbing	O
to	O
the	O
deadly	O
virus	O
.	O

Many	O
of	O
the	O
symptoms	O
initially	O
experienced	O
by	O
CSR	other-disease
sufferers	O
are	O
effects	O
of	O
an	O
extended	O
activation	O
of	O
the	O
human	O
body	O
's	O
fight-or-flight	O
response	O
.	O

to	O
be	O
differentiated	O
from	O
colonic	other-disease
cutoff	other-disease
sign	other-disease
which	O
is	O
a	O
dilatation	O
of	O
a	O
segment	O
of	O
large	O
bowel	O
.	O

Other	O
well	O
known	O
causes	O
include	O
diseases	O
of	O
the	O
kidney	other-disease
.	O

Latent	O
syphilis	other-disease
is	O
defined	O
as	O
having	O
serologic	O
proof	O
of	O
infection	O
without	O
symptoms	O
of	O
disease	O
.	O

In	O
normal	other-disease
pressure	other-disease
hydrocephalus	other-disease
,	O
expansion	O
of	O
the	O
lateral	O
ventricles	O
causes	O
distortion	O
of	O
the	O
fibers	O
of	O
the	O
corona	O
radiata	O
.	O

Acute	O
HIV	other-disease
infection	O
can	O
mimic	O
signs	O
similar	O
to	O
those	O
of	O
infectious	O
mononucleosis	O
,	O
and	O
tests	O
should	O
be	O
performed	O
for	O
pregnant	O
women	O
for	O
the	O
same	O
reason	O
as	O
toxoplasmosis	other-disease
.	O

This	O
is	O
almost	O
exactly	O
matching	O
the	O
aberrant	O
splicing	O
pattern	O
seen	O
in	O
post-mortem	O
SZ	other-disease
patient	O
’	O
s	O
brains	O
.	O

Also	O
applicable	O
is	O
the	O
Virchow	other-disease
's	other-disease
triad	other-disease
of	other-disease
blood	other-disease
stasis	other-disease
,	O
endothelial	other-disease
injury	other-disease
,	O
and	O
hypercoagulable	other-disease
state	other-disease
.	O

There	O
is	O
no	O
cure	O
for	O
Gerstmann	other-disease
syndrome	O
.	O

Iatrogenesis	other-disease
may	O
thus	O
include	O
mental	O
suffering	O
via	O
medical	O
beliefs	O
or	O
a	O
practitioner	O
's	O
statements	O
.	O

Microcytic	other-disease
anemia	other-disease
ultimately	O
develops	O
in	O
respect	O
to	O
inadequate	O
HBB	O
protein	O
for	O
sufficient	O
red	O
blood	O
cell	O
functioning	O
.	O

``	O
MDC1	O
``	O
has	O
anti-apoptotic	O
properties	O
by	O
directly	O
inhibiting	O
the	O
apoptotic	O
activity	O
of	O
the	O
tumor	other-disease
suppressing	O
protein	O
p53	O
.	O

Wakatsuki	O
died	O
of	O
Angina	other-disease
pectoris	O
at	O
his	O
summer	O
home	O
in	O
Itō	O
,	O
Shizuoka	O
on	O
November	O
20	O
,	O
1949	O
.	O

It	O
can	O
be	O
caused	O
by	O
mutations	O
of	O
specific	O
genes	O
,	O
damage	O
to	O
the	O
pituitary	O
gland	O
,	O
Turner	other-disease
's	other-disease
syndrome	other-disease
,	O
poor	O
nutrition	O
,	O
or	O
even	O
stress	O
(	O
leading	O
to	O
psychogenic	O
dwarfism	O
)	O
.	O

In	O
Morocco	O
,	O
neonatal	other-disease
tetanus	other-disease
accounted	O
for	O
20	O
%	O
of	O
neonatal	O
deaths	O
in	O
1987	O
but	O
only	O
2	O
%	O
in	O
1992	O
.	O

Expressive	other-disease
aphasia	other-disease
occurs	O
in	O
approximately	O
12	O
%	O
of	O
new	O
cases	O
of	O
aphasia	other-disease
caused	O
by	O
stroke	other-disease
.	O

The	O
long-acting	O
injectable	O
form	O
of	O
risperidone	O
may	O
be	O
advantageous	O
over	O
long	O
acting	O
first	O
generation	O
antipsychotics	O
,	O
as	O
it	O
is	O
better	O
tolerated	O
(	O
fewer	O
extrapyramidal	O
effects	O
)	O
and	O
because	O
long	O
acting	O
injectable	O
formulations	O
of	O
first	O
generation	O
antipsychotics	O
may	O
increase	O
the	O
risk	O
of	O
depression	other-disease
.	O

Monkeypox	other-disease
as	O
a	O
disease	O
in	O
humans	O
was	O
first	O
associated	O
with	O
an	O
illness	O
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
(	O
formerly	O
Zaire	O
)	O
,	O
in	O
the	O
town	O
of	O
Basankusu	O
,	O
Équateur	O
Province	O
,	O
in	O
1970	O
.	O

``	O
FLCN	O
``	O
mutations	O
and	O
lung	O
lesions	O
have	O
also	O
been	O
identified	O
in	O
familial	O
cases	O
of	O
pneumothorax	other-disease
where	O
other	O
features	O
of	O
Birt–Hogg–Dubé	other-disease
syndrome	other-disease
are	O
absent	O
.	O

Usually	O
both	O
categories	O
are	O
present	O
in	O
chronic	other-disease
diarrhea	other-disease
of	O
infants	O
.	O

Anthony	O
became	O
sick	O
with	O
ergotism	other-disease
in	O
1231	O
,	O
and	O
went	O
to	O
the	O
woodland	O
retreat	O
at	O
Camposampiero	O
with	O
two	O
other	O
friars	O
for	O
a	O
respite	O
.	O

Baclofen	other-disease
and	O
tizanidine	other-disease
are	O
the	O
most	O
commonly	O
used	O
oral	O
drugs	O
for	O
treating	O
spasticity	other-disease
;	O
an	O
intrathecal	O
baclofen	O
pump	O
can	O
be	O
used	O
for	O
severe	other-disease
spasticity	other-disease
.	O

One	O
of	O
the	O
most	O
important	O
management	O
techniques	O
to	O
controlling	O
WSMV	other-disease
is	O
by	O
eliminating	O
“	O
volunteer	O
”	O
,	O
or	O
seedlings	O
from	O
the	O
previous	O
years	O
’	O
infected	O
crop	O
,	O
wheat	O
plants	O
.	O

S.	O
aureus	O
is	O
also	O
implicated	O
in	O
toxic	other-disease
shock	other-disease
syndrome	other-disease
;	O
during	O
the	O
1980s	O
some	O
tampons	O
allowed	O
the	O
rapid	O
growth	O
of	O
S.	O
aureus	O
,	O
which	O
released	O
toxins	O
that	O
were	O
absorbed	O
into	O
the	O
bloodstream	O
.	O

People	O
can	O
develop	O
permanent	O
disabilities	O
including	O
``	O
cognitive	other-disease
deficits	other-disease
,	O
ataxia	other-disease
,	O
hemiparesis	other-disease
,	O
blindness	other-disease
,	O
deafness	other-disease
,	O
or	O
amputation	other-disease
following	other-disease
gangrene	other-disease
``	O
.	O

The	O
hospital	O
offered	O
in-patient	O
treatment	O
for	O
children	O
up	O
to	O
the	O
age	O
of	O
three	O
,	O
diagnosed	O
as	O
premature	other-disease
,	O
malnourished	other-disease
or	O
dyspeptic	other-disease
.	O

Henri	O
Ellenberger	O
called	O
Jung	O
's	O
intense	O
experience	O
a	O
``	O
creative	O
illness	O
''	O
and	O
compared	O
it	O
favorably	O
to	O
Freud	O
's	O
own	O
period	O
of	O
what	O
he	O
called	O
neurasthenia	other-disease
and	O
hysteria	other-disease
.	O

It	O
is	O
a	O
photosensitive	O
skin	O
disorder	O
,	O
a	O
different	O
subtype	O
of	O
cutaneous	other-disease
lupus	other-disease
erythematosus	other-disease
(	O
CLE	other-disease
)	O
from	O
discoid	other-disease
lupus	other-disease
erythematosus	other-disease
(	O
DLE	other-disease
)	O
or	O
subacute	other-disease
CLE	other-disease
(	O
SCLE	other-disease
)	O
.	O

The	O
opposite	O
is	O
hypothermia	other-disease
,	O
which	O
occurs	O
when	O
the	O
temperature	O
drops	O
below	O
that	O
required	O
to	O
maintain	O
normal	O
metabolism	O
.	O

The	O
exact	O
causes	O
of	O
the	O
disappearance	O
of	O
the	O
Norse	O
settlements	O
toward	O
the	O
end	O
of	O
the	O
15th	O
century	O
remain	O
unverified	O
,	O
but	O
probably	O
resulted	O
from	O
a	O
combination	O
of	O
the	O
Little	O
Ice	O
Age	O
's	O
cooling	O
temperatures	O
,	O
soil	O
erosion	O
,	O
abandonment	O
by	O
Norway	O
after	O
the	O
Black	other-disease
Plague	other-disease
and	O
political	O
turmoils	O
,	O
more	O
convenient	O
ways	O
for	O
Europeans	O
to	O
procure	O
furs	O
and	O
a	O
mercantile	O
eclipsing	O
by	O
the	O
Hanseatic	O
League	O
,	O
and	O
competition	O
from	O
the	O
Inuit	O
moving	O
southward	O
.	O

caused	O
by	O
gene	O
duplication	O
)	O
results	O
in	O
CMT1A	other-disease
,	O
and	O
too	O
little	O
PMP22	O
(	O
e.g	O
.	O

Radiation	O
exposure	O
to	O
the	O
head	O
and	O
neck	O
may	O
be	O
for	O
historic	O
indications	O
such	O
as	O
tonsillar	O
and	O
adenoid	other-disease
hypertrophy	other-disease
,	O
``	O
enlarged	O
thymus	O
''	O
,	O
acne	other-disease
vulgaris	other-disease
,	O
or	O
current	O
indications	O
such	O
as	O
Hodgkin	other-disease
's	other-disease
lymphoma	other-disease
.	O

If	O
the	O
test	O
shows	O
higher	O
levels	O
than	O
normal	O
,	O
it	O
means	O
they	O
have	O
hemoglobinemia	other-disease
.	O

Many	O
of	O
the	O
other	O
drugs	O
have	O
a	O
low	O
to	O
very	O
low	O
risk	O
to	O
develop	O
DIL	other-disease
.	O

Counselors	O
can	O
also	O
provide	O
some	O
psycho-education	O
on	O
alcoholism	other-disease
and	O
its	O
effects	O
on	O
family	O
members	O
of	O
alcoholics	O
.	O

Oligohydramnios	O
can	O
be	O
caused	O
by	O
infection	O
,	O
kidney	O
dysfunction	O
or	O
malformation	O
(	O
since	O
much	O
of	O
the	O
late	O
amniotic	O
fluid	O
volume	O
is	O
urine	O
)	O
,	O
procedures	O
such	O
as	O
chorionic	O
villus	O
sampling	O
(	O
CVS	other-disease
)	O
,	O
and	O
preterm	O
premature	O
rupture	O
of	O
membranes	O
(	O
PPROM	other-disease
)	O
.	O

The	O
molecule	O
is	O
highly	O
expressed	O
in	O
a	O
variety	O
of	O
cancer	O
cell	O
types	O
,	O
most	O
notably	O
breast	other-disease
cancer	other-disease
.	O

His	O
understanding	O
of	O
the	O
nature	O
of	O
the	O
rotational	O
element	O
of	O
scoliosis	other-disease
was	O
given	O
by	O
a	O
postmortem	O
he	O
performed	O
on	O
an	O
eminent	O
surgeon	O
and	O
geologist	O
,	O
Gideon	O
Mantell	O
.	O

Primary	O
sclerosing	O
cholangitis	O
is	O
one	O
of	O
the	O
major	O
known	O
risk	O
factors	O
for	O
cholangiocarcinoma	O
,	O
a	O
cancer	O
of	O
the	O
biliary	O
tree	O
,	O
for	O
which	O
the	O
lifetime	O
risk	O
among	O
patients	O
with	O
PSC	other-disease
is	O
10-15	O
%	O
.	O

The	O
clinical	O
features	O
of	O
TBS	other-disease
overlap	O
with	O
VATER	other-disease
and	O
VACTERL	other-disease
associations	O
,	O
oculo-auriculo-vertebral	other-disease
(	O
OAV	other-disease
)	O
spectrum	O
,	O
branchio-oto-renal	other-disease
(	O
BOR	other-disease
)	O
syndrome	O
,	O
and	O
Fanconi	other-disease
anemia	other-disease
and	O
other	O
'anus-hand-ear	O
'	O
syndromes	O
.	O

In	O
1991	O
,	O
the	O
World	O
Health	O
Assembly	O
agreed	O
that	O
Guinea	other-disease
worm	O
disease	O
should	O
be	O
eradicated	O
.	O

Congestive	other-disease
heart	other-disease
failure	other-disease
and	O
cardiac	other-disease
arrhythmia	other-disease
are	O
the	O
leading	O
causes	O
of	O
death	O
,	O
but	O
patients	O
with	O
less	O
severe	O
symptoms	O
can	O
live	O
into	O
their	O
60s	O
or	O
older	O
.	O

Research	O
efforts	O
during	O
the	O
80-90s	O
have	O
shown	O
that	O
myocardial	other-disease
ischemia	other-disease
also	O
induces	O
changes	O
to	O
the	O
depolarization	O
phase	O
and	O
confirmed	O
the	O
use	O
of	O
HFQRS-RMS	O
as	O
a	O
quantitative	O
diagnostic	O
measure	O
of	O
supply	O
myocardial	other-disease
ischemia	other-disease
and	O
demand	O
myocardial	other-disease
(	other-disease
stress-induced	other-disease
)	other-disease
ischemia	other-disease
.	O

Her	O
father	O
died	O
of	O
lung	other-disease
cancer	other-disease
when	O
Billie	O
was	O
9	O
years	O
old	O
.	O

He	O
enforced	O
the	O
use	O
of	O
anti-	O
malarial	other-disease
drugs	O
as	O
part	O
of	O
an	O
emphasis	O
on	O
individual	O
health	O
,	O
established	O
realistic	O
jungle	O
warfare	O
training	O
,	O
rebuilt	O
the	O
army	O
's	O
self-respect	O
by	O
winning	O
easy	O
small-scale	O
victories	O
and	O
developed	O
local	O
military	O
infrastructure	O
.	O

Individuals	O
who	O
have	O
HLA-B	O
*	O
1502	O
are	O
more	O
likely	O
to	O
experience	O
a	O
severe	O
skin	O
disorder	O
called	O
Stevens–Johnson	other-disease
syndrome	other-disease
in	O
response	O
to	O
carbamazepine	O
(	O
a	O
drug	O
used	O
to	O
treat	O
seizures	O
)	O
.	O

Likewise	O
,	O
mutations	O
in	O
PRC2	O
genes	O
were	O
related	O
to	O
hematological	O
conditions	O
such	O
as	O
acute	other-disease
lymphoblastic	other-disease
leukemia	other-disease
(	O
ALL	other-disease
)	O
,	O
which	O
is	O
a	O
form	O
of	O
leukemia	other-disease
.	O

Author	O
and	O
neurologist	O
Oliver	O
Sacks	O
once	O
described	O
the	O
case	O
of	O
a	O
drummer	O
with	O
Tourette	other-disease
's	other-disease
who	O
used	O
his	O
tics	O
to	O
give	O
him	O
a	O
certain	O
``	O
flair	O
''	O
or	O
``	O
special	O
sound	O
''	O
to	O
his	O
drumming	O
.	O

BSS	other-disease
presents	O
as	O
a	O
bleeding	O
disorder	O
due	O
to	O
the	O
inability	O
of	O
platelets	O
to	O
bind	O
and	O
aggregate	O
at	O
sites	O
of	O
vascular	O
endothelial	O
injury	O
.	O

A	O
pseudocyst	other-disease
stage	O
has	O
been	O
recorded	O
and	O
may	O
be	O
the	O
form	O
taken	O
during	O
transmission	O
via	O
the	O
fecal-oral	O
route.7,8	O

Specifically	O
,	O
common	O
side	O
effects	O
include	O
difficulty	O
becoming	O
aroused	O
,	O
lack	O
of	O
interest	O
in	O
sex	O
,	O
and	O
anorgasmia	other-disease
(	O
trouble	O
achieving	O
orgasm	O
)	O
.	O

At	O
the	O
age	O
of	O
61	O
,	O
he	O
died	O
of	O
complications	O
of	O
pulmonary	other-disease
hypertension	other-disease
after	O
a	O
brief	O
hospitalization	O
.	O

The	O
2020	O
competition	O
was	O
cancelled	O
as	O
part	O
of	O
the	O
effort	O
to	O
minimize	O
the	O
COVID-19	other-disease
pandemic	O
.	O

Post	O
-mortem	O
SZ	other-disease
brains	O
have	O
upregulated	O
expression	O
of	O
both	O
DISC1	O
and	O
ERBB4	O
.	O

Polycythemia	other-disease
is	O
sometimes	O
called	O
erythrocytosis	other-disease
,	O
but	O
the	O
terms	O
are	O
not	O
synonymous	O
,	O
because	O
polycythemia	other-disease
refers	O
to	O
any	O
increase	O
in	O
red	O
blood	O
mass	O
(	O
due	O
to	O
an	O
erythrocytosis	O
or	O
not	O
)	O
,	O
whereas	O
erythrocytosis	other-disease
only	O
refers	O
to	O
a	O
documented	O
increase	O
of	O
red	O
cell	O
count	O
.	O

MDF	O
The	O
Bipolar	O
Organisation	O
was	O
established	O
in	O
1983	O
(	O
as	O
the	O
``	O
Manic	O
Depression	O
Fellowship	O
``	O
)	O
to	O
enable	O
people	O
affected	O
by	O
bipolar	other-disease
disorder	other-disease
to	O
take	O
control	O
of	O
their	O
lives	O
.	O

Typically	O
follicular	other-disease
hyperplasia	other-disease
is	O
categorized	O
as	O
a	O
benign	other-disease
lymphadenopathy	other-disease
.	O

Many	O
patients	O
with	O
a	O
foramen	other-disease
secundum	other-disease
that	O
persists	O
into	O
adulthood	O
will	O
remain	O
asymptomatic	O
throughout	O
their	O
lives	O
.	O

This	O
underdevelopment	O
of	O
the	O
front	O
of	O
the	O
eye	O
,	O
known	O
as	O
anterior	other-disease
segment	other-disease
dysgenesis	other-disease
(	O
which	O
includes	O
Peters	other-disease
'	other-disease
anomaly	other-disease
)	O
,	O
can	O
lead	O
to	O
an	O
increased	O
risk	O
of	O
glaucoma	other-disease
from	O
high	O
intraocular	O
pressure	O
,	O
due	O
to	O
impaired	O
eye	O
fluid	O
drainage	O
,	O
though	O
this	O
had	O
n't	O
been	O
reported	O
in	O
any	O
of	O
the	O
affected	O
individuals	O
.	O

DiNovo	O
successfully	O
proposed	O
a	O
bill	O
to	O
recognize	O
Post-Traumatic	other-disease
Stress	other-disease
Disorder	other-disease
(	O
PTSD	other-disease
)	O
as	O
a	O
work	O
place	O
injury	O
for	O
first	O
responders	O
fast-tracking	O
their	O
Workplace	O
Safety	O
and	O
Insurance	O
Board	O
benefits	O
.	O

In	O
the	O
2016-2017	O
outbreak	O
,	O
a	O
third	O
dose	O
of	O
the	O
MMR	other-disease
vaccine	O
was	O
given	O
to	O
college	O
students	O
who	O
had	O
a	O
previous	O
history	O
of	O
vaccination	O
.	O

The	O
most	O
common	O
cause	O
of	O
chronic	other-disease
urinary	other-disease
retention	other-disease
is	O
BPH	other-disease
.	O

The	O
recurrence	O
of	O
rheumatic	other-disease
fever	other-disease
is	O
relatively	O
common	O
in	O
the	O
absence	O
of	O
maintenance	O
of	O
low	O
dose	O
antibiotics	O
,	O
especially	O
during	O
the	O
first	O
three	O
to	O
five	O
years	O
after	O
the	O
first	O
episode	O
.	O

High-altitude	other-disease
pulmonary	other-disease
edema	other-disease
(	O
HAPE	other-disease
)	O
is	O
a	O
life-threatening	O
form	O
of	O
non-cardiogenic	O
pulmonary	O
edema	O
(	O
fluid	O
accumulation	O
in	O
the	O
lungs	O
)	O
that	O
occurs	O
in	O
otherwise	O
healthy	O
people	O
at	O
altitudes	O
typically	O
above	O
.	O

The	O
addition	O
of	O
GM3	O
to	O
bladder	other-disease
cancer	other-disease
cells	O
also	O
decreases	O
their	O
cell	O
adhesion	O
and	O
inhibits	O
tumor	O
growth	O
.	O

Babesiosis	other-disease
may	O
be	O
suspected	O
when	O
a	O
person	O
with	O
such	O
an	O
exposure	O
history	O
develops	O
persistent	O
fevers	O
and	O
hemolytic	other-disease
anemia	other-disease
.	O

The	O
thyroid	other-disease
disease	other-disease
,	O
in	O
this	O
condition	O
,	O
is	O
autoimmune	O
in	O
nature	O
and	O
approximately	O
5	O
%	O
of	O
people	O
with	O
myasthenia	other-disease
gravis	other-disease
also	O
have	O
hyperthyroidism	other-disease
.	O

In	O
many	O
cases	O
,	O
however	O
,	O
especially	O
in	O
people	O
with	O
alcoholic	other-disease
intoxication	other-disease
,	O
hypoglycemia	other-disease
appears	O
to	O
be	O
a	O
more	O
common	O
cause	O
.	O

Marwood	O
died	O
in	O
1883	O
from	O
pneumonia	other-disease
and	O
jaundice	other-disease
and	O
was	O
buried	O
at	O
Trinity	O
Church	O
,	O
Horncastle	O
,	O
Lincolnshire	O
.	O

Bullous	other-disease
keratopathy	other-disease
that	O
is	O
characterized	O
by	O
corneal	O
stromal	O
edema	O
related	O
to	O
cell	O
loss	O
and	O
endothelial	O
decompensation	O
as	O
well	O
as	O
subepithelial	O
fibrosis	O
and	O
corneal	O
vascularization	O
in	O
further	O
cases	O
,	O
results	O
vision	O
problems	O
due	O
to	O
loss	O
of	O
corneal	O
transparency	O
.	O

Löfgren	other-disease
syndrome	O
consists	O
of	O
the	O
triad	O
of	O
erythema	O
nodosum	O
,	O
bilateral	O
hilar	O
lymphadenopathy	O
on	O
chest	O
radiograph	O
,	O
and	O
joint	O
pain	O
.	O

Noncyclic	other-disease
acute	other-disease
wound	other-disease
pain	other-disease
is	O
intermittent	O
and	O
usually	O
occurs	O
during	O
procedures	O
such	O
as	O
sharp	O
debridement	O
.	O

The	O
SDHD	O
gene	O
variants	O
associated	O
with	O
Cowden	other-disease
syndrome	other-disease
and	O
Cowden-like	other-disease
syndrome	other-disease
change	O
single	O
amino	O
acids	O
in	O
the	O
SDHD	O
protein	O
,	O
which	O
likely	O
alters	O
the	O
function	O
of	O
the	O
SDH	O
enzyme	O
.	O

Shah	O
Jahan	O
II	O
ascended	O
the	O
throne	O
on	O
6	O
June	O
1719	O
after	O
the	O
death	O
of	O
his	O
younger	O
brother	O
Rafi	O
ud-Darajat	O
due	O
to	O
tuberculosis	other-disease
.	O

Lo	O
died	O
at	O
the	O
age	O
of	O
54	O
from	O
colorectal	other-disease
cancer	other-disease
at	O
Shatin	O
Hospital	O
in	O
Hong	O
Kong	O
.	O

Up	O
to	O
9	O
%	O
of	O
VLBWI	other-disease
with	O
birth	O
weights	O
of	O
&	O
lt	O
;	O
1,000	O
g	O
develop	O
these	O
fungus	O
infections	O
leading	O
to	O
sepsis	other-disease
or	O
meningitis	other-disease
.	O

Canada	other-disease
's	other-disease
Pandemic	other-disease
Influenza	other-disease
Plan	O
was	O
released	O
most	O
recently	O
in	O
2017	O
by	O
the	O
Canadian	O
Pandemic	O
Influenza	O
Preparedness	O
(	O
CPIP	O
)	O
Task	O
Group	O
.	O

The	O
patient	O
was	O
a	O
12-year-old	O
girl	O
with	O
rheumatic	other-disease
mitral	other-disease
stenosis	other-disease
.	O

Esophageal	other-disease
dysphagia	other-disease
is	O
a	O
form	O
of	O
dysphagia	O
where	O
the	O
underlying	O
cause	O
arises	O
from	O
the	O
body	O
of	O
the	O
esophagus	O
,	O
lower	O
esophageal	O
sphincter	O
,	O
or	O
cardia	O
of	O
the	O
stomach	O
,	O
usually	O
due	O
to	O
mechanical	O
causes	O
or	O
motility	O
problems	O
.	O

The	O
hospital	O
is	O
still	O
serving	O
the	O
public	O
and	O
came	O
into	O
the	O
international	O
spotlight	O
when	O
it	O
was	O
designated	O
as	O
the	O
sole	O
treatment	O
centre	O
for	O
the	O
SARS	other-disease
epidemic	O
which	O
struck	O
Singapore	O
in	O
2003	O
.	O

For	O
example	O
,	O
defects	O
in	O
nucleotide	O
excision	O
repair	O
pathways	O
are	O
associated	O
with	O
premature	O
aging	O
phenotypes	O
in	O
diseases	O
such	O
as	O
Xeroderma	other-disease
pigmentosum	other-disease
and	O
Trichothiodystrophy	other-disease
.	O

The	O
2003–04	O
season	O
began	O
poorly	O
,	O
and	O
in	O
November	O
2003	O
Alexander	O
suffered	O
a	O
cerebral	other-disease
aneurysm	other-disease
.	O

Monoclonal	O
antibodies	O
used	O
for	O
autoimmune	O
diseases	O
include	O
infliximab	O
and	O
adalimumab	O
,	O
which	O
are	O
effective	O
in	O
rheumatoid	other-disease
arthritis	other-disease
,	O
Crohn	other-disease
's	other-disease
disease	other-disease
,	O
ulcerative	other-disease
colitis	other-disease
and	O
ankylosing	other-disease
spondylitis	other-disease
by	O
their	O
ability	O
to	O
bind	O
to	O
and	O
inhibit	O
TNF-α	O
.	O

This	O
disease	O
causes	O
weakness	O
,	O
anemia	other-disease
,	O
skin	other-disease
hemorrhages	other-disease
,	O
and	O
gum	O
disease	O
(	O
gingivitis	other-disease
)	O
.	O

The	O
World	O
Health	O
Organization	O
classifies	O
Buruli	other-disease
ulcer	other-disease
into	O
three	O
categories	O
depending	O
on	O
the	O
severity	O
of	O
its	O
symptoms	O
.	O

Early	O
latent	O
syphilis	other-disease
is	O
infectious	O
as	O
up	O
to	O
25	O
%	O
of	O
people	O
can	O
develop	O
a	O
recurrent	O
secondary	O
infection	O
(	O
during	O
which	O
spirochetes	O
are	O
actively	O
replicating	O
and	O
are	O
infectious	O
)	O
.	O

Her	O
first	O
diagnosis	O
was	O
for	O
stage	other-disease
IIA	other-disease
breast	other-disease
cancer	other-disease
in	O
2002	O
.	O

Metabolic	other-disease
syndrome	other-disease
,	O
hypertension	other-disease
,	O
diabetes	other-disease
and	O
obesity	other-disease
have	O
also	O
been	O
linked	O
to	O
its	O
use	O
.	O

Vitamin	O
B12	other-disease
deficiency	other-disease
in	O
the	O
US	O
and	O
the	O
UK	O
is	O
estimated	O
to	O
occur	O
in	O
about	O
6	O
percent	O
of	O
those	O
under	O
the	O
age	O
of	O
60	O
,	O
and	O
20	O
percent	O
of	O
those	O
over	O
the	O
age	O
of	O
60	O
.	O

It	O
was	O
observed	O
that	O
sometimes	O
patients	O
who	O
developed	O
high	other-disease
fevers	other-disease
were	O
cured	O
of	O
syphilis	other-disease
.	O

Smoldering	other-disease
Waldenström	other-disease
's	other-disease
macroglobulinemia	other-disease
is	O
diagnosed	O
in	O
asymptomatic	O
individuals	O
that	O
have	O
a	O
serum	O
IgM	O
level	O
30	O
gram/liter	O
and/or	O
a	O
bone	O
marrow	O
lymphoplasmacytoid	O
cell	O
infilatrate	O
&	O
gt	O
;	O
10	O
%	O
of	O
total	O
nucleated	O
cells	O
.	O

The	O
mites	O
also	O
have	O
the	O
ability	O
to	O
transfer	O
WSMV	other-disease
in	O
between	O
wheat	O
and	O
corn	O
crops	O
,	O
allowing	O
the	O
virus	O
to	O
persist	O
year-round	O
.	O

Young	O
’	O
s	O
discovery	O
of	O
doubletime	O
mutants	O
in	O
1998	O
was	O
soon	O
followed	O
by	O
the	O
2001	O
discovery	O
of	O
a	O
form	O
of	O
Familial	other-disease
Advanced	other-disease
Sleep	other-disease
Phase	other-disease
Syndrome	other-disease
(	O
FASPS	other-disease
)	O
in	O
humans	O
,	O
which	O
is	O
linked	O
to	O
an	O
hPer2	O
polymorphism	O
that	O
removes	O
a	O
serine	O
normally	O
phosphorylated	O
by	O
Casein	O
kinase	O
1	O
.	O

A	O
member	O
of	O
the	O
2017	O
National	O
Constituent	O
Assembly	O
and	O
the	O
Governor	O
of	O
the	O
Capital	O
District	O
,	O
Darío	O
Vivas	O
tested	O
positive	O
for	O
COVID-19	other-disease
on	O
19	O
July	O
.	O

There	O
are	O
coincidences	O
in	O
Leonard	O
Arthur	O
's	O
family	O
that	O
relate	O
to	O
Down	other-disease
syndrome	other-disease
.	O

Complications	O
may	O
include	O
cellulitis	other-disease
or	O
poststreptococcal	other-disease
glomerulonephritis	other-disease
.	O

Like	O
dopamine	O
,	O
norepinephrine	O
,	O
and	O
serotonin	O
,	O
the	O
trace	O
amines	O
have	O
been	O
implicated	O
in	O
a	O
vast	O
array	O
of	O
human	O
disorders	O
of	O
affect	O
and	O
cognition	O
,	O
such	O
as	O
ADHD	other-disease
,	O
depression	other-disease
and	O
schizophrenia	O
,	O
among	O
others	O
.	O

VEGFR-2	O
is	O
overexpressed	O
in	O
several	O
cancers	O
,	O
for	O
example	O
ovarian	other-disease
,	O
[	O
[	O
thyroid	other-disease
]	O
]	O
,	O
[	O
[	O
melanoma	other-disease
]	O
]	O
and	O
[	O
[	O
medulloblastoma	other-disease
]	O
]	O
.	O

In	O
order	O
to	O
be	O
diagnosed	O
with	O
dysgraphia	other-disease
,	O
one	O
must	O
have	O
a	O
cluster	O
,	O
but	O
not	O
necessarily	O
all	O
,	O
of	O
the	O
following	O
symptoms	O
:	O

A	O
stress	other-disease
cough	other-disease
is	O
when	O
the	O
airways	O
of	O
the	O
throat	O
are	O
blocked	O
to	O
the	O
point	O
that	O
causes	O
a	O
reflexive	O
spasm	O
.	O

Separation	other-disease
anxiety	other-disease
is	O
a	O
normal	O
part	O
of	O
development	O
in	O
babies	O
or	O
children	O
,	O
and	O
it	O
is	O
only	O
when	O
this	O
feeling	O
is	O
excessive	O
or	O
inappropriate	O
that	O
it	O
can	O
be	O
considered	O
a	O
disorder	O
.	O

Similarly	O
,	O
treatment	O
of	O
ejaculatory	other-disease
dysfunction	other-disease
such	O
as	O
premature	other-disease
ejaculation	other-disease
is	O
dependent	O
on	O
the	O
etiology	O
.	O

Nicastrin	O
(	O
abbreviated	O
NCT	O
)	O
is	O
a	O
protein	O
that	O
is	O
part	O
of	O
the	O
gamma	O
secretase	O
protein	O
complex	O
,	O
which	O
is	O
one	O
of	O
the	O
proteases	O
involved	O
in	O
processing	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
to	O
the	O
short	O
Alzheimer	other-disease
's	O
disease-associated	O
peptide	O
amyloid	O
beta	O
.	O

People	O
with	O
chronic	other-disease
breathing	other-disease
disorders	other-disease
such	O
as	O
asthma	other-disease
use	O
this	O
as	O
a	O
bronchodilator	O
to	O
make	O
breathing	O
easier	O
.	O

They	O
often	O
cause	O
an	O
initial	O
flare-up	O
of	O
acne	other-disease
and	O
facial	O
flushing	O
and	O
can	O
cause	O
significant	O
skin	O
irritation	O
.	O

Acute	other-disease
overdosage	other-disease
is	O
often	O
manifested	O
by	O
emesis	O
,	O
lethargy	O
,	O
ataxia	O
,	O
tachycardia	O
,	O
and	O
seizures	O
.	O

However	O
,	O
untreated	O
persistent	O
hypoglycemia	other-disease
can	O
lead	O
to	O
permanent	O
brain	O
damage	O
.	O

These	O
measures	O
were	O
intended	O
to	O
overcome	O
the	O
congestion	O
of	O
urban	O
church	O
crypts	O
and	O
graveyards	O
,	O
and	O
were	O
prompted	O
by	O
a	O
number	O
of	O
outbreaks	O
of	O
highly	O
contagious	O
diseases	O
linked	O
to	O
inadequate	O
burial	O
practices	O
in	O
urban	O
areas	O
,	O
especially	O
the	O
black	O
plague	O
which	O
had	O
led	O
to	O
the	O
Plague	other-disease
Riot	other-disease
in	O
Moscow	O
in	O
1771	O
.	O

In	O
patients	O
with	O
AMS	other-disease
,	O
the	O
onset	O
of	O
HACE	other-disease
is	O
usually	O
indicated	O
by	O
vomiting	O
,	O
headache	O
that	O
does	O
not	O
respond	O
to	O
non-steroidal	O
anti-inflammatory	O
drugs	O
,	O
hallucinations	O
,	O
and	O
stupor	O
.	O

Arab	O
texts	O
from	O
this	O
period	O
contain	O
discussions	O
of	O
melancholia	other-disease
,	O
mania	other-disease
,	O
hallucinations	other-disease
,	O
delusions	other-disease
,	O
and	O
other	O
mental	O
disorders	O
.	O

TopoTarget	O
is	O
also	O
looking	O
into	O
more	O
drugs	O
that	O
interrupt	O
HDAC	O
activity	O
,	O
not	O
only	O
for	O
cancer	O
therapy	O
,	O
but	O
for	O
diseases	O
like	O
malaria	other-disease
and	O
CNS	other-disease
disorders	other-disease
.	O

If	O
mood	O
disorder	O
episodes	O
are	O
present	O
for	O
the	O
majority	O
and	O
residual	O
course	O
of	O
the	O
illness	O
and	O
up	O
until	O
the	O
diagnosis	O
,	O
the	O
patient	O
can	O
be	O
diagnosed	O
with	O
Schizoaffective	other-disease
Disorder	other-disease
.	O

During	O
Elvira	O
's	O
tenure	O
at	O
Frost	O
Bank	O
,	O
she	O
spent	O
her	O
evenings	O
at	O
nearby	O
Santa	O
Rosa	O
Hospital	O
caring	O
for	O
her	O
younger	O
brother	O
,	O
Henry	O
,	O
who	O
wound	O
up	O
passing	O
away	O
from	O
Hodgkins	other-disease
disease	other-disease
in	O
1943	O
,	O
at	O
age	O
14	O
.	O

Protein	O
C	O
in	O
plasma	O
in	O
the	O
steady	O
state	O
has	O
a	O
half	O
life	O
of	O
6-	O
to	O
10-hour	O
,	O
therefore	O
,	O
patients	O
with	O
severe	O
protein	other-disease
C	other-disease
deficiency	other-disease
and	O
presenting	O
with	O
purpura	other-disease
fulminans	other-disease
can	O
be	O
treated	O
acutely	O
with	O
an	O
initial	O
bolus	O
of	O
protein	O
C	O
concentrate	O
100	O
IU/kg	O
followed	O
by	O
50	O
IU	O
/kg	O
every	O
6	O
hours	O
.	O

Depression	other-disease
due	O
to	O
physical	O
illness	O
is	O
diagnosed	O
as	O
a	O
mood	other-disease
disorder	other-disease
due	O
to	O
a	O
general	O
medical	O
condition	O
.	O

This	O
led	O
to	O
a	O
corresponding	O
increase	O
in	O
gene	O
expression	O
,	O
which	O
was	O
similar	O
to	O
the	O
increased	O
histone	O
lysine	O
acetylation	O
at	O
these	O
gene	O
promoters	O
in	O
type	other-disease
1	other-disease
diabetes	other-disease
and	O
type	other-disease
2	other-disease
diabetes	other-disease
patients	O
compared	O
to	O
healthy	O
control	O
volunteers	O
.	O

Other	O
clinical	O
signs	O
include	O
lethargy	O
,	O
depression	other-disease
,	O
and	O
reduced	O
normal	O
grooming	O
behaviour	O
.	O

This	O
suggests	O
that	O
this	O
region	O
is	O
key	O
in	O
producing	O
confabulatory	O
responses	O
,	O
and	O
that	O
memory	O
deficit	O
is	O
important	O
but	O
not	O
necessary	O
in	O
confabulation	other-disease
.	O

Studies	O
consistently	O
find	O
a	O
strong	O
association	O
between	O
increased	O
body	O
mass	O
index	O
and	O
plantar	other-disease
fasciitis	other-disease
in	O
the	O
non-athletic	O
population	O
.	O

Pericarditis	other-disease
caused	O
by	O
tuberculosis	O
is	O
difficult	O
to	O
diagnose	O
,	O
because	O
definitive	O
diagnosis	O
requires	O
culturing	O
``	O
Mycobacterium	O
tuberculosis	O
``	O
from	O
aspirated	O
pericardial	O
fluid	O
or	O
pericardial	O
,	O
which	O
requires	O
high	O
technical	O
skill	O
and	O
is	O
often	O
not	O
diagnostic	O
(	O
the	O
yield	O
from	O
culture	O
is	O
low	O
even	O
with	O
optimum	O
specimens	O
)	O
.	O

Type	other-disease
2	other-disease
diabetes	other-disease
is	O
associated	O
with	O
an	O
increase	O
in	O
average	O
bulbar	O
conjunctival	O
vessel	O
diameter	O
and	O
capillary	O
loss	O
.	O

Fungal	other-disease
sinusitis	other-disease
occurs	O
most	O
commonly	O
in	O
middle-aged	O
populations	O
.	O

Hanson	O
died	O
of	O
Creutzfeldt–Jakob	other-disease
disease	O
in	O
a	O
hospital	O
in	O
Woodbury	O
,	O
Minnesota	O
.	O

Vitamin	other-disease
B12	other-disease
deficiency	other-disease
causes	O
particular	O
changes	O
to	O
the	O
metabolism	O
of	O
two	O
clinically	O
relevant	O
substances	O
in	O
humans	O
:	O

Other	O
entities	O
which	O
are	O
accompanied	O
by	O
multiple	other-disease
lipomas	other-disease
include	O
Proteus	other-disease
syndrome	other-disease
,	O
Cowden	other-disease
syndrome	other-disease
and	O
related	O
disorders	O
due	O
to	O
PTEN	other-disease
gene	other-disease
mutations	other-disease
,	O
benign	other-disease
symmetric	other-disease
lipomatosis	other-disease
(	O
Madelung	other-disease
disease	other-disease
)	O
,	O
Dercum	other-disease
's	other-disease
Disease	other-disease
,	O
familial	other-disease
lipodystrophy	other-disease
,	O
hibernomas	other-disease
,	O
epidural	other-disease
steroid	other-disease
injections	other-disease
with	other-disease
epidural	other-disease
lipomatosis	other-disease
,	O
and	O
familial	other-disease
angiolipomatosis	other-disease
.	O

The	O
following	O
investigations	O
may	O
help	O
in	O
making	O
the	O
diagnosis	O
of	O
malakoplakia	other-disease
:	O

Hearing	O
impairment	O
may	O
also	O
be	O
the	O
result	O
of	O
certain	O
diseases	O
such	O
as	O
CMV	other-disease
or	O
Ménière	other-disease
's	other-disease
disease	other-disease
and	O
these	O
can	O
be	O
diagnosed	O
from	O
the	O
shape	O
of	O
the	O
audiogram	O
.	O

Such	O
examples	O
include	O
cancer	O
development	O
and	O
progression	O
,	O
Dyskeratosis	other-disease
Congenita	other-disease
(	O
DC	other-disease
)	O
,	O
Idiopathic	other-disease
Pulmonary	other-disease
Fibrosis	other-disease
(	O
IPF	other-disease
)	O
,	O
Aplastic	other-disease
Anemia	other-disease
(	O
AA	other-disease
)	O
,	O
Astrocytoma	other-disease
,	O
and	O
Cryptogenic	other-disease
Liver	other-disease
Cirrhosis	other-disease
.	O

It	O
was	O
found	O
that	O
within	O
this	O
population	O
,	O
there	O
was	O
limited	O
education	O
and	O
even	O
if	O
the	O
Peruvian	O
men	O
knew	O
their	O
personal	O
risk	O
for	O
the	O
HIV	other-disease
infection	other-disease
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
try	O
and	O
obtain	O
contraception	O
.	O

Overproduction	O
of	O
cortisol	O
leads	O
to	O
Cushing	other-disease
's	other-disease
syndrome	other-disease
,	O
whereas	O
insufficient	O
production	O
is	O
associated	O
with	O
Addison	other-disease
's	other-disease
disease	other-disease
.	O

Tennis	other-disease
elbow	other-disease
or	O
lateral	other-disease
epicondylitis	other-disease
is	O
a	O
chronic	O
or	O
an	O
acute	O
inflammation	O
of	O
the	O
tendons	O
that	O
arise	O
from	O
the	O
outer	O
part	O
of	O
the	O
elbow	O
.	O

Most	O
of	O
these	O
hypoglycemic	other-disease
newborns	O
are	O
asymptomatic	O
and	O
have	O
a	O
normal	O
blood	O
glucose	O
level	O
within	O
days	O
.	O

Amyotrophic	other-disease
lateral	other-disease
sclerosis	other-disease
(	O
ALS	other-disease
)	O
,	O
also	O
known	O
as	O
Lou	other-disease
Gehrig	other-disease
's	other-disease
Disease	other-disease
is	O
a	O
progressive	O
neurodegenerative	O
disease	O
that	O
affects	O
nerve	O
cells	O
in	O
the	O
brain	O
and	O
the	O
spinal	O
cord	O
.	O

Pneumothorax	O
is	O
a	O
well-known	O
complication	O
of	O
PCP	other-disease
.	O

King	O
was	O
further	O
criticized	O
for	O
failing	O
to	O
join	O
the	O
battle	O
against	O
AIDS	other-disease
,	O
allegedly	O
because	O
he	O
feels	O
uncomfortable	O
talking	O
about	O
condoms	O
.	O

Post	O
mortem	O
analysis	O
has	O
shown	O
lowered	O
levels	O
of	O
BDNF	O
in	O
the	O
brain	O
tissues	O
of	O
people	O
with	O
Alzheimer	other-disease
's	O
disease	O
,	O
although	O
the	O
nature	O
of	O
the	O
connection	O
remains	O
unclear	O
.	O

After	O
Lady	O
Flora	O
's	O
death	O
from	O
Bright	other-disease
's	other-disease
Disease	other-disease
in	O
April	O
1887	O
,	O
aged	O
33	O
,	O
he	O
remained	O
unmarried	O
for	O
nearly	O
seventeen	O
years	O
.	O

Risk	O
factors	O
for	O
OSA	other-disease
include	O
being	O
overweight	O
,	O
a	O
family	O
history	O
of	O
the	O
condition	O
,	O
allergies	O
,	O
a	O
small	O
breathing	O
airway	O
,	O
and	O
enlarged	O
tonsils	O
.	O

They	O
can	O
reduce	O
inflammation	O
and	O
histamine	O
production	O
in	O
the	O
nasal	O
passages	O
,	O
and	O
have	O
been	O
shown	O
to	O
relieve	O
nasal	other-disease
congestion	other-disease
,	O
runny	other-disease
nose	other-disease
,	O
itchy	other-disease
nose	other-disease
and	O
sneezing	other-disease
.	O

Technically	O
speaking	O
,	O
schizotypal	other-disease
personality	other-disease
disorder	other-disease
may	O
also	O
be	O
considered	O
an	O
``	O
extended	other-disease
phenotype	other-disease
``	O
that	O
helps	O
geneticists	O
track	O
the	O
familial	O
or	O
genetic	O
transmission	O
of	O
the	O
genes	O
that	O
are	O
implicated	O
in	O
schizophrenia	other-disease
.	O

People	O
with	O
asthma	other-disease
have	O
higher	O
rates	O
of	O
anxiety	other-disease
,	O
psychological	other-disease
stress	other-disease
,	O
and	O
depression	other-disease
.	O

Sleep	other-disease
apnea	other-disease
is	O
often	O
diagnosed	O
with	O
an	O
overnight	O
sleep	O
study	O
.	O

Turmeric	O
is	O
commonly	O
used	O
for	O
conditions	O
involving	O
pain	O
and	O
inflammation	O
,	O
such	O
as	O
osteoarthritis	other-disease
.	O

there	O
is	O
no	O
specific	O
treatment	O
for	O
Nipah	other-disease
virus	other-disease
infection	other-disease
.	O

HFpEF	other-disease
occurs	O
when	O
the	O
left	O
ventricle	O
contracts	O
normally	O
during	O
systole	O
,	O
but	O
the	O
ventricle	O
is	O
stiff	O
and	O
does	O
not	O
relax	O
normally	O
during	O
diastole	O
,	O
which	O
impairs	O
filling	O
.	O

Autosomal	other-disease
recessive	other-disease
polycystic	other-disease
kidney	other-disease
disease	other-disease
(	O
ARPKD	other-disease
)	O
(	O
OMIM	O
#	O
263200	O
)	O
is	O
the	O
lesser	O
common	O
of	O
the	O
two	O
types	O
of	O
PKD	other-disease
,	O
with	O
an	O
incidence	O
of	O
1:20,000	O
live	O
births	O
and	O
is	O
typically	O
identified	O
in	O
the	O
first	O
few	O
weeks	O
after	O
birth	O
.	O

Low	O
thyroid	O
hormone	O
levels	O
in	O
turn	O
increase	O
the	O
likelihood	O
of	O
developing	O
depression	other-disease
.	O

Lymphangioleiomyomatoses	other-disease
are	O
fluid-filled	O
hypodense	O
structures	O
present	O
in	O
the	O
retroperitoneal	O
regions	O
of	O
the	O
abdomen	O
and	O
pelvis	O
in	O
about	O
30	O
%	O
of	O
LAM	other-disease
patients	O
.	O

Only	O
specialized	O
laboratories	O
can	O
adequately	O
diagnose	O
``	O
Babesia	other-disease
``	O
infection	O
in	O
humans	O
,	O
so	O
``	O
Babesia	other-disease
``	O
infections	O
are	O
considered	O
highly	O
under-reported	O
.	O

Jaundice	other-disease
is	O
classified	O
into	O
three	O
categories	O
,	O
depending	O
on	O
which	O
part	O
of	O
the	O
physiological	O
mechanism	O
the	O
pathology	O
affects	O
.	O

Mutations	O
of	O
this	O
gene	O
are	O
commonly	O
found	O
in	O
a	O
variety	O
of	O
cancers	O
:	O
in	O
primary	other-disease
hepatocellular	other-disease
carcinoma	other-disease
,	O
colorectal	other-disease
cancer	other-disease
,	O
ovarian	other-disease
carcinoma	other-disease
,	O
breast	other-disease
cancer	other-disease
,	O
lung	other-disease
cancer	other-disease
and	O
glioblastoma	other-disease
.	O

Mark	O
Arnold	O
Wainberg	O
,	O
(	O
21	O
April	O
1945	O
–	O
11	O
April	O
2017	O
)	O
was	O
a	O
Canadian	O
HIV/AIDS	other-disease
researcher	O
and	O
HIV/AIDS	other-disease
activist	O
.	O

Post-infectious	O
encephalitis	other-disease
tends	O
to	O
be	O
relatively	O
mild	O
,	O
whereas	O
post-infectious	O
encephalomyelitis	other-disease
has	O
a	O
case-fatality	O
rate	O
of	O
up	O
to	O
10	O
%	O
.	O

Autoimmune	other-disease
GFAP	other-disease
Astrocytopathy	other-disease
is	O
an	O
autoimmune	O
disease	O
in	O
which	O
the	O
immune	O
system	O
of	O
the	O
patient	O
attacks	O
a	O
protein	O
of	O
the	O
nervous	O
system	O
called	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
.	O

Endothelial	O
dysfunction	O
results	O
in	O
hypertension	O
and	O
many	O
of	O
the	O
other	O
symptoms	O
and	O
complications	O
associated	O
with	O
pre-eclampsia	other-disease
.	O

Protein	O
C	O
in	O
plasma	O
in	O
the	O
steady	O
state	O
has	O
a	O
half	O
life	O
of	O
6-	O
to	O
10-hour	O
,	O
therefore	O
,	O
patients	O
with	O
severe	O
protein	O
C	O
deficiency	O
and	O
presenting	O
with	O
purpura	other-disease
fulminans	other-disease
can	O
be	O
treated	O
acutely	O
with	O
an	O
initial	O
bolus	O
of	O
protein	O
C	O
concentrate	O
100	O
IU/kg	O
followed	O
by	O
50	O
IU	O
/kg	O
every	O
6	O
hours	O
.	O

It	O
was	O
later	O
discovered	O
that	O
the	O
cowpox	other-disease
vaccination	O
only	O
worked	O
temporarily	O
against	O
the	O
invasion	O
of	O
smallpox	other-disease
and	O
the	O
procedure	O
would	O
need	O
to	O
be	O
repeated	O
several	O
times	O
through	O
one	O
's	O
lifetime	O
to	O
remain	O
smallpox	other-disease
free	O
.	O

Neuro-imaging	O
should	O
also	O
be	O
used	O
to	O
look	O
for	O
a	O
stroke	O
,	O
tumor	O
,	O
infection	O
,	O
or	O
another	O
pathology	O
in	O
the	O
setting	O
of	O
conduction	O
aphasia	other-disease
.	O

Neurodegeneration	other-disease
is	O
the	O
progressive	O
loss	O
of	O
structure	O
or	O
function	O
of	O
neurons	O
,	O
including	O
their	O
death	O
.	O

In	O
April	O
2018	O
,	O
Levy	O
announced	O
that	O
he	O
had	O
Amyotrophic	other-disease
lateral	other-disease
sclerosis	other-disease
in	O
an	O
Op-Ed	O
arguing	O
for	O
educational	O
reforms	O
for	O
college	O
admissions	O
,	O
including	O
the	O
ending	O
of	O
legacy	O
admissions	O
and	O
increased	O
financial	O
aid	O
.	O

Lingual	other-disease
thyroid	other-disease
is	O
4-7	O
times	O
more	O
common	O
in	O
females	O
,	O
with	O
symptoms	O
developing	O
during	O
puberty	O
,	O
pregnancy	O
or	O
menopause	O
.	O

A	O
number	O
of	O
patients	O
with	O
essential	O
tremor	O
also	O
exhibit	O
many	O
of	O
the	O
same	O
neuropsychiatric	O
disturbances	O
seen	O
in	O
idiopathic	O
Parkinson	other-disease
's	O
disease	O
.	O

Antithrombin	O
deficiency	O
is	O
present	O
in	O
0.2	O
%	O
of	O
the	O
general	O
population	O
and	O
0.5–7.5	O
%	O
of	O
people	O
with	O
venous	other-disease
thrombosis	other-disease
.	O

Events	O
reported	O
have	O
included	O
coronary	other-disease
artery	other-disease
vasospasm	other-disease
,	O
transient	other-disease
myocardial	other-disease
ischemia	other-disease
,	O
myocardial	other-disease
infarction	other-disease
,	O
ventricular	other-disease
tachycardia	other-disease
,	O
and	O
ventricular	other-disease
fibrillation	other-disease
(	O
V-Fib	other-disease
)	O
.	O

LAL	other-disease
Deficiency	other-disease
is	O
a	O
serious	O
,	O
life-threatening	O
disease	O
associated	O
with	O
early	O
mortality	O
and	O
significant	O
morbidity	O
.	O

Coached	O
by	O
former	O
NBA	O
player	O
Rick	O
Brunson	O
,	O
Wagner	O
Jr	O
.	O
helped	O
lead	O
Camden	O
to	O
25	O
consecutive	O
victories	O
before	O
the	O
team	O
's	O
season	O
was	O
ended	O
due	O
to	O
the	O
COVID-19	other-disease
pandemic	other-disease
.	O

Jacksonian	other-disease
march	other-disease
or	O
Jacksonian	other-disease
seizure	other-disease
is	O
a	O
phenomenon	O
where	O
a	O
simple	O
partial	O
seizure	O
spreads	O
from	O
the	O
distal	O
part	O
of	O
the	O
limb	O
toward	O
the	O
ipsilateral	O
face	O
(	O
on	O
same	O
side	O
of	O
body	O
)	O
.	O

The	O
Bubonic	other-disease
Plague	other-disease
struck	O
again	O
in	O
1839	O
and	O
the	O
city	O
stagnated	O
,	O
as	O
it	O
lacked	O
political	O
and	O
economic	O
stability	O
.	O

The	O
name	O
is	O
derived	O
from	O
the	O
Greek	O
root	O
``	O
pemphix	other-disease
``	O
,	O
meaning	O
``	O
pu	O
stule	other-disease
``	O
.	O

High	O
dosages	O
cause	O
pancytopenia	O
and	O
hemorrhagic	other-disease
cystitis	other-disease
.	O

In	O
Koro	other-disease
,	O
a	O
patient	O
is	O
overcome	O
with	O
the	O
belief	O
that	O
his	O
penis	O
is	O
actively	O
shrinking	O
,	O
and	O
it	O
may	O
be	O
in	O
imminent	O
danger	O
of	O
disappearing	O
.	O

In	O
the	O
16th	O
century	O
,	O
Francisco	O
Hernández	O
de	O
Toledo	O
relates	O
:	O
``	O
the	O
cooking	O
of	O
the	O
roots	O
and	O
bark	O
moisten	O
the	O
tongue	O
of	O
those	O
who	O
have	O
a	O
fever	other-disease
,	O
relieves	O
the	O
pains	O
of	O
the	O
chest	O
and	O
if	O
they	O
are	O
not	O
removed	O
milk	O
evacuates	O
bile	O
and	O
phlegmatic	O
humors	O
by	O
the	O
Upper	O
or	O
lower	O
duct	O
.	O

Dysentery	other-disease
swept	O
through	O
the	O
camp	O
and	O
days	O
passed	O
between	O
the	O
instances	O
of	O
distribution	O
of	O
bread	O
to	O
some	O
.	O

Intracranial	O
pressure	O
may	O
be	O
increased	O
due	O
to	O
medications	O
such	O
as	O
high-dose	O
vitamin	O
A	O
derivatives	O
(	O
e.g.	O
,	O
isotretinoin	O
for	O
acne	other-disease
)	O
,	O
long-term	O
tetracycline	O
antibiotics	O
(	O
for	O
a	O
variety	O
of	O
skin	O
conditions	O
)	O
and	O
hormonal	O
contraceptives	O
.	O

Prognathism	other-disease
and	O
very	O
thick	O
fingernails	O
as	O
well	O
as	O
acanthosis	other-disease
nigricans	other-disease
were	O
also	O
described	O
.	O

Research	O
also	O
suggests	O
that	O
low-dose	O
rivaroxaban	O
plus	O
aspirin	O
is	O
effective	O
as	O
a	O
new	O
anti-thrombotic	O
regimen	O
for	O
PAD	other-disease
.	O

It	O
was	O
first	O
marketed	O
as	O
a	O
drug	O
to	O
treat	O
epilepsy	O
in	O
Switzerland	O
in	O
1963	O
under	O
the	O
brand	O
name	O
``	O
Tegretol	O
``	O
;	O
its	O
use	O
for	O
trigeminal	other-disease
neuralgia	other-disease
(	O
formerly	O
known	O
as	O
tic	other-disease
douloureux	other-disease
)	O
was	O
introduced	O
at	O
the	O
same	O
time	O
.	O

Those	O
with	O
Autism	other-disease
Spectrum	other-disease
Disorder	other-disease
(	O
ASD	other-disease
)	O
can	O
have	O
hyperacusis	other-disease
,	O
which	O
is	O
an	O
abnormal	O
sensitivity	O
to	O
sound	O
.	O

The	O
week-long	O
campaign	O
offered	O
HIV	other-disease
,	O
Hepatitis	other-disease
B	other-disease
and	O
Hepatitis	other-disease
C	other-disease
testing	O
in	O
emergency	O
departments	O
around	O
the	O
United	O
Kingdom	O
.	O

For	O
example	O
,	O
in	O
delusional	other-disease
jealousy	other-disease
,	O
where	O
a	O
person	O
believes	O
that	O
his	O
partner	O
is	O
being	O
unfaithful	O
(	O
and	O
may	O
even	O
follow	O
her	O
into	O
the	O
bathroom	O
believing	O
her	O
to	O
be	O
seeing	O
her	O
lover	O
even	O
during	O
the	O
briefest	O
of	O
partings	O
)	O
,	O
it	O
may	O
actually	O
be	O
true	O
that	O
the	O
partner	O
is	O
having	O
sexual	O
relations	O
with	O
another	O
person	O
.	O

Kubba	O
and	O
Young	O
pointed	O
out	O
a	O
number	O
of	O
other	O
conceivable	O
,	O
if	O
unlikely	O
,	O
diagnoses	O
,	O
besides	O
cystic	other-disease
fibrosis	other-disease
and	O
alpha	other-disease
1-antitrypsin	other-disease
deficiency	other-disease
:	O
eosinophilic	other-disease
granulomatosis	other-disease
with	other-disease
polyangiitis	other-disease
,	O
allergic	other-disease
bronchopulmonary	other-disease
aspergillosis	other-disease
,	O
hypogammaglobulinemia	other-disease
,	O
idiopathic	other-disease
pulmonary	other-disease
haemosiderosis	other-disease
,	O
lung	other-disease
abscesses	other-disease
,	O
and	O
pulmonary	other-disease
arteriovenous	other-disease
malformations	other-disease
.	O

Leukotoxin	O
destroys	O
host	O
leukocytes	O
and	O
causes	O
tissue	other-disease
necrosis	other-disease
.	O

In	O
2011	O
,	O
Pampers	O
joined	O
with	O
UNICEF	O
to	O
target	O
maternal	O
and	O
neonatal	other-disease
tetanus	other-disease
in	O
Yemen	O
.	O

After	O
the	O
Noad	O
Lahat	O
fight	O
in	O
early	O
2016	O
,	O
Rivas	O
was	O
diagnosed	O
with	O
testicular	other-disease
cancer	other-disease
which	O
was	O
successfully	O
treated	O
.	O

Sudden	O
explosive	O
noises	O
typical	O
of	O
high-performance	O
car	O
exhausts	O
and	O
car	O
alarms	O
are	O
types	O
of	O
noise	O
pollution	O
that	O
can	O
affect	O
people	O
with	O
ASD	other-disease
.	O

A1AT	O
is	O
indeed	O
the	O
protease	O
inhibitor	O
most	O
often	O
involved	O
in	O
disease	O
,	O
namely	O
in	O
alpha-1	other-disease
antitrypsin	other-disease
deficiency	other-disease
.	O

when	O
sick	O
with	O
tuberculosis	other-disease
in	O
December	O
1839	O
,	O
he	O
died	O
untimely	O
three	O
months	O
later	O

It	O
should	O
not	O
be	O
confused	O
with	O
periorbital	other-disease
cellulitis	other-disease
,	O
which	O
refers	O
to	O
cellulitis	other-disease
anterior	other-disease
to	other-disease
the	other-disease
septum	other-disease
.	O

Purpura	other-disease
fulminans	other-disease
secondary	O
to	O
severe	O
infection	O
is	O
self-limiting	O
.	O

SKI	O
has	O
been	O
linked	O
to	O
various	O
cancers	O
including	O
human	O
melanomas	other-disease
,	O
esophageal	other-disease
squamous	other-disease
cell	other-disease
carcinoma	other-disease
,	O
cervical	other-disease
cancer	other-disease
and	O
the	O
process	O
of	O
tumor	O
progression	O
.	O

ARS	other-disease
is	O
generally	O
rare	O
.	O

For	O
such	O
patients	O
,	O
the	O
anxiety	O
sensitivity	O
index	O
may	O
have	O
better	O
predictivity	O
for	O
anxiety	O
disorders	O
,	O
while	O
the	O
Beck	O
anxiety	O
inventory	O
may	O
misleadingly	O
suggest	O
anxiety	O
for	O
patients	O
with	O
dysautonomia	other-disease
.	O

HCM	other-disease
can	O
be	O
distinguished	O
from	O
other	O
inherited	O
causes	O
of	O
cardiomyopathy	O
by	O
its	O
autosomal	O
dominant	O
pattern	O
,	O
whereas	O
Fabry	other-disease
disease	O
and	O
Friedreich	other-disease
Ataxia	other-disease
are	O
inherited	O
in	O
an	O
autosomal	O
recessive	O
pattern	O
.	O

Such	O
a	O
method	O
has	O
been	O
applied	O
to	O
analyze	O
the	O
diffusion	O
of	O
endemic	O
diseases	O
such	O
as	O
the	other-disease
Dengue	other-disease
fever	other-disease
in	O
Colombia	O
,	O
as	O
well	O
as	O
the	O
diffusion	O
of	O
emergent	O
diseases	O
such	O
as	O
COVID-19	other-disease
in	O
Spain	O
and	O
Colombia	O
.	O

This	O
is	O
used	O
to	O
assess	O
any	O
problems	O
in	O
the	O
surrounding	O
structures	O
such	O
as	O
bone	other-disease
fractures	other-disease
,	O
chondrocalcinosis	other-disease
,	O
and	O
inflammatory	other-disease
arthritis	other-disease
which	O
may	O
predispose	O
to	O
septic	other-disease
arthritis	other-disease
.	O

On	O
the	O
evening	O
of	O
November	O
2	O
,	O
2008	O
,	O
in	O
North	O
Las	O
Vegas	O
,	O
Nevada	O
,	O
Tolbert	O
suffered	O
a	O
heart	other-disease
attack	other-disease
while	O
driving	O
alone	O
near	O
the	O
Obama	O
campaign	O
offices	O
.	O

If	O
the	O
vaccine	O
is	O
for	O
hepatitis	other-disease
A	other-disease
only	O
,	O
two	O
doses	O
are	O
given	O
6–18	O
months	O
apart	O
depending	O
on	O
the	O
manufacturer	O
.	O

Many	O
studies	O
have	O
presented	O
evidence	O
for	O
and	O
against	O
association	O
of	O
autism	other-disease
with	O
viral	O
infection	O
after	O
birth	O
.	O

Chronic	other-disease
kidney	other-disease
disease	other-disease
is	O
commonly	O
associated	O
with	O
sleep	O
symptoms	O
and	O
excessive	O
daytime	O
sleepiness	O
.	O

During	O
his	O
leadership	O
at	O
WHO	O
he	O
notoriously	O
had	O
a	O
conflict	O
with	O
then	O
head	O
of	O
the	O
WHO	O
's	O
Global	O
Programme	O
on	O
AIDS	other-disease
(	O
GPA	O
)	O
,	O
Jonathan	O
Mann	O
,	O
which	O
resulted	O
in	O
Mann	O
's	O
resignation	O
.	O

LET	other-disease
is	O
usually	O
found	O
on	O
sun-exposed	O
areas	O
of	O
the	O
body	O
.	O

Byers	O
'	O
debut	O
novel	O
``	O
Idiopathy	O
``	O
,	O
a	O
satire	O
based	O
on	O
the	O
spread	O
of	O
a	O
BSE	other-disease
-like	O
disease	O
,	O
received	O
a	O
Betty	O
Trask	O
Award	O
and	O
the	O
Waterstones	O
11	O
prize	O
.	O

Scoliosis	other-disease
is	O
also	O
common	O
.	O

The	O
tricuspid	O
valve	O
can	O
be	O
affected	O
by	O
rheumatic	other-disease
fever	other-disease
,	O
which	O
can	O
cause	O
tricuspid	other-disease
stenosis	other-disease
or	O
tricuspid	other-disease
regurgitation	other-disease
.	O

Migraine	other-disease
surgery	O
which	O
involves	O
decompression	O
of	O
certain	O
nerves	O
around	O
the	O
head	O
and	O
neck	O
may	O
be	O
an	O
option	O
in	O
certain	O
people	O
who	O
do	O
not	O
improve	O
with	O
medications	O
.	O

The	O
two	O
most	O
common	O
syndromes	O
under	O
this	O
``	O
umbrella	O
''	O
are	O
:	O
Leopard	other-disease
syndrome	other-disease
(	O
LS	other-disease
)	O
and	O
Noonan	other-disease
syndrome	other-disease
(	O
NS	other-disease
)	O
.	O

In	O
the	O
United	O
States	O
,	O
Hansen	other-disease
's	O
disease	O
is	O
tracked	O
by	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
(	O
CDC	O
)	O
,	O
with	O
a	O
total	O
of	O
92	O
cases	O
being	O
reported	O
in	O
2002	O
.	O

Cyclic	other-disease
acute	other-disease
wound	other-disease
pain	other-disease
may	O
be	O
experienced	O
in	O
conjunction	O
with	O
chronic	other-disease
wound	other-disease
pain	other-disease
and	O
occurs	O
during	O
regular	O
routines	O
such	O
as	O
dressing	O
changes	O
or	O
repositioning	O
.	O

The	O
one	other-disease
and	other-disease
a	other-disease
half	other-disease
syndrome	other-disease
is	O
a	O
rare	O
weakness	O
in	O
eye	O
movement	O
affecting	O
both	O
eyes	O
,	O
in	O
which	O
one	O
can	O
not	O
move	O
laterally	O
at	O
all	O
,	O
and	O
the	O
other	O
can	O
move	O
only	O
in	O
outward	O
direction	O
.	O

K562	O
cells	O
are	O
of	O
the	O
erythroleukemia	other-disease
type	O
,	O
and	O
the	O
cell	O
line	O
is	O
derived	O
from	O
a	O
53-year-old	O
female	O
chronic	O
myelogenous	O
leukemia	other-disease
patient	O
in	O
blast	O
crisis	O
.	O

The	O
subtypes	O
of	O
schizophrenia	other-disease
were	O
eliminated	O
because	O
of	O
a	O
lack	O
of	O
clear	O
distinction	O
among	O
the	O
subtypes	O
and	O
low	O
validity	O
of	O
classification	O
.	O

This	O
monograph	O
was	O
published	O
after	O
a	O
diagnosis	O
of	O
metastatic	other-disease
stage	other-disease
IV	other-disease
breast	other-disease
cancer	other-disease
in	O
2009	O
.	O

Any	O
S.	O
aureus	O
infection	O
can	O
cause	O
the	O
staphylococcal	other-disease
scalded	other-disease
skin	other-disease
syndrome	other-disease
,	O
a	O
cutaneous	O
reaction	O
to	O
exotoxin	O
absorbed	O
into	O
the	O
bloodstream	O
.	O

In	O
2020	O
,	O
increased	O
attacks	O
,	O
both	O
physically	O
and	O
verbally	O
,	O
have	O
occurred	O
against	O
Asian-Americans	O
as	O
a	O
result	O
of	O
COVID-19	other-disease
paranoia	O
and	O
racism	O
.	O

Microscopically	O
there	O
are	O
epithelioid	other-disease
granulomas	other-disease
and	O
vasculitis	other-disease
in	O
the	O
subcutaneous	O
tissue	O
,	O
making	O
it	O
a	O
form	O
of	O
paniculitis	other-disease
.	O

However	O
,	O
the	O
promotion	O
of	O
safe	O
sex	O
and	O
contraception	O
throughout	O
the	O
HIV/AIDS	other-disease
epidemic	other-disease
and	O
the	O
promotion	O
of	O
positive	O
LGBT	O
themes	O
has	O
increased	O
awareness	O
and	O
normalized	O
the	O
concept	O
of	O
sexual	O
diversity	O
within	O
Peru	O
.	O

Early	O
latent	O
syphilis	other-disease
is	O
defined	O
by	O
the	O
World	O
Health	O
Organization	O
as	O
less	O
than	O
2	O
years	O
after	O
original	O
infection	O
.	O

On	O
July	O
30	O
,	O
2016	O
,	O
Plewa	O
suffered	O
a	O
stroke	O
following	O
their	O
game	O
against	O
Richmond	O
Kickers	O
caused	O
by	O
Protein	other-disease
S	other-disease
deficiency	other-disease
which	O
is	O
a	O
rare	O
blood	O
disorder	O
which	O
can	O
lead	O
to	O
an	O
increased	O
risk	O
of	O
thrombosis	O
.	O

A	O
20th	O
anniversary	O
concert	O
event	O
was	O
held	O
in	O
May	O
1988	O
at	O
the	O
United	O
Nations	O
General	O
Assembly	O
to	O
benefit	O
children	O
with	O
AIDS	other-disease
.	O

The	O
HIV-1	O
viral	O
envelope	O
glycoprotein	O
gp120	O
can	O
directly	O
inhibit	O
the	O
phosphorylation	O
of	O
GFAP	O
and	O
GFAP	O
levels	O
can	O
be	O
decreased	O
in	O
response	O
to	O
chronic	O
infection	O
with	O
HIV-1	other-disease
,	O
varicella	other-disease
zoster	other-disease
,	O
and	O
pseudorabies	other-disease
.	O

Nausea	other-disease
and	O
vomiting	other-disease
may	O
be	O
initiated	O
by	O
various	O
stimuli	O
,	O
through	O
different	O
neuronal	O
pathways	O
.	O

These	O
levels	O
,	O
taken	O
as	O
a	O
set	O
,	O
can	O
be	O
rapidly	O
performed	O
to	O
indicate	O
several	O
common	O
acute	O
conditions	O
requiring	O
immediate	O
specific	O
medical	O
treatment	O
,	O
such	O
as	O
dehydration	other-disease
/	O
hypovolemia	other-disease
,	O
water	other-disease
intoxication	other-disease
(	O
which	O
can	O
present	O
with	O
similar	O
symptoms	O
to	O
dehydration	O
but	O
requires	O
the	O
opposite	O
treatment	O
)	O
,	O
diabetic	other-disease
shock	other-disease
(	O
either	O
ketoacidosis	other-disease
,	O
hyperglycemia	other-disease
or	O
hypoglycemia	other-disease
)	O
,	O
congestive	other-disease
heart	other-disease
failure	other-disease
,	O
kidney	other-disease
failure	other-disease
or	O
liver	other-disease
failure	other-disease
,	O
various	O
substance	O
overdoses	O
or	O
adverse	O
reactions	O
,	O
and	O
others	O
.	O

On	O
19	O
December	O
2019	O
,	O
it	O
was	O
publicly	O
revealed	O
Burrow	O
had	O
been	O
diagnosed	O
with	O
Motor	other-disease
Neurone	other-disease
Disease	other-disease
(	O
MND	other-disease
)	O
.	O

In	O
a	O
1994	O
article	O
,	O
for	O
example	O
,	O
Betinho	O
anticipated	O
one	O
of	O
the	O
main	O
trends	O
of	O
the	O
HIV	other-disease
/	O
AIDS	other-disease
epidemic	O
in	O
Brazil	O
:	O
its	O
pauperisation	O
.	O

She	O
started	O
learning	O
American	O
Sign	O
Language	O
at	O
17	O
,	O
before	O
she	O
found	O
out	O
she	O
had	O
Ménière	other-disease
's	other-disease
disease	other-disease
,	O
which	O
leads	O
to	O
hearing	O
loss	O
.	O

Germ	O
cell	O
tumor	O
(	O
GCT	other-disease
)	O
is	O
a	O
neoplasm	O
derived	O
from	O
germ	O
cells	O
.	O

LAL	other-disease
Deficiency	other-disease
affects	O
patients	O
of	O
all	O
ages	O
with	O
sudden	O
and	O
unpredictable	O
clinical	O
complications	O
manifesting	O
from	O
infancy	O
through	O
adulthood	O
.	O

%	O
-	O
Johnson	O
is	O
an	O
injury	O
replacement	O
for	O
Joseph	O
who	O
suffered	O
a	O
bone	other-disease
bruise	other-disease
in	O
his	O
right	O
knee	O
.	O

There	O
is	O
an	O
increased	O
risk	O
of	O
coronary	other-disease
heart	other-disease
disease	other-disease
.	O

In	O
2005	O
,	O
a	O
field	O
evaluation	O
of	O
a	O
novel	O
handheld	O
microscope	O
was	O
undertaken	O
in	O
Uganda	O
for	O
the	O
diagnosis	O
of	O
intestinal	O
schistosomiasis	other-disease
by	O
a	O
team	O
led	O
by	O
Russell	O
Stothard	O
from	O
the	O
Natural	O
History	O
Museum	O
of	O
London	O
,	O
working	O
with	O
the	O
Schistosomiasis	O
Control	O
Initiative	O
,	O
London	O
.	O

According	O
to	O
the	O
recent	O
'	O
WHO	O
vaccine-preventable	O
diseases	O
:	O
monitoring	O
system	O
'	O
reported	O
cases	O
for	O
Diphtheria	other-disease
were	O
0	O
,	O
Measles	other-disease
were	O
9	O
,	O
Rubella	other-disease
were	O
7	O
,	O
Mumps	other-disease
were	O
544	O
and	O
Tetanus	other-disease
(	O
total	O
)	O
were	O
16	O
cases	O
in	O
2016	O
.	O

In	O
this	O
congress	O
,	O
various	O
dermatological	O
diseases	O
such	O
as	O
lichen	other-disease
,	O
pityriasis	other-disease
rubra	other-disease
pilaris	other-disease
,	O
pemphigus	other-disease
,	O
trichophytosis	other-disease
,	O
syphilis	other-disease
,	O
and	O
leprosy	other-disease
were	O
discussed	O
,	O
and	O
Muhtar	O
presented	O
a	O
paper	O
on	O
``	O
syphilitic	other-disease
chancre	other-disease
without	O
lymphadenopathy	other-disease
``	O
.	O

The	O
images	O
showcase	O
both	O
Horn	other-disease
Head	other-disease
and	O
Splitting	other-disease
Headache	other-disease
and	O
will	O
be	O
part	O
of	O
the	O
Premium	O
DNA	O
toy	O
line	O
.	O

The	O
pathophysiology	other-disease
of	other-disease
nephritic	other-disease
syndrome	other-disease
is	O
dependent	O
on	O
the	O
underlying	O
disease	O
process	O
,	O
which	O
can	O
vary	O
depending	O
on	O
what	O
condition	O
the	O
nephritic	other-disease
syndrome	other-disease
is	O
secondary	O
to	O
.	O

Symptoms	O
of	O
this	O
agnosia	other-disease
can	O
vary	O
depending	O
on	O
the	O
area	O
of	O
the	O
brain	O
affected	O
.	O

The	O
prevalence	O
of	O
HIV	other-disease
/	O
AIDS	other-disease
in	O
the	O
Dominican	O
Republic	O
in	O
2011	O
stood	O
at	O
approximately	O
0.7	O
%	O
,	O
which	O
is	O
relatively	O
low	O
by	O
Caribbean	O
standards	O
,	O
with	O
an	O
estimated	O
62,000	O
HIV	other-disease
/	O
AIDS	other-disease
-positive	O
Dominicans	O
.	O

Viruses	O
have	O
long	O
been	O
suspected	O
as	O
triggers	O
for	O
immune-mediated	O
diseases	O
such	O
as	O
multiple	O
sclerosis	O
but	O
showing	O
a	O
direct	O
role	O
for	O
viral	O
causation	O
is	O
difficult	O
in	O
those	O
diseases	O
,	O
and	O
mechanisms	O
,	O
whereby	O
viral	O
infections	O
could	O
lead	O
to	O
autism	other-disease
,	O
are	O
speculative	O
.	O

Percentages	O
in	O
the	O
table	O
below	O
refer	O
to	O
the	O
percentage	O
of	O
people	O
with	O
the	O
MEN	O
type	O
who	O
develop	O
the	O
neoplasia	other-disease
type	other-disease
.	O

In	O
1993	O
,	O
an	O
outbreak	O
of	O
HCPS	other-disease
,	O
then	O
unrecognized	O
,	O
occurred	O
in	O
the	O
Four	O
Corners	O
region	O
of	O
the	O
United	O
States	O
and	O
led	O
to	O
the	O
discovery	O
of	O
the	O
``	O
Sin	O
Nombre	O
orthohantavirus	O
``	O
.	O

Chronic	other-disease
neutrophilic	other-disease
leukemia	other-disease
(	O
CNL	other-disease
)	O
is	O
a	O
rare	O
myeloproliferative	O
neoplasm	O
that	O
features	O
a	O
persistent	O
neutrophilia	O
in	O
peripheral	O
blood	O
,	O
myeloid	O
hyperplasia	O
in	O
bone	O
marrow	O
,	O
hepatosplenomegaly	O
,	O
and	O
the	O
absence	O
of	O
the	O
Philadelphia	O
chromosom	O
e	O
or	O
a	O
BCR/ABL	O
fusion	O
gene	O
.	O

She	O
fell	O
ill	O
in	O
June	O
1642	O
,	O
and	O
died	O
of	O
a	O
bout	O
of	O
pleurisy	other-disease
in	O
destitution	O
on	O
3	O
July	O
1642	O
,	O
a	O
few	O
months	O
before	O
Richelieu	O
.	O

Potential	O
complications	O
and	O
side	O
effects	O
from	O
the	O
procedure	O
include	O
lip	O
and	O
chin	other-disease
hypoanesthesia	other-disease
,	O
seromas	other-disease
,	O
edema	other-disease
,	O
transient	O
dysphagia	O
and	O
aspiration	O
,	O
and	O
surgical	O
site	O
infection	O
.	O

These	O
masculine	O
characteristics	O
include	O
:	O
clitoral	other-disease
hypertrophy	other-disease
,	O
androgenic	other-disease
alopecia	other-disease
,	O
growth	O
of	O
body	O
hair	O
and	O
deepening	O
of	O
the	O
vocal	O
cords	O
.	O

Glypican	O
3	O
immunostaining	O
has	O
utility	O
for	O
differentiating	O
hepatocellular	other-disease
carcinoma	other-disease
(	O
HCC	other-disease
)	O
and	O
dysplastic	O
changes	O
in	O
cirrhotic	other-disease
livers	other-disease
;	O
HCC	other-disease
stains	O
with	O
glypican	O
3	O
,	O
while	O
liver	O
with	O
dysplastic	O
changes	O
and/or	O
cirrhotic	O
changes	O
does	O
not	O
.	O

Chronic	O
phase	O
chronic	other-disease
myelogenous	other-disease
leukemia	other-disease
is	O
a	O
phase	O
of	O
chronic	other-disease
myelogenous	other-disease
leukemia	other-disease
in	O
which	O
5	O
%	O
or	O
fewer	O
of	O
the	O
cells	O
in	O
the	O
blood	O
and	O
bone	O
marrow	O
are	O
blast	O
cells	O
(	O
immature	O
blood	O
cells	O
)	O
.	O

Product	O
Red	O
is	O
another	O
initiative	O
begun	O
by	O
Bono	O
and	O
Bobby	O
Shriver	O
to	O
raise	O
money	O
for	O
the	O
Global	O
Fund	O
to	O
Fight	O
AIDS	other-disease
,	O
Tuberculosis	other-disease
,	O
and	O
Malaria	other-disease
.	O

Breast	other-disease
cancer	other-disease
was	O
also	O
listed	O
as	O
a	O
significant	O
condition	O
on	O
her	O
death	O
certificate	O
.	O

It	O
is	O
well	O
accepted	O
that	O
alternative	O
splicing	O
has	O
a	O
role	O
in	O
SZ	other-disease
pathology	O
.	O

Dive	O
history	O
as	O
recorded	O
by	O
a	O
personal	O
dive	O
computer	O
or	O
bottom	O
timer	O
can	O
indicate	O
a	O
probability	O
of	O
gas	O
bubbles	O
being	O
a	O
consequence	O
of	O
decompression	O
sickness	O
,	O
lung	O
overpressure	O
induced	O
arterial	other-disease
gas	other-disease
embolism	other-disease
or	O
an	O
artifact	O
of	O
post	O
mortem	O
recovery	O
decompression	O
.	O

Anosognosia	other-disease
is	O
a	O
condition	O
in	O
which	O
a	O
person	O
who	O
suffers	O
certain	O
disability	O
seems	O
unaware	O
of	O
the	O
existence	O
of	O
their	O
disability	O
.	O

Pulmonary	other-disease
and	O
tricuspid	other-disease
valve	other-disease
diseases	other-disease
are	O
right	O
heart	O
diseases	O
.	O

Because	O
Scheie	other-disease
syndrome	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
,	O
affected	O
persons	O
have	O
two	O
nonworking	O
copies	O
of	O
the	O
gene	O
.	O

In	O
March	O
2020	O
,	O
during	O
the	O
COVID-19	other-disease
pandemic	O
,	O
the	O
restaurant	O
began	O
selling	O
pizza	O
,	O
wings	O
,	O
desserts	O
and	O
more	O
through	O
food	O
delivery	O
services	O
under	O
the	O
virtual	O
brand	O
Pasqually	O
's	O
Pizza	O
&	O
amp	O
;	O
Wings	O
.	O

Growth	other-disease
hormone	other-disease
deficiency	other-disease
(	O
GHD	other-disease
)	O
is	O
a	O
medical	O
condition	O
in	O
which	O
the	O
body	O
produces	O
insufficient	O
growth	O
hormone	O
.	O

Cyclothymia	other-disease
,	O
known	O
today	O
as	O
cyclothymic	other-disease
disorder	other-disease
,	O
tends	O
to	O
be	O
underdiagnosed	O
due	O
to	O
its	O
low	O
intensity	O
.	O

Titers	O
to	O
GM1	other-disease
in	O
other	O
diseases	O
(	O
rheumatoid	other-disease
arthritis	other-disease
,	O
primary	other-disease
Sjögren	other-disease
's	other-disease
syndrome	other-disease
and	O
systemic	other-disease
lupus	other-disease
erythematosus	other-disease
)	O
was	O
also	O
elevated	O
.	O

The	O
diseases	O
also	O
causes	O
a	O
reduction	O
in	O
the	O
maturation	O
of	O
erythroblasts	O
to	O
circulating	O
red	O
blood	O
cells	O
and	O
,	O
consequently	O
,	O
mild	other-disease
anemia	other-disease
.	O

This	O
strategy	O
is	O
supported	O
by	O
treating	O
resveratrol	O
,	O
an	O
inhibitor	O
of	O
acetylation	O
of	O
STAT3	O
,	O
in	O
cancer	other-disease
cell	O
line	O
reverses	O
aberrant	O
CpG	O
island	O
methylation	O
.	O

Pathogens	O
commonly	O
implicated	O
in	O
travelers	O
'	O
diarrhea	other-disease
appear	O
in	O
the	O
table	O
in	O
this	O
section	O
.	O

The	O
average	O
lifetime	O
prevalence	O
found	O
was	O
6.7	O
%	O
for	O
MDD	other-disease
(	O
with	O
a	O
relatively	O
low	O
lifetime	O
prevalence	O
rate	O
in	O
higher-quality	O
studies	O
,	O
compared	O
to	O
the	O
rates	O
typically	O
highlighted	O
of	O
5–12	O
%	O
for	O
men	O
and	O
10–25	O
%	O
for	O
women	O
)	O
,	O
and	O
rates	O
of	O
3.6	O
%	O
for	O
dysthymia	other-disease
and	O
0.8	O
%	O
for	O
Bipolar	other-disease
1	other-disease
.	O

The	O
presentation	O
of	O
pseudohyperaldosteronism	other-disease
varies	O
depending	O
on	O
the	O
cause	O
.	O

India	O
reports	O
over	O
50	O
%	O
of	O
the	O
world	O
's	O
leprosy	other-disease
cases	O
.	O

One	O
serious	O
effect	O
on	O
envenomed	O
victims	O
is	O
hemorrhage	other-disease
syndrome	other-disease
.	O

A	O
characteristic	O
feature	O
of	O
Stickler	other-disease
syndrome	O
is	O
a	O
somewhat	O
flattened	O
facial	O
appearance	O
.	O

Heparin-induced	other-disease
thrombocytopenia	other-disease
(	O
HIT	other-disease
)	O
is	O
due	O
to	O
an	O
immune	O
system	O
reaction	O
against	O
the	O
anticoagulant	O
drug	O
heparin	O
(	O
or	O
its	O
derivatives	O
)	O
.	O

This	O
can	O
manifest	O
as	O
a	O
coloboma	other-disease
(	other-disease
hole	other-disease
)	other-disease
in	other-disease
the	other-disease
iris	other-disease
,	O
cataracts	other-disease
,	O
opacity	other-disease
of	other-disease
the	other-disease
cornea	other-disease
(	O
leukoma	other-disease
)	O
,	O
sclerocornea	other-disease
(	O
in	O
which	O
the	O
white	O
of	O
the	O
eye	O
blends	O
into	O
the	O
cornea	O
)	O
,	O
a	O
small	other-disease
cornea	other-disease
(	O
microcornea	other-disease
)	O
and	O
synechia	other-disease
(	O
in	O
which	O
the	O
iris	O
adheres	O
to	O
the	O
cornea	O
or	O
lens	O
)	O
.	O

A	O
potential	O
link	O
of	O
ZDHHC11	O
with	O
bladder	other-disease
cancer	other-disease
has	O
been	O
suggested	O
by	O
the	O
discovery	O
that	O
5	O
out	O
of	O
9	O
high-grade	O
bladder	other-disease
cancer	other-disease
samples	O
surveyed	O
contained	O
a	O
duplication	O
of	O
the	O
5p15.33	O
genomic	O
region	O
.	O

As	O
DISC1	O
function	O
is	O
involved	O
in	O
neurogenesis	O
and	O
neuroplasticity	O
,	O
vulnerability	O
to	O
schizophrenia	other-disease
may	O
involve	O
dysfunction	O
in	O
the	O
hippocampus	O
,	O
a	O
brain	O
region	O
in	O
which	O
adult	O
neurogenesis	O
occurs	O
.	O

Humans	O
with	O
double	O
allelic	O
loss	O
of	O
CCR5	O
are	O
virtually	O
immune	O
to	O
HIV	other-disease
acquired	O
via	O
the	O
sexual	O
route	O
(	O
though	O
can	O
be	O
infected	O
by	O
IV	O
transmission	O
of	O
CXCR4	other-disease
tropic	O
viruses	O
)	O
.	O

The	O
slightly	O
higher	O
preference	O
for	O
SSRIs	O
over	O
SNRIs	O
as	O
a	O
first	O
choice	O
for	O
treatment	O
of	O
anxiety	other-disease
disorders	other-disease
may	O
have	O
been	O
influenced	O
by	O
the	O
observation	O
of	O
poorer	O
tolerability	O
of	O
the	O
SNRIs	O
in	O
comparison	O
to	O
SSRIs	O
in	O
systematic	O
reviews	O
of	O
studies	O
of	O
depressed	O
patients	O
.	O

Wernicke–Korsakoff	other-disease
syndrome	other-disease
(	O
WKS	other-disease
)	O
is	O
a	O
severe	O
neurological	O
disorder	O
caused	O
by	O
thiamine	O
(	O
vitamin	O
B1	O
)	O
deficiency	O
,	O
and	O
is	O
usually	O
associated	O
with	O
chronic	O
excessive	O
alcohol	O
consumption	O
.	O

She	O
died	O
in	O
1919	O
at	O
age	O
29	O
,	O
due	O
to	O
the	O
Spanish	other-disease
influenza	other-disease
epidemic	other-disease
.	O

A	O
chronic	other-disease
wet	other-disease
cough	other-disease
is	O
a	O
cough	O
where	O
excess	O
mucus	O
is	O
present	O
and	O
depending	O
on	O
the	O
colour	O
of	O
the	O
phlegm	O
,	O
bacterial	O
infections	O
may	O
be	O
present	O
.	O

These	O
results	O
suggested	O
that	O
PKC-ι	O
is	O
involved	O
in	O
signaling	O
pathways	O
which	O
upregulate	O
EMT	O
in	O
melanoma	other-disease
.	O

All	O
known	O
prion	other-disease
diseases	other-disease
are	O
untreatable	O
and	O
fatal	O
.	O

However	O
,	O
the	O
number	O
of	O
symptoms	O
and	O
severity	O
of	O
symptoms	O
may	O
depend	O
on	O
how	O
severe	O
the	O
anemia	other-disease
is	O
.	O

Defective	O
laminins	O
can	O
cause	O
muscles	O
to	O
form	O
improperly	O
,	O
leading	O
to	O
a	O
form	O
of	O
muscular	other-disease
dystrophy	other-disease
,	O
lethal	O
skin	O
blistering	O
disease	O
(	O
junctional	other-disease
epidermolysis	other-disease
bullosa	other-disease
)	O
and	O
defects	O
of	O
the	O
kidney	O
filter	O
(	O
nephrotic	other-disease
syndrome	other-disease
)	O
.	O

PAH	O
deficiency	O
causes	O
a	O
spectrum	O
of	O
disorders	O
,	O
including	O
classic	O
phenylketonuria	other-disease
(	O
PKU	other-disease
)	O
and	O
mild	other-disease
hyperphenylalaninemia	other-disease
(	O
also	O
known	O
as	O
``	O
hyperphe	other-disease
``	O
or	O
``	O
mild	other-disease
HPA	other-disease
``	O
)	O
,	O
a	O
less	O
severe	O
accumulation	O
of	O
phenylalanine	O
.	O

Insulin-resistant	other-disease
diabetes	other-disease
developed	O
,	O
and	O
the	O
patients	O
died	O
during	O
childhood	O
of	O
ketoacidosis	other-disease
and	O
intercurrent	O
infections	O
.	O

Myasthenia	O
gravis	O
rarely	O
improves	O
after	O
thyroid	other-disease
treatment	O
and	O
the	O
relationship	O
between	O
the	O
two	O
entities	O
is	O
not	O
well	O
understood	O
.	O

In	O
May	O
2008	O
,	O
it	O
was	O
revealed	O
he	O
was	O
suffering	O
from	O
bone	O
cancer	other-disease
.	O

WSMV	other-disease
often	O
overwinters	O
on	O
the	O
seeds	O
,	O
and	O
can	O
spread	O
to	O
a	O
field	O
planted	O
after	O
the	O
infected	O
seedlings	O
have	O
sprouted	O
.	O

30	O
%	O
of	O
all	O
patients	O
have	O
cirrhosis	O
associated	O
with	O
GAVE	other-disease
.	O

This	O
includes	O
allergic	other-disease
rhinitis	other-disease
(	O
hay	other-disease
fever	other-disease
)	O
and	O
hives	other-disease
.	O

Reduced	O
HRV	O
has	O
been	O
shown	O
to	O
be	O
a	O
predictor	O
of	O
mortality	O
after	O
myocardial	other-disease
infarction	other-disease
although	O
others	O
have	O
shown	O
that	O
the	O
information	O
in	O
HRV	O
relevant	O
to	O
acute	O
myocardial	O
infarction	O
survival	O
is	O
fully	O
contained	O
in	O
the	O
mean	O
heart	O
rate	O
.	O

In	O
contrast	O
neighboring	O
Haiti	O
has	O
an	O
HIV	other-disease
/	O
AIDS	other-disease
rate	O
more	O
than	O
double	O
that	O
of	O
the	O
Dominican	O
Republic	O
.	O

Individuals	O
with	O
DIOS	other-disease
may	O
be	O
predisposed	O
to	O
bowel	other-disease
obstruction	other-disease
,	O
though	O
it	O
is	O
a	O
separate	O
entity	O
than	O
true	O
constipation	O
.	O

After	O
a	O
major	O
public	O
health	O
effort	O
,	O
Uganda	O
in	O
2011	O
was	O
certified	O
as	O
having	O
eliminated	O
tetanus	other-disease
.	O

CES-I	other-disease
with	O
its	O
more	O
favourable	O
prognosis	O
may	O
become	O
CES-R	other-disease
at	O
a	O
later	O
stage	O
.	O

In	O
1987–1994	O
,	O
there	O
were	O
no	O
subtypes	O
and	O
thus	O
it	O
was	O
not	O
distinguished	O
from	O
hyperactive	O
ADHD	other-disease
in	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
(	O
DSM-III-R	O
)	O
.	O

Erysipelas	other-disease
must	O
be	O
differentiated	O
from	O
h	O
erpes	other-disease
zoster	other-disease
,	O
angioedema	other-disease
,	O
contact	other-disease
dermatitis	other-disease
,	O
erythema	other-disease
chronicum	other-disease
migrans	other-disease
of	other-disease
early	other-disease
Lyme	other-disease
disease	other-disease
,	O
gout	other-disease
,	O
septic	other-disease
arthritis	other-disease
,	O
septic	other-disease
bursitis	other-disease
,	O
vasculitis	other-disease
,	O
allergic	other-disease
reaction	other-disease
to	O
an	O
insect	O
bite	O
,	O
acute	other-disease
drug	other-disease
reaction	other-disease
,	O
deep	other-disease
venous	other-disease
thrombosis	other-disease
and	O
diffuse	other-disease
inflammatory	other-disease
carcinoma	other-disease
of	other-disease
the	other-disease
breast	other-disease
.	O

These	O
interactions	O
would	O
be	O
expected	O
to	O
be	O
most	O
significant	O
with	O
long-term	O
diazepam	other-disease
therapy	O
,	O
and	O
their	O
clinical	O
significance	O
is	O
variable	O
.	O

Brugada	other-disease
syndrome	other-disease
(	O
BrS	other-disease
)	O
is	O
a	O
genetic	O
disorder	O
in	O
which	O
the	O
electrical	O
activity	O
within	O
the	O
heart	O
is	O
abnormal	O
.	O

A	O
review	O
that	O
pooled	O
surveys	O
of	O
mood	O
disorders	O
in	O
different	O
countries	O
up	O
to	O
2000	O
found	O
12-month	O
prevalence	O
rates	O
of	O
4.1	O
%	O
for	O
major	other-disease
depressive	other-disease
disorder	other-disease
(	O
MDD	other-disease
)	O
,	O
2	O
%	O
for	O
dysthymic	other-disease
disorder	other-disease
and	O
0.72	O
%	O
for	O
bipolar	other-disease
1	other-disease
disorder	other-disease
.	O

Several	O
standardized	O
test	O
batteries	O
exist	O
for	O
diagnosing	O
and	O
classifying	O
aphasias	other-disease
.	O

The	O
latent	O
phase	O
of	O
syphilis	other-disease
can	O
last	O
many	O
years	O
after	O
which	O
,	O
without	O
treatment	O
,	O
approximately	O
15-40	O
%	O
of	O
people	O
can	O
develop	O
tertiary	O
syphilis	other-disease
.	O

Hyperpituitarism	other-disease
is	O
the	O
condition	O
where	O
the	O
pituitary	O
secretes	O
excessive	O
amounts	O
of	O
hormones	O
.	O

When	O
Hemoglobin	O
O-Arab	O
co-inherits	O
with	O
Hemoglobin	O
S	O
,	O
it	O
produces	O
a	O
syndrome	O
with	O
similarities	O
in	O
severity	O
to	O
sickle	other-disease
cell	other-disease
anaemia	other-disease
,	O
having	O
severe	O
haemolytic	O
anaemia	O
and	O
red	O
cells	O
denser	O
than	O
normal	O
with	O
occurrences	O
of	O
some	O
cells	O
as	O
dense	O
as	O
if	O
contract	O
with	O
sickle	other-disease
cell	other-disease
anaemia	other-disease
.	O

X-linked	other-disease
thrombocytopenia	other-disease
is	O
typically	O
diagnosed	O
in	O
infancy	O
.	O

Avian	other-disease
influenza	other-disease
is	O
sometimes	O
called	O
avian	other-disease
flu	other-disease
,	O
and	O
colloquially	O
,	O
bird	O
flu	O
.	O

PTHS	other-disease
is	O
characterized	O
by	O
developmental	O
delay	O
,	O
possible	O
breathing	O
problems	O
of	O
episodic	other-disease
hyperventilation	other-disease
and/or	O
breath-holding	O
while	O
awake	O
,	O
recurrent	O
seizures	other-disease
/	O
epilepsy	other-disease
,	O
gastrointestinal	O
issues	O
,	O
and	O
distinctive	O
facial	O
features	O
.	O

The	O
gunman	O
,	O
Huan	O
Yun	O
Xiang	O
,	O
was	O
acquitted	O
of	O
crimes	O
related	O
to	O
the	O
shootings	O
due	O
to	O
mental	other-disease
impairment	other-disease
,	O
and	O
is	O
currently	O
under	O
psychiatric	O
care	O
.	O

HACE	other-disease
was	O
first	O
described	O
by	O
a	O
medical	O
officer	O
stationed	O
in	O
Chile	O
in	O
1913	O
,	O
but	O
few	O
took	O
note	O
of	O
it	O
.	O

Consulting	O
with	O
an	O
environmental	O
medicine	O
specialist	O
helped	O
,	O
and	O
through	O
the	O
rest	O
of	O
1998	O
Porcellino	O
's	O
health	O
began	O
to	O
improve	O
—	O
but	O
then	O
he	O
was	O
diagnosed	O
with	O
obsessive	other-disease
compulsive	other-disease
disorder	other-disease
(	O
OCD	other-disease
)	O
.	O

The	O
first	O
case	O
of	O
Hansen	other-disease
's	other-disease
disease	other-disease
in	O
Queensland	O
had	O
been	O
discovered	O
in	O
1855	O
.	O

Psychosis	other-disease
originally	O
defeated	O
Kaz	O
Hayashi	O
in	O
the	O
first	O
round	O
,	O
but	O
was	O
unable	O
to	O
compete	O
in	O
the	O
semifinals	O
,	O
so	O
Hayashi	O
was	O
allowed	O
back	O
into	O
the	O
tournament	O
.	O

It	O
is	O
infamous	O
for	O
playing	O
host	O
to	O
the	O
final	O
performance	O
of	O
British	O
comic	O
actor	O
Sid	O
James	O
who	O
died	O
of	O
a	O
heart	other-disease
attack	other-disease
whilst	O
on	O
stage	O
in	O
1976	O
.	O

Other	O
disorders	O
need	O
to	O
be	O
ruled	O
out	O
before	O
diagnosing	O
major	other-disease
depressive	other-disease
disorder	other-disease
.	O

Cystic	other-disease
fibrosis	other-disease
is	O
the	O
most	O
common	O
life-threatening	O
autosomal	O
recessive	O
disease	O
in	O
the	O
United	O
States	O
and	O
Europe	O
.	O

Treatments	O
are	O
not	O
always	O
successful	O
,	O
especially	O
when	O
the	O
cause	O
of	O
POIS	other-disease
in	O
a	O
particular	O
patient	O
has	O
not	O
been	O
determined	O
.	O

This	O
finding	O
helps	O
in	O
the	O
early	O
diagnosis	O
of	O
Hereditary	other-disease
hemochromatosis	other-disease
,	O
especially	O
while	O
serum	O
ferritin	O
still	O
remains	O
low	O
.	O

Transfusion	O
of	O
unsafe	O
blood	O
that	O
has	O
not	O
been	O
screened	O
for	O
window	O
period	O
,	O
cases	O
of	O
viral	O
infections	O
could	O
increase	O
the	O
risk	O
of	O
Transfusion	other-disease
Transmitted	other-disease
Infections	other-disease
(	O
TTIs	other-disease
)	O
and	O
at	O
times	O
be	O
life-threatening	O
.	O

Alcoholics	O
may	O
have	O
anemia	O
from	O
several	O
causes	O
;	O
they	O
may	O
also	O
develop	O
thrombocytopenia	other-disease
from	O
direct	O
toxic	O
effect	O
on	O
megakaryocytes	O
,	O
or	O
from	O
hypersplenism	other-disease
.	O

The	O
drugs	O
were	O
designed	O
to	O
inhibit	O
HIV	other-disease
from	O
replicating	O
by	O
binding	O
to	O
the	O
protease	O
.	O

Dilated	other-disease
cardiomyopathy	other-disease
implies	O
that	O
the	O
muscle	O
damage	O
has	O
resulted	O
in	O
enlargement	O
of	O
the	O
heart	O
.	O

She	O
is	O
an	O
ambassador	O
for	O
the	O
Nelson	O
Mandela	O
's	O
``	O
46664	O
''	O
campaign	O
,	O
raising	O
awareness	O
towards	O
AIDS	other-disease
in	O
Africa	O
.	O

Infectious	O
causes	O
include	O
syphilis	other-disease
(	O
commonest	O
)	O
,	O
followed	O
by	O
other	O
bacterial	O
infections	O
(	O
TB	other-disease
,	O
Leprosy	other-disease
and	O
Lyme	other-disease
disease	O
)	O
and	O
parasitic	O
infections	O
(	O
Acanthamoeba	other-disease
,	O
Onchocerciasis	other-disease
or	O
river	other-disease
blindness	other-disease
,	O
Leishmaniasis	other-disease
,	O
Trypanosoma	other-disease
cruzi	other-disease
or	O
``	O
Chagas	other-disease
disease	other-disease
``	O
,	O
Trypanosoma	other-disease
brucei	other-disease
or	O
``	O
African	other-disease
sleeping	other-disease
sickness	other-disease
``	O
and	O
microsporidia	other-disease
)	O

Therefore	O
,	O
isoniazid-induced	O
pyridoxine	O
deficiency	O
causes	O
insufficient	O
heme	O
formation	O
in	O
early	O
red	O
blood	O
cells	O
,	O
leading	O
to	O
sideroblastic	other-disease
anemia	other-disease
.	O

Shortly	O
before	O
his	O
death	O
,	O
he	O
tested	O
positive	O
for	O
COVID-19	other-disease
,	O
which	O
was	O
later	O
listed	O
as	O
the	O
cause	O
of	O
death	O
.	O

La	O
Rue	O
died	O
of	O
a	O
heart	other-disease
attack	other-disease
at	O
Saint	O
John	O
's	O
Health	O
Center	O
in	O
Santa	O
Monica	O
,	O
California	O
,	O
at	O
the	O
age	O
of	O
81	O
.	O

Symptoms	O
of	O
ischemic	other-disease
colitis	other-disease
vary	O
depending	O
on	O
the	O
severity	O
of	O
the	O
ischemia	O
.	O

Two	O
years	O
after	O
the	O
original	O
infection	O
the	O
person	O
will	O
enter	O
late	O
latent	O
syphilis	other-disease
and	O
is	O
not	O
as	O
infectious	O
as	O
the	O
early	O
phase	O
.	O

Herpes	other-disease
simplex	other-disease
virus	other-disease
1	other-disease
and	other-disease
2	other-disease
(	O
HSV	other-disease
1	other-disease
and	O
HSV	other-disease
2	other-disease
)	O
are	O
part	O
of	O
the	O
alpha	O
subfamily	O
of	O
HHVs	other-disease
.	O

He	O
conceived	O
the	O
NAMES	O
Project	O
AIDS	other-disease
Memorial	O
Quilt	O
,	O
which	O
has	O
become	O
,	O
at	O
54	O
tons	O
,	O
the	O
world	O
's	O
largest	O
piece	O
of	O
community	O
folk	O
art	O
as	O
of	O
2016	O
.	O

On	O
hematoxylin-	O
eosin	O
staining	O
,	O
the	O
fibrin	other-disease
ring	other-disease
granuloma	other-disease
consists	O
of	O
a	O
central	O
lipid	O
vacuole	O
(	O
usually	O
washed-out	O
during	O
fixing	O
and	O
staining	O
,	O
leaving	O
only	O
an	O
empty	O
hole	O
)	O
surrounded	O
by	O
a	O
dense	O
red	O
fibrin	O
ring	O
and	O
epithelioid	O
macrophages	O
.	O

The	O
FDA	O
says	O
that	O
it	O
has	O
known	O
for	O
some	O
time	O
that	O
the	O
morcellators	O
could	O
spread	O
uterine	other-disease
cancer	other-disease
,	O
but	O
the	O
recent	O
attention	O
given	O
to	O
the	O
subject	O
because	O
of	O
the	O
death	O
of	O
Barbara	O
Leary	O
led	O
them	O
to	O
reopen	O
the	O
investigation	O
,	O
and	O
they	O
discovered	O
a	O
higher	O
risk	O
than	O
was	O
initially	O
reported	O
.	O

The	O
cause	O
of	O
death	O
was	O
complications	O
of	O
COVID-19	other-disease
.	O

Is	O
estimated	O
that	O
only	O
5–14	O
%	O
of	O
patients	O
with	O
WE	other-disease
are	O
diagnosed	O
in	O
life	O
.	O

The	O
hereditary	O
conditions	O
–	O
Marfan	other-disease
syndrome	other-disease
,	O
homocystinuria	other-disease
,	O
Ehlers–Danlos	other-disease
syndromes	other-disease
,	O
alpha	other-disease
1-antitrypsin	other-disease
deficiency	other-disease
(	O
which	O
leads	O
to	O
emphysema	other-disease
)	O
,	O
and	O
Birt–Hogg–Dubé	other-disease
syndrome	other-disease
–	O
have	O
all	O
been	O
linked	O
to	O
familial	O
pneumothorax	other-disease
.	O

Additionally	O
,	O
reduction	O
in	O
GFAP	O
expression	O
has	O
also	O
been	O
reported	O
in	O
Wernicke	other-disease
's	other-disease
encephalopathy	other-disease
.	O

It	O
usually	O
occurs	O
due	O
to	O
a	O
tracheoarterial	other-disease
fistula	other-disease
,	O
an	O
abnormal	O
connection	O
between	O
the	O
trachea	O
and	O
nearby	O
blood	O
vessels	O
,	O
and	O
most	O
commonly	O
manifests	O
between	O
3	O
days	O
to	O
6	O
weeks	O
after	O
the	O
procedure	O
is	O
done	O
.	O

This	O
antibody	O
is	O
related	O
to	O
Hashimoto	other-disease
's	other-disease
thyroiditis	other-disease
and	O
Graves	other-disease
'	other-disease
disease	other-disease
.	O

With	O
the	O
first	O
episode	O
of	O
low	other-disease
back	other-disease
pain	other-disease
the	O
hope	O
is	O
a	O
complete	O
cure	O
;	O
however	O
,	O
if	O
the	O
problem	O
becomes	O
chronic	O
,	O
the	O
goals	O
may	O
change	O
to	O
pain	O
management	O
and	O
the	O
recovery	O
of	O
as	O
much	O
function	O
as	O
possible	O
.	O

The	O
following	O
names	O
represent	O
a	O
step-wise	O
pathologic	O
progression	O
in	O
the	O
natural	O
course	O
of	O
adenocarcinoma	O
development	O
;	O
Adenocarcinoma	other-disease
in	other-disease
situ	other-disease
(	O
AIS	other-disease
)	O
,	O
Minimally	other-disease
invasive	other-disease
adenocarcinoma	other-disease
(	O
MIA	other-disease
)	O
,	O
and	O
Invasive	other-disease
adenocarcinoma	other-disease
.	O

After	O
an	O
Adderall	other-disease
binge	O
,	O
he	O
leaves	O
Ted	O
.	O

The	O
causes	O
of	O
acquired	other-disease
antithrombin	other-disease
deficiency	other-disease
are	O
easier	O
to	O
find	O
than	O
the	O
hereditary	O
deficiency	O
.	O

Cure	O
inveterate	other-disease
ulcers	other-disease
of	O
the	O
lips	O
or	O
any	O
other.	O
``	O

Menopause	O
is	O
usually	O
diagnosed	O
through	O
symptoms	O
of	O
vaginal	other-disease
atrophy	other-disease
,	O
pelvic	other-disease
exams	other-disease
,	O
and	O
taking	O
a	O
comprehensive	O
medical	O
history	O
consisting	O
of	O
last	O
menstruation	O
cycle	O
.	O

Many	O
people	O
with	O
CF	other-disease
use	O
probiotics	O
,	O
which	O
are	O
thought	O
to	O
be	O
able	O
to	O
correct	O
intestinal	O
dysbiosis	O
and	O
inflammation	O
,	O
but	O
the	O
clinical	O
trial	O
evidence	O
regarding	O
the	O
effectiveness	O
of	O
probiotics	O
for	O
reducing	O
pulmonary	O
exacerbations	O
in	O
people	O
with	O
CF	other-disease
is	O
uncertain	O
.	O

Unfortunately	O
,	O
when	O
he	O
attempted	O
to	O
take	O
on	O
a	O
number	O
of	O
locals	O
to	O
replenish	O
his	O
crew	O
he	O
discovered	O
they	O
were	O
infected	O
with	O
lycanthropy	other-disease
.	O

During	O
his	O
term	O
,	O
Guinea	other-disease
Worm	other-disease
Disease	other-disease
was	O
eradicated	O
in	O
Nigeria	O
for	O
which	O
the	O
WHO	O
in	O
December	O
2013	O
certificated	O
Nigeria	O
as	O
a	O
Guinea	O
Worm	O
Free	O
country	O
.	O

A	O
mission	O
based	O
in	O
the	O
United	O
States	O
has	O
been	O
helping	O
to	O
combat	O
AIDS	other-disease
in	O
the	O
country	O
.	O

If	O
the	O
patient	O
experiences	O
psychotic	O
symptoms	O
without	O
mood	O
symptoms	O
for	O
longer	O
than	O
a	O
two-week	O
period	O
,	O
their	O
diagnosis	O
is	O
either	O
Schizophrenia	other-disease
or	O
Schizoaffective	other-disease
Disorder	other-disease
.	O

Hypoglycemia	other-disease
is	O
also	O
found	O
in	O
many	O
people	O
with	O
hypothermia	other-disease
,	O
as	O
hypothermia	other-disease
may	O
be	O
a	O
result	O
of	O
hypoglycemia	other-disease
.	O

A	O
small	O
percentage	O
of	O
cases	O
occur	O
when	O
only	O
some	O
of	O
the	O
body	O
's	O
cells	O
have	O
an	O
extra	O
copy	O
;	O
such	O
cases	O
are	O
called	O
mosaic	other-disease
Patau	other-disease
.	O

Other	O
angiogenesis	O
inhibitors	O
are	O
also	O
being	O
investigated	O
as	O
potential	O
ovarian	other-disease
cancer	other-disease
treatments	O
.	O

Distal	other-disease
RTA	other-disease
has	O
also	O
been	O
linked	O
to	O
specific	O
genetic	O
mutations	O
that	O
will	O
alter	O
when	O
the	O
disease	O
will	O
present	O
in	O
the	O
patient	O
's	O
life	O
.	O

Walter	O
T.	O
Bailey	O
died	O
on	O
February	O
21	O
,	O
1941	O
from	O
pneumonia	other-disease
and	O
complications	O
caused	O
by	O
heart	other-disease
disease	other-disease
.	O

Sarcoidosis	other-disease
is	O
typically	O
treated	O
with	O
systemic	O
corticosteroids	O
.	O

Patau	other-disease
syndrome	other-disease
is	O
the	O
result	O
of	O
trisomy	other-disease
13	other-disease
,	O
meaning	O
each	O
cell	O
in	O
the	O
body	O
has	O
three	O
copies	O
of	O
chromosome	O
13	O
instead	O
of	O
the	O
usual	O
two	O
.	O

In	O
his	O
role	O
as	O
Dean	O
of	O
the	O
UCSF	O
School	O
of	O
Dentistry	O
,	O
Greene	O
's	O
leadership	O
during	O
the	O
AIDS	other-disease
epidemic	O
of	O
the	O
1980s	O
led	O
to	O
worldwide	O
adoption	O
of	O
non-discriminatory	O
treatment	O
of	O
all	O
patients	O
regardless	O
of	O
sexual	O
orientation	O
and	O
other	O
potential	O
risk	O
factors	O
.	O

Some	O
form	O
of	O
aphasia	other-disease
occurs	O
in	O
34	O
to	O
38	O
%	O
of	O
stroke	other-disease
patients	O
.	O

During	O
an	O
inflammatory	other-disease
response	other-disease
,	O
P-selectin	O
is	O
expressed	O
on	O
endothelial	O
cells	O
first	O
,	O
followed	O
by	O
E-selectin	O
later	O
.	O

In	O
patients	O
suffering	O
from	O
demyelinating	other-disease
neuropathy	other-disease
,	O
symptoms	O
are	O
due	O
to	O
slow	O
nerve	O
conduction	O
velocities	O
,	O
however	O
people	O
with	O
axonal	other-disease
degradation	other-disease
have	O
average	O
to	O
normal	O
nerve	O
conduction	O
velocities	O
.	O

This	O
contributes	O
to	O
the	O
urinary	O
incontinence	O
seen	O
with	O
NPH	other-disease
.	O

The	O
different	O
cutoffs	O
increased	O
the	O
reported	O
benefits	O
of	O
Vioxx	O
(	O
reduced	O
stomach	O
problems	O
)	O
relative	O
to	O
the	O
risks	O
(	O
increased	O
heart	other-disease
attacks	other-disease
)	O
.	O

This	O
includes	O
the	O
``	O
Andes	O
orthohantavirus	O
``	O
,	O
one	O
of	O
the	O
primary	O
causes	O
of	O
HCPS	other-disease
in	O
South	O
America	O
and	O
the	O
only	O
hantavirus	O
known	O
to	O
be	O
capable	O
of	O
person-to-person	O
transmission	O
.	O

It	O
was	O
announced	O
in	O
January	O
2009	O
that	O
a	O
character	O
with	O
Asperger	other-disease
syndrome	other-disease
would	O
be	O
arriving	O
in	O
March	O
and	O
would	O
``	O
immediately	O
cause	O
some	O
consternation	O
amongst	O
her	O
fellow	O
colleagues	O
.	O
''	O

malnutrition	other-disease
problems	O
.	O

Radiation	O
therapy	O
appears	O
to	O
prolong	O
survival	O
in	O
people	O
with	O
resected	O
extrahepatic	other-disease
cholangiocarcinoma	other-disease
,	other-disease
and	O
the	O
few	O
reports	O
of	O
its	O
use	O
in	O
unresectable	O
cholangiocarcinoma	other-disease
appear	O
to	O
show	O
improved	O
survival	O
,	O
but	O
numbers	O
are	O
small	O
.	O

Myocardial	other-disease
infarction	other-disease
(	O
``	O
Heart	other-disease
attack	other-disease
''	other-disease
)	O
refers	O
to	O
heart	O
muscle	O
damage	O
due	O
to	O
insufficient	O
blood	O
supply	O
,	O
usually	O
as	O
a	O
result	O
of	O
a	O
blocked	O
coronary	O
artery	O
.	O

The	O
disease	O
is	O
restricted	O
to	O
individuals	O
with	O
Down	other-disease
syndrome	other-disease
or	O
genetic	O
changes	O
similar	O
to	O
those	O
in	O
Down	other-disease
syndrome	other-disease
,	O
develops	O
during	O
pregnancy	O
or	O
shortly	O
after	O
birth	O
,	O
and	O
resolves	O
within	O
3	O
months	O
,	O
or	O
in	O
about	O
10	O
%	O
of	O
cases	O
,	O
progresses	O
to	O
acute	other-disease
megakaryoblastic	other-disease
leukemia	other-disease
.	O

Fainting	other-disease
can	O
be	O
caused	O
by	O
excessive	O
parasympathetic	O
and	O
vagal	O
activity	O
that	O
slows	O
the	O
heart	O
and	O
decreases	O
perfusion	O
of	O
the	O
brain	O
.	O

Also	O
,	O
ketotic	other-disease
hypoglycemia	other-disease
has	O
been	O
reported	O
in	O
several	O
individuals	O
and	O
usually	O
presents	O
itself	O
around	O
the	O
age	O
of	O
three	O
.	O

Correcting	O
hyponatremia	other-disease
too	O
quickly	O
can	O
lead	O
to	O
complications	O
.	O

Compared	O
to	O
classic	O
PKU	other-disease
patients	O
,	O
patients	O
with	O
``	O
hyperphe	other-disease
``	O
have	O
greater	O
PAH	O
enzyme	O
activity	O
and	O
are	O
able	O
to	O
tolerate	O
larger	O
amounts	O
of	O
phenylalanine	O
in	O
their	O
diets	O
.	O

Subtypes	O
of	O
schizophrenia	other-disease
are	O
no	O
longer	O
recognized	O
as	O
separate	O
conditions	O
from	O
schizophrenia	other-disease
by	O
DSM-5	O
or	O
ICD-11	O
.	O

The	O
studies	O
also	O
discovered	O
an	O
abnormally	O
high	O
rate	O
of	O
hypokalemia	other-disease
among	O
subjects	O
.	O

These	O
abnormalities	O
are	O
also	O
seen	O
as	O
symptoms	O
of	O
schizophrenia	other-disease
.	O

The	O
technique	O
became	O
,	O
and	O
remains	O
,	O
standard	O
practice	O
for	O
the	O
initial	O
management	O
of	O
small	other-disease
bowel	other-disease
obstruction	other-disease
in	O
the	O
context	O
of	O
previous	O
abdominal	O
surgery	O
.	O

An	O
epidural	O
blood	O
patch	O
is	O
the	O
typical	O
treatment	O
for	O
a	O
CSF	other-disease
leak	other-disease
,	O
where	O
up	O
to	O
20	O
cubic	O
centimeters	O
of	O
the	O
patient	O
's	O
blood	O
is	O
drawn	O
,	O
then	O
injected	O
into	O
either	O
the	O
lumbar	O
or	O
cervical	O
spine	O
,	O
close	O
to	O
the	O
known	O
or	O
suspected	O
site	O
of	O
the	O
leak	O
.	O

A	O
physical	O
examination	O
that	O
is	O
positive	O
for	O
abdominal	O
pain	O
categorized	O
as	O
McBurney	O
’	O
s	O
point	O
tenderness	O
,	O
Von	O
Blumberg	O
's	O
sign	O
,	O
Rovsing	O
's	O
sign	O
,	O
Dunphy	O
's	O
sign	O
and	O
Psoas	O
sign	O
,	O
could	O
all	O
indicate	O
acute	O
appendicitis	other-disease
and	O
lead	O
to	O
misdiagnosis	O
.	O

At	O
this	O
time	O
,	O
Tatiana	O
suffered	O
from	O
a	O
sleep	other-disease
apnea	other-disease
condition	O
that	O
occasionally	O
caused	O
her	O
to	O
stop	O
breathing	O
for	O
up	O
to	O
20	O
seconds	O
.	O

New	O
outbreaks	O
can	O
occur	O
if	O
a	O
person	O
carrying	O
the	O
virus	O
travels	O
to	O
another	O
region	O
where	O
``	O
A.	other-disease
albopictus	other-disease
``	O
is	O
common	O
.	O

Drug	O
abuse	O
is	O
increasing	O
among	O
street	O
children	O
and	O
rates	O
of	O
HIV/AIDS	other-disease
are	O
increasing	O
due	O
to	O
intravenous	O
drug	O
usage	O
.	O

Other	O
example	O
could	O
be	O
AIDS	other-disease
,	O
where	O
an	O
HIV	O
infection	O
can	O
produce	O
several	O
clinical	O
stages	O
.	O

Hypohidrosis	other-disease
is	O
a	O
disorder	O
in	O
which	O
a	O
person	O
exhibits	O
diminished	O
sweating	O
in	O
response	O
to	O
appropriate	O
stimuli	O
.	O

Evidence	O
of	O
efficacy	O
in	O
adults	O
is	O
limited	O
,	O
but	O
one	O
study	O
found	O
positive	O
results	O
in	O
children	O
with	O
comorbid	other-disease
ADHD	other-disease
.	O

Making	O
the	O
diagnosis	O
of	O
HCM	other-disease
often	O
involves	O
a	O
family	O
history	O
or	O
pedigree	O
,	O
an	O
electrocardiogram	O
,	O
echocardiogram	O
,	O
and	O
stress	O
testing	O
.	O

There	O
are	O
many	O
parallels	O
between	O
different	O
neurodegenerative	other-disease
disorders	other-disease
including	O
atypical	O
protein	O
assemblies	O
as	O
well	O
as	O
induced	O
cell	O
death	O
.	O

The	O
screenplay	O
gave	O
a	O
backstory	O
of	O
Casper	O
being	O
the	O
ghost	O
of	O
Casper	O
McFadde	O
n	O
,	O
a	O
boy	O
who	O
died	O
of	O
pneumonia	other-disease
at	O
12	O
,	O
though	O
some	O
of	O
the	O
comics	O
,	O
particularly	O
in	O
the	O
1960s	O
,	O
portrayed	O
him	O
as	O
born	O
a	O
ghost	O
to	O
ghost	O
parents	O
.	O

Although	O
the	O
popular	O
conception	O
of	O
Peyronie	other-disease
's	other-disease
disease	other-disease
is	O
that	O
it	O
always	O
involves	O
curvature	O
of	O
the	O
penis	O
,	O
the	O
scar	O
tissue	O
sometimes	O
causes	O
divots	O
or	O
indentations	O
rather	O
than	O
curvature	O
.	O

This	O
research	O
was	O
a	O
continuation	O
of	O
earlier	O
work	O
from	O
the	O
same	O
team	O
which	O
showed	O
that	O
replacing	O
the	O
α-methyl	O
group	O
of	O
MDMA	O
with	O
larger	O
aromatic	O
ring	O
systems	O
produced	O
compounds	O
which	O
lacked	O
psychoactivity	O
and	O
neurotoxicity	O
,	O
but	O
had	O
potent	O
anti-cancer	O
effects	O
against	O
Burkitt	other-disease
's	other-disease
lymphoma	other-disease
cells	O
``	O
in	O
vitro	O
''	O
.	O

Myalgia	other-disease
(	O
muscular	O
pain	O
)	O
and	O
arthralgia	other-disease
(	O
joint	O
pain	O
)	O
are	O
rare	O
side	O
effects	O
.	O

The	O
data	O
suggest	O
a	O
link	O
between	O
hypertrophic	other-disease
cardiomyopathy	other-disease
and	O
CD36	O
but	O
this	O
needs	O
to	O
be	O
confirmed	O
.	O

Destruction	O
to	O
the	O
inferior	O
parietal	O
lobule	O
of	O
the	O
dominant	O
hemisphere	O
results	O
in	O
Gerstmann	other-disease
's	other-disease
syndrome	other-disease
:	O
right-to-left	other-disease
confusion	other-disease
,	O
finger	other-disease
agnosia	other-disease
,	O
dysgraphia	other-disease
and	other-disease
dyslexia	other-disease
,	O
dyscalculia	other-disease
,	O
contralateral	other-disease
hemianopia	other-disease
,	O
or	O
lower	other-disease
quadrantanopia	other-disease
.	O

Mutations	O
in	O
this	O
gene	O
have	O
been	O
associated	O
with	O
various	O
forms	O
of	O
Charcot-Marie-Tooth	other-disease
Disease	other-disease
and	O
neuropathy	O
.	O

While	O
battling	O
life-threatening	O
Hodgkin	other-disease
's	other-disease
lymphoma	other-disease
and	O
enduring	O
chemotherapy	O
throughout	O
2002–2003	O
,	O
Simpson	O
remained	O
involved	O
with	O
rugby	O
league	O
by	O
volunteering	O
as	O
assistant	O
coach	O
for	O
the	O
school	O
's	O
2nd	O
XIII	O
in	O
early	O
2003	O
.	O

Although	O
``	O
melancholia	other-disease
``	O
remained	O
the	O
dominant	O
diagnostic	O
term	O
,	O
``	O
depression	other-disease
``	O
gained	O
increasing	O
currency	O
in	O
medical	O
treatises	O
and	O
was	O
a	O
synonym	O
by	O
the	O
end	O
of	O
the	O
century	O
;	O
German	O
psychiatrist	O
Emil	O
Kraepelin	O
may	O
have	O
been	O
the	O
first	O
to	O
use	O
it	O
as	O
the	O
overarching	O
term	O
,	O
referring	O
to	O
different	O
kinds	O
of	O
melancholia	other-disease
as	O
``	O
depressive	O
states	O
''	O
.	O

He	O
died	O
shortly	O
after	O
from	O
the	O
Spanish	other-disease
flu	other-disease
in	O
his	O
twenties	O
.	O

Nevus	other-disease
comedonicus	other-disease
(	O
also	O
known	O
as	O
a	O
``	O
comedo	other-disease
nevus	other-disease
``	O
)	O
is	O
characterized	O
by	O
closely	O
arranged	O
,	O
grouped	O
,	O
often	O
linear	O
,	O
slightly	O
elevated	O
papules	O
that	O
have	O
at	O
their	O
center	O
keratinous	O
plugs	O
resembling	O
comedones	other-disease
.	O

Given	O
that	O
DCGM	O
occurs	O
before	O
other	O
clinical	O
and	O
pathological	O
changes	O
occur	O
,	O
it	O
is	O
unlikely	O
to	O
be	O
due	O
to	O
the	O
gross	O
cell	O
loss	O
observed	O
in	O
Alzheimer	other-disease
’	other-disease
s	other-disease
disease	other-disease
.	O

In	O
Bloom	other-disease
syndrome	other-disease
,	O
those	O
afflicted	O
most	O
often	O
die	O
of	O
cancer	other-disease
.	O

Iatrogenesis	other-disease
is	O
the	O
causation	O
of	O
a	O
disease	O
,	O
a	O
harmful	O
complication	O
,	O
or	O
other	O
ill	O
effect	O
by	O
any	O
medical	O
activity	O
,	O
including	O
diagnosis	O
,	O
intervention	O
,	O
error	O
,	O
or	O
negligence	O
.	O

Surveillance	O
for	O
cholangiocarcinoma	O
in	O
patients	O
with	O
PSC	other-disease
is	O
encouraged	O
,	O
with	O
some	O
experts	O
recommending	O
annual	O
surveillance	O
with	O
a	O
specialized	O
imaging	O
study	O
and	O
serum	O
markers	O
,	O
although	O
consensus	O
regarding	O
the	O
modality	O
and	O
interval	O
has	O
yet	O
to	O
be	O
established	O
.	O

People	O
with	O
stuporous	O
catatonia	other-disease
may	O
also	O
show	O
purposeless	O
,	O
repetitive	O
movements	O
(	O
stereotypy	O
)	O
.	O

Fibromyalgia	other-disease
was	O
first	O
defined	O
in	O
1990	O
,	O
with	O
updated	O
criteria	O
in	O
2011	O
.	O

MEITL	other-disease
is	O
only	O
1/5	O
to	O
1/10	O
as	O
common	O
as	O
EATL	other-disease
.	O

In	O
2003	O
,	O
Martin	O
led	O
the	O
military	O
medical	O
team	O
that	O
examined	O
and	O
cared	O
for	O
the	O
United	O
States	O
Marines	O
ill	O
with	O
malaria	other-disease
contracted	O
while	O
spending	O
two	O
weeks	O
ashore	O
in	O
Liberia	O
.	O

Drugs	O
Hitchings	O
'	O
team	O
worked	O
on	O
included	O
2,6-diaminopurine	O
(	O
a	O
compound	O
to	O
treat	O
leukemia	other-disease
)	O
and	O
p-chlorophenoxy-2,4-diaminopyrimidine	O
(	O
a	O
folic	O
acid	O
antagonist	O
)	O
.	O

It	O
was	O
announced	O
in	O
January	O
2009	O
that	O
a	O
character	O
with	O
Asperger	other-disease
syndrome	other-disease
would	O
be	O
arriving	O
in	O
March	O
and	O
would	O
``	O
immediately	O
cause	O
some	O
consternation	O
amongst	O
her	O
fellow	O
colleagues	O
.	O
''	O

His	O
eldest	O
brother	O
,	O
John	O
,	O
worked	O
in	O
the	O
hops	O
brokerage	O
business	O
and	O
was	O
an	O
innovator	O
in	O
the	O
cultivation	O
of	O
new	O
hop	O
varieties	O
;	O
the	O
middle	O
brother	O
,	O
Fred	O
,	O
was	O
a	O
screenwriter	O
;	O
and	O
his	O
sister	O
Greta	O
died	O
of	O
pneumonia	other-disease
before	O
he	O
was	O
born	O
.	O

In	O
cases	O
of	O
obstructed	O
flow	O
in	O
the	O
Heubner	other-disease
's	O
artery	O
,	O
the	O
individual	O
may	O
experience	O
infarction	O
in	O
those	O
subcortical	O
areas	O
and	O
thus	O
hemiparesis	other-disease
.	O

He	O
was	O
found	O
guilty	O
of	O
rebellion	O
and	O
sentenced	O
to	O
confinement	O
in	O
the	O
dungeons	O
of	O
old	O
Fort	O
Marion	O
at	O
St.	O
Augustine	O
,	O
Florida	O
,	O
and	O
vulnerable	O
to	O
malaria	other-disease
and	O
measles	other-disease
.	O

For	O
post-infection	O
purpura	other-disease
fulminans	other-disease
,	O
new	O
lesions	O
will	O
occur	O
while	O
neutralising	O
autoantibodies	O
are	O
present	O
(	O
1–2	O
weeks	O
after	O
presentation	O
)	O
.	O

The	O
United	O
States	O
has	O
the	O
highest	O
mortality	O
rate	O
among	O
patients	O
with	O
ESRD	other-disease
.	O

The	O
major	other-disease
(	other-disease
``	other-disease
type	other-disease
1	other-disease
''	other-disease
)	other-disease
thrombophilias	other-disease
are	O
rare	O
.	O

Infertility	other-disease
is	O
a	O
known	O
risk	O
factor	O
for	O
gynecologic	O
cancers	O
.	O

Mutations	O
of	O
Aire	O
gene	O
in	O
human	O
cause	O
a	O
rare	O
autoimmune	O
disorder	O
called	O
Autoimmune	other-disease
Polyendocrinopathy	other-disease
Candidiasis	other-disease
Ectodermal	other-disease
Distrophy	other-disease
(	O
APECED	other-disease
)	O
.	O
,	O
which	O
usually	O
manifests	O
in	O
combination	O
with	O
other	O
autoimmune	O
diseases	O
e.g	O
.	O

Blood	O
pressure	O
then	O
spontaneously	O
and	O
rapidly	O
returns	O
to	O
normal	O
,	O
so	O
the	O
period	O
of	O
hypotension	other-disease
and	O
symptoms	O
is	O
short	O
(	O
&	O
lt	O
;	O
30	O
s	O
)	O
.	O

It	O
is	O
used	O
in	O
the	O
treatment	O
of	O
vaginal	other-disease
candidiasis	other-disease
,	other-disease
for	O
the	O
protozoal	other-disease
infection	other-disease
trichomoniasis	other-disease
,	O
and	O
mixed	O
infections	O
.	O

Like	O
other	O
restaurants	O
,	O
since	O
mid-March	O
2020	O
,	O
the	O
COVID-19	other-disease
pandemic	O
caused	O
Zaxby	O
's	O
dine-in	O
lobbies	O
to	O
shut	O
down	O
indefinitely	O
.	O

A	O
person	O
with	O
spatial	other-disease
dysgraphia	other-disease
has	O
a	O
defect	O
in	O
the	O
understanding	O
of	O
space	O
.	O

Additional	O
reviews	O
agree	O
,	O
with	O
studies	O
finding	O
that	O
vaccines	O
are	O
not	O
linked	O
to	O
autism	other-disease
even	O
in	O
high	O
risk	O
populations	O
with	O
autistic	O
siblings	O
.	O

At	O
the	O
time	O
it	O
was	O
proposed	O
,	O
Da	other-disease
Costa	other-disease
's	other-disease
syndrome	other-disease
was	O
seen	O
as	O
a	O
very	O
desirable	O
physiological	O
explanation	O
for	O
``	O
soldier	O
's	O
heart	O
''	O
.	O

Mutation	O
in	O
the	O
CACNA1C	O
gene	O
,	O
the	O
single-nucleotide	O
polymorphism	O
located	O
in	O
the	O
third	O
intron	O
of	O
the	O
Cav1.2	O
gene	O
,	O
are	O
associated	O
with	O
a	O
variant	O
of	O
Long	other-disease
QT	other-disease
syndrome	other-disease
called	O
Timothy	other-disease
's	other-disease
syndrome	other-disease
and	O
also	O
with	O
Brugada	O
syndrome	O
.	O

He	O
died	O
young	O
,	O
likely	O
from	O
the	O
Bubonic	other-disease
Plague	other-disease
that	O
afflicted	O
Genoa	O
in	O
1657	O
.	O

Sadeque	O
died	O
of	O
renal	other-disease
failure	other-disease
and	O
chest	other-disease
congestion	other-disease
at	O
Karachi	O
on	O
8	O
January	O
2015	O
at	O
the	O
age	O
of	O
72	O
.	O

He	O
was	O
then	O
approached	O
by	O
classics	O
professor	O
Gregory	O
Nagy	O
who	O
suggested	O
that	O
the	O
topic	O
might	O
be	O
expanded	O
into	O
a	O
full-length	O
book	O
on	O
the	O
nature	O
and	O
treatment	O
of	O
PTSD	other-disease
.	O

Paraplegia	other-disease
is	O
a	O
condition	O
usually	O
resulting	O
from	O
injury	O
to	O
the	O
spinal	O
cord	O
.	O

In	O
September	O
2017	O
the	O
US	O
FDA	O
approved	O
its	O
use	O
for	O
``	O
adult	O
patients	O
who	O
have	O
hormone	O
receptor	O
(	O
HR	O
)	O
-positive	O
,	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
-negative	O
advanced	O
or	O
metastatic	O
breast	other-disease
cancer	other-disease
that	O
has	O
progressed	O
after	O
taking	O
therapy	O
that	O
alters	O
a	O
patient	O
’	O
s	O
hormones	O
''	O
.	O

In	O
January	O
2008	O
,	O
Kaman	O
revealed	O
that	O
he	O
was	O
misdiagnosed	O
with	O
Attention-deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
at	O
age	O
2½	O
.	O

Even	O
more	O
rarely	O
,	O
splenic	other-disease
rupture	other-disease
can	O
occur	O
after	O
colonoscopy	other-disease
because	O
of	O
adhesions	O
between	O
the	O
colon	O
and	O
the	O
spleen	O
.	O

In	O
1998	O
the	O
Orientale	O
villages	O
of	O
Durba	O
and	O
Watsa	O
were	O
the	O
center	O
of	O
an	O
outbreak	O
of	O
Marburg	other-disease
virus	O
disease	O
among	O
gold	O
mine	O
workers	O
.	O

The	O
effectiveness	O
of	O
both	O
aspirin	O
and	O
clopidogrel	O
,	O
to	O
reduce	O
risk	O
of	O
cardiovascular	O
ischemic	O
events	O
in	O
people	O
with	O
symptomatic	O
PAD	other-disease
is	O
not	O
well	O
established	O
.	O

Autoimmune	O
conditions	O
related	O
to	O
gluten	other-disease
include	O
celiac	other-disease
disease	other-disease
,	O
dermatitis	other-disease
herpetiformis	other-disease
,	O
and	O
gluten	other-disease
ataxia	other-disease
.	O

He	O
died	O
of	O
pancreatic	other-disease
cancer	other-disease
at	O
the	O
age	O
of	O
71	O
.	O

Huntington	other-disease
's	other-disease
disease	other-disease
occurs	O
when	O
the	O
cytosolic	O
protein	O
Huntingtin	O
(	O
Htt	O
)	O
has	O
an	O
additional	O
35	O
glutamine	O
residues	O
added	O
to	O
its	O
amino	O
terminal	O
region	O
.	O

At	O
the	O
trial	O
of	O
Torsney	O
,	O
which	O
began	O
in	O
October	O
,	O
1977	O
,	O
his	O
defense	O
maintained	O
that	O
the	O
killing	O
resulted	O
from	O
a	O
psychotic	O
episode	O
due	O
to	O
``	O
automatism	other-disease
of	other-disease
Penfield	other-disease
,	O
''	O
named	O
for	O
neurosurgeon	O
Wilder	O
Penfield	O
.	O

Endometrial	other-disease
atrophy	other-disease
,	O
uterine	other-disease
fibroids	other-disease
,	O
and	O
endometrial	other-disease
cancer	other-disease
are	O
common	O
causes	O
of	O
postmenopausal	O
vaginal	O
bleeding	O
.	O

Due	O
to	O
its	O
subtle	O
presentation	O
,	O
MAIS	other-disease
is	O
not	O
typically	O
investigated	O
except	O
in	O
the	O
case	O
of	O
male	O
infertility	O
,	O
thus	O
its	O
true	O
prevalence	O
is	O
unknown	O
.	O

In	O
1991	O
,	O
student	O
Jill	O
Stewart	O
started	O
IU	O
Dance	O
Marathon	O
in	O
honor	O
of	O
her	O
friend	O
,	O
Ryan	O
White	O
,	O
who	O
died	O
from	O
AIDS	other-disease
the	O
year	O
before	O
.	O

Primary	other-disease
progressive	other-disease
aphasia	other-disease
(	O
PPA	other-disease
)	O
is	O
a	O
syndrome	O
characterized	O
by	O
a	O
progressive	O
language	O
deficit	O
without	O
other	O
features	O
of	O
dementia	O
for	O
at	O
least	O
two	O
years	O
.	O

Diseases	O
categorized	O
as	O
primary	O
autonomic	O
failure	O
usually	O
include	O
pure	other-disease
autonomic	other-disease
failure	other-disease
and	O
multiple	other-disease
system	other-disease
atrophy	other-disease
.	O

His	O
laboratory	O
primarily	O
studies	O
HIV	other-disease
reverse	O
transcriptase	O
,	O
the	O
molecular	O
basis	O
for	O
drug	O
resistance	O
,	O
and	O
gene	O
therapy	O
.	O

Clomifene	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
malignant	O
melanomas	O
and	O
thyroid	other-disease
cancer	other-disease
.	O

A	O
recent	O
study	O
shows	O
that	O
Par6	O
associates	O
with	O
PKC-ι	O
but	O
not	O
with	O
PKC-zeta	O
in	O
melanoma	other-disease
.	O

Patients	O
with	O
blepharospasm	other-disease
have	O
normal	O
eyes	O
.	O

There	O
is	O
not	O
even	O
complete	O
agreement	O
about	O
the	O
causal	O
relationship	O
between	O
the	O
swine	O
flu	O
vaccine	O
and	O
Guillain-Barré	other-disease
syndrome	O
,	O
as	O
noted	O
in	O
Gina	O
Kolata	O
's	O
book	O
``	O
Flu	O
:	O
The	O
Story	O
of	O
the	O
Great	O
Influenza	O
Pandemic	O
of	O
1918	O
and	O
the	O
Search	O
for	O
the	O
Virus	O
That	O
Caused	O
It	O
``	O
.	O

There	O
are	O
2	O
possibilities	O
to	O
evaluate	O
splenomegaly	other-disease
in	O
the	O
clinical	O
examination	O
:	O
percussion	O
and	O
palpation	O
.	O

In	O
December	O
1989	O
,	O
Botox	other-disease
was	O
approved	O
by	O
the	O
U.S	O
.	O
FDA	O
for	O
the	O
treatment	O
of	O
strabismus	other-disease
,	O
blepharospasm	other-disease
,	O
and	O
hemifacial	other-disease
spasm	other-disease
in	O
patients	O
over	O
12	O
years	O
old	O
.	O

For	O
a	O
diagnosis	O
of	O
sleep	other-disease
apnea	other-disease
,	O
more	O
than	O
five	O
episodes	O
per	O
hour	O
must	O
occur	O
.	O

According	O
to	O
guidelines	O
,	O
taking	O
aspirin	O
or	O
clopidogrel	O
is	O
recommended	O
to	O
reduce	O
MI	other-disease
,	O
stroke	O
,	O
and	O
other	O
causes	O
of	O
vascular	O
death	O
in	O
people	O
with	O
symptomatic	O
peripheral	O
artery	O
disease	O
.	O

Cardiac	other-disease
arrest	other-disease
and	O
asystole	other-disease
refer	O
to	O
situations	O
in	O
which	O
``	O
no	O
''	O
cardiac	O
output	O
occurs	O
at	O
all	O
.	O

Injections	O
are	O
most	O
commonly	O
used	O
on	O
patients	O
having	O
been	O
exposed	O
to	O
hepatitis	other-disease
A	other-disease
or	O
measles	other-disease
,	O
or	O
to	O
make	O
a	O
kidney	O
donor	O
and	O
a	O
recipient	O
compatible	O
regardless	O
of	O
blood	O
type	O
or	O
tissue	O
match	O
.	O

It	O
is	O
sometimes	O
used	O
off-label	O
for	O
the	O
treatment	O
of	O
fibromyalgia	other-disease
.	O

On	O
December	O
9	O
,	O
Health	O
Canada	O
approved	O
the	O
tozinameran	O
COVID-19	other-disease
vaccine	O
developed	O
by	O
BioNTech	O
and	O
Pfizer	O
for	O
use	O
in	O
Canada	O
.	O

The	O
search	O
for	O
a	O
lazaret	O
site	O
in	O
northern	O
Queensland	O
followed	O
a	O
succession	O
of	O
other	O
attempts	O
to	O
segregate	O
Hansen	other-disease
's	other-disease
disease	other-disease
patients	O
.	O

Kuma	O
died	O
in	O
late	O
November	O
2018	O
as	O
the	O
result	O
of	O
a	O
stroke	other-disease
,	O
shortly	O
before	O
his	O
17th	O
birthday	O
.	O

In	O
addition	O
to	O
its	O
crucial	O
role	O
in	O
cancer	O
,	O
p53	O
has	O
been	O
implicated	O
in	O
other	O
diseases	O
including	O
diabetes	other-disease
,	O
cell	other-disease
death	other-disease
after	other-disease
ischemia	other-disease
,	O
and	O
various	O
neurodegenerative	other-disease
diseases	other-disease
such	O
as	O
Huntington	other-disease
,	O
Parkinson	other-disease
,	O
and	O
Alzheimer	other-disease
.	O

One	O
of	O
van	O
Riebeeck	O
's	O
tasks	O
include	O
planting	O
a	O
vineyard	O
,	O
falsely	O
believing	O
the	O
consumption	O
of	O
grapes	O
and	O
the	O
wine	O
produced	O
from	O
them	O
is	O
effective	O
in	O
avoiding	O
scurvy	other-disease
among	O
sailors	O
on	O
long	O
sea	O
voyages	O
.	O

This	O
was	O
a	O
long-term	O
interest	O
of	O
Gull	O
's	O
dating	O
back	O
at	O
least	O
to	O
his	O
three	O
Goulstonian	O
lectures	O
of	O
1848	O
,	O
titled	O
``	O
On	O
the	O
nervous	O
system	O
''	O
,	O
``	O
Paraplegia	other-disease
``	O
and	O
``	O
Cervical	other-disease
paraplegia	other-disease
–	O
hemiplegia	other-disease
``	O
.	O

In	O
1993	O
the	O
Senegalese	O
sex	O
worker	O
organisation	O
``	O
Association	O
for	O
Women	O
at	O
risk	O
from	O
AIDS	O
(	O
AWA	O
)	O
''	O
was	O
formed	O
out	O
of	O
an	O
AIDS	other-disease
prevention	O
scheme	O
at	O
Dakar	O
polytechnic	O
.	O

He	O
died	O
in	O
office	O
at	O
the	O
age	O
of	O
66	O
on	O
26	O
January	O
1948	O
in	O
Ankara	O
after	O
a	O
heart	other-disease
attack	other-disease
.	O

Groenewegen	O
was	O
diagnosed	O
with	O
Type	other-disease
1	other-disease
Diabetes	other-disease
at	O
the	O
age	O
of	O
nine	O
,	O
but	O
did	O
not	O
let	O
this	O
disease	O
control	O
her	O
,	O
persisting	O
to	O
become	O
a	O
member	O
of	O
the	O
Canada	O
women	O
's	O
national	O
softball	O
team	O
at	O
the	O
age	O
of	O
17	O
.	O

Hypokalemia	other-disease
(	O
low	O
blood	O
potassium	O
levels	O
)	O
causes	O
symptoms	O
of	O
fatigue	O
,	O
muscle	O
weakness	O
,	O
and	O
at	O
its	O
most	O
extreme	O
,	O
paralysis	O
.	O

Increased	O
concentrations	O
of	O
GM3	O
in	O
bladder	other-disease
cancer	other-disease
cells	O
reduces	O
the	O
malignancy	O
potential	O
of	O
those	O
cells	O
and	O
induces	O
apoptosis	O
.	O

They	O
discovered	O
that	O
small	O
electrical	O
shocks	O
could	O
induce	O
ventricular	other-disease
fibrillation	other-disease
in	O
dogs	O
,	O
and	O
that	O
larger	O
charges	O
would	O
reverse	O
the	O
condition	O
.	O

HACE	other-disease
must	O
be	O
distinguished	O
from	O
conditions	O
with	O
similar	O
symptoms	O
,	O
including	O
stroke	O
,	O
intoxication	O
,	O
psychosis	O
,	O
diabetic	O
symptoms	O
,	O
meningitis	O
,	O
or	O
ingestion	O
of	O
toxic	O
substances	O
.	O

Infertility	other-disease
is	O
a	O
common	O
disease	O
affecting	O
young	O
adults	O
.	O

It	O
may	O
be	O
caused	O
by	O
cervical	other-disease
myelopathy	other-disease
.	O

Prathama	O
on	O
World	O
Thalassemia	O
Day	O
2016	O
,	O
introduced	O
Nucleic	O
acid	O
testing	O
(	O
NAT	O
)	O
of	O
donated	O
blood	O
to	O
reduce	O
the	O
risk	O
of	O
transfusion	other-disease
transmitted	other-disease
infections	other-disease
(	O
TTIs	other-disease
)	O
in	O
people	O
receiving	O
blood	O
.	O

is	O
a	O
subtype	O
of	O
anosognosia	other-disease
in	O
which	O
the	O
person	O
suffering	O
from	O
hemiplegia	other-disease
neglects	O
one	O
half	O
of	O
their	O
body	O
.	O

Hypno-Hustler	other-disease
later	O
appeared	O
at	O
the	O
Vil-Anon	O
meeting	O
with	O
Armadillo	other-disease
,	O
Big	other-disease
Wheel	other-disease
,	O
Equinox	other-disease
,	O
Man-Bull	other-disease
,	O
and	O
Schizoid	other-disease
Man	other-disease
.	O

CCR5	O
is	O
a	O
co-receptor	O
for	O
HIV	other-disease
,	O
and	O
binding	O
of	O
CCL3L1	O
to	O
CCR5	O
inhibits	O
HIV	other-disease
entry	O
.	O

Underexcretion	O
of	O
uric	O
acid	O
by	O
the	O
kidney	O
is	O
the	O
primary	O
cause	O
of	O
hyperuricemia	other-disease
in	O
about	O
90	O
%	O
of	O
cases	O
,	O
while	O
overproduction	O
is	O
the	O
cause	O
in	O
less	O
than	O
10	O
%	O
.	O

NAMRU-3	O
through	O
a	O
collaboration	O
with	O
the	O
WHO	O
in	O
the	O
early	O
1970s	O
was	O
instrumental	O
in	O
developing	O
typhoid	other-disease
and	O
Group	O
A	O
Meningococcal	O
meningitis	O
vaccines	O
.	O

The	O
Australian	O
Cervical	O
Cancer	O
Foundation	O
(	O
ACCF	O
)	O
,	O
founded	O
in	O
2008	O
,	O
promotes	O
'women	O
's	O
health	O
by	O
eliminating	O
cervical	other-disease
cancer	other-disease
and	O
enabling	O
treatment	O
for	O
women	O
with	O
cervical	other-disease
cancer	other-disease
and	O
related	O
health	O
issues	O
,	O
in	O
Australia	O
and	O
in	O
developing	O
countries	O
.	O
'	O

Conversely	O
,	O
for	O
intra-abdominal	other-disease
fibromatosis	other-disease
without	O
evidence	O
of	O
FAP	other-disease
extensive	O
surgery	O
may	O
still	O
be	O
required	O
for	O
local	O
symptoms	O
,	O
but	O
the	O
risk	O
of	O
recurrence	O
is	O
low	O
.	O

As	O
such	O
,	O
it	O
is	O
used	O
to	O
treat	O
warts	other-disease
,	O
psoriasis	other-disease
,	O
acne	other-disease
,	O
ringworm	other-disease
,	O
dandruff	other-disease
,	O
and	O
ichthyosis	other-disease
.	O

In	O
2009	O
,	O
after	O
three	O
World	O
Rabies	O
Days	O
,	O
the	O
Global	O
Alliance	O
for	O
Rabies	O
Control	O
estimated	O
that	O
rabies	other-disease
prevention	O
and	O
awareness	O
events	O
had	O
taken	O
place	O
in	O
over	O
100	O
countries	O
,	O
that	O
nearly	O
100	O
million	O
people	O
worldwide	O
had	O
been	O
educated	O
about	O
rabies	other-disease
and	O
that	O
nearly	O
3	O
million	O
dogs	O
had	O
been	O
vaccinated	O
during	O
events	O
linked	O
to	O
the	O
campaign	O
.	O

Hyperglycemia	other-disease
may	O
be	O
present	O
,	O
as	O
glucose	O
consumption	O
by	O
cells	O
and	O
insulin	O
secretion	O
both	O
decrease	O
,	O
and	O
tissue	O
sensitivity	O
to	O
insulin	O
may	O
be	O
blunted	O
.	O

The	O
city	O
wall	O
in	O
the	O
film	O
is	O
an	O
important	O
motif	O
,	O
as	O
its	O
dilapidated	O
state	O
reflects	O
not	O
only	O
the	O
physical	O
destruction	O
of	O
the	O
war	O
,	O
but	O
also	O
the	O
general	O
post-war	O
depression	O
of	O
the	O
people	O
;	O
the	O
latter	O
is	O
personified	O
by	O
the	O
male	O
protagonist	O
,	O
Dai	O
Liyan	O
,	O
who	O
suffers	O
from	O
a	O
psychosomatic	other-disease
illness	other-disease
as	O
he	O
struggles	O
to	O
cope	O
with	O
the	O
destruction	O
and	O
decline	O
of	O
his	O
estate	O
following	O
the	O
War	O
.	O

It	O
is	O
difficult	O
to	O
diagnose	O
mesenteric	other-disease
ischemia	other-disease
early	O
.	O

Nishioka	O
suffered	O
an	O
Achilles	other-disease
tendon	other-disease
rupture	other-disease
twice	O
during	O
that	O
year	O
.	O

Histone	O
acetyltransferases	O
(	O
HATs	O
)	O
and	O
HDACs	O
have	O
been	O
found	O
to	O
play	O
key	O
roles	O
in	O
genes	O
linked	O
to	O
diabetes	other-disease
.	O

In	O
2008	O
,	O
the	O
World	O
Health	O
Organization	O
defined	O
a	O
specific	O
type	O
of	O
lymphoma	other-disease
,	O
enteropathy-associated	other-disease
T	other-disease
cell	other-disease
lymphoma	other-disease
(	O
EATL	other-disease
)	O
,	O
as	O
having	O
two	O
different	O
types	O
:	O
EATL	other-disease
type	other-disease
I	other-disease
,	O
a	O
lymphoma	other-disease
occurring	O
in	O
patients	O
with	O
the	O
chronic	O
,	O
autoimmune	O
GI	other-disease
tract	other-disease
disorder	other-disease
,	O
celiac	other-disease
disease	other-disease
,	O
and	O
EATL	other-disease
type	other-disease
II	other-disease
,	O
a	O
similar	O
bowel	O
lymphoma	O
that	O
was	O
not	O
associated	O
with	O
celiac	O
disease	O
.	O

There	O
are	O
two	O
distinct	O
types	O
of	O
HIT	other-disease
1	O
)	O
immune-mediated	O
and	O
2	O
)	O
non-immune	O
mediated	O
.	O

Mitochondrial	other-disease
acetoacetyl-CoA	other-disease
thiolase	O
deficiency	O
is	O
easily	O
diagnosed	O
by	O
urinary	O
organic	O
acid	O
analysis	O
and	O
can	O
be	O
confirmed	O
by	O
enzymatic	O
analysis	O
of	O
cultured	O
skin	O
fibroblasts	O
or	O
blood	O
leukocytes	O
.	O

However	O
,	O
it	O
was	O
well	O
known	O
at	O
the	O
time	O
that	O
plague	other-disease
was	O
highly	O
contagious	O
,	O
so	O
it	O
has	O
been	O
speculated	O
that	O
Lucrezia	O
was	O
simply	O
afraid	O
to	O
contract	O
the	O
virulent	O
and	O
frequently-fatal	O
disease	O
.	O

Also	O
,	O
in	O
a	O
comparison	O
between	O
precancerous	O
lesion	O
of	O
the	O
cervix	O
uteri	O
and	O
invasive	other-disease
cervical	other-disease
cancer	other-disease
,	O
c-Fos	O
expression	O
was	O
significantly	O
lower	O
in	O
precancerous	O
lesions	O
.	O

Amyloid	O
beta	O
is	O
considered	O
to	O
contribute	O
to	O
the	O
development	O
of	O
Alzheimer	other-disease
's	O
disease	O
,	O
and	O
there	O
exist	O
concerns	O
that	O
sacubitril	O
may	O
promote	O
the	O
development	O
of	O
Alzheimer	other-disease
's	O
disease	O
.	O

Diarrhea	other-disease
happens	O
when	O
the	O
amount	O
of	O
fluids	O
absorbed	O
in	O
the	O
intestine	O
does	O
not	O
match	O
the	O
amount	O
secreted	O
.	O

Eleven	O
outbreaks	O
of	O
H5N1	other-disease
were	O
reported	O
worldwide	O
in	O
June	O
2008	O
in	O
five	O
countries	O
(	O
China	O
,	O
Egypt	O
,	O
Indonesia	O
,	O
Pakistan	O
and	O
Vietnam	O
)	O
compared	O
to	O
65	O
outbreaks	O
in	O
June	O
2006	O
and	O
55	O
in	O
June	O
2007	O
.	O

Rabies	other-disease
medication	O
is	O
also	O
very	O
expensive	O
for	O
the	O
average	O
Tanzanian	O
.	O

Pemphigus	other-disease
(	O
or	O
)	O
is	O
a	O
rare	O
group	O
of	O
blistering	other-disease
autoimmune	other-disease
diseases	O
that	O
affect	O
the	O
skin	O
and	O
mucous	O
membranes	O
.	O

The	O
franchisee	O
retained	O
it	O
from	O
the	O
former	O
business	O
in	O
the	O
building	O
in	O
light	O
of	O
COVID-19	other-disease
pandemic	O
safe	O
practices	O
.	O

Noonan	other-disease
syndrome	O
with	O
multiple	O
lentigines	O
(	O
NSML	other-disease
)	O
which	O
is	O
part	O
of	O
a	O
group	O
called	O
Ras/MAPK	O
pathway	O
syndromes	O
,	O
is	O
a	O
rare	O
autosomal	O
dominant	O
,	O
multisystem	O
disease	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
protein	O
tyrosine	O
phosphatase	O
,	O
non-receptor	O
type	O
11	O
gene	O
(	O
``	O
PTPN11	O
``	O
)	O
.	O

This	O
explains	O
why	O
ferritin	O
levels	O
remain	O
relative	O
low	O
in	O
Hereditary	other-disease
hemochromatosis	other-disease
,	O
while	O
transferrin	O
saturation	O
is	O
high	O
.	O

In	O
1981	O
Schwartz	O
led	O
one	O
of	O
the	O
three	O
groups	O
that	O
first	O
described	O
AIDS-associated	other-disease
Kaposi	other-disease
sarcoma	other-disease
(	O
KS-AIDS	other-disease
)	O
.	O

Referencing	O
her	O
death	O
certificate	O
,	O
the	O
principal	O
cause	O
of	O
death	O
was	O
pulmonary	other-disease
tuberculosis	other-disease
,	O
with	O
a	O
contributing	O
cause	O
given	O
as	O
dementia	other-disease
praecox	other-disease
psychosis	other-disease
.	O

Mounier-Kuhn	other-disease
syndrome	other-disease
is	O
a	O
rare	O
congenital	O
disorder	O
of	O
an	O
abnormally	O
enlarged	O
trachea	O
,	O
characterised	O
by	O
absent	O
elastic	O
fibres	O
,	O
smooth	O
muscle	O
thinning	O
,	O
and	O
a	O
tendency	O
to	O
get	O
recurrent	O
respiratory	O
tract	O
infections	O
.	O

The	O
third	O
dose	O
of	O
the	O
MMR	other-disease
vaccine	O
was	O
associated	O
with	O
a	O
78.1	O
%	O
reduced	O
risk	O
of	O
infection	O
.	O

Thrombocytopenia	other-disease
(	O
low	O
blood	O
platelets	O
)	O
is	O
unusual	O
.	O

He	O
charged	O
people	O
a	O
set	O
amount	O
of	O
money	O
for	O
participating	O
in	O
the	O
``	O
hunts	O
for	O
pedophiles	other-disease
``	O
,	O
often	O
described	O
as	O
a	O
``	O
safari	O
''	O
by	O
the	O
members	O
of	O
the	O
movement	O
.	O

The	O
symptoms	O
are	O
the	O
same	O
for	O
both	O
meningitis	other-disease
and	O
aseptic	other-disease
meningitis	other-disease
but	O
the	O
severity	O
of	O
the	O
symptoms	O
and	O
the	O
treatment	O
can	O
depend	O
on	O
the	O
certain	O
cause	O
.	O

By	O
1975	O
,	O
resulting	O
from	O
several	O
serious	O
injuries	O
that	O
led	O
to	O
hospitalization	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
Salvatore	O
was	O
cured	O
of	O
his	O
impulse	other-disease
control	other-disease
disorder	other-disease
that	O
was	O
the	O
root	O
cause	O
of	O
his	O
addiction	O
to	O
high	O
speed	O
.	O

Loss-of-function	O
mutations	O
in	O
the	O
STAT3	O
gene	O
result	O
in	O
Hyperimmunoglobulin	other-disease
E	other-disease
syndrome	O
,	O
associated	O
with	O
recurrent	O
infections	O
as	O
well	O
as	O
disordered	O
bone	O
and	O
tooth	O
development	O
.	O

Sometimes	O
,	O
people	O
with	O
Barrett	other-disease
's	other-disease
esophagus	other-disease
have	O
no	O
heartburn	O
symptoms	O
at	O
all	O
.	O

Linaclotide	O
is	O
used	O
to	O
treat	O
irritable	other-disease
bowel	other-disease
syndrome	other-disease
with	O
constipation	O
and	O
chronic	other-disease
constipation	other-disease
with	O
no	O
known	O
cause	O
.	O

While	O
no	O
relationship	O
exists	O
between	O
the	O
severity	O
of	O
heartburn	other-disease
and	O
the	O
development	O
of	O
Barrett	other-disease
's	other-disease
esophagus	other-disease
,	O
a	O
relationship	O
does	O
exist	O
between	O
chronic	other-disease
heartburn	other-disease
and	O
the	O
development	O
of	O
Barrett	other-disease
's	other-disease
esophagus	other-disease
.	O

He	O
also	O
set	O
up	O
Scotland	O
's	O
endoscopic	O
surveillance	O
service	O
for	O
Barrett	other-disease
's	other-disease
esophagus	other-disease
(	O
ESBE	O
)	O
between	O
1988–1991	O
at	O
Ninewells	O
Hospital	O
of	O
Dundee	O

He	O
died	O
in	O
2001	O
having	O
suffered	O
from	O
cystic	other-disease
fibrosis	other-disease
.	O

GM2-gangliosidosis	other-disease
,	O
AB	O
variant	O
is	O
a	O
rare	O
,	O
autosomal	O
recessive	O
metabolic	O
disorder	O
that	O
causes	O
progressive	O
destruction	O
of	O
nerve	O
cells	O
in	O
the	O
brain	O
and	O
spinal	O
cord	O
.	O

Such	O
injections	O
are	O
less	O
common	O
in	O
modern	O
medical	O
practice	O
than	O
they	O
were	O
previously	O
,	O
and	O
injections	O
of	O
gamma	O
globulin	O
previously	O
recommended	O
for	O
travelers	O
have	O
largely	O
been	O
replaced	O
by	O
the	O
use	O
of	O
hepatitis	other-disease
A	other-disease
vaccine	O
.	O

Diminished	O
cerebral	O
glucose	O
metabolism	O
(	O
DCGM	O
)	O
may	O
not	O
be	O
solely	O
an	O
artifact	O
of	O
brain	O
cell	O
loss	O
since	O
it	O
occurs	O
in	O
asymptomatic	O
patients	O
at	O
risk	O
for	O
Alzheimer	other-disease
’	other-disease
s	other-disease
disease	other-disease
,	O
such	O
as	O
patients	O
homozygous	O
for	O
the	O
epsilon	O
4	O
variant	O
of	O
the	O
apolipoprotein	O
E	O
gene	O
(	O
APOE4	O
,	O
a	O
genetic	O
risk	O
factor	O
for	O
Alzheimer	other-disease
’	other-disease
s	other-disease
disease	other-disease
)	O
,	O
as	O
well	O
as	O
in	O
inherited	O
forms	O
of	O
Alzheimer	other-disease
’	other-disease
s	other-disease
disease	other-disease
.	O

It	O
is	O
a	O
variant	O
of	O
migraine	other-disease
in	O
which	O
the	O
patient	O
may	O
experience	O
aura	O
symptoms	O
such	O
as	O
scintillating	other-disease
scotoma	other-disease
,	O
nausea	other-disease
,	O
photophobia	other-disease
,	O
hemiparesis	other-disease
hemiparesis	other-disease
and	O
other	O
migraine	other-disease
symptoms	O
but	O
does	O
not	O
experience	O
headache	other-disease
.	O

Paroxysmal	other-disease
nocturnal	other-disease
hemoglobinuria	other-disease
(	O
PNH	other-disease
)	O
is	O
a	O
rare	O
condition	O
resulting	O
from	O
acquired	O
alterations	O
in	O
the	O
``	O
PIGA	O
``	O
gene	O
,	O
which	O
plays	O
a	O
role	O
in	O
the	O
protection	O
of	O
blood	O
cells	O
from	O
the	O
complement	O
system	O
.	O

Eye	O
Movement	O
Desensitization	O
and	O
Reprocessing	O
(	O
EMDR	O
)	O
is	O
a	O
form	O
of	O
therapy	O
created	O
by	O
Dr.	O
Francine	O
Shapiro	O
to	O
help	O
treat	O
conditions	O
such	O
as	O
Post-traumatic	other-disease
Stress	other-disease
Disorder	other-disease
(	O
PTSD	other-disease
)	O
.	O

Other	O
conditions	O
affecting	O
the	O
trigeminal	O
nerve	O
(	O
V	O
)	O
include	O
trigeminal	other-disease
neuralgia	other-disease
,	O
herpes	other-disease
zoster	other-disease
,	O
sinusitis	other-disease
pain	other-disease
,	O
presence	O
of	O
a	O
dental	other-disease
abscess	other-disease
,	O
and	O
cluster	other-disease
headaches	other-disease
.	O

In	O
2011	O
,	O
researchers	O
reported	O
the	O
discovery	O
of	O
an	O
antibody	O
effective	O
against	O
all	O
types	O
of	O
the	O
influenza	other-disease
A	other-disease
virus	O
.	O

Hereditary	O
antithrombin	O
deficiency	O
results	O
in	O
a	O
state	O
of	O
increased	O
coagulation	O
which	O
may	O
lead	O
to	O
venous	other-disease
thrombosis	other-disease
.	O

The	O
inaugural	O
ride	O
raised	O
£	O
124,000	O
for	O
Leukaemia	other-disease
&	other-disease
amp	other-disease
;	other-disease
Lymphoma	other-disease
Research	O
(	O
then	O
the	O
Leukaemia	O
Research	O
Fund	O
)	O
.	O

Anterior	O
pituitary	O
function	O
must	O
be	O
normal	O
for	O
all	O
other	O
axes	O
in	O
CHH	other-disease
as	O
it	O
is	O
an	O
isolated	O
disorder	O
.	O

Chest	O
X-rays	O
are	O
frequently	O
used	O
to	O
aid	O
in	O
the	O
diagnosis	O
of	O
CHF	other-disease
.	O

By	O
far	O
the	O
most	O
common	O
cause	O
of	O
IK	other-disease
is	O
syphilitic	other-disease
disease	O
.	O

Although	O
women	O
with	O
normal	O
pregnancy	O
experience	O
a	O
low	O
platelet	O
count	O
,	O
women	O
experiencing	O
a	O
continuous	O
drop	O
in	O
platelet	O
will	O
be	O
diagnosed	O
with	O
thrombocytopenia	other-disease
and	O
women	O
with	O
levels	O
greater	O
than	O
70,000	O
/	O
μL	O
will	O
be	O
diagnosed	O
with	O
gestational	other-disease
thrombocytopenia	other-disease
.	O

After	O
being	O
hospitalized	O
for	O
three	O
days	O
at	O
Tulane	O
Medical	O
Center	O
in	O
New	O
Orleans	O
,	O
Crosby	O
died	O
on	O
March	O
27	O
,	O
2015	O
,	O
aged	O
62	O
,	O
from	O
complications	O
of	O
diabetes	other-disease
and	O
a	O
stroke	other-disease
.	O

Phobophobia	other-disease
shares	O
the	O
symptoms	O
of	O
many	O
other	O
anxiety	O
disorders	O
,	O
more	O
specifically	O
panic	other-disease
attacks	other-disease
and	O
generalized	other-disease
anxiety	other-disease
disorder	other-disease
:	O

Injuries	other-disease
to	other-disease
the	other-disease
spinal	other-disease
cord	other-disease
are	O
classified	O
as	O
quadriplegia	other-disease
or	O
paraplegia	other-disease
depending	O
on	O
the	O
location	O
of	O
damage	O
to	O
the	O
spinal	O
cord	O
,	O
also	O
known	O
as	O
the	O
severity	O
of	O
the	O
injury	O
.	O

Exfoliative	O
toxin	O
is	O
responsible	O
for	O
the	O
majority	O
of	O
symptoms	O
seen	O
in	O
canine	O
pyoderma	other-disease
and	O
otitis	other-disease
i.e	O
.	O

Because	O
of	O
the	O
COVID-19	other-disease
pandemic	O
,	O
the	O
Society	O
's	O
2020	O
convention	O
,	O
planned	O
for	O
Boston	O
,	O
Massachusetts	O
,	O
was	O
rescheduled	O
tentatively	O
for	O
June	O
2022	O
.	O

R-loop	O
accumulation	O
has	O
been	O
associated	O
with	O
a	O
number	O
of	O
diseases	O
,	O
including	O
amyotrophic	other-disease
lateral	other-disease
sclerosis	other-disease
type	other-disease
4	other-disease
(	O
ALS4	other-disease
)	O
,	O
ataxia	other-disease
oculomotor	other-disease
apraxia	other-disease
type	other-disease
2	other-disease
(	O
AOA2	other-disease
)	O
,	O
Aicardi–Goutières	other-disease
syndrome	other-disease
,	O
Angelman	other-disease
syndrome	other-disease
,	O
Prader–Willi	other-disease
syndrome	other-disease
,	O
and	O
cancer	O
.	O

Thyroid-stimulating	O
hormone	O
(	O
TSH	O
)	O
deficiency	O
leads	O
to	O
hypothyroidism	O
(	O
lack	O
of	O
production	O
of	O
thyroxine	O
(	O
T4	other-disease
)	O
and	O
triiodothyronine	O
(	O
T3	other-disease
)	O
in	O
the	O
thyroid	O
)	O
.	O

There	O
are	O
criticisms	O
within	O
the	O
scientific	O
community	O
about	O
directing	O
resources	O
to	O
repurposing	O
drugs	O
specifically	O
developed	O
for	O
HIV	other-disease
/	O
AIDS	other-disease
because	O
such	O
drugs	O
are	O
unlikely	O
to	O
be	O
effective	O
against	O
a	O
virus	O
lacking	O
the	O
specific	O
HIV-1	other-disease
protease	O
they	O
target	O
.	O

Damage	other-disease
to	other-disease
the	other-disease
trigeminal	other-disease
nerve	other-disease
leads	O
to	O
loss	O
of	O
sensation	O
in	O
an	O
affected	O
area	O
.	O

These	O
tests	O
are	O
capable	O
of	O
identifying	O
conduction	O
aphasia	other-disease
with	O
relative	O
accuracy	O
.	O

The	O
Yellow	other-disease
Fever	other-disease
would	O
have	O
come	O
from	O
Asunción	O
,	O
Paraguay	O
,	O
brought	O
by	O
Argentine	O
soldiers	O
returning	O
from	O
the	O
war	O
just	O
fought	O
in	O
that	O
country	O
,	O
having	O
previously	O
spread	O
in	O
the	O
city	O
of	O
Corrientes	O
.	O

K562	O
cells	O
were	O
the	O
first	O
human	O
immortalised	O
myelogenous	O
leukemia	other-disease
cell	O
line	O
to	O
be	O
established	O
.	O

Teratogens	other-disease
such	O
as	O
stress	O
can	O
alter	O
prenatal	O
neural	O
development	O
,	O
leading	O
to	O
diminished	O
competence	O
after	O
birth	O
.	O

Pemphigus	other-disease
foliaceus	other-disease
in	O
animals	O
produces	O
clusters	O
of	O
small	O
vesicles	O
that	O
quickly	O
evolve	O
into	O
pustules	O
.	O

It	O
consists	O
of	O
fashioning	O
two	O
orthogonal	O
and	O
deep	O
central	O
grooves	O
in	O
the	O
crystalline	O
lens	O
nucleus	O
,	O
followed	O
by	O
mechanical	O
fracturing	O
of	O
the	O
cataract	other-disease
with	O
the	O
phacoemulsification	O
probe	O
and	O
second	O
instrument	O
.	O

Kevin	O
has	O
Alzheimer	other-disease
’	other-disease
s	other-disease
and	O
dementia	other-disease
.	O

At	O
least	O
five	O
variants	O
in	O
the	O
SDHD	O
gene	O
have	O
been	O
identified	O
in	O
people	O
with	O
Cowden	other-disease
syndrome	other-disease
or	O
a	O
similar	O
disorder	O
called	O
Cowden-like	other-disease
syndrome	other-disease
.	O

Transient	other-disease
myeloproliferative	other-disease
disease	other-disease
involves	O
the	O
excessive	O
proliferation	O
of	O
non-malignant	O
megakaryoblasts	O
.	O

Second-generation	O
antipsychotics	O
,	O
including	O
risperidone	O
,	O
are	O
effective	O
in	O
the	O
treatment	O
of	O
manic	O
symptoms	O
in	O
acute	O
manic	other-disease
or	other-disease
mixed	other-disease
exacerbations	other-disease
of	O
bipolar	other-disease
disorder	other-disease
.	O

It	O
is	O
normally	O
difficult	O
to	O
distinguish	O
a	O
case	O
of	O
Kallmann	other-disease
syndrome	other-disease
(	O
KS	other-disease
)	O
/	O
hypogonadotropic	other-disease
hypogonadism	other-disease
(	O
HH	other-disease
)	O
from	O
a	other-disease
straightforward	other-disease
constitutional	other-disease
delay	other-disease
of	other-disease
puberty	other-disease
.	O

A	O
lipodystrophy	other-disease
can	O
be	O
a	O
lump	O
or	O
small	O
dent	O
in	O
the	O
skin	O
that	O
forms	O
when	O
a	O
person	O
performs	O
injections	O
repeatedly	O
in	O
the	O
same	O
spot	O
.	O

DNA	O
testing	O
is	O
now	O
the	O
preferred	O
method	O
of	O
establishing	O
a	O
diagnosis	O
for	O
MEN	other-disease
2B	other-disease
,	O
and	O
is	O
thought	O
to	O
be	O
almost	O
100	O
%	O
sensitive	O
and	O
specific	O
.	O

Ovarian	other-disease
cancer	other-disease
G-protein	O
coupled	O
receptor	O
1	O
is	O
a	O
protein	O
that	O
in	O
humans	O
is	O
encoded	O
by	O
the	O
``	O
GPR68	O
``	O
gene	O
.	O

Estrogen	O
esters	O
are	O
used	O
in	O
hormone	O
therapy	O
,	O
hormonal	O
contraception	O
,	O
and	O
high-dose	O
estrogen	O
therapy	O
(	O
e.g.	O
,	O
for	O
prostate	other-disease
cancer	other-disease
and	O
breast	other-disease
cancer	other-disease
)	O
,	O
among	O
other	O
indications	O
.	O

Therefore	O
,	O
IIH	other-disease
can	O
only	O
be	O
diagnosed	O
if	O
there	O
is	O
no	O
alternative	O
explanation	O
for	O
the	O
symptoms	O
.	O

Cleve	O
Jones	O
(	O
born	O
October	O
11	O
,	O
1954	O
)	O
is	O
an	O
American	O
AIDS	other-disease
and	O
LGBT	O
rights	O
activist	O
.	O

Cerebral	O
deposition	O
of	O
amyloid	O
beta	O
peptide	O
is	O
an	O
early	O
and	O
critical	O
feature	O
of	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
and	O
a	O
frequent	O
complication	O
of	O
Down	other-disease
syndrome	other-disease
.	O

In	O
contrast	O
,	O
patients	O
may	O
report	O
temporary	O
relief	O
with	O
a	O
diagnostic	O
pudendal	other-disease
nerve	other-disease
block	other-disease
(	O
see	O
Injections	O
)	O
,	O
typically	O
infiltrated	O
near	O
the	O
ischial	other-disease
spine	other-disease
.	O

In	O
2017	O
,	O
the	O
extended	O
release	O
formulation	O
was	O
approved	O
for	O
use	O
in	O
the	O
treatment	O
of	O
levodopa-induced	other-disease
dyskinesia	other-disease
.	O

Secondary	O
features	O
can	O
include	O
dementia	O
,	O
optic	O
atrophy	O
,	O
bilateral	O
deafness	O
,	O
peripheral	O
neuropathy	O
,	O
spasticity	O
,	O
multiple	O
lipomata	O
,	O
and/or	O
cardiomyopathy	O
with	O
Wolff	other-disease
Parkinson-White	other-disease
syndrome	O
.	O

Moghaddam	O
continues	O
to	O
probe	O
the	O
brain	O
mechanisms	O
involved	O
in	O
cognition	O
and	O
emotion	O
in	O
brain	O
areas	O
implicated	O
in	O
schizophrenia	other-disease
,	O
anxiety	other-disease
,	O
attention	other-disease
deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
(	O
ADHD	other-disease
)	O
,	O
and	O
addiction	other-disease
,	O
while	O
also	O
performing	O
leaderships	O
roles	O
to	O
oversee	O
long-term	O
planning	O
and	O
enhance	O
collaboration	O
within	O
the	O
OHSU	O
behavioral	O
neuroscience	O
department	O
.	O

Brain	other-disease
ischemia	other-disease
is	O
insufficient	O
blood	O
flow	O
to	O
the	O
brain	O
,	O
and	O
can	O
be	O
acute	O
or	O
chronic	O
.	O

A	O
Cochrane	O
review	O
of	O
low-level	O
laser	O
therapy	O
found	O
unclear	O
evidence	O
of	O
benefit	O
,	O
whereas	O
another	O
review	O
found	O
short-term	O
pain	O
relief	O
for	O
osteoarthritic	other-disease
knees	other-disease
.	O

Additionally	O
,	O
it	O
has	O
yet	O
to	O
be	O
associated	O
with	O
reducing	O
adverse	O
cardiovascular	O
events	O
including	O
myocardial	other-disease
infarction	other-disease
and	O
stroke	other-disease
,	O
or	O
overall	O
all-cause	O
mortality	O
reduction	O
in	O
clinical	O
trials	O
.	O

The	O
Leicestershire	O
Perinatal	O
Mortality	O
Survey	O
for	O
the	O
years	O
1976	O
to	O
1982	O
found	O
high	O
incidences	O
of	O
Meckel	other-disease
syndrome	other-disease
in	O
Gujarati	O
immigrants	O
.	O

On	O
July	O
25	O
,	O
2008	O
,	O
the	O
Food	O
and	O
Agriculture	O
Organization	O
(	O
FAO	O
)	O
released	O
an	O
Avian	other-disease
Influenza	other-disease
Disease	other-disease
Emergency	O
Situation	O
Update	O
,	O
reporting	O
that	O
H5N1	O
pathogenicity	O
was	O
continuing	O
to	O
gradually	O
rise	O
in	O
endemic	O
areas	O
but	O
the	O
avian	other-disease
influenza	other-disease
disease	other-disease
situation	O
in	O
farmed	O
birds	O
was	O
being	O
held	O
in	O
check	O
by	O
vaccination	O
.	O

It	O
is	O
also	O
sometimes	O
found	O
on	O
the	O
hand	O
of	O
the	O
affected	O
side	O
of	O
patients	O
with	O
Poland	other-disease
syndrome	other-disease
,	O
and	O
craniosynostosis	O
.	O

Over	O
the	O
weekend	O
,	O
the	O
workers	O
lose	O
the	O
tolerance	O
,	O
and	O
when	O
they	O
are	O
re-exposed	O
on	O
Monday	O
,	O
the	O
drastic	O
vasodilation	O
produces	O
a	O
fast	O
heart	O
rate	O
,	O
dizziness	O
,	O
and	O
a	O
headache	O
,	O
this	O
is	O
referred	O
to	O
as	O
``	O
Monday	other-disease
disease	other-disease
.	O
''	O

Adab	O
has	O
investigated	O
the	O
epidemiology	O
of	O
COPD	other-disease
in	O
the	O
United	O
Kingdom	O
.	O

In	O
a	O
study	O
of	O
over	O
2500	O
people	O
resident	O
in	O
Taiwan	O
,	O
a	O
blood	O
lead	O
level	O
exceeding	O
7.5	O
microg/dL	O
(	O
a	O
small	O
elevation	O
)	O
had	O
odds	O
ratios	O
of	O
1.92	O
(	O
95	O
%	O
CI	O
:	O
1.18-3.10	O
)	O
for	O
renal	O
dysfunction	O
and	O
2.72	O
(	O
95	O
%	O
CI	O
:	O
1.64-4.52	O
)	O
for	O
hyperuricemia	other-disease
.	O

Malnutrition	other-disease
results	O
from	O
the	O
convergence	O
of	O
poverty	O
,	O
inequitable	O
food	O
distribution	O
,	O

Acute	other-disease
urinary	other-disease
retention	other-disease
is	O
treated	O
by	O
placement	O
of	O
a	O
urinary	O
catheter	O
(	O
small	O
thin	O
flexible	O
tube	O
)	O
into	O
the	O
bladder	O
.	O

Deletion	O
of	O
the	O
GABRB3	O
gene	O
results	O
in	O
Angelman	other-disease
syndrome	other-disease
in	O
humans	O
,	O
depending	O
on	O
the	O
parental	O
origin	O
of	O
the	O
deletion	O
.	O

The	O
disease	O
has	O
a	O
similar	O
cause	O
to	O
Hirschsprung	other-disease
's	other-disease
disease	other-disease
in	O
humans	O
.	O

About	O
50	O
%	O
of	O
individuals	O
with	O
Ebstein	other-disease
's	other-disease
anomaly	other-disease
have	O
an	O
associated	O
shunt	O
between	O
the	O
right	O
and	O
left	O
atria	O
,	O
either	O
an	O
atrial	O
septal	O
defect	O
or	O
a	O
patent	O
foramen	O
ovale	O
.	O

Williams	O
was	O
diagnosed	O
with	O
Attention	other-disease
deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
(	O
ADHD	other-disease
)	O
and	O
Tourette	other-disease
syndrome	other-disease
as	O
a	O
child	O
.	O

Hypothyroidism	other-disease
,	O
irritable	other-disease
bowel	other-disease
syndrome	other-disease
,	O
attention	other-disease
deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
(	O
ADHD	other-disease
)	O
,	O
and	O
thin	O
tooth	O
enamel	O
are	O
associated	O
with	O
NPS	other-disease
,	O
but	O
whether	O
these	O
are	O
related	O
or	O
simply	O
coincidences	O
are	O
unclear	O
.	O

Some	O
other	O
neurodegenerative	O
diseases	O
including	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
(	O
AD	other-disease
)	O
,	O
dementia	other-disease
with	other-disease
Lewy	other-disease
bodies	other-disease
(	O
DLB	other-disease
)	O
,	O
chronic	other-disease
traumatic	other-disease
encephalopathy	other-disease
(	O
CTE	other-disease
)	O
and	O
frontotemporal	other-disease
dementia	other-disease
(	O
FTD	other-disease
)	O
also	O
show	O
commonalities	O
with	O
CBD	other-disease
.	O

AB	O
variant	O
is	O
caused	O
by	O
a	O
failure	O
in	O
the	O
gene	O
that	O
makes	O
an	O
enzyme	O
cofactor	O
for	O
beta-hexosaminidase	O
,	O
called	O
the	O
GM2	other-disease
activator	O
.	O

The	O
testing	O
for	O
both	O
meningitis	other-disease
and	O
aseptic	other-disease
meningitis	other-disease
is	O
mostly	O
the	O
same	O
.	O

Biotron	O
has	O
identified	O
a	O
new	O
class	O
of	O
viral	O
proteins	O
as	O
targets	O
for	O
potential	O
intervention	O
,	O
and	O
is	O
developing	O
novel	O
small	O
molecule	O
therapeutics	O
that	O
target	O
these	O
proteins	O
,	O
specifically	O
the	O
p7	O
protein	O
of	O
Hepatitis	other-disease
C	other-disease
and	O
Vpu	O
protein	O
of	O
HIV	O
.	O

In	O
common	O
forms	O
of	O
MTHFR	other-disease
deficiency	other-disease
,	O
elevated	O
plasma	O
homocysteine	O
levels	O
have	O
sometimes	O
been	O
treated	O
with	O
Vitamin	O
B12	O
and	O
low	O
doses	O
of	O
folic	O
acid	O
.	O

Attention	other-disease
deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
predominantly	O
inattentive	O
(	O
ADHD-PI	other-disease
or	O
ADHD-I	other-disease
)	O
,	O
is	O
one	O
of	O
the	O
three	O
presentations	O
of	O
attention	other-disease
deficit	other-disease
hyperactivity	other-disease
disorder	other-disease
(	O
ADHD	other-disease
)	O
.	O

In	O
1998	O
in	O
Uganda	O
,	O
3,433	O
tetanus	other-disease
cases	O
were	O
recorded	O
in	O
newborn	O
babies	O
;	O
of	O
these	O
,	O
2,403	O
died	O
.	O

from	O
Department	O
of	O
Rehabilitation	O
and	O
Mental	O
Health	O
Counseling	O
,	O
University	O
of	O
South	O
Florid	O
a	O
say	O
``	O
An	O
example	O
of	O
a	O
person	O
who	O
may	O
benefit	O
from	O
discovery	O
is	O
an	O
individual	O
with	O
autism	other-disease
.	O

This	O
stage	O
is	O
useful	O
for	O
identifying	O
patients	O
with	O
bacterial	other-disease
overgrowth	other-disease
syndrome	other-disease
.	O

The	O
regiment	O
fought	O
under	O
General	O
Sir	O
John	O
Moore	O
in	O
the	O
retreat	O
to	O
Corunna	O
,	O
and	O
on	O
returning	O
to	O
England	O
they	O
were	O
part	O
of	O
the	O
Walcheren	O
Campaign	O
in	O
the	O
Netherlands	O
where	O
many	O
were	O
struck	O
down	O
with	O
malaria	other-disease
.	O

When	O
Giotto	O
died	O
on	O
8	O
January	O
1337	O
,	O
Andrea	O
Pisano	O
continued	O
the	O
building	O
until	O
work	O
was	O
halted	O
due	O
to	O
the	O
Black	other-disease
Death	other-disease
in	O
1348	O
.	O

Conduct	other-disease
disorder	other-disease
is	O
associated	O
with	O
both	O
structural	O
abnormalities	O
,	O
and	O
functional	O
abnormalities	O
during	O
affective	O
tasks	O
.	O

Omalizumab	O
inhibits	O
human	O
immunoglobulin	O
E	O
(	O
IgE	O
)	O
and	O
is	O
useful	O
in	O
treating	O
moderate-to-severe	O
allergic	other-disease
asthma	other-disease
.	O

Increased	O
nuclear	O
β-catenin	O
levels	O
have	O
also	O
been	O
noted	O
in	O
basal	other-disease
cell	other-disease
carcinoma	other-disease
(	O
BCC	other-disease
)	O
,	O
head	other-disease
and	other-disease
neck	other-disease
squamous	other-disease
cell	other-disease
carcinoma	other-disease
(	O
HNSCC	other-disease
)	O
,	O
prostate	other-disease
cancer	other-disease
(	O
CaP	other-disease
)	O
,	O
pilomatrixoma	other-disease
(	O
PTR	other-disease
)	O
and	O
medulloblastoma	other-disease
(	O
MDB	other-disease
)	O
These	O
observations	O
may	O
or	O
may	O
not	O
implicate	O
a	O
mutation	O
in	O
the	O
β-catenin	O
gene	O
:	O
other	O
Wnt	O
pathway	O
components	O
can	O
also	O
be	O
faulty	O
.	O

In	O
2011	O
Mooy	O
travelled	O
abroad	O
to	O
England	O
to	O
trial	O
with	O
League	O
1	O
club	O
Crewe	O
Alexandra	O
,	O
he	O
subsequently	O
fractured	O
his	O
knee	O
against	O
Wigan	other-disease
and	O
a	O
bone	O
tumour	O
was	O
discovered	O
in	O
his	O
knee	O
during	O
recovery	O
.	O

Haemochromatosis	other-disease
arthropathy	O
includes	O
degenerative	O
osteoarthritis	other-disease
and	O
chondrocalcinosis	other-disease
.	O

The	O
most	O
common	O
early	O
signs	O
of	O
ischemic	other-disease
colitis	other-disease
include	O
abdominal	O
pain	O
(	O
often	O
left-sided	O
)	O
,	O
with	O
mild	O
to	O
moderate	O
amounts	O
of	O
rectal	O
bleeding	O
.	O

A	O
major	O
systematic	O
review	O
in	O
2008	O
demonstrated	O
that	O
the	O
suction	O
technique	O
introduced	O
by	O
Wangensteen	O
was	O
successful	O
in	O
65	O
%	O
to	O
81	O
%	O
of	O
patients	O
with	O
small	other-disease
bowel	other-disease
obstruction	other-disease
without	O
peritonitis	other-disease
,	O
avoiding	O
the	O
need	O
for	O
surgery	O
.	O

It	O
can	O
be	O
used	O
to	O
treat	O
trauma	other-disease
nightmares	other-disease
,	O
sleep	other-disease
disturbance	other-disease
and	O
chronic	other-disease
PTSD	other-disease
.	O

Hampton	O
remained	O
active	O
until	O
a	O
stroke	other-disease
in	O
Paris	O
in	O
1991	O
led	O
to	O
a	O
collapse	O
on	O
stage	O
.	O

The	O
laboratory	O
specialises	O
in	O
researching	O
and	O
developing	O
antibody	O
type	O
treatments	O
for	O
adults	O
and	O
children	O
with	O
currently	O
incurable	O
types	O
of	O
leukaemia	other-disease
.	O

The	O
young	O
director	O
succumbed	O
to	O
Spanish	other-disease
Influenza	other-disease
and	O
died	O
later	O
that	O
year	O
;	O
October	O
23	O
,	O
1918	O
,	O
at	O
the	O
age	O
of	O
28	O
.	O

Between	O
1999	O
and	O
2009	O
,	O
Berra	O
worked	O
in	O
various	O
pharmaceutical	O
laboratories	O
around	O
Lyon	O
,	O
including	O
Boehringer	O
Ingelheim	O
(	O
1999-2001	O
)	O
and	O
Bristol	O
Myers	O
Squibb	O
(	O
2001-2006	O
)	O
,	O
where	O
she	O
conducted	O
research	O
on	O
cervical	other-disease
cancer	other-disease
and	O
Hepatitis	other-disease
B	other-disease
.	O

In	O
1983	O
,	O
at	O
the	O
onset	O
of	O
the	O
AIDS	other-disease
pandemic	O
Jones	O
co-founded	O
the	O
San	O
Francisco	O
AIDS	O
Foundation	O
,	O
which	O
has	O
grown	O
into	O
one	O
of	O
the	O
largest	O
and	O
most	O
influential	O
People	O
with	O
AIDS	other-disease
advocacy	O
organizations	O
in	O
the	O
United	O
States	O
.	O

c-Fos	O
has	O
also	O
been	O
identified	O
as	O
independent	O
predictor	O
of	O
decreased	O
survival	O
in	O
breast	other-disease
cancer	other-disease
.	O

XX	other-disease
male	other-disease
syndrome	other-disease
occurs	O
when	O
there	O
has	O
been	O
a	O
recombination	O
in	O
the	O
formation	O
of	O
the	O
male	O
gametes	O
,	O
causing	O
the	O
SRY	O
portion	O
of	O
the	O
Y	O
chromosome	O
to	O
move	O
to	O
the	O
X	O
chromosome	O
.	O

The	O
use	O
of	O
prophylactic	O
antibiotics	O
in	O
ischemic	other-disease
colitis	other-disease
has	O
not	O
been	O
prospectively	O
evaluated	O
in	O
humans	O
,	O
but	O
many	O
authorities	O
recommend	O
their	O
use	O
based	O
on	O
the	O
animal	O
data	O
.	O

This	O
association	O
between	O
weight	O
and	O
plantar	other-disease
fasciitis	other-disease
is	O
not	O
present	O
in	O
the	O
athletic	O
population	O
.	O

Though	O
it	O
is	O
named	O
for	O
associated	O
low	O
platelet	O
counts	O
,	O
HIT	other-disease
is	O
strongly	O
associated	O
with	O
risk	O
of	O
venous	other-disease
and	other-disease
arterial	other-disease
thrombosis	other-disease
.	O

More	O
than	O
a	O
century	O
later	O
,	O
the	O
appearance	O
of	O
this	O
disease	O
in	O
young	O
gay	O
men	O
in	O
New	O
York	O
City	O
,	O
San	O
Francisco	O
and	O
other	O
coastal	O
cities	O
in	O
the	O
United	O
States	O
was	O
one	O
of	O
the	O
first	O
indications	O
that	O
a	O
new	O
disease	O
,	O
now	O
called	O
AIDS	other-disease
,	O
had	O
appeared	O
.	O

In	O
a	O
revised	O
system	O
of	O
classification	O
adopted	O
by	O
the	O
Scientific	O
and	O
Standardization	O
Committee	O
of	O
the	O
International	O
Society	O
on	O
Thrombosis	O
and	O
Haemostasis	O
,	O
type	other-disease
Ib	other-disease
cases	O
are	O
now	O
designated	O
as	O
type	other-disease
II	other-disease
PE	other-disease
,	O
Pleiotrophic	O
effect	O
.	O

Wasting	other-disease
is	O
caused	O
by	O
acute	O
malnutrition	O
.	O

Presence	O
of	O
tissue	O
bubbles	O
during	O
autopsy	O
is	O
not	O
necessarily	O
an	O
indication	O
of	O
DCS	other-disease
as	O
gas	O
will	O
come	O
out	O
of	O
solution	O
when	O
a	O
body	O
is	O
decompressed	O
by	O
recovering	O
to	O
the	O
surface	O
.	O

In	O
intra-abdominal	other-disease
fibromatosi	other-disease
s	O
associated	O
with	O
Familial	other-disease
adenomatous	other-disease
polyposis	other-disease
(	O
FAP	other-disease
)	O
,	O
surgery	O
is	O
avoided	O
if	O
possible	O
due	O
to	O
high	O
rates	O
of	O
recurrence	O
within	O
the	O
abdomen	O
carrying	O
significant	O
morbidity	O
and	O
mortality	O
.	O

Affected	O
birds	O
tend	O
to	O
appear	O
depressed	O
with	O
reduced	O
appetite	O
,	O
diarrhea	other-disease
,	O
and	O
depigmentation	O
.	O

Marilee	O
Shapiro	O
Asher	O
(	O
November	O
17	O
,	O
1912	O
–	O
September	O
11	O
,	O
2020	O
)	O
was	O
an	O
American	O
sculptor	O
,	O
author	O
and	O
survivor	O
of	O
both	O
the	O
Spanish	other-disease
Flu	other-disease
and	O
COVID-19	other-disease
.	O

As	O
MARFORPAC	O
commander	O
,	O
Goodman	O
also	O
led	O
the	O
development	O
of	O
U.S.	O
Pacific	O
Command	O
's	O
Consequence	O
Support	O
Force	O
503	O
functional	O
plan	O
to	O
address	O
the	O
United	O
States	O
'	O
military	O
response	O
to	O
the	O
threat	O
of	O
an	O
Avian	other-disease
Influenza	other-disease
Pandemic	other-disease
outbreak	O
in	O
the	O
Asia-Pacific	O
region	O
.	O

Acute	other-disease
coronary	other-disease
syndrome	other-disease
,	O
including	O
heart	other-disease
attack	other-disease
or	O
unstable	other-disease
angina	other-disease
,	O
is	O
the	O
number	O
one	O
cause	O
of	O
death	O
in	O
America	O
.	O

Conduct	other-disease
disorder	other-disease
(	O
CD	other-disease
)	O
is	O
a	O
disorder	O
diagnosed	O
in	O
childhood	O
that	O
parallels	O
the	O
characteristics	O
found	O
in	O
ASPD	other-disease
and	O
is	O
characterized	O
by	O
a	O
repetitive	O
and	O
persistent	O
pattern	O
of	O
behavior	O
in	O
which	O
the	O
basic	O
rights	O
of	O
others	O
or	O
major	O
age-appropriate	O
norms	O
are	O
violated	O
.	O

All	O
suspected	O
cases	O
of	O
Nipah	other-disease
virus	other-disease
infection	other-disease
should	O
be	O
isolated	O
.	O

Buruli	other-disease
ulcers	other-disease
can	O
appear	O
anywhere	O
on	O
the	O
body	O
,	O
but	O
are	O
typically	O
on	O
the	O
limbs	O
.	O

In	O
alpha	other-disease
1-antitrypsin	other-disease
deficiency	other-disease
,	O
the	O
important	O
neutrophil	O
enzyme	O
elastase	O
is	O
not	O
adequately	O
inhibited	O
by	O
alpha	O
1-antitrypsin	O
,	O
leading	O
to	O
excessive	O
tissue	O
damage	O
in	O
the	O
presence	O
of	O
inflammation	O
–	O
the	O
most	O
prominent	O
one	O
being	O
pulmonary	other-disease
emphysema	other-disease
.	O

Many	O
patients	O
exhibit	O
spastic	other-disease
diplegia	other-disease
,	O
a	O
condition	O
characterized	O
by	O
increased	O
muscle	O
tone	O
and	O
spasticity	O
in	O
the	O
lower	O
body	O
.	O

Myocarditis	other-disease
and	O
pericarditis	other-disease
that	O
occur	O
as	O
a	O
result	O
of	O
mumps	other-disease
may	O
lead	O
to	O
endocardial	other-disease
fibroelastosis	other-disease
,	O
i.e	O
.	O

Trichotillomania	other-disease
alone	O
is	O
believed	O
to	O
affect	O
10	O
million	O
people	O
in	O
the	O
United	O
States	O
.	O

James	O
Paget	O
first	O
proposed	O
the	O
idea	O
of	O
venous	O
thrombosis	O
causing	O
upper	O
extremity	O
pain	O
and	O
swelling	O
,	O
and	O
Leopold	O
von	O
Schrötter	O
later	O
linked	O
the	O
clinical	O
syndrome	O
to	O
thrombosis	O
of	O
the	O
axillary	O
and	O
subclavian	other-disease
veins	other-disease
.	O

Thus	O
,	O
the	O
clinical	O
presentation	O
may	O
resemble	O
pheochromocytoma	other-disease
or	O
Kawasaki	other-disease
disease	other-disease
.	O

The	O
cause	O
of	O
RAS	other-disease
is	O
not	O
clear	O
.	O

Surgery	O
of	O
the	O
anal	other-disease
fistula	other-disease
to	O
drain	O
an	O
abscess	other-disease
treats	O
the	O
fistula	O
and	O
reduces	O
likelihood	O
of	O
its	O
recurrence	O
and	O
the	O
need	O
for	O
repeated	O
surgery	O
.	O

They	O
involve	O
a	O
progression	O
of	O
the	O
location	O
of	O
the	O
seizure	other-disease
in	O
the	O
brain	O
,	O
which	O
leads	O
to	O
a	O
``	O
march	O
''	O
of	O
the	O
motor	O
presentation	O
of	O
symptoms	O
.	O

The	O
BSGT	O
is	O
used	O
for	O
patients	O
with	O
strabismus	other-disease
to	O
test	O
for	O
suppression	O
,	O
normal	O
retinal	O
correspondence	O
or	O
abnormal	O
retinal	O
correspondence	O
,	O
particularly	O
in	O
cases	O
of	O
manifest	O
strabismus	O
.	O

Clearly	O
heavy	O
periods	O
at	O
menarche	O
and	O
menopause	O
may	O
settle	O
spontaneously	O
(	O
the	O
menarche	O
being	O
the	O
start	O
and	O
menopause	other-disease
being	O
the	O
cessation	O
of	O
periods	O
)	O
.	O

Her	O
first	O
priorities	O
were	O
patients	O
who	O
had	O
tuberculosis	other-disease
and	O
those	O
who	O
were	O
expectant	O
mothers	O
.	O

He	O
is	O
a	O
researcher	O
of	O
autoimmune	O
diseases	O
,	O
with	O
focus	O
on	O
antiphospholipid	other-disease
syndrome	other-disease
and	O
lupus	other-disease
.	O

RCC	O
is	O
a	O
training	O
centre	O
for	O
cancer	other-disease
education	O
and	O
research	O
by	O
national	O
and	O
international	O
organizations	O
such	O
as	O
WHO	O
,	O
IAEA	O
and	O
UICC	O
.	O

Pericarditis	other-disease
can	O
progress	O
to	O
pericardial	other-disease
effusion	other-disease
and	O
eventually	O
cardiac	O
tamponade	O
.	O

Surgical	O
correction	O
options	O
are	O
also	O
available	O
,	O
but	O
the	O
decision	O
to	O
proceed	O
with	O
surgery	O
should	O
be	O
made	O
with	O
caution	O
as	O
convergence	other-disease
insufficiency	other-disease
generally	O
does	O
not	O
improve	O
with	O
surgery	O
.	O

The	O
precipitating	O
infections	O
that	O
may	O
lead	O
to	O
septic	O
shock	O
if	O
severe	O
enough	O
include	O
but	O
are	O
not	O
limited	O
to	O
appendicitis	other-disease
,	O
pneumonia	other-disease
,	O
bacteremia	other-disease
,	O
diverticulitis	other-disease
,	O
pyelonephritis	other-disease
,	O
meningitis	other-disease
,	O
pancreatitis	other-disease
,	O
necrotizing	other-disease
fasciitis	other-disease
,	O
MRSA	other-disease
and	O
mesenteric	other-disease
ischemia	other-disease
.	O

Loss	O
of	O
IL-2	O
can	O
thereby	O
contribute	O
to	O
the	O
development	O
of	O
autoimmunity	O
in	O
NOD	other-disease
mice	O
.	O

Other	O
diseases	O
,	O
including	O
a	O
probable	O
Typhus	other-disease
outbreak	other-disease
in	O
1546	O
,	O
influenza	other-disease
and	O
smallpox	other-disease
together	O
in	O
1558	O
,	O
smallpox	other-disease
again	O
in	O
1589	O
,	O
diphtheria	other-disease
in	O
1614	O
,	O
and	O
measles	other-disease
in	O
1618	O
,	O
all	O
ravaged	O
the	O
Inca	O
people	O
.	O

HIV-1	O
protease	O
is	O
one	O
of	O
the	O
best	O
known	O
aspartic	O
proteases	O
,	O
and	O
an	O
attractive	O
target	O
for	O
the	O
treatment	O
of	O
AIDS	other-disease
.	O

Gene	O
duplication	O
of	O
PMP22	O
is	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
CMT	other-disease
where	O
the	O
overproduction	O
of	O
PMP22	O
results	O
in	O
defects	O
in	O
multiple	O
signalling	O
pathways	O
and	O
dysfunction	O
of	O
transcriptional	O
factors	O
like	O
KNOX20	O
,	O
SOX10	O
and	O
EGR2	O
.	O

The	O
causes	O
that	O
contribute	O
to	O
the	O
greatest	O
number	O
of	O
deaths	O
are	O
high	other-disease
blood	other-disease
pressure	other-disease
at	O
550,000	O
,	O
followed	O
by	O
diabetes	other-disease
at	O
418,000	O
,	O
and	O
glomerulonephritis	other-disease
at	O
238,000	O
.	O

A	O
nationwide	O
survey	O
in	O
the	O
Netherlands	O
based	O
on	O
patients	O
with	O
genetic	O
confirmation	O
of	O
the	O
diagnosis	O
estimates	O
that	O
the	O
minimal	O
incidence	O
of	O
CAIS	other-disease
is	O
one	O
in	O
99,000	O
.	O

Symptoms	O
of	O
mild	other-disease
hypothermia	other-disease
may	O
be	O
vague	O
,	O
with	O
sympathetic	O
nervous	O
system	O
excitation	O
(	O
shivering	O
,	O
high	O
blood	O
pressure	O
,	O
fast	O
heart	O
rate	O
,	O
fast	O
respiratory	O
rate	O
,	O
and	O
contraction	O
of	O
blood	O
vessels	O
)	O
.	O

Because	O
medications	O
have	O
been	O
linked	O
to	O
approximately	O
22	O
%	O
to	O
28	O
%	O
of	O
all	O
cases	O
of	O
dysgeusia	other-disease
,	O
researching	O
a	O
treatment	O
for	O
this	O
particular	O
cause	O
has	O
been	O
important	O
.	O

A	O
relationship	O
between	O
late-onset	O
hypogonadism	other-disease
and	O
risk	O
of	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
has	O
been	O
hypothesized	O
,	O
and	O
some	O
small	O
clinical	O
studies	O
have	O
been	O
conducted	O
to	O
investigate	O
the	O
prevention	O
of	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
in	O
men	O
with	O
late-onset	O
hypogonadism	other-disease
;	O
as	O
of	O
2009	O
,	O
results	O
were	O
inconclusive	O
.	O

Separation	other-disease
anxiety	other-disease
disorder	other-disease
(	O
SepAD	other-disease
)	O
is	O
the	O
feeling	O
of	O
excessive	O
and	O
inappropriate	O
levels	O
of	O
anxiety	O
over	O
being	O
separated	O
from	O
a	O
person	O
or	O
place	O
.	O

Anisocoria	other-disease
is	O
the	O
condition	O
of	O
one	O
pupil	O
being	O
more	O
dilated	O
than	O
the	O
other	O
.	O

She	O
wrote	O
that	O
the	O
CDC	O
did	O
not	O
have	O
a	O
``	O
specific	O
set	O
of	O
tests	O
and	O
symptoms	O
to	O
define	O
Guillain-Barré	other-disease
``	O
and	O
that	O
since	O
doctors	O
who	O
reported	O
cases	O
already	O
knew	O
that	O
a	O
link	O
was	O
suspected	O
,	O
a	O
bias	O
in	O
reporting	O
was	O
introduced	O
.	O

In	O
1889	O
in	O
New	O
York	O
City	O
,	O
Charles	O
McBurney	O
described	O
the	O
presentation	O
and	O
pathogenesis	O
of	O
appendicitis	other-disease
accurately	O
and	O
developed	O
the	O
teaching	O
that	O
an	O
early	O
appendectomy	O
was	O
the	O
best	O
treatment	O
to	O
avoid	O
perforation	O
and	O
peritonitis	O
.	O

Benzodiazepines	O
are	O
psychoactive	O
drugs	O
known	O
to	O
reduce	O
anxiety	other-disease
.	O

He	O
was	O
attacked	O
by	O
paralysis	other-disease
about	O
1860	O
,	O
and	O
died	O
of	O
bronchitis	other-disease
in	O
Dublin	O
25	O
February	O
1862	O
.	O

She	O
has	O
completed	O
murine	O
studies	O
looking	O
at	O
how	O
over	O
the	O
counter	O
Histamine	O
2	O
receptor	O
antagonists	O
,	O
such	O
as	O
Ranitidine	O
,	O
can	O
slow	O
or	O
reduce	O
the	O
growth	O
of	O
tumors	other-disease
such	O
as	O
those	O
in	O
breast	other-disease
cancer	other-disease
.	O

Geneticists	O
studying	O
these	O
premature-aging	other-disease
syndromes	other-disease
propose	O
that	O
caretaker	O
genes	O
that	O
determine	O
cell	O
fate	O
also	O
play	O
a	O
significant	O
role	O
in	O
aging	O
.	O

Polyhydramnios	other-disease
occurs	O
in	O
embryos	O
presenting	O
with	O
a	O
tracheoesophageal	O
fistula	O
as	O
the	O
liquid	O
produced	O
by	O
the	O
lungs	O
supposedly	O
pass	O
to	O
the	O
stomach	O
,	O
in	O
the	O
amniotic	O
fluid	O
.	O

Controversy	O
remains	O
today	O
whether	O
this	O
disorder	O
is	O
a	O
subtype	O
of	O
acute	other-disease
myeloid	other-disease
leukemia	other-disease
or	O
myelodysplastic	other-disease
syndromes	other-disease
;	O
however	O
,	O
it	O
is	O
currently	O
classified	O
as	O
a	O
form	O
of	O
AML	other-disease
.	O

Because	O
of	O
its	O
antioxidants	O
,	O
it	O
is	O
also	O
used	O
for	O
hay	other-disease
fever	other-disease
,	O
depression	other-disease
,	O
high	other-disease
cholesterol	other-disease
,	O
a	O
type	O
of	O
liver	O
disease	O
,	O
and	O
itching	O
.	O

Persons	O
with	O
autism	other-disease
may	O
be	O
resistant	O
to	O
change	O
and	O
may	O
not	O
be	O
comfortable	O
in	O
offices	O
or	O
other	O
unfamiliar	O
settings	O
.	O

Common	O
adverse	O
effects	O
in	O
studies	O
were	O
temporary	other-disease
bradycardia	other-disease
(	O
slow	other-disease
heartbeat	other-disease
)	O
,	O
usually	O
at	O
the	O
beginning	O
of	O
the	O
treatment	O
,	O
dyspnoea	other-disease
(	O
breathing	other-disease
difficulties	other-disease
)	O
,	O
and	O
increased	other-disease
liver	other-disease
enzymes	other-disease
(	O
without	O
symptoms	O
)	O
.	O

Autoimmune	other-disease
conditions	O
:	O
Autoimmune	other-disease
conditions	O
are	O
commonly	O
considered	O
as	O
a	O
risk	O
factor	O
that	O
has	O
been	O
associated	O
with	O
non-Hodgkin	other-disease
lymphomas	other-disease
,	O
with	O
Celiac	other-disease
Disease	other-disease
having	O
an	O
established	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
Extranodal	other-disease
T-cell	other-disease
lymphoma	other-disease
subtypes	O
.	O

It	O
is	O
concerned	O
with	O
the	O
immediate	O
local	O
effects	O
of	O
the	O
Chernobyl	other-disease
disaster	O
.	O

Additionally	O
,	O
it	O
has	O
been	O
correlated	O
with	O
Acute	other-disease
fatty	other-disease
liver	other-disease
of	other-disease
pregnancy	other-disease
(	O
AFLP	other-disease
)	O
disease	O
.	O

BCG	other-disease
disease	other-disease
is	O
an	O
adverse	O
effect	O
of	O
the	O
Bacillus	O
Calmette-Guérin	O
vaccine	O
.	O

When	O
the	O
HIV/AIDS	other-disease
epidemic	other-disease
emerged	O
in	O
the	O
1980s	O
,	O
the	O
media	O
spread	O
panic	O
about	O
the	O
disease	O
and	O
its	O
origins	O
in	O
``	O
sexual	O
promiscuity	O
''	O
within	O
gay	O
communities	O
.	O

Potential	O
applications	O
for	O
this	O
research	O
include	O
blood	O
glucose	O
monitoring	O
systems	O
to	O
help	O
manage	O
diabetes	other-disease
mellitus	other-disease
.	O

BoDV-1	other-disease
and	other-disease
2	other-disease
cause	O
abnormal	O
behaviour	O
and	O
fatality	O
.	O

Invasive	other-disease
adenocarcinoma	other-disease
of	O
the	O
lung	O
includes	O
a	O
heterogenous	O
mixture	O
of	O
subtypes	O
and	O
variants	O
.	O

Shortly	O
after	O
Pitman	O
's	O
retirement	O
at	O
the	O
age	O
of	O
65	O
,	O
he	O
was	O
diagnosed	O
with	O
cancer	other-disease
and	O
subsequently	O
died	O
at	O
Rhos-on-Sea	O
,	O
Denbighshire	O
on	O
5	O
June	O
1998	O
.	O

In	O
left	O
ventricular	other-disease
failure	other-disease
,	O
evidence	O
may	O
exist	O
of	O
vascular	O
redistribution	O
(	O
upper	other-disease
lobe	other-disease
blood	other-disease
diversion	other-disease
or	O
cephalization	other-disease
)	O
,	O
Kerley	O
lines	O
,	O
cuffing	O
of	O
the	O
areas	O
around	O
the	O
bronchi	O
,	O
and	O
interstitial	other-disease
edema	other-disease
.	O

Leukaemia	O
&	O
amp	O
;	O
Lymphoma	O
Research	O
fund	O
scientific	O
research	O
focused	O
on	O
finding	O
causes	O
and	O
improving	O
diagnosis	O
and	O
treatment	O
of	O
all	O
types	O
of	O
blood	O
cancer	O
including	O
leukaemia	other-disease
,	O
lymphoma	other-disease
and	O
myeloma	other-disease
.	O

Medical	O
experts	O
told	O
Andrew	O
there	O
was	O
no	O
treatment	O
available	O
and	O
that	O
he	O
would	O
have	O
to	O
manage	O
suffering	O
from	O
lactose	other-disease
intolerance	other-disease
for	O
the	O
rest	O
of	O
his	O
life	O
.	O

She	O
has	O
been	O
a	O
lead	O
investigator	O
on	O
UK	O
ovarian	other-disease
cancer	other-disease
screening	O
trials	O
and	O
on	O
studies	O
of	O
ovarian	other-disease
cancer	other-disease
symptoms	O
notably	O
the	O
UK	O
Collaborative	O
Trial	O
of	O
Ovarian	O
Cancer	O
Screening	O
(	O
UKCTOCS	O
)	O
,	O
which	O
forms	O
the	O
evidence	O
base	O
for	O
current	O
ovarian	other-disease
cancer	other-disease
screening	O
guidelines	O
.	O

After	O
the	O
2020	O
minor	O
league	O
season	O
was	O
cancelled	O
due	O
to	O
the	O
COVID-19	other-disease
pandemic	O
,	O
Shugart	O
was	O
invited	O
to	O
participate	O
in	O
the	O
Red	O
Sox	O
'	O
fall	O
instructional	O
league	O
.	O

Neonatal	other-disease
myasthenia	other-disease
gravis	other-disease
is	O
a	O
very	O
rare	O
condition	O
in	O
which	O
a	O
mother	O
with	O
myasthenia	other-disease
gravis	other-disease
passes	O
down	O
her	O
antibodies	O
to	O
her	O
infant	O
through	O
the	O
placenta	O
,	O
causing	O
the	O
it	O
to	O
be	O
born	O
with	O
antibodies	O
that	O
will	O
attach	O
self-antigens	O
.	O

On	O
6	O
May	O
2020	O
,	O
Eunice	O
moderated	O
an	O
online	O
webinar	O
for	O
Medecins	O
Sans	O
Frontieres	O
or	O
Doctors	O
without	O
Borders	O
titled	O
``	O
Live	O
Chat	O
on	O
COVID-19	other-disease
:	O
How	O
MSF	O
Responds	O
to	O
a	O
Pandemic	O
''	O
.	O

Initial	O
research	O
focused	O
on	O
their	O
role	O
in	O
human	O
disease	O
:	O
alpha	O
1-antitrypsin	O
deficiency	O
is	O
one	O
of	O
the	O
most	O
common	O
genetic	O
disorders	O
,	O
causing	O
emphysema	other-disease
,	O
and	O
antithrombin	O
deficiency	O
results	O
in	O
thrombosis	other-disease
.	O

In	O
1981	O
he	O
first	O
described	O
acral	other-disease
acanthotic	other-disease
anomaly	other-disease
(	O
acral	other-disease
acanthosis	other-disease
nigricans	other-disease
)	O
.	O

Genetic	O
defects	O
involving	O
aquaporin	O
genes	O
have	O
been	O
associated	O
with	O
several	O
human	O
diseases	O
including	O
nephrogenic	other-disease
diabetes	other-disease
insipidus	other-disease
and	O
neuromyelitis	other-disease
optica	other-disease
.	O

11.5	O
%	O
of	O
people	O
with	O
a	O
spontaneous	other-disease
pneumothorax	other-disease
have	O
a	O
family	O
member	O
who	O
has	O
previously	O
experienced	O
a	O
pneumothorax	other-disease
.	O

Discontinuation	O
of	O
heparin	O
is	O
critical	O
in	O
a	O
case	O
of	O
heparin-induced	other-disease
thrombocytopenia	other-disease
(	O
HIT	other-disease
)	O
.	O

A	O
seminoma	other-disease
is	O
a	O
germ	O
cell	O
tumor	O
of	O
the	O
testicle	O
or	O
,	O
more	O
rarely	O
,	O
the	O
mediastinum	O
or	O
other	O
extra-gonadal	O
locations	O
.	O

Mutations	O
in	O
the	O
gene	O
have	O
been	O
shown	O
to	O
cause	O
defects	O
in	O
the	O
protein	O
glycosylation	O
pathway	O
which	O
manifest	O
as	O
congenital	other-disease
disorder	other-disease
of	other-disease
glycosylation	other-disease
type	other-disease
Ia	other-disease
.	O

In	O
severe	O
forms	O
,	O
botulism	other-disease
leads	O
to	O
paralysis	O
of	O
the	O
breathing	O
muscles	O
and	O
causes	O
respiratory	O
failure	O
.	O

GM3	O
has	O
been	O
found	O
to	O
reduce	O
the	O
motility	O
of	O
ovarian	other-disease
cancer	other-disease
cells	O
,	O
colorectal	other-disease
cancer	other-disease
cells	O
,	O
and	O
gastric	other-disease
cancer	other-disease
cells	O
.	O

Psychosurgery	O
has	O
now	O
become	O
a	O
rare	O
procedure	O
and	O
is	O
not	O
a	O
recommended	O
treatment	O
for	O
schizophrenia	other-disease
.	O

Mitochondrial	other-disease
acetoacetyl-CoA	other-disease
thiolase	O
deficiency	O
,	O
known	O
earlier	O
as	O
β-ketothiolase	O
deficiency	O
,	O
is	O
an	O
inborn	O
error	O
of	O
metabolism	O
involving	O
isoleucine	O
catabolism	O
and	O
ketone	O
body	O
metabolism	O
.	O

Before	O
the	O
riot	O
the	O
Minamata	other-disease
disease	other-disease
issue	O
had	O
been	O
skirted	O
by	O
the	O
national	O
media	O
and	O
had	O
been	O
chiefly	O
a	O
local	O
issue	O
.	O

Measles	other-disease
first	O
arrived	O
in	O
Samoa	O
in	O
1893	O
,	O
carried	O
by	O
a	O
steamer	O
from	O
New	O
Zealand	O
.	O

It	O
is	O
not	O
definitely	O
established	O
whether	O
they	O
had	O
HACE	other-disease
or	O
acute	O
decompression	O
sickness	O
.	O

BDD	other-disease
is	O
different	O
from	O
Koro	other-disease
.	O

Thyroid	other-disease
cancer	other-disease
arising	O
in	O
the	O
background	O
of	O
radiation	O
is	O
often	O
multifocal	O
with	O
a	O
high	O
incidence	O
of	O
lymph	O
node	O
metastasis	O
and	O
has	O
a	O
poor	O
prognosis	O
.	O

Long-chain	O
L-3-hydroxyacyl-coenzyme	O
A	O
dehydrogenase	O
deficiency	O
is	O
associated	O
with	O
some	O
pregnancy-specific	O
disorders	O
,	O
including	O
preeclampsia	other-disease
,	O
HELLP	other-disease
syndrome	O
(	O
hemolysis	other-disease
,	O
elevated	O
liver	O
enzymes	O
,	O
low	O
platelets	O
)	O
,	O
hyperemesis	other-disease
gravidarum	other-disease
,	O
acute	other-disease
fatty	other-disease
liver	other-disease
of	other-disease
pregnancy	other-disease
,	O
and	O
maternal	other-disease
floor	other-disease
infarct	other-disease
of	other-disease
the	other-disease
placenta	other-disease
.	O

Elevated	O
blood	O
lead	O
is	O
significantly	O
correlated	O
with	O
both	O
impaired	other-disease
kidney	other-disease
function	other-disease
and	O
hyperuricemia	other-disease
(	O
although	O
the	O
causal	O
relationship	O
among	O
these	O
correlations	O
is	O
not	O
known	O
)	O
.	O

The	O
Guard	O
During	O
Ischemia	O
Against	O
Necrosis	O
(	O
GUARDIAN	O
)	O
trial	O
was	O
conducted	O
to	O
determine	O
whether	O
cariporide	O
reduced	O
the	O
incidence	O
of	O
mortality	O
and	O
myocardial	other-disease
infarction	other-disease
in	O
at-risk	O
patients	O
.	O

Smith–Fineman–Myers	other-disease
syndrome	other-disease
(	O
SFMS1	other-disease
)	O
is	O
a	O
congenital	O
disorder	O
that	O
causes	O
birth	O
defects	O
.	O

Auditory	other-disease
verbal	other-disease
agnosia	other-disease
(	O
AVA	other-disease
)	O
is	O
not	O
the	O
same	O
as	O
auditory	O
agnosia	O
;	O
patients	O
with	O
(	O
nonverbal	O
)	O
auditory	other-disease
agnosia	other-disease
have	O
a	O
relatively	O
more	O
intact	O
speech	O
comprehension	O
system	O
despite	O
their	O
impaired	O
recognition	O
of	O
nonspeech	O
sounds	O
.	O

Anxiety	other-disease
disorders	other-disease
often	O
co-occur	O
with	O
ASPD	other-disease
,	O
and	O
contrary	O
to	O
assumptions	O
,	O
psychopathy	O
can	O
sometimes	O
be	O
marked	O
by	O
anxiety	O
;	O
this	O
appears	O
to	O
be	O
related	O
to	O
items	O
from	O
Factor	O
2	O
but	O
not	O
Factor	O
1	O
of	O
the	O
PCL-R	O
.	O
Psychopathy	other-disease
is	O
also	O
associated	O
with	O
substance	O
use	O
disorders	O
.	O

The	O
exact	O
rates	O
for	O
cyclothymia	other-disease
have	O
not	O
been	O
widely	O
studied	O
.	O

Hepatic	other-disease
encephalopathy	other-disease
(	O
HE	other-disease
)	O
is	O
an	O
altered	O
level	O
of	O
consciousness	O
as	O
a	O
result	O
of	O
liver	O
failure	O
.	O

While	O
collecting	O
material	O
for	O
this	O
work	O
Plant	O
contracted	O
malaria	other-disease
in	O
Maputaland	O
,	O
dying	O
at	O
Lake	O
St.	O
Lucia	O
in	O
1858	O
.	O

Also	O
,	O
a	O
condition	O
similar	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	other-disease
)	O
may	O
occur	O
in	O
patients	O
with	O
severe	O
Pneumocystis	other-disease
pneumonia	O
,	O
and	O
such	O
individuals	O
may	O
require	O
intubation	O
.	O

Working	O
with	O
the	O
Egyptian	O
ministry	O
of	O
Health	O
,	O
initial	O
diseases	O
studied	O
included	O
brucellosis	other-disease
,	O
cholera	other-disease
,	O
meningitis	other-disease
,	O
schistosomiasis	other-disease
,	O
smallpox	other-disease
and	O
tick-borne	other-disease
illnesses	other-disease
.	O

Among	O
other	O
awards	O
and	O
honours	O
,	O
Hardy	O
has	O
won	O
the	O
Breakthrough	O
Prize	O
in	O
Life	O
Sciences	O
for	O
dissecting	O
the	O
causes	O
of	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
,	O
Parkinson	other-disease
's	other-disease
disease	other-disease
and	O
frontotemporal	other-disease
dementia	other-disease
;	O
the	O
MetLife	O
prize	O
for	O
research	O
into	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
,	O
and	O
the	O
Potamkin	O
Prize	O
for	O
his	O
work	O
in	O
describing	O
the	O
first	O
genetic	O
mutations	O
in	O
the	O
amyloid	O
gene	O
in	O
Alzheimer	other-disease
's	other-disease
disease	other-disease
,	O
in	O
1991	O
.	O

The	O
actor	O
had	O
Strabismus	other-disease
or	O
cross-eye	other-disease
problem	O
,	O
which	O
helped	O
him	O
get	O
comedic	O
roles	O
.	O

Also	O
,	O
past	O
medical	O
history	O
and	O
family	O
history	O
may	O
provide	O
indications	O
to	O
the	O
etiology	O
of	O
the	O
palpitations	other-disease
.	O

Also	O
,	O
a	O
CACNA1C	O
risk	O
allele	O
has	O
been	O
associated	O
to	O
a	O
disruption	O
in	O
brain	O
connectivity	O
in	O
patients	O
with	O
bipolar	other-disease
disorder	other-disease
,	O
while	O
not	O
or	O
only	O
to	O
a	O
minor	O
degree	O
,	O
in	O
their	O
unaffected	O
relatives	O
or	O
healthy	O
controls	O
.	O

African	other-disease
blackwood	other-disease
dermatitis	other-disease
is	O
a	O
condition	O
characterized	O
by	O
an	O
allergic	O
contact	O
dermatitis	O
associated	O
with	O
a	O
musical	O
instrument	O
made	O
of	O
a	O
particular	O
type	O
of	O
wood	O
.	O

The	O
players	O
have	O
disabilities	O
such	O
as	O
Cerebral	other-disease
Palsy	other-disease
,	O
Duchenne	other-disease
muscular	other-disease
dystrophy	other-disease
,	O
Spina	other-disease
Bifida	other-disease
and	O
Hydrocephalus	other-disease
.	O

These	O
partners	O
include	O
the	O
Greater	O
Boston	O
YMCA	O
,	O
Bird	O
Street	O
Community	O
Center	O
,	O
the	O
Watertown	O
Boys	O
and	O
Girls	O
Clu	O
b	O
,	O
and	O
Mass	O
General	O
Hospital	O
's	O
Aspire	O
program	O
for	O
children	O
with	O
Asperger	other-disease
's	other-disease
syndrome	other-disease
.	O

His	O
work	O
identified	O
a	O
link	O
between	O
cigarette	O
smoke	O
exposure	O
and	O
ACE2	O
over-expression	O
,	O
which	O
could	O
make	O
smokers	O
and	O
COPD	other-disease
patients	O
more	O
vulnerable	O
to	O
COVID19	other-disease
.	O

Wu	O
funded	O
virus	O
research	O
at	O
the	O
Oregon	O
Health	O
and	O
Science	O
University	O
that	O
may	O
be	O
the	O
first	O
effective	O
treatment	O
and	O
vaccine	O
for	O
AIDS	other-disease
.	O

In	O
August	O
2014	O
,	O
she	O
contracted	O
Dengue	other-disease
fever	other-disease
during	O
the	O
2014	O
Dengue	O
fever	O
outbreak	O
.	O

Orkin	O
has	O
been	O
involved	O
with	O
several	O
initiatives	O
to	O
increase	O
testing	O
rates	O
of	O
HIV	other-disease
/	O
AIDS	other-disease
,	O
and	O
in	O
2015	O
she	O
launched	O
``	O
Going	O
Viral	O
``	O
,	O
a	O
week	O
to	O
raise	O
awareness	O
of	O
blood-borne	O
viruses	O
.	O

Mumps	other-disease
meningitis	other-disease
typically	O
resolves	O
within	O
3–10	O
days	O
without	O
long-term	O
complications	O
.	O

In	O
1987	O
,	O
Shay	O
shifted	O
from	O
neuropathology	O
to	O
the	O
study	O
of	O
posttraumatic	other-disease
stress	other-disease
disorder	other-disease
(	O
PTSD	other-disease
)	O
and	O
published	O
a	O
short	O
article	O
linking	O
the	O
combat	O
histories	O
of	O
patients	O
at	O
the	O
VA	O
with	O
the	O
experience	O
of	O
war	O
described	O
in	O
Homer	O
's	O
``	O
Iliad	O
``	O
.	O

Spinal	other-disease
cord	other-disease
injury	other-disease
is	O
damage	O
to	O
the	O
spinal	O
cord	O
that	O
causes	O
changes	O
in	O
its	O
function	O
,	O
either	O
temporary	O
or	O
permanent	O
.	O

Physical	O
effects	O
of	O
teratogens	other-disease
are	O
common	O
,	O
but	O
endocrine	O
effects	O
are	O
harder	O
to	O
measure	O
.	O

A	O
filtered	O
and	O
purified	O
influenza	other-disease
A	other-disease
vaccine	O
for	O
humans	O
has	O
been	O
developed	O
and	O
many	O
countries	O
have	O
stockpiled	O
it	O
to	O
allow	O
a	O
quick	O
administration	O
to	O
the	O
population	O
in	O
the	O
event	O
of	O
an	O
avian	O
influenza	O
pandemic	O
.	O

The	O
play	O
depicts	O
the	O
experiences	O
of	O
Kate	O
Winter	O
(	O
Cropper	O
)	O
,	O
a	O
young	O
woman	O
with	O
schizophrenia	other-disease
,	O
and	O
her	O
experiences	O
with	O
the	O
medical	O
professionals	O
who	O
attempt	O
to	O
care	O
for	O
her	O
in	O
a	O
mental	O
hospital	O
.	O

When	O
septic	other-disease
arthritis	other-disease
is	O
suspected	O
,	O
x-rays	O
should	O
generally	O
be	O
taken	O
.	O

Since	O
the	O
acetylation	O
of	O
STAT3	O
is	O
important	O
for	O
its	O
oncogenic	O
activity	O
and	O
the	O
fact	O
that	O
the	O
level	O
of	O
acetylated	O
STAT3	O
is	O
high	O
in	O
cancer	other-disease
cells	O
,	O
it	O
is	O
implied	O
that	O
targeting	O
acetylated	O
STAT3	O
for	O
chemoprevention	O
and	O
chemotherapy	O
is	O
a	O
promising	O
strategy	O
.	O

Schizophrenia	other-disease
affects	O
1	O
%	O
of	O
the	O
general	O
population	O
and	O
is	O
highly	O
heritable	O
,	O
providing	O
an	O
indication	O
of	O
a	O
genetic	O
basis	O
.	O

In	O
general	O
,	O
jaundice	other-disease
is	O
present	O
when	O
blood	O
levels	O
of	O
bilirubin	O
exceed	O
3	O
mg/dl	O
.	O

The	O
distinction	O
between	O
bronchial	other-disease
asthma	other-disease
and	O
cardiac	other-disease
asthma	other-disease
is	O
especially	O
important	O
because	O
some	O
treatments	O
for	O
bronchial	other-disease
asthma	other-disease
,	O
including	O
inhalers	O
,	O
may	O
worsen	O
cardiac	other-disease
asthma	other-disease
or	O
cause	O
severe	O
heart	other-disease
arrhythmias	other-disease
.	O

According	O
to	O
Tom	O
Newberry	O
,	O
the	O
spokesperson	O
for	O
GTC	O
,	O
the	O
company	O
plans	O
to	O
acquire	O
additional	O
approval	O
for	O
treatment	O
of	O
those	O
with	O
non-hereditary	other-disease
antithrombin	other-disease
deficiency	other-disease
.	O

HSP90	O
beta	O
has	O
been	O
identified	O
as	O
one	O
of	O
the	O
autoantigenic	O
biomarkers	O
and	O
targets	O
involved	O
in	O
human	other-disease
ovarian	other-disease
autoimmune	other-disease
disease	other-disease
leading	O
to	O
ovarian	O
failure	O
and	O
thereby	O
infertility	O
.	O

In	O
addition	O
to	O
hemorrhagic	other-disease
cystitis	other-disease
,	O
temporary	O
hematuria	O
can	O
also	O
be	O
seen	O
in	O
bladder	O
infection	O
or	O
in	O
children	O
as	O
a	O
result	O
of	O
viral	O
infection	O
.	O

Those	O
with	O
pre-eclampsia	other-disease
may	O
have	O
a	O
lower	O
risk	O
of	O
breast	O
cancer	O
.	O

In	O
some	O
cases	O
,	O
tics	O
may	O
not	O
be	O
inherited	O
;	O
these	O
cases	O
are	O
identified	O
as	O
``	O
sporadic	O
''	O
Tourette	other-disease
syndrome	O
(	O
also	O
known	O
as	O
tourettism	other-disease
)	O
because	O
a	O
genetic	O
link	O
is	O
missing	O
.	O

There	O
is	O
a	O
large	O
outpatient	O
movement	O
disorder	O
clinic	O
,	O
specialising	O
in	O
multidisciplinary	O
team	O
management	O
of	O
Parkinson	other-disease
's	O
disease	O
,	O
dystonia	other-disease
,	O
progressive	other-disease
supranuclear	other-disease
palsy	other-disease
,	O
and	O
related	O
diseases	O
.	O

Finally	O
,	O
rupture	O
of	O
the	O
anterior	O
or	O
posterior	O
communicating	O
artery	O
,	O
subarachnoid	other-disease
hemorrhage	other-disease
,	O
and	O
encephalitis	other-disease
are	O
also	O
possible	O
causes	O
of	O
confabulation	other-disease
.	O

Multi-component	O
HIV	other-disease
prevention	O
programmes	O
that	O
include	O
NSE	O
reduce	O
drug-related	O
HIV	other-disease
risk	O
behaviors	O
and	O
enhance	O
the	O
impact	O
of	O
harm	O
reduction	O
services	O
.	O

Alterations	O
of	O
PMP22	O
gene	O
expression	O
are	O
associated	O
with	O
a	O
variety	O
of	O
neuropathies	other-disease
,	O
such	O
as	O
Charcot–Marie–Tooth	other-disease
type	other-disease
1A	other-disease
(	O
CMT1A	other-disease
)	O
,	O
Dejerine–Sottas	other-disease
disease	other-disease
,	O
and	O
Hereditary	other-disease
Neuropathy	other-disease
with	other-disease
Liability	other-disease
to	other-disease
Pressure	other-disease
Palsy	other-disease
(	O
HNPP	other-disease
)	O
.	O

Candida	O
can	O
colonize	O
the	O
gastrointestinal	O
tract	O
of	O
low	O
birthweight	O
infants	O
(	O
LBI	other-disease
)	O
.	O

Therefore	O
,	O
by	O
inhibiting	O
osteoclasts	O
,	O
it	O
prevents	O
osteoporosis	other-disease
.	O

The	O
size	O
of	O
the	O
monocular	other-disease
scotoma	other-disease
is	O
5×7	O
degrees	O
of	O
visual	O
angle	O
.	O

Complications	O
from	O
PSC	other-disease
-associated	O
cancers	O
account	O
for	O
40	O
%	O
of	O
deaths	O
from	O
PSC	other-disease
.	O

In	O
1980	O
Edmund	O
Klein	O
,	O
Schwartz	O
and	O
associates	O
published	O
in	O
``	O
Cancer	O
''	O
one	O
of	O
the	O
first	O
effective	O
treatments	O
of	O
Kaposi	other-disease
’	other-disease
s	other-disease
sarcoma	other-disease
,	other-disease
a	O
type	O
of	O
cancer	O
that	O
became	O
more	O
frequent	O
as	O
the	O
AIDS	other-disease
epidemic	O
unfolded	O
.	O

Unilateral	O
tinnitus	O
(	O
ringing	O
or	O
hissing	O
in	O
the	O
ears	O
)	O
is	O
also	O
a	O
hallmark	O
symptom	O
of	O
acoustic	other-disease
neuroma	other-disease
.	O

RLS	other-disease
is	O
identified	O
by	O
the	O
strong	O
urge	O
to	O
move	O
and	O
is	O
a	O
dopamine-dependent	O
disorder	O
.	O

Congenital	O
apical	O
displacement	O
of	O
the	O
tricuspid	O
valve	O
is	O
called	O
Ebstein	other-disease
's	other-disease
anomaly	other-disease
and	O
typically	O
causes	O
significant	O
tricuspid	O
regurgitation	O
.	O

This	O
phase	O
may	O
last	O
from	O
several	O
months	O
to	O
several	O
years	O
,	O
and	O
there	O
may	O
be	O
no	O
symptoms	O
of	O
leukemia	other-disease
.	O

Presentation	O
of	O
nephrotoxicity	other-disease
can	O
appear	O
as	O
Fanconi	O
syndrome	O
,	O
acute	O
kidney	O
injury	O
,	O
or	O
decline	O
of	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
.	O

Obstructive	other-disease
sleep	other-disease
apnea	other-disease
or	O
sleep	other-disease
apnea	other-disease
is	O
defined	O
as	O
either	O
cessation	O
of	O
breathing	O
(	O
apnea	O
)	O
for	O
10	O
seconds	O
,	O
or	O
a	O
decrease	O
in	O
normal	O
breathing	O
(	O
hypopnea	O
)	O
with	O
an	O
associated	O
desaturation	O
in	O
oxygen	O
and	O
arousal	O
during	O
sleep	O
that	O
lasts	O
at	O
least	O
10	O
seconds	O
.	O

This	O
was	O
the	O
fifth	O
of	O
eight	O
seasons	O
that	O
``	O
League	O
Awards	O
``	O
,	O
a	O
precursor	O
to	O
the	O
Major	other-disease
League	other-disease
Baseball	other-disease
Most	O
Valuable	O
Player	O
Award	O
(	O
introduced	O
in	O
1931	O
)	O
,	O
were	O
issued	O
.	O

While	O
some	O
feel	O
the	O
diagnosis	O
of	O
fibromyalgia	other-disease
may	O
negatively	O
affect	O
a	O
person	O
,	O
other	O
research	O
finds	O
it	O
to	O
be	O
beneficial	O
.	O

The	O
study	O
found	O
that	O
36	O
percent	O
of	O
the	O
cancer	O
patients	O
had	O
HPV	other-disease
compared	O
to	O
only	O
1	O
percent	O
of	O
the	O
healthy	O
control	O
group	O
.	O

In	O
the	O
advanced	O
stages	O
it	O
can	O
result	O
in	O
a	O
coma	other-disease
.	O

Nutritional	other-disease
anemia	other-disease
is	O
caused	O
by	O
a	O
lack	O
of	O
iron	O
,	O
protein	O
,	O
vitamin	O
B12	O
,	O
and	O
other	O
vitamins	O
and	O
minerals	O
that	O
needed	O
for	O
the	O
formation	O
of	O
hemoglobin	O
.	O

Mutations	O
in	O
this	O
gene	O
have	O
been	O
associated	O
with	O
Catch	other-disease
22	other-disease
syndrome	other-disease
as	O
well	O
as	O
cardiac	other-disease
and	other-disease
craniofacial	other-disease
defects	other-disease
.	O

GSK	O
investigated	O
losmapimod	O
as	O
a	O
therapeutic	O
for	O
COPD	other-disease
,	O
but	O
multiple	O
phase	O
II	O
clinical	O
trials	O
failed	O
to	O
show	O
that	O
losmapimod	O
improves	O
exercise	O
tolerance	O
,	O
lung	O
function	O
,	O
arterial	O
inflammation	O
,	O
endothelial	O
function	O
,	O
or	O
rate	O
of	O
COPD	other-disease
exacerbations	O
in	O
subjects	O
with	O
COPD	other-disease
.	O

Agonists	O
of	O
the	O
melatonin	O
receptor	O
have	O
a	O
number	O
of	O
therapeutic	O
applications	O
including	O
treatment	O
of	O
sleep	other-disease
disorders	other-disease
and	O
depression	other-disease
.	O

Dati	O
survived	O
two	O
bouts	O
of	O
Bubonic	other-disease
plague	other-disease
that	O
struck	O
his	O
family	O
,	O
and	O
would	O
go	O
on	O
to	O
outlive	O
three	O
of	O
his	O
wives	O
and	O
19	O
of	O
his	O
children	O
.	O

Whilst	O
COPD	other-disease
is	O
common	O
,	O
it	O
is	O
frequently	O
undiagnosed	O
,	O
and	O
Adab	O
has	O
argued	O
that	O
both	O
clinicians	O
and	O
patients	O
need	O
access	O
to	O
more	O
information	O
.	O

This	O
finding	O
has	O
led	O
to	O
the	O
initiation	O
of	O
AD	O
clinical	O
trials	O
of	O
metal	O
chaperones	O
targeting	O
metal-induced	O
aggregation	O
of	O
beta-amyloid	O
in	O
AD	O
and	O
of	O
alpha-synuclein	O
and	O
Lewy	O
bodies	O
in	O
Parkinson	other-disease
disease	O
(	O
being	O
carried	O
out	O
by	O
Alterity	O
Therapeutics	O
,	O
formally	O
Prana	O
Biotechnology	O
,	O
co-founded	O
by	O
Dr	O
.	O
Tanzi	O
)	O
.	O

He	O
then	O
expanded	O
on	O
his	O
paper	O
of	O
1908	O
in	O
Dementia	O
Praecox	O
oder	O
Gruppe	O
der	O
Schizophrenie…Bleuler	O
is	O
credited	O
with	O
the	O
introduction	O
of	O
two	O
concepts	O
fundamental	O
to	O
the	O
analysis	O
of	O
schizophrenia	O
:	O
autism	other-disease
,	O
denoting	O
the	O
loss	O
of	O
contact	O
with	O
reality	O
,	O
frequently	O
through	O
indulgence	O
in	O
bizarre	O
fantasy	O
;	O
and	O
ambivalence	O
,	O
denoting	O
the	O
coexistence	O
of	O
mutually	O
exclusive	O
contradictions	O
within	O
the	O
psyche	O
.	O
''	O

This	O
type	O
of	O
aneurysm	other-disease
is	O
typically	O
congenital	O
and	O
may	O
be	O
associated	O
with	O
heart	O
defects	O
.	O

No	O
other	O
person	O
with	O
total	O
insomnia	other-disease
has	O
lived	O
for	O
such	O
a	O
long	O
period	O
of	O
time	O
.	O

Bovine	other-disease
ephemeral	other-disease
fever	other-disease
,	O
vibriosis	other-disease
,	O
closterial	other-disease
diseases	other-disease
,	O
neonatal	other-disease
calf	other-disease
mortality	other-disease
,	O
calf	other-disease
scours	other-disease
and	O
internal	other-disease
parasites	other-disease
account	O
for	O
a	O
combined	O
estimated	O
$	O
333.4	O
million	O
AUD	O
in	O
costs	O
annually	O
.	O

Infertile	other-disease
women	O
are	O
at	O
a	O
higher	O
risk	O
of	O
developing	O
ovarian	other-disease
cancer	other-disease
and	O
endometrial	other-disease
cancer	other-disease
when	O
compared	O
to	O
fertile	O
women	O
.	O

Insomnia	other-disease
,	O
chronic	other-disease
respiratory	other-disease
infections	other-disease
,	O
general	other-disease
pain	other-disease
and	O
discomfort	other-disease
,	O
impotence	other-disease
,	other-disease
flatulence	other-disease
,	O
and	O
bowel	other-disease
complaints	other-disease
were	O
all	O
reported	O
.	O

Papillamitosis	other-disease
is	O
associated	O
,	O
as	O
has	O
been	O
mentioned	O
before	O
,	O
with	O
symptoms	O
and/or	O
clinical	O
signs	O
such	O
as	O
dilated	other-disease
superficial	other-disease
veins	other-disease
,	O
varicose	other-disease
veins	other-disease
and	O
changes	O
in	O
the	O
skin	O
.	O

Nonetheless	O
,	O
one	O
of	O
methyldopa	O
's	O
still	O
current	O
indications	O
is	O
in	O
the	O
management	O
of	O
pregnancy-induced	other-disease
hypertension	other-disease
(	O
PIH	other-disease
)	O
,	O
as	O
it	O
is	O
relatively	O
safe	O
in	O
pregnancy	O
compared	O
to	O
many	O
other	O
antihypertensives	O
which	O
may	O
affect	O
the	O
fetus	O
.	O

Metastatic	other-disease
breast	other-disease
cancer	other-disease
represents	O
the	O
most	O
devastating	O
attribute	O
of	O
cancer	O
and	O
it	O
is	O
considered	O
an	O
advanced-stage	O
event	O
.	O

Separation	other-disease
anxiety	other-disease
disorder	other-disease
affects	O
roughly	O
7	O
%	O
of	O
adults	O
and	O
4	O
%	O
of	O
children	O
,	O
but	O
the	O
childhood	O
cases	O
tend	O
to	O
be	O
more	O
severe	O
;	O
in	O
some	O
instances	O
,	O
even	O
a	O
brief	O
separation	O
can	O
produce	O
panic	O
.	O

Levodopa	O
has	O
been	O
reported	O
to	O
improve	O
symptoms	O
in	O
patients	O
with	O
Parkinson	other-disease
’	other-disease
s	other-disease
disease	other-disease
and	O
progressive	O
supranuclear	other-disease
palsy	other-disease
.	O

Jenner	O
extracted	O
the	O
pus	O
of	O
one	O
of	O
the	O
lesions	O
formed	O
by	O
cowpox	other-disease
on	O
Nelmes	O
to	O
another	O
individual	O
who	O
had	O
never	O
had	O
smallpox	other-disease
,	O
an	O
eight-year-old	O
boy	O
called	O
James	O
Phipps	O
.	O

Using	O
the	O
YP7	O
murine	O
monoclonal	O
antibody	O
,	O
GPC3	O
protein	O
expression	O
is	O
found	O
in	O
HCC	other-disease
,	O
not	O
in	O
normal	O
liver	O
and	O
cholangiocarcinoma	O
.	O

The	O
vaccine	O
contains	O
living	O
``	O
Mycobacterium	O
bovis	O
``	O
BCG	O
,	O
and	O
in	O
BCG	other-disease
disease	other-disease
,	O
the	O
bacterium	O
causes	O
a	O
disease	O
in	O
persons	O
vaccinated	O
.	O

During	O
the	O
Great	other-disease
Plague	other-disease
of	other-disease
London	other-disease
in	O
1665	O
,	O
people	O
boarded	O
coaches	O
at	O
Whitehall	O
,	O
then	O
at	O
the	O
edge	O
of	O
urban	O
London	O
,	O
in	O
an	O
attempt	O
to	O
escape	O
.	O

She	O
researched	O
on	O
various	O
topics	O
of	O
IVF	O
&	O
amp	O
;	O
Infertility	other-disease
during	O
her	O
specialization	O
.	O

Patients	O
with	O
lcSSc	other-disease
commonly	O
induce	O
pulmonary	O
artery	O
hypertension	O
which	O
may	O
result	O
in	O
cor	O
pulmonale	O
(	O
heart	O
failure	O
due	O
to	O
increased	O
pulmonary	O
artery	O
pressure	O
)	O
.	O

Marie	O
Curie	O
,	O
famous	O
for	O
her	O
pioneering	O
work	O
in	O
the	O
field	O
of	O
radioactivity	O
,	O
died	O
of	O
aplastic	other-disease
anemia	other-disease
after	O
working	O
unprotected	O
with	O
radioactive	O
materials	O
for	O
a	O
long	O
period	O
of	O
time	O
;	O
the	O
damaging	O
effects	O
of	O
ionizing	O
radiation	O
were	O
not	O
then	O
known	O
.	O

Telethonin	O
specifically	O
interacts	O
with	O
the	O
pro-apoptotic	O
protein	O
Siva	O
,	O
suggesting	O
that	O
Telethonin	O
may	O
be	O
involved	O
in	O
the	O
mechanism	O
underlying	O
Coxsackievirus	other-disease
B3	other-disease
infection	O
in	O
acute	O
and	O
chronic	O
myocarditis	O

Consequently	O
,	O
the	O
World	O
Health	O
Organization	O
(	O
2016	O
)	O
redefined	O
these	O
lymphomas	other-disease
as	O
separate	O
entities	O
,	O
terming	O
the	O
celiac	other-disease
disease-associated	other-disease
lymphoma	other-disease
as	O
enteropathy-associted	other-disease
T	other-disease
cell	other-disease
lymphoma	other-disease
(	O
EATL	other-disease
)	O
and	O
the	O
lymphoma	other-disease
not	O
associated	O
with	O
celiac	O
disease	O
as	O
monomorphic	other-disease
epitheliotropic	other-disease
intestinal	other-disease
T	other-disease
cell	other-disease
lymphoma	other-disease
(	O
MEITL	other-disease
)	O
.	O

In	O
a	O
2013	O
study	O
in	O
a	O
comparison	O
of	O
15	O
antipsychotic	O
drugs	O
in	O
effectiveness	O
in	O
treating	O
schizophrenic	other-disease
symptoms	other-disease
,	O
paliperidone	O
was	O
ranked	O
fifth	O
and	O
demonstrated	O
standard-high	O
effectiveness	O
.	O

The	O
glue	O
must	O
not	O
get	O
into	O
blood	O
vessels	O
,	O
as	O
this	O
could	O
lead	O
to	O
clotting	O
in	O
the	O
form	O
of	O
thromboembolism	other-disease
or	O
disseminated	other-disease
intravascular	other-disease
coagulation	other-disease
,	O
or	O
to	O
anaphylaxis	other-disease
(	O
a	O
severe	O
allergic	O
reaction	O
)	O
.	O

The	O
differential	O
diagnosis	O
of	O
congenital	other-disease
hyperinsulinism	other-disease
is	O
consistent	O
with	O
PMM2-CDG	other-disease
,	O
as	O
well	O
as	O
several	O
syndromes	O
.	O

This	O
case	O
reported	O
that	O
``	O
S.	O
equinus	O
``	O
is	O
a	O
rare	O
but	O
easily	O
treatable	O
cause	O
of	O
peritonitis	other-disease
in	O
CAPD	other-disease
patients	O
.	O

Four	O
deaths	O
were	O
registered	O
in	O
the	O
official	O
adverse	O
event	O
register	O
,	O
and	O
while	O
in	O
only	O
two	O
cases	O
a	O
clear	O
causal	O
link	O
was	O
considered	O
to	O
be	O
in	O
place	O
,	O
two	O
other	O
cases	O
were	O
diagnosed	O
with	O
a	O
disease	O
which	O
in	O
scientific	O
peer-reviewed	O
articles	O
(	O
case	O
descriptions	O
)	O
have	O
been	O
mistakenly	O
first	O
made	O
,	O
and	O
afterward	O
have	O
been	O
noticed	O
to	O
be	O
disseminated	O
BCG	other-disease
infections	other-disease
.	O

Research	O
have	O
been	O
made	O
on	O
the	O
effect	O
of	O
biological	O
differences	O
between	O
male	O
and	O
female	O
on	O
the	O
exposure	O
to	O
both	O
Post-Traumatic	other-disease
Stress	other-disease
Disorder	other-disease
(	O
PTSD	other-disease
)	O
and	O
Depression	other-disease
.	O

Due	O
to	O
the	O
association	O
of	O
dyspepsia	other-disease
with	O
non-celiac	other-disease
gluten	other-disease
sensitivity	other-disease
,	O
a	O
gluten-free	O
diet	O
can	O
relieve	O
the	O
symptoms	O
.	O

There	O
he	O
lived	O
the	O
simple	O
life	O
of	O
a	O
holy	O
man	O
until	O
in	O
May	O
1968	O
he	O
died	O
,	O
aged	O
59	O
,	O
of	O
bleeding	O
from	O
a	O
chronic	other-disease
stomach	other-disease
ulcer	other-disease
.	O

Matt	O
Helm	O
,	O
code	O
name	O
``	O
Eric	O
``	O
,	O
travels	O
to	O
London	O
,	O
England	O
and	O
eventually	O
to	O
Scotland	O
in	O
order	O
to	O
stop	O
a	O
mad	O
scientist	O
who	O
plans	O
to	O
unleash	O
a	O
new	O
Black	other-disease
Plague	other-disease
upon	O
the	O
world	O
.	O

Unfortunately	O
,	O
other	O
treponemal	O
infections	O
such	O
as	O
yaws	other-disease
,	O
bejel	other-disease
,	O
and	O
pinta	other-disease
and	O
possibly	O
nonpathogenic	O
commensal	O
treponemes	O
can	O
result	O
in	O
a	O
positive	O
.	O

Large-scale	O
genetic	O
analyses	O
have	O
shown	O
the	O
possibility	O
that	O
CACNA1C	O
is	O
associated	O
with	O
bipolar	other-disease
disorder	other-disease
and	O
subsequently	O
also	O
with	O
schizophrenia	other-disease
.	O

The	O
arthropathy	O
can	O
,	O
therefore	O
,	O
be	O
an	O
early	O
clue	O
as	O
to	O
the	O
diagnosis	O
of	O
haemochromatosis	other-disease
.	O

Myasthenia	other-disease
gravis	other-disease
is	O
an	O
autoimmune	O
disease	O
,	O
where	O
the	O
body	O
produces	O
antibodies	O
targeted	O
against	O
the	O
acetylcholine	O
receptor	O
on	O
the	O
postsynaptic	O
membrane	O
in	O
the	O
neuromuscular	O
junction	O
.	O

Generally	O
,	O
high-altitude	other-disease
pulmonary	other-disease
edema	other-disease
(	O
HAPE	other-disease
)	O
or	O
AMS	other-disease
precede	O
HACE	other-disease
.	O

However	O
subsequent	O
reports	O
asserted	O
that	O
Google	O
Flu	other-disease
Trends	O
'	O
predictions	O
have	O
sometimes	O
been	O
very	O
inaccurate—especially	O
over	O
the	O
interval	O
2011–2013	O
,	O
when	O
it	O
consistently	O
overestimated	O
relative	O
flu	O
incidence	O
,	O
and	O
over	O
one	O
interval	O
in	O
the	O
2012-2013	O
flu	O
season	O
predicted	O
twice	O
as	O
many	O
doctors	O
'	O
visits	O
as	O
the	O
CDC	O
recorded	O
.	O

Reductions	O
in	O
HbA	O
available	O
overall	O
to	O
fill	O
the	O
red	O
blood	O
cells	O
in	O
turn	O
leads	O
to	O
microcytic	other-disease
anemia	other-disease
.	O

Similar	O
to	O
a	O
tinel	other-disease
sign	other-disease
digital	other-disease
palpitation	other-disease
of	O
the	O
ischial	other-disease
spine	other-disease
may	O
produce	O
pain	O
.	O

Differentiating	O
between	O
dissociative	other-disease
identity	other-disease
disorder	other-disease
and	O
psychotic	other-disease
disorders	other-disease
is	O
not	O
done	O
by	O
listing	O
first-rank	O
symptoms	O
as	O
these	O
conditions	O
have	O
a	O
considerable	O
overlap	O
yet	O
a	O
different	O
overall	O
clinical	O
picture	O
and	O
treatment	O
approach	O
.	O

Amyloid	other-disease
beta	O
monomers	O
are	O
soluble	O
and	O
contain	O
short	O
regions	O
of	O
beta	O
sheet	O
and	O
polyproline	O
II	O
helix	O
secondary	O
structures	O
in	O
solution	O
,	O
though	O
they	O
are	O
largely	O
alpha	O
helical	O
in	O
membranes	O
;	O
however	O
,	O
at	O
sufficiently	O
high	O
concentration	O
,	O
they	O
undergo	O
a	O
dramatic	O
conformational	O
change	O
to	O
form	O
a	O
beta	O
sheet-rich	O
tertiary	O
structure	O
that	O
aggregates	O
to	O
form	O
amyloid	O
fibrils	O
.	O

The	O
New	O
Zealand	O
Government	O
Earthquake	O
Commission	O
recommends	O
that	O
products	O
such	O
as	O
Blu	O
Tack	O
should	O
be	O
used	O
to	O
prevent	O
ornaments	O
and	O
small	O
household	O
items	O
from	O
falling	O
or	O
moving	O
in	O
the	O
event	O
of	O
an	O
earthquake	other-disease
.	O

In	O
a	O
study	O
in	O
a	O
transgenic	O
mouse	O
model	O
of	O
Alzheimer	other-disease
's	O
disease	O
,	O
meldonium	O
increased	O
cognition	O
and	O
mental	O
performance	O
by	O
reducing	O
amyloid	O
beta	O
deposition	O
in	O
the	O
hippocampus	O
.	O

Another	O
aspect	O
of	O
this	O
phenomenon	O
occurs	O
in	O
type	other-disease
I	other-disease
glycogenosis	other-disease
,	O
when	O
chronic	other-disease
hypoglycemia	other-disease
before	O
diagnosis	O
may	O
be	O
better	O
tolerated	O
than	O
acute	other-disease
hypoglycemia	other-disease
after	O
treatment	O
is	O
underway	O
.	O

A	O
complete	O
and	O
detailed	O
history	O
and	O
physical	O
examination	O
are	O
two	O
essential	O
elements	O
of	O
the	O
evaluation	O
of	O
a	O
patient	O
with	O
palpitations	other-disease
.	O

Abnormal	O
sensory	O
gating	O
may	O
be	O
behind	O
symptoms	O
of	O
schizophrenia	other-disease
such	O
as	O
sensory	O
overload	O
and	O
difficulty	O
concentrating	O
.	O

Such	O
mutations	O
and	O
epigenetic	O
alterations	O
can	O
give	O
rise	O
to	O
cancer	O
(	O
see	O
malignant	other-disease
neoplasms	other-disease
)	O
.	O

The	O
genetic	O
conditions	O
such	O
as	O
Liddle	other-disease
's	other-disease
syndrome	other-disease
and	O
Congenital	other-disease
adrenal	other-disease
hyperplasia	other-disease
present	O
in	O
childhood	O
or	O
earlier	O
in	O
life	O
than	O
the	O
acquired	O
causes	O
which	O
can	O
present	O
at	O
any	O
age	O
.	O

Other	O
examples	O
of	O
insufficient	O
immune	O
tolerance	O
in	O
pregnancy	O
are	O
Rh	other-disease
disease	other-disease
and	O
pre-eclampsia	other-disease
:	O

They	O
also	O
can	O
be	O
used	O
against	O
the	O
c-KIT	O
and	O
JAK-STAT	O
signaling	O
pathways	O
,	O
which	O
are	O
involved	O
in	O
many	O
cancers	O
and	O
may	O
be	O
involved	O
in	O
epithelioid	other-disease
sarcoma	other-disease
.	O

However	O
,	O
hypotonia	other-disease
caused	O
by	O
cerebellar	other-disease
dysfunction	other-disease
or	O
motor	O
neuron	O
diseases	O
can	O
be	O
progressive	O
and	O
life-threatening	O
.	O

Hereditary	O
loss-of-function	O
mutations	O
of	O
APC	O
cause	O
a	O
condition	O
known	O
as	O
Familial	other-disease
Adenomatous	other-disease
Polyposis	other-disease
.	O

It	O
is	O
used	O
to	O
treat	O
hereditary	other-disease
angioedema	other-disease
.	O

The	O
most	O
common	O
cause	O
of	O
chronic	O
urinary	O
retention	O
is	O
BPH	other-disease
.	O

Rebound	other-disease
insomnia	other-disease
is	O
insomnia	O
that	O
occurs	O
following	O
discontinuation	O
of	O
sedative	O
substances	O
taken	O
to	O
relieve	O
primary	O
insomnia	O
.	O

Electrolyte	O
imbalances	O
remain	O
the	O
same	O
,	O
while	O
in	O
severe	O
cases	O
symptoms	O
can	O
advance	O
to	O
amino	other-disease
aciduria	other-disease
and	O
hyperammonemia	other-disease
.	O

Toxic	O
shock	O
and	O
sepsis	other-disease
may	O
occur	O
if	O
too	O
many	O
host	O
cells	O
undergo	O
pyroptosis	O
,	O
owing	O
to	O
either	O
overstimulation	O
of	O
the	O
immune	O
system	O
by	O
the	O
released	O
cytoplasmic	O
contents	O
or	O
to	O
host	O
cell	O
depletion	O
.	O

Cramp	other-disease
fasciculation	other-disease
syndrome	other-disease
(	O
CFS	other-disease
)	O
is	O
a	O
rare	O
peripheral	O
nerve	O
hyperexcitability	O
disorder	O
.	O

Research	O
shows	O
that	O
ACOAs	O
feel	O
less	O
like	O
blaming	O
their	O
parents	O
for	O
their	O
alcoholism	other-disease
after	O
learning	O
that	O
alcoholism	other-disease
is	O
a	O
disease	O
,	O
rather	O
than	O
a	O
behavior	O
.	O

There	O
is	O
currently	O
no	O
international	O
consensus	O
on	O
the	O
definition	O
of	O
mild	other-disease
HPA	other-disease
,	O
however	O
it	O
is	O
most	O
frequently	O
diagnosed	O
at	O
blood	O
Phe	O
levels	O
between	O
2-6	O
mg/dL	O
.	O

Novella	O
's	O
academic	O
specialization	O
is	O
in	O
neurology	O
,	O
including	O
more	O
specifically	O
,	O
amyotrophic	other-disease
lateral	other-disease
sclerosis	other-disease
(	O
ALS	other-disease
)	O
,	O
myasthenia	other-disease
gravis	other-disease
and	O
neuromuscular	other-disease
disorders	other-disease
,	O
neurophysiology	other-disease
,	O
and	O
the	O
treatment	O
of	O
hyperactive	other-disease
neurological	other-disease
disorders	other-disease
.	O

Spinal	O
muscular	O
atrophy	O
with	O
lower	O
extremity	O
predominance	O
2A	O
(	O
SMALED2A	other-disease
)	O
is	O
a	O
rare	O
neuromuscular	O
disorder	O
characterised	O
by	O
muscle	O
weakness	O
predominantly	O
in	O
legs	O
.	O

Several	O
clinical	O
trials	O
have	O
been	O
performed	O
to	O
assess	O
the	O
safety	O
and	O
effectivity	O
of	O
epigenetic	O
therapy	O
as	O
a	O
pretreatment	O
in	O
cancer	other-disease
therapy	O
.	O

Their	O
daughter	O
,	O
Caroline	O
Montgomery	O
Marriott	O
,	O
was	O
killed	O
by	O
the	O
Spanish	other-disease
Flu	other-disease
epidemic	O
in	O
1918	O
.	O

Cystic	other-disease
fibrosis	other-disease
is	O
an	O
inherited	O
autosomal	O
recessive	O
genetic	O
disorder	O
that	O
occurs	O
through	O
a	O
mutation	O
in	O
a	O
single	O
gene	O
that	O
codes	O
for	O
the	O
cystic	other-disease
fibrosis	other-disease
transmembrane	O
conductance	O
regulator	O
.	O

Infertility	other-disease
after	O
anti-sperm	O
antibody	O
binding	O
can	O
be	O
caused	O
by	O
autoagglutination	O
,	O
sperm	O
cytotoxicity	O
,	O
blockage	O
of	O
sperm	O
-	O
ovum	O
interaction	O
,	O
and	O
inadequate	O
motility	O
.	O

It	O
is	O
similar	O
to	O
the	O
ristocetin	O
cofactor	O
assay	O
but	O
has	O
the	O
added	O
benefit	O
in	O
that	O
it	O
helps	O
in	O
the	O
diagnosis	O
of	O
type	other-disease
2B/pseudo	other-disease
von	other-disease
Willebrand	other-disease
disease	other-disease
(	O
vWD	other-disease
)	O
and	O
Bernard–Soulier	other-disease
syndrome	O
because	O
it	O
uses	O
patient	O
's	O
live	O
endogenous	O
platelets	O
,	O
whereas	O
ristocetin	O
cofactor	O
assay	O
tests	O
the	O
function	O
of	O
only	O
the	O
vWF	O
and	O
not	O
the	O
platelets	O
.	O

Even	O
though	O
the	O
family	O
may	O
not	O
have	O
a	O
history	O
of	O
Sandhoff	other-disease
disease	O
,	O
it	O
is	O
possible	O
for	O
two	O
individuals	O
to	O
have	O
a	O
child	O
with	O
the	O
disease	O
.	O

After	O
battling	O
with	O
leukemia	other-disease
for	O
some	O
years	O
,	O
Mansa	O
Nettey	O
founded	O
the	O
Leukemia	O
Project	O
Foundation	O
in	O
Ghana	O
.	O

Neurodegeneration	other-disease
can	O
be	O
found	O
in	O
many	O
different	O
levels	O
of	O
neuronal	O
circuitry	O
ranging	O
from	O
molecular	O
to	O
systemic	O
.	O

Otitis	other-disease
externa	other-disease
may	O
be	O
acute	O
(	O
lasting	O
less	O
than	O
six	O
weeks	O
)	O
or	O
chronic	O
(	O
lasting	O
more	O
than	O
three	O
months	O
)	O
.	O

Floppy	other-disease
infant	other-disease
syndrome	other-disease
and	other-disease
sedation	other-disease
in	O
the	O
newborn	O
may	O
also	O
occur	O
.	O

Electrostimulation	O
techniques	O
such	O
as	O
TENS	O
have	O
been	O
used	O
for	O
twenty	O
years	O
to	O
treat	O
osteoarthritis	other-disease
in	O
the	O
knee	O
,	O
however	O
there	O
is	O
no	O
conclusive	O
evidence	O
to	O
show	O
that	O
it	O
reduces	O
pain	O
or	O
disability	O
.	O

DSM-5	O
states	O
that	O
if	O
a	O
patient	O
only	O
experiences	O
psychotic	O
symptoms	O
during	O
a	O
mood	O
episode	O
,	O
their	O
diagnosis	O
is	O
Mood	other-disease
Disorder	other-disease
with	O
Psychotic	other-disease
Features	other-disease
and	O
not	O
Schizophrenia	other-disease
or	O
Schizoaffective	other-disease
Disorder	other-disease
.	O

Thickened	O
liquids	O
play	O
a	O
vital	O
role	O
in	O
reducing	O
risk	O
of	O
aspiration	O
for	O
dysphagia	other-disease
patients	O
.	O

MMN	other-disease
will	O
present	O
with	O
asymmetrical	O
motor	O
neuropathy	O
where	O
reflexes	O
are	O
usually	O
preserved	O
(	O
or	O
slightly	O
increased	O
)	O
,	O
affecting	O
upper	O
limb	O
more	O
than	O
lower	O
limb	O
.	O

US	O
First	O
case	O
of	O
canine	other-disease
zoonosis	other-disease
confirmed	O
.	O

It	O
causes	O
the	O
disease	other-disease
plague	other-disease
,	O
which	O
takes	O
three	O
main	O
forms	O
:	O
pneumonic	other-disease
,	O
septicemic	other-disease
,	O
and	O
bubonic	other-disease
.	O

In	O
1973	O
,	O
the	O
FDA	O
approved	O
amantadine	O
for	O
use	O
in	O
the	O
treatment	O
of	O
Parkinson	other-disease
's	other-disease
disease	other-disease
.	O

Autism	other-disease
spectrum	other-disease
disorder	other-disease
(	O
ASD	other-disease
)	O
,	O
central	O
nervous	O
system	O
dysfunction	O
and	O
depression	O
have	O
all	O
been	O
found	O
to	O
be	O
impacted	O
by	O
the	O
microbiota	O
.	O

Additionally	O
,	O
in	O
2006	O
scientists	O
announced	O
that	O
they	O
had	O
genetically	O
engineered	O
cattle	O
lacking	O
a	O
necessary	O
gene	O
for	O
prion	O
production	O
–	O
thus	O
theoretically	O
making	O
them	O
immune	O
to	O
BSE	other-disease
,	O
building	O
on	O
research	O
indicating	O
that	O
mice	O
lacking	O
normally	O
occurring	O
prion	O
protein	O
are	O
resistant	O
to	O
infection	O
by	O
scrapie	O
prion	O
protein	O
.	O

K	O
aposi	other-disease
's	other-disease
sarcoma	other-disease
is	O
a	O
tumor	O
that	O
is	O
caused	O
by	O
a	O
virus	O
,	O
Kaposi	O
's	O
sarcoma-associated	O
herpesvirus	O
or	O
KSHV	O
,	O
discovered	O
in	O
1993	O
.	O

Side	O
effects	O
may	O
include	O
headaches	other-disease
,	O
nausea	other-disease
and	O
nose	O
bleeds	O
.	O

Members	O
of	O
the	O
herpes	other-disease
virus	O
family	O
may	O
have	O
a	O
role	O
in	O
autism	other-disease
,	O
but	O
the	O
evidence	O
so	O
far	O
is	O
anecdotal	O
.	O

In	O
addition	O
to	O
promoting	O
tumor	other-disease
-suppression	O
activity	O
,	O
RhoA	O
also	O
has	O
inherent	O
impact	O
upon	O
the	O
efficacy	O
of	O
drugs	O
in	O
relation	O
to	O
cancer	other-disease
functionality	O
and	O
could	O
be	O
applied	O
to	O
gene	O
therapy	O
protocols	O
in	O
future	O
research	O
.	O

Hypoalbuminemia	other-disease
is	O
common	O
in	O
critically	O
ill	O
patients	O
.	O

Low-set	O
ears	O
are	O
the	O
most	O
common	O
cranial	O
dysmorphism	O
seen	O
in	O
3C	other-disease
syndrome	other-disease
,	O
and	O
ocular	other-disease
coloboma	other-disease
is	O
the	O
least	O
common	O
of	O
the	O
non-concurrent	O
symptoms	O
(	O
cleft	other-disease
lip	other-disease
co-occurring	O
with	O
cleft	other-disease
palate	other-disease
is	O
the	O
least	O
common	O
)	O
.	O

The	O
hematoma	other-disease
usually	O
extends	O
into	O
the	O
nasal	O
passage	O
.	O

Without	O
treatment	O
,	O
individuals	O
with	O
impetigo	other-disease
typically	O
get	O
better	O
within	O
three	O
weeks	O
.	O

The	O
HIV	other-disease
infection	other-disease
in	O
Peru	O
was	O
largely	O
attributed	O
to	O
homosexual	O
or	O
bisexual	O
behavior	O
.	O

Loss	O
of	O
the	O
retinoblastoma	O
(	O
RB	O
)	O
protein	O
induces	O
androgen	O
receptor	O
deregulation	O
in	O
castration-resistant	O
prostate	other-disease
cancer	other-disease
by	O
deregulating	O
'	O
E2F1	O
expression	O
''	O
.	O
''	O

The	O
informant	O
said	O
that	O
the	O
girl	O
she	O
had	O
seen	O
had	O
the	O
same	O
coloboma	other-disease
of	other-disease
the	other-disease
iris	other-disease
as	O
Madeleine	O
.	O

Renal	other-disease
insufficiency	other-disease
is	O
always	O
progressive	O
with	O
a	O
very	O
poor	O
prognosis	O
,	O
with	O
survival	O
at	O
1	O
and	O
2	O
months	O
of	O
20	O
and	O
10	O
%	O
respectively	O
.	O

Unlike	O
the	O
M2	O
inhibitors	O
,	O
which	O
work	O
only	O
against	O
the	O
influenza	other-disease
A	other-disease
,	O
neuraminidase	O
inhibitors	O
act	O
against	O
both	O
influenza	other-disease
A	other-disease
and	O
influenza	other-disease
B	other-disease
.	O

Left	O
untreated	O
,	O
pemphigus	other-disease
foliaceus	other-disease
in	O
animals	O
is	O
life-threatening	O
,	O
leading	O
to	O
not	O
only	O
loss	O
of	O
condition	O
but	O
also	O
secondary	O
infection	O
.	O

When	O
suspected	O
on	O
the	O
basis	O
of	O
the	O
clinical	O
presentation	O
or	O
physical	O
findings	O
,	O
the	O
diagnosis	O
of	O
GnRH	other-disease
insensitivity	other-disease
should	O
be	O
confirmed	O
biochemically	O
.	O

Many	O
strains	O
of	O
HIV	other-disease
use	O
CCR5	O
as	O
a	O
co-receptor	O
to	O
enter	O
and	O
infect	O
host	O
cells	O
.	O

A	O
2-time	O
cancer	O
survivor	O
,	O
Kalemis	O
was	O
diagnosed	O
with	O
Non-Hodgkin	other-disease
’	other-disease
s	other-disease
Lymphoma	other-disease
in	O
1998	O
and	O
with	O
Chronic	other-disease
Myloed	other-disease
Leukemia	other-disease
in	O
2005	O
.	O

It	O
is	O
decreased	O
in	O
the	O
nephrotic	other-disease
syndrome	other-disease
and	O
absence	O
could	O
indicate	O
possible	O
alpha	other-disease
1-antitrypsin	other-disease
deficiency	other-disease
.	O

Hemorrhagic	other-disease
cystitis	other-disease
or	O
haemorrhagic	other-disease
cystitis	other-disease
is	O
an	O
inflammation	O
of	O
the	O
bladder	O
defined	O
by	O
lower	O
urinary	O
tract	O
symptoms	O
that	O
include	O
dysuria	O
,	O
hematuria	O
,	O
and	O
hemorrhage	O
.	O

The	O
Hungarian	other-disease
Music	other-disease
Awards	other-disease
(	O
Golden	other-disease
Giraffe	other-disease
Awards	other-disease
,	O
before	O
2004	O
)	O
is	O
an	O
annual	O
award	O
ceremony	O
held	O
by	O
the	O
Hungarian	O
music	O
industry	O
association	O
Mahasz	O
since	O
1992	O
.	O

Diagnosis	O
is	O
relatively	O
easy	O
when	O
all	O
the	O
symptoms	O
of	O
narcolepsy	other-disease
are	O
present	O
,	O
but	O
if	O
the	O
sleep	O
attacks	O
are	O
isolated	O
and	O
cataplexy	O
is	O
mild	O
or	O
absent	O
,	O
diagnosis	O
is	O
more	O
difficult	O
.	O

The	O
key	O
components	O
of	O
a	O
detailed	O
history	O
include	O
age	O
of	O
onset	O
,	O
description	O
of	O
the	O
symptoms	O
including	O
rhythm	O
,	O
situations	O
that	O
commonly	O
result	O
in	O
the	O
symptoms	O
,	O
mode	O
of	O
onset	O
(	O
rapid	O
or	O
gradual	O
)	O
,	O
duration	O
of	O
symptoms	O
,	O
factors	O
that	O
relieve	O
symptoms	O
(	O
rest	O
,	O
Valsalva	O
)	O
,	O
positions	O
and	O
other	O
associated	O
symptoms	O
such	O
as	O
chest	other-disease
pain	other-disease
,	O
lightheadedness	other-disease
or	O
syncope	other-disease
.	O

It	O
is	O
sometimes	O
associated	O
with	O
Marfan	other-disease
syndrome	other-disease
or	O
Loeys–Dietz	other-disease
syndrome	other-disease
,	O
but	O
may	O
also	O
result	O
from	O
Ehlers–Danlos	other-disease
syndrome	other-disease
,	O
bicuspid	O
aortic	O
valve	O
,	O
atherosclerosis	O
,	O
hypoplastic	O
left	O
heart	O
syndrome	O
,	O
syphilis	O
,	O
cystic	O
medial	O
necrosis	O
,	O
chest	O
injury	O
,	O
or	O
infective	O
endocarditis	O
.	O

When	O
12-week-old	O
Bernard	O
Myers	O
died	O
in	O
the	O
hospital	O
after	O
being	O
caught	O
in	O
the	O
tear	O
gas	O
attack	O
,	O
a	O
government	O
investigation	O
reported	O
he	O
died	O
of	O
enteritis	other-disease
,	O
and	O
a	O
hospital	O
spokesman	O
said	O
the	O
tear	O
gas	O
``	O
did	O
n't	O
do	O
it	O
any	O
good	O
.	O
''	O

These	O
compounds	O
are	O
therefore	O
thought	O
to	O
work	O
best	O
on	O
tumors	other-disease
that	O
contain	O
normal	O
or	O
``	O
wild-type	O
''	O
p53	O
.	O

A	O
number	O
of	O
genetic	O
conditions	O
including	O
multiple	other-disease
endocrine	other-disease
neoplasia	other-disease
syndromes	O
also	O
increase	O
the	O
risk	O
.	O

Systemic	other-disease
contact	other-disease
dermatitis	other-disease
(	O
SCD	other-disease
)	O
is	O
defined	O
as	O
a	O
dermatitis	other-disease
occurring	O
in	O
an	O
epi-cutaneously	O
contact-sensitized	O
person	O
when	O
exposed	O
to	O
haptens	O
systemically	O
such	O
as	O
orally	O
,	O
per	O
rectum	O
,	O
intravesically	O
,	O
transcutaneously	O
,	O
intrauterinely	O
,	O
intravenously	O
,	O
or	O
by	O
inhalation	O
.	O

However	O
,	O
researchers	O
are	O
uncertain	O
whether	O
the	O
identified	O
SDHD	O
gene	O
variants	O
are	O
directly	O
associated	O
with	O
Cowden	other-disease
syndrome	other-disease
and	O
Cowden-like	other-disease
syndrome	other-disease
.	O

Most	O
children	O
older	O
than	O
6	O
months	O
of	O
age	O
who	O
have	O
acute	O
otitis	other-disease
media	other-disease
do	O
not	O
benefit	O
from	O
treatment	O
with	O
antibiotics	O
.	O

Gangrene	other-disease
is	O
caused	O
by	O
a	O
critically	O
insufficient	O
blood	O
supply	O
(	O
e.g.	O
,	O
peripheral	other-disease
vascular	other-disease
disease	other-disease
)	O
or	O
infection	O
.	O

Human	other-disease
breast	other-disease
cancer	other-disease
metastasizes	O
to	O
multiple	O
distant	O
organs	O
such	O
as	O
the	O
brain	O
,	O
lungs	O
,	O
bones	O
and	O
liver	O
.	O

Strabismus	other-disease
may	O
also	O
be	O
classified	O
based	O
on	O
time	O
of	O
onset	O
,	O
either	O
congenital	O
,	O
acquired	O
,	O
or	O
secondary	O
to	O
another	O
pathological	O
process	O
.	O

Sleep	other-disease
apnea	other-disease
may	O
be	O
either	O
obstructive	other-disease
sleep	other-disease
apnea	other-disease
(	O
OSA	other-disease
)	O
in	O
which	O
breathing	O
is	O
interrupted	O
by	O
a	O
blockage	O
of	O
air	O
flow	O
,	O
central	other-disease
sleep	other-disease
apnea	other-disease
(	O
CSA	other-disease
)	O
in	O
which	O
regular	O
unconscious	O
breath	O
simply	O
stops	O
,	O
or	O
a	O
combination	O
of	O
the	O
two	O
.	O

Vaccination	O
became	O
mandatory	O
in	O
smallpox	other-disease
districts	O
during	O
the	O
1827	O
epidemic	O
and	O
physicians	O
were	O
required	O
to	O
report	O
cases	O
of	O
smallpox	other-disease
in	O
1834	O
.	O

In	O
September	O
2020	O
,	O
Sizzler	O
USA	O
,	O
filled	O
for	O
Chapter	O
11	O
bankruptcy	O
protection	O
blaming	O
the	O
COVID-19	other-disease
pandemic	O
for	O
hurting	O
sales	O
.	O

All	O
forms	O
of	O
botulism	other-disease
lead	O
to	O
paralysis	O
that	O
typically	O
starts	O
with	O
the	O
muscles	O
of	O
the	O
face	O
and	O
then	O
spreads	O
towards	O
the	O
limbs	O
.	O

It	O
is	O
used	O
for	O
the	O
treatment	O
of	O
schizophrenia	other-disease
and	O
schizoaffective	other-disease
disorder	other-disease
.	O

BFRBs	other-disease
may	O
affect	O
at	O
least	O
1	O
out	O
of	O
20	O
people	O
.	O

Sexual	other-disease
dysfunction	other-disease
is	O
particularly	O
common	O
among	O
people	O
affected	O
by	O
panic	other-disease
disorder	other-disease
(	O
who	O
may	O
fear	O
that	O
a	O
panic	O
attack	O
will	O
occur	O
during	O
sexual	O
arousal	O
)	O
and	O
posttraumatic	other-disease
stress	other-disease
disorder	other-disease
.	O

reported	O
cases	O
of	O
a	O
difference	O
disease—the	O
``	O
multiple	other-disease
mucosal	other-disease
neuroma	other-disease
syndrome	other-disease
``	O
—having	O
the	O
physical	O
phenotype	O
of	O
MEN2B	other-disease
,	O
but	O
without	O
variations	O
in	O
the	O
RET	O
gene	O
and	O
without	O
malignancy	O
.	O

Antigenic	O
drift	O
occurs	O
in	O
all	O
types	O
of	O
influenza	O
including	O
influenza	other-disease
A	other-disease
,	O
influenza	other-disease
B	other-disease
and	O
influenza	other-disease
C	other-disease
.	O
Antigenic	O
shift	O
,	O
however	O
,	O
occurs	O
only	O
in	O
influenza	other-disease
A	other-disease
because	O
it	O
infects	O
more	O
than	O
just	O
humans	O
.	O

Antithrombin	other-disease
III	other-disease
deficiency	other-disease
(	O
abbreviated	O
ATIII	other-disease
deficiency	other-disease
)	O
is	O
a	O
deficiency	O
of	O
antithrombin	O
III	O
.	O

Allowing	O
pet	O
cats	O
to	O
lick	O
open	O
wounds	O
can	O
cause	O
cellulitis	other-disease
and	O
sepsis	other-disease
due	O
to	O
bacterial	O
infections	O
.	O

People	O
with	O
the	O
so-called	O
segmental	O
progerias	other-disease
are	O
vulnerable	O
to	O
different	O
sets	O
of	O
diseases	O
.	O

Cystic	other-disease
fibrosis	other-disease
can	O
lead	O
to	O
infertility	O
in	O
men	O
.	O

Japan	O
Ten	O
H1N1	other-disease
-infected	O
pigs	O
are	O
discovered	O
in	O
a	O
swine	O
herd	O
in	O
Osaka	O
Prefecture	O
,	O
the	O
first	O
reported	O
case	O
of	O
zoonosis	O
in	O
Asia	O
.	O

The	O
presence	O
of	O
a	O
single	O
transverse	O
palmar	O
crease	O
can	O
be	O
,	O
but	O
is	O
not	O
always	O
,	O
a	O
symptom	O
associated	O
with	O
abnormal	O
medical	O
conditions	O
,	O
such	O
as	O
fetal	other-disease
alcohol	other-disease
syndrome	other-disease
,	O
or	O
with	O
genetic	other-disease
chromosomal	other-disease
abnormalities	other-disease
,	O
including	O
Down	other-disease
syndrome	other-disease
(	other-disease
chromosome	other-disease
21	other-disease
)	other-disease
,	O
cri	other-disease
du	other-disease
chat	other-disease
syndrome	other-disease
(	other-disease
chromosome	other-disease
5	other-disease
)	other-disease
,	O
Klinefelter	other-disease
syndrome	other-disease
,	O
Wolf-Hirschhorn	other-disease
Syndrome	other-disease
,	O
Noonan	other-disease
syndrome	other-disease
(	other-disease
chromosome	other-disease
12	other-disease
)	other-disease
,	O
Patau	other-disease
syndrome	other-disease
(	other-disease
chromosome	other-disease
13	other-disease
)	other-disease
,	O
IDIC	other-disease
15/Dup15q	other-disease
(	other-disease
chromosome	other-disease
15	other-disease
)	other-disease
,	O
Edward	other-disease
's	other-disease
syndrome	other-disease
(	other-disease
chromosome	other-disease
18	other-disease
)	other-disease
,	O
and	O
Aarskog-Scott	other-disease
syndrome	other-disease
(	other-disease
X-linked	other-disease
recessive	other-disease
)	other-disease
,	O
or	O
autosomal	other-disease
recessive	other-disease
disorder	other-disease
,	O
such	O
as	O
Leukocyte	other-disease
adhesion	other-disease
deficiency-2	other-disease
(	other-disease
LAD2	other-disease
)	other-disease
.	O

A	O
variant	O
of	O
subacute	other-disease
lymphocytic	other-disease
thyroiditis	other-disease
occurs	O
postpartum	O
:	O
postpartum	other-disease
thyroiditis	other-disease
.	O

He	O
had	O
begun	O
to	O
suffer	O
in	O
1962	O
from	O
a	O
condition	O
known	O
as	O
psoriatic	other-disease
arthropathy	other-disease
causing	O
arthritis	other-disease
to	O
develop	O
in	O
his	O
joints	O
as	O
well	O
as	O
affecting	O
his	O
skin	O
with	O
psoriasis	other-disease
.	O

GCTs	other-disease
that	O
originate	O
outside	O
the	O
gonads	O
may	O
be	O
birth	O
defects	O
resulting	O
from	O
errors	O
during	O
development	O
of	O
the	O
embryo	O
.	O

BRT	other-disease
’	other-disease
s	other-disease
tuberculosis	other-disease
(	O
TB	other-disease
)	O
testing	O
is	O
performed	O
using	O
the	O
Interferon-gamma	O
release	O
assay	O
T-SPOT.TB	O
.	O

Following	O
its	O
introduction	O
in	O
the	O
United	O
States	O
in	O
February	O
1984	O
,	O
ESWL	O
was	O
rapidly	O
and	O
widely	O
accepted	O
as	O
a	O
treatment	O
alternative	O
for	O
renal	other-disease
and	other-disease
ureteral	other-disease
stones	other-disease
.	O

There	O
she	O
selflessly	O
sacrificed	O
herself	O
for	O
the	O
good	O
of	O
others	O
,	O
herself	O
suffering	O
from	O
Typhoid	other-disease
fever	other-disease
.	O

The	O
FDA	O
granted	O
orphan	O
drug	O
designation	O
for	O
Hodgkin	other-disease
's	other-disease
lymphoma	other-disease
in	O
2004	O
.	O

In	O
obstructive	other-disease
sleep	other-disease
apnea	other-disease
,	O
affected	O
individuals	O
are	O
categorized	O
based	O
on	O
how	O
many	O
apneas	O
or	O
hypopneas	O
(	O
apnea-hypopnea	O
index	O
or	O
AHI	O
)	O
or	O
events	O
they	O
have	O
per	O
hour	O
.	O

It	O
can	O
be	O
due	O
to	O
an	O
increase	O
in	O
the	O
number	O
of	O
red	O
blood	O
cells	O
(	O
``	O
absolute	other-disease
polycythemia	other-disease
``	O
)	O
or	O
to	O
a	O
decrease	O
in	O
the	O
volume	O
of	O
plasma	O
(	O
``	O
relative	other-disease
polycythemia	other-disease
``	O
)	O
.	O

These	O
include	O
the	O
Child	other-disease
PTSD	other-disease
Symptom	other-disease
Scale	O
(	O
CPSS	O
)	O
,	O
Child	O
Trauma	O
Screening	O
Questionnaire	O
,	O
and	O
UCLA	O
Post-traumatic	other-disease
Stress	other-disease
Disorder	other-disease
Reaction	O
Index	O
for	O
``	O
DSM-IV	O
''	O
.	O

The	O
appropriate	O
treatment	O
for	O
binocular	other-disease
diplopia	other-disease
depends	O
upon	O
the	O
cause	O
of	O
the	O
condition	O
producing	O
the	O
symptoms	O
.	O

Another	O
type	O
of	O
work-related	O
asthma	other-disease
is	O
``	O
work-exacerbated	other-disease
asthma	other-disease
``	O
(	O
WEA	other-disease
)	O
which	O
is	O
asthma	other-disease
worsened	O
by	O
workplace	O
conditions	O
but	O
not	O
caused	O
by	O
it	O
.	O

In	O
osteosarcoma	other-disease
and	O
endometrial	other-disease
carcinoma	other-disease
,	O
c-Fos	O
overexpression	O
was	O
associated	O
with	O
high-grade	O
lesions	O
and	O
poor	O
prognosis	O
.	O

Traumatic	other-disease
brain	other-disease
injury	other-disease
(	O
TBI	other-disease
)	O
can	O
also	O
result	O
in	O
confabulation	other-disease
.	O

Acephalgic	other-disease
migraine	other-disease
is	O
also	O
referred	O
to	O
as	O
amigrainous	other-disease
migraine	other-disease
,	O
ocular	other-disease
migraine	other-disease
,	O
ophthalmic	other-disease
migraine	other-disease
or	O
optical	other-disease
migraine	other-disease
,	O
last	O
three	O
being	O
misnomers	O
.	O

The	O
surveillance	O
system	O
detects	O
,	O
alerts	O
,	O
and	O
predicts	O
future	O
regional	O
and	O
national	O
epidemics	O
specifically	O
for	O
influenza	other-disease
,	O
gastroenteritis	other-disease
and	O
Varicella	other-disease
zoster	other-disease
.	O

In	O
bladder	other-disease
cancer	other-disease
cells	O
,	O
GM3	O
show	O
antiproliferative	O
effects	O
.	O

Pericardial	O
fluid	O
with	O
an	O
interferon-γ	O
level	O
greater	O
than	O
50/ml	O
is	O
highly	O
specific	O
for	O
tuberculous	other-disease
pericarditis	other-disease
.	O

Arthur	O
's	O
mother-in-law	O
,	O
Janet	O
Brain	O
's	O
mother	O
,	O
was	O
Stella	O
Langdon	O
Down	O
,	O
the	O
granddaughter	O
of	O
John	O
Langdon	O
Down	O
who	O
gave	O
the	O
first	O
systematic	O
description	O
of	O
Down	other-disease
syndrome	other-disease
in	O
1867	O
and	O
after	O
whom	O
the	O
syndrome	O
is	O
named	O
.	O

However	O
,	O
not	O
long	O
after	O
the	O
break	O
,	O
dark	O
clouds	O
gathered	O
around	O
the	O
team	O
as	O
coach	O
Karl	O
was	O
diagnosed	O
with	O
neck	O
and	O
throat	other-disease
cancer	other-disease
.	O

Growth	other-disease
hormone	other-disease
deficiency	other-disease
has	O
been	O
reported	O
in	O
several	O
individuals	O
with	O
18p-	O
,	O
though	O
not	O
at	O
the	O
same	O
frequency	O
as	O
in	O
the	O
distal	O
18q-	O
population	O
.	O

Partial	O
cerebral	other-disease
cortex	other-disease
infarction	other-disease
from	O
global	O
brain	other-disease
ischemia	other-disease
typically	O
manifests	O
as	O
watershed	other-disease
stroke	other-disease
.	O

Minimizing	O
or	O
postponing	O
this	O
resistance	O
would	O
the	O
necessary	O
dose	O
to	O
eradicate	O
the	O
tumor	other-disease
,	O
thus	O
diminishing	O
drug	O
toxicity	O
.	O

Washington	O
State	O
tourist	O
guides	O
in	O
the	O
1920s	O
referred	O
to	O
Soap	O
Lake	O
as	O
the	O
``	O
world	O
's	O
greatest	O
mineral	O
sea	O
''	O
and	O
people	O
afflicted	O
with	O
Buerger	other-disease
's	other-disease
disease	other-disease
found	O
that	O
bathing	O
in	O
the	O
lake	O
would	O
cure	O
their	O
illnesses	O
.	O

While	O
in	O
some	O
individuals	O
gingivitis	other-disease
never	O
progresses	O
to	O
periodontitis	other-disease
,	O
periodontitis	other-disease
is	O
always	O
preceded	O
by	O
gingivitis	other-disease
.	O

HIV	other-disease
enters	O
host	O
cells	O
in	O
the	O
blood	O
by	O
attaching	O
itself	O
to	O
receptors	O
on	O
the	O
surface	O
of	O
the	O
CD4+	O
cell	O
.	O

STAT5	O
is	O
important	O
for	O
regulatory	O
T	O
cell	O
(	O
Treg	O
)	O
differentiation	O
and	O
function	O
,	O
which	O
may	O
explain	O
why	O
many	O
STAT	other-disease
GOF	other-disease
patients	O
have	O
low	O
Tregs	O
.	O

Most	O
patients	O
will	O
not	O
exhibit	O
all	O
of	O
these	O
symptoms	O
,	O
but	O
more	O
than	O
one	O
of	O
these	O
symptoms	O
will	O
be	O
present	O
in	O
a	O
patient	O
who	O
has	O
been	O
diagnosed	O
with	O
MERRF	other-disease
disease	O
.	O

False	other-disease
memory	other-disease
syndrome	other-disease
is	O
a	O
condition	O
in	O
which	O
a	O
person	O
's	O
identity	O
and	O
interpersonal	O
relationships	O
center	O
on	O
a	O
memory	O
of	O
a	O
traumatic	O
experience	O
that	O
is	O
objectively	O
false	O
but	O
that	O
the	O
person	O
strongly	O
believes	O
occurred	O
.	O

To	O
comply	O
with	O
the	O
new	O
health	O
and	O
safety	O
protocols	O
implemented	O
by	O
Six	O
Flags	O
due	O
to	O
the	O
COVID-19	other-disease
pandemic	O
during	O
2020	O
,	O
the	O
company	O
announced	O
that	O
their	O
Halloween	O
event	O
will	O
be	O
rebranded	O
to	O
Hallowfest	O
.	O

This	O
surgery	O
was	O
thought	O
to	O
have	O
also	O
triggered	O
his	O
Type	other-disease
1	other-disease
diabetes	other-disease
which	O
shortly	O
followed	O
the	O
surgery	O
.	O

In	O
the	O
late	O
1990s	O
,	O
Helm	O
was	O
diagnosed	O
with	O
throat	other-disease
cancer	other-disease
after	O
suffering	O
hoarseness	O
.	O

Both	O
of	O
these	O
entities	O
can	O
be	O
considered	O
subtypes	O
of	O
Hashimoto	other-disease
's	other-disease
thyroiditis	other-disease
and	O
have	O
an	O
autoimmune	O
basis	O
.	O

Rarely	O
(	O
&	O
lt	O
;	O
5	O
%	O
)	O
children	O
with	O
BWS	other-disease
will	O
continue	O
to	O
have	O
hypoglycemia	other-disease
after	O
the	O
neonatal	O
period	O
and	O
require	O
more	O
intensive	O
treatment	O
.	O

Destruction	O
to	O
the	O
inferior	O
parietal	O
lobule	O
of	O
the	O
non-dominant	O
hemisphere	O
results	O
in	O
topographic	other-disease
memory	other-disease
loss	other-disease
,	O
anosognosia	other-disease
,	O
construction	other-disease
apraxia	other-disease
,	O
dressing	other-disease
apraxia	other-disease
,	O
contralateral	other-disease
sensory	other-disease
neglect	other-disease
,	O
contralateral	other-disease
hemianopia	other-disease
,	O
or	O
lower	other-disease
quadrantanopia	other-disease
.	O

In	O
2011	O
,	O
Treacy	O
became	O
an	O
ambassador	O
for	O
the	O
Michael	O
Jackson	O
Legacy	O
foundation	O
(	O
a	O
charitable	O
organisation	O
dedicated	O
to	O
continuing	O
Jackson	O
's	O
humanitarian	O
legacy	O
)	O
,	O
which	O
helped	O
HIV	other-disease
children	O
and	O
built	O
orphanages	O
for	O
abandoned	O
orphans	O
.	O

At	O
the	O
beginning	O
of	O
the	O
AIDS	other-disease
epidemic	O
in	O
the	O
early	O
1980s	O
,	O
cyclosporiasis	other-disease
was	O
identified	O
as	O
one	O
of	O
the	O
most	O
important	O
opportunistic	O
infections	O
among	O
AIDS	other-disease
patients	O
.	O

Autoimmune	other-disease
polyendocrine	other-disease
syndrome	other-disease
type	other-disease
1	other-disease
is	O
inherited	O
in	O
an	O
autosomal	O
recessive	O
manner	O
.	O

SIADH	other-disease
is	O
typically	O
treated	O
by	O
correcting	O
the	O
underlying	O
cause	O
and	O
with	O
fluid	O
restriction	O
while	O
high	other-disease
volume	other-disease
hyponatremia	other-disease
is	O
typically	O
treated	O
with	O
both	O
fluid	O
restriction	O
and	O
a	O
diet	O
low	O
in	O
salt	O
.	O

Noonan	other-disease
syndrome	other-disease
is	O
an	O
autosomal	O
dominant	O
multisystem	O
disorder	O
characterized	O
by	O
a	O
wide	O
phenotypic	O
spectrum	O
including	O
distinctive	O
facial	O
dysmorphism	O
,	O
postnatal	O
growth	O
retardation	O
,	O
short	O
stature	O
,	O
ectodermal	O
and	O
skeletal	O
defects	O
,	O
congenital	O
heart	O
anomalies	O
,	O
renal	O
anomalies	O
,	O
lymphatic	O
malformations	O
,	O
bleeding	O
difficulties	O
and	O
variable	O
cognitive	O
deficits	O
.	O

A	O
large	O
number	O
of	O
human	O
gene	O
defects	O
can	O
cause	O
ectrodactyly	other-disease
.	O

In	O
a	O
large	O
Asian	O
series	O
of	O
Distal	O
renal	O
Tubular	O
Acidosis	O
in	O
Sjogren	other-disease
's	other-disease
Syndrome	other-disease
,	O
late	O
diagnosis	O
is	O
a	O
rule	O
in	O
spite	O
of	O
overt	O
hypokalemic	O
periodic	O
paralysis	O
in	O
a	O
vast	O
majority	O
of	O
them	O

Most	O
of	O
these	O
cases	O
are	O
now	O
thought	O
to	O
be	O
manifestation	O
of	O
tuberculosis	other-disease
and	O
indeed	O
they	O
respond	O
well	O
to	O
anti-tuberculous	O
treatment	O
.	O

Another	O
clinical	O
sign	O
of	O
CHH	other-disease
,	O
more	O
specifically	O
Kallmann	other-disease
syndrome	other-disease
,	O
is	O
a	O
lack	O
of	O
a	O
sense	O
of	O
smell	O
due	O
to	O
the	O
altered	O
migration	O
of	O
GnRH	O
neurons	O
on	O
the	O
olfactory	O
placode	O
.	O

Robin	other-disease
sequence	O
includes	O
a	O
U-shaped	O
or	O
sometimes	O
V-shaped	O
cleft	O
palate	O
(	O
an	O
opening	O
in	O
the	O
roof	O
of	O
the	O
mouth	O
)	O
with	O
a	O
tongue	O
that	O
is	O
too	O
large	O
for	O
the	O
space	O
formed	O
by	O
the	O
small	O
lower	O
jaw	O
.	O

It	O
is	O
therefore	O
important	O
for	O
the	O
country	O
to	O
have	O
a	O
strong	O
and	O
competent	O
veterinary	O
laboratory	O
industry	O
to	O
help	O
with	O
the	O
diagnosis	O
of	O
diseases	O
,	O
especially	O
emerging	O
diseases	O
such	O
as	O
Bovine	other-disease
spongiform	other-disease
encephalopathy	other-disease
(	O
BSE	other-disease
–	O
mad	other-disease
cow	other-disease
disease	other-disease
)	O
and	O
to	O
test	O
the	O
safety	O
of	O
meat	O
and	O
other	O
animal	O
products	O
.	O

Hypoglycemia	other-disease
in	O
newborns	O
with	O
BWS	other-disease
should	O
be	O
managed	O
according	O
to	O
standard	O
protocols	O
for	O
treating	O
neonatal	O
hypoglycemia	other-disease
.	O

Some	O
sources	O
have	O
argued	O
that	O
mitral	other-disease
regurgitation	other-disease
and	O
mitral	other-disease
valve	other-disease
prolapse	other-disease
are	O
common	O
after	O
age	O
40	O
,	O
if	O
the	O
ostium	other-disease
secundum	other-disease
is	O
not	O
repaired	O
by	O
age	O
24	O
.	O

Since	O
Sandhoff	other-disease
disease	O
was	O
only	O
discovered	O
in	O
1968	O
,	O
there	O
are	O
years	O
the	O
disease	O
has	O
gone	O
undetected	O
because	O
of	O
misdiagnoses	O
.	O

His	O
research	O
on	O
cyclothymia	other-disease
paved	O
the	O
way	O
for	O
understanding	O
the	O
childhood	O
antecedents	O
of	O
bipolarity	O
,	O
and	O
helped	O
in	O
the	O
worldwide	O
renaissance	O
of	O
the	O
temperament	O
field	O
.	O

Glutamic	O
acid	O
decarboxylase	O
autoantibody	O
(	O
GADA	O
)	O
,	O
islet	O
cell	O
autoantibody	O
(	O
ICA	O
)	O
,	O
insulinoma-associated	O
(	O
IA-2	O
)	O
autoantibody	O
,	O
and	O
zinc	O
transporter	O
autoantibody	O
(	O
ZnT8	O
)	O
testing	O
should	O
be	O
performed	O
in	O
order	O
to	O
correctly	O
diagnose	O
diabetes	other-disease
.	O

Pulmonary	other-disease
valve	other-disease
diseases	other-disease
are	O
the	O
least	O
common	O
heart	O
valve	O
disease	O
in	O
adults	O
.	O

The	O
bucket	O
was	O
invented	O
to	O
curb	O
or	O
reduce	O
Cholera	other-disease
,	O
Diarrhoea	other-disease
among	O
other	O
diseases	O
.	O

It	O
develops	O
after	O
secondary	O
syphilis	other-disease
and	O
is	O
divided	O
into	O
early	O
latent	O
and	O
late	O
latent	O
stages	O
.	O

Apnea	O
can	O
also	O
be	O
observed	O
during	O
periods	O
of	O
heightened	O
emotion	O
,	O
such	O
as	O
during	O
crying	O
or	O
accompanied	O
by	O
the	O
Valsalva	other-disease
maneuver	O
when	O
a	O
person	O
laughs	O
.	O

Hepatorenal	other-disease
syndrome	other-disease
is	O
one	O
of	O
the	O
more	O
serious	O
complications	O
in	O
patients	O
with	O
an	O
acute	other-disease
decompensation	other-disease
of	other-disease
cirrhosis	other-disease
and	O
increased	O
portal	other-disease
hypertension	other-disease
.	O

On	O
July	O
2nd	O
2020	O
,	O
Dickinson	O
died	O
at	O
his	O
Highgate	O
home	O
of	O
peritonitis	other-disease
resulting	O
from	O
a	O
gut	other-disease
obstruction	other-disease
.	O

This	O
can	O
cause	O
individuals	O
with	O
ASD	other-disease
to	O
avoid	O
environments	O
with	O
noise	O
pollution	O
,	O
which	O
in	O
turn	O
can	O
result	O
in	O
isolation	O
and	O
negatively	O
affect	O
their	O
quality	O
of	O
life	O
.	O

In	O
battling	O
the	O
twin	O
obstacles	O
of	O
Attention	other-disease
Deficit	other-disease
Disorder	other-disease
and	O
dyslexia	other-disease
,	O
his	O
love	O
for	O
writing	O
found	O
ways	O
to	O
persevere	O
.	O

The	O
family	O
grew	O
to	O
include	O
two	O
daughters	O
and	O
two	O
sons	O
by	O
1920	O
when	O
Isabel	O
died	O
in	O
the	O
Spanish	other-disease
Flu	other-disease
epidemic	O
.	O

However	O
due	O
to	O
the	O
COVID-19	other-disease
Pandemic	O
the	O
baggage	O
car	O
has	O
been	O
temporarily	O
removed	O
from	O
the	O
consist	O
.	O

Other	O
problems	O
include	O
premature	other-disease
epiphyseal	other-disease
closure	O
and	O
calcification	other-disease
of	other-disease
tendons	other-disease
and	other-disease
ligaments	other-disease
.	O

Although	O
7000	O
to	O
8000	O
new	O
cases	O
of	O
testicular	other-disease
cancer	other-disease
occur	O
in	O
the	O
United	O
States	O
yearly	O
,	O
only	O
400	O
men	O
are	O
expected	O
to	O
die	O
of	O
the	O
disease	O
.	O

In	O
children	O
,	O
hypothyroidism	O
leads	O
to	O
delayed	O
growth	O
and	O
in	O
extreme	O
inborn	O
forms	O
to	O
a	O
syndrome	O
called	O
``	O
cretinism	other-disease
``	O
.	O

Hemangiosarcoma	other-disease
can	O
cause	O
a	O
wide	O
variety	O
of	O
hematologic	O
and	O
hemostatic	O
abnormalities	O
,	O
including	O
anemia	other-disease
,	O
thrombocytopenia	other-disease
(	O
low	O
platelet	O
count	O
)	O
,	O
disseminated	other-disease
intravascular	other-disease
coagulation	other-disease
(	O
DIC	other-disease
)	O
;	O
presence	O
of	O
nRBC	O
,	O
schistocytes	other-disease
,	O
and	O
acanthocytes	other-disease
in	other-disease
the	other-disease
blood	other-disease
smear	other-disease
;	O
and	O
leukocytosis	other-disease
with	other-disease
neutrophilia	other-disease
,	other-disease
left	other-disease
shift	other-disease
,	other-disease
and	other-disease
monocytosis	other-disease
.	O

Pesitvirus	other-disease
(	O
BVDV	other-disease
)	O
was	O
identified	O
as	O
the	O
second	O
largest	O
costing	O
disease	O
with	O
an	O
estimated	O
$	O
114	O
million	O
AUD	O
annually	O
spent	O
on	O
the	O
treatment	O
,	O
prevention	O
and	O
production	O
loss	O
.	O

Fibromyalgia	other-disease
is	O
estimated	O
to	O
affect	O
2–8	O
%	O
of	O
the	O
population	O
.	O

Three	O
types	O
of	O
nociceptive	O
pain	O
are	O
experienced	O
with	O
chronic	O
wounds	O
;	O
``	O
cyclic	other-disease
acute	other-disease
wound	other-disease
pain	other-disease
``	O
,	O
``	O
non	other-disease
cyclic	other-disease
acute	other-disease
wound	other-disease
pain	other-disease
``	O
,	O
and	O
``	O
chronic	other-disease
wound	other-disease
pain	other-disease
``	O
.	O

p53	O
mutations	O
can	O
result	O
in	O
a	O
significant	O
checkpoint	O
deficit	O
,	O
which	O
has	O
important	O
implications	O
in	O
the	O
treatment	O
of	O
cancer	other-disease
.	O

Defective	O
efferocytosis	O
has	O
been	O
demonstrated	O
in	O
such	O
diseases	O
as	O
cystic	other-disease
fibrosis	other-disease
and	other-disease
bronchiectasis	other-disease
,	O
Chronic	other-disease
obstructive	other-disease
pulmonary	other-disease
disease	other-disease
,	O
asthma	other-disease
and	other-disease
idiopathic	other-disease
pulmonary	other-disease
fibrosis	other-disease
,	O
rheumatoid	other-disease
arthritis	other-disease
,	O
systemic	other-disease
lupus	other-disease
erythematosus	other-disease
,	O
glomerulonephritis	other-disease
and	other-disease
atherosclerosis	other-disease
.	O